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ABSTRACT
The asymmetric synthesis of quaternary stereocenters remains a challenging problem in organic
synthesis. Past work from the Stoltz laboratory has resulted in methodology to install quaternary
stereocenters α- or γ- to carbonyl compounds. Thus, the asymmetric synthesis of β-quaternary
stereocenters was a desirable objective, and was accomplished by engineering the palladium-
catalyzed addition of arylmetal organometallic reagents to α,β-unsaturated conjugate acceptors.
Herein, we described the rational design of a palladium-catalyzed conjugate addition reactions
utilizing a catalyst derived from palladium(II) trifluoroacetate and pyridinooxazole ligands. This
reaction is highly tolerant of protic solvents and oxygen atmosphere, making it a practical and
operationally simple reaction. The mild conditions facilitate a remarkably high functional group
tolerance, including carbonyls, halogens, and fluorinated functional groups. Furthermore, the
reaction catalyzed conjugate additions with high enantioselectivity with conjugate acceptors of 5-,
6-, and 7-membered ring sizes. Extension of the methodology toward the asymmetric synthesis of
flavanone products is presented, as well.
A computational and experimental investigation into the reaction mechanism provided a
stereochemical model for enantioinduction, whereby the α-methylene protons adjacent the enone
carbonyl clashes with the tert-butyl groups of the chiral ligand. Additionally, it was found that the
addition of water and ammonium hexafluorophosphate significantly increases the reaction rate
without sacrificing enantioselectivity. The synergistic effects of these additives allowed for the
reaction to proceed at a lower temperature, and thus facilitated expansion of the substrate scope to
sensitive functional groups such as protic amides and aryl bromides. Investigations into a scale-up
synthesis of the chiral ligand (S)-tert-butylPyOx are also presented. This three-step synthetic route
allowed for synthesis of the target compound of greater than 10 g scale.
Finally, the application of the newly developed conjugate addition reaction toward the synthesis of
the taiwaniaquinoid class of terpenoid natural products is discussed. The conjugate addition reaction
formed the key benzylic quaternary stereocenter in high enantioselectivity, joining together the
majority of the carbons in the taiwaniaquinoid scaffold. Efforts toward the synthesis of the B-ring
are presented.
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Palladium-catalyzed conjugate addition constitutes a diverse array of reactions
designed to insert the olefin of a conjugate acceptor into an aryl-palladium bond,
followed by hydrolytic turnover of the palladium enolate. The study of these reactions
has led to the disclosure of a number of catalytic systems for the synthesis and
asymmetric synthesis of benzylic stereocenters. This review briefly covers the
chronological development of these catalytic reactions, specifically discussing the
mechanistic hypotheses and studies underlying the key developments. These systems are
compared and contrasted with the conjugate addition manifolds operating with copper
and rhodium catalysts, and a discussion of both advantages and disadvantages of
palladium systems are presented.
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1.1 Motivations for palladium-catalyzed conjugate addition
β-substituted ketones are important intermediates in synthetic organic chemistry. Historically,
these compounds were accessed by Michael addition, the 1,4-addition of malonate-derived
nucleophiles to appropriate α,β-unsaturated acceptor compounds. Since the discovery of the
Michael reaction, a number of metal-based reagents have been developed as conjugate addition
nucleophiles. More recently, many of these processes have been rendered enantioselective by
employing chiral ligands and transition metal catalysts.1 Asymmetric conjugate additions are
well-established from copper2 and rhodium3 catalysts, and have seen expansion to the formation
of quaternary stereocenters.4 However, each metal system has its drawbacks. Use of copper
catalysts typically requires highly reactive stoichiometric organomagnesium, organozinc, or
organoaluminum reagents. These reagents are incompatible with many functional groups, and the
conditions required to successfully add these reagents to conjugate acceptors typically require
rigorously dry, deoxygenated solvents and extended reaction times at cryogenic temperatures.
Rhodium-catalyzed reactions typically employ less reactive (and thus highly functional group
tolerant) boron-based reagents, however, the expensive rhodium precatalysts are often oxygen
sensitive and thermally unstable rhodium(I) dimers. While not as sensitive to water as the copper-
catalyzed conditions, the rhodium-catalyzed reactions are highly oxygen sensitive.
Palladium-catalyzed conjugate additions combine the most favorable characteristics of
the copper and rhodium systems. They often utilize easily-handled boron (or sometimes silicon)
reagents, which do not require rigorously anhydrous reaction conditions or cryogenic reaction
temperatures, and react via palladium(II)-catalyzed cycles that are not prohibitively sensitive to
oxygen. Additionally, many of these reactions employ common palladium sources, ligands, and
solvents. Combined, these advantages convey a simple reaction procedure that does not employ
excessively expensive or sensitive reagents. However, palladium-catalyzed conjugate addition is
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significantly less explored than the copper or rhodium systems, and room for future development
exists.
This review will briefly describe the recent advances in the synthesis of β-arylketones via
palladium-catalyzed 1,4-addition of aryl organometal reagents to enones, including the recent
development of asymmetric processes.
1.1.1 Oxidative Heck reaction of allylic alcohols
Early methods for the palladium-catalyzed synthesis of β-aryl compounds did not involve
arylmetal insertion into enone olefins directly, but rather utilized Heck reactions on rigged
substrates designed to afford 1,4-addition products. Larock and coworkers describe a strategy for
the arylation of cyclic allylic alcohols based on the Heck reaction whereby β-hydride elimination
affords an enol that tautomerizers to give the formal 1,4-addition product (Scheme 1.1).5
Palladium-catalyzed Heck addition of aryliodides 1 to cyclopentenol 2 cleanly furnished β-
arylated ketone 3 (Scheme 1.1a), however analogous reaction with cyclohexenol 4 furnished two
arylated products 5 and 6, indicating divergent reaction mechanisms (Scheme 1.1b).
Scheme 1.1 Divergent reactivity of five- and six-membered cyclic allylic alcohols.
OH
I
X
1 2
Pd(OAc)2 (5 mol %)
n-Bu4NCl, KOAc
DMF, 80 °C
O
X 3X = H, OMe, CO2Et
a. Phenylation of 2-cyclopenten-1-ol
b. Divergent reactivity of phenylation of 2-cyclohexen-1-ol
OH
I
X
1 4
Pd(OAc)2 (5 mol %)
n-Bu4NCl, KOAc
DMF, 80 °C
5
X = H, OMe, CO2Et
O
X 6
O
X
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Larock and coworkers rationalized the divergent outcomes by suggesting two possible
isomeric olefin insertion pathways by which the arylpalladium species could react. Phenylation of
the olefin carbon distal to the alcohol would generate alkylpalladium 5, which would furnish
desired enol 6 upon β-hydride elimination (Figure 1.1). This enol tautomerizes readily to β-
arylated ketone 7, the expected product. However, isomeric olefin insertion would generate
alkylpalladium 8. β-hydride elimination of this species generates homoallylic alcohol 9, which
cannot itself tautomerize to observed ketone product 11, but can undergo a series of migratory
insertion/β-hydride elimination events to “chain walk” to enol 10, which can tautomerize to
observed α-arylated ketone 7.
Figure 1.1 Mechanistic rationale for reaction products
OH
4
OH
5
Ph
XPd
H
OH
6
Ph
X(H)Pd O
7
Ph
Ph–Pd–X
Ph–Pd–X
OH
8
XPd
Ph
H
OH
9
Ph
X(H)Pd
OH
Ph
Pd(H)X O
Ph
10 11
β-hydride
elimination
– HX, Pd(0)
– HX, Pd(0)
β-hydride
elimination
chain
walking
H
A direct, palladium-catalyzed 1,4-addition to an enone system would require a different
mechanism for turning over the metal catalyst. This mechanism necessarily differs from the Heck
reaction in two of the elementary steps of the catalytic cycle: formation of the arylpalladium
species and turnover of the alkylpalladium species.6 The currently accepted mechanism is very
similar to the analogous mechanism put forth by Hayashi for rhodium-catalyzed conjugate
addition reactions.3 The first key difference between direct conjugate addition reactions and the
Heck reaction is that the catalyst is a palladium(II) species (12) and no redox reactions occur at
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the metal center (Figure 1.2). This redox neutral catalytic cycle is a direct result of the mechanism
of catalyst turnover. Thus, oxidative addition is not a suitable step to form arylpalladium 13, and
this aryl moiety must be introduced by transmetallation. Insertion of enone 14 into the
arylpalladium bond furnishes alkylpalladium 15, an intermediate common to both catalytic
cycles. Here, a possible side reaction of the catalytic cycles forms if alkylpalladium 15 undergoes
β-hydride elimination to furnish Heck-type product 16 and a palladium hydride, which is readily
reduced by loss of HX to palladium(0), a species that is off the productive catalytic cycle. In the
conjugate addition catalytic cycle, enolate 15, or as its tautomer palladium enolate 17, undergoes
protonolysis to furnish β-arylated product 18. Water-mediated hydrolysis likely forms a
palladium hydroxide species, and the active catalyst for conjugate addition reactions (12) is often
believed to be a palladium(II) hydroxide due to the species’ ability to undergo transmetallation
rapidly with arylboron reagents. Thus, a closed catalytic cycle is completed when hydrolysis of
palladium enolate 17 regenerates palladium(II) 12.
Figure 1.2 Mechanistic discrepancy between 1,4-addition and Heck reaction catalytic cycles
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O Ar
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–HX
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1.2 Palladium-catalyzed reactions using Brønsted or Lewis acid additives
A number of groups have reported the use palladium catalysts to promote the conjugate
addition of arylmetal species to conjugate acceptors utilizing Brønsted or Lewis acid additives or
solvents. The first reports from the early-1980s employ ArHgCl or Ar4Sn reagents in conjunction
with tetrabutylammonium chloride additives and Brønsted acid reaction solvents to facilitate the
1,4-addition.7 However, it was not until the mid-1990s that widespread investigation of
palladium-catalyzed conjugate addition began to manifest.
1.2.1 Antimony salts as stoichiometric additives
Uemura and coworkers first reported the use of antimony(III) chloride as a stoichiometric
Lewis acid to promote the palladium-catalyzed addition of tetraphenylborates to conjugate
acceptors (Scheme 1.2).8 They hypothesize that protonolysis of a B–Ph bond is catalyzed by the
acetic acid solvent, and that triphenylborane is the active reagent. Phenylenone 18 is successfully
transformed to diphenyl ketone 19. Later works suggest a mechanism implicating palladium(0)
oxidative addition of one of the aryl–B bonds to form the active arylpalladium complex. Turnover
is hypothesized to be accomplished by antimony-coordination of the carbonyl (20) and
subsequent intramolecular chlorodepalladation (i.e., 2 1 ). Hydrolysis of the enolate is
accomplished with acetic acid to yield diaryl ketone 19. The author of this review suggests that
the known decomposition products of triphenylborane- phenylboroxine or phenylboronic acid-
are likely to be the active reagents. Additionally, it follows that this reaction may follow a
palladium(II), redox neutral, catalytic cycle by invoking transmetallation from these arylboron
reagents as opposed to direct oxidative addition of a B–aryl bond. Work from Uemura
demonstrating arylboronic acids as competent arylation reagents supports this view,8d as does a
preponderance of subsequent palladium/arylboron reagent work to be discussed herein.
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Scheme 1.2 SbCl3-mediated conjugate addition and mechanistic rationale
a. SbCl3-catalyzed addition of aryltetrafluoroborate
Ph Me
O
Ph4BK (1 equiv), NaOAc (2 equiv)
Pd(OAc)2 (10 mol%), SbCl3 (10 mol%)
AcOH, 25 °C, 24 h
(91% yield)
Ph Me
OPh
b. Mechanistic proposal for catalyst turnover
Ph Me
OPh
[PdBPh2]
SbHCl3
Ph
Ph
O
Me
Sb[Ph2BPd]
ClCl
Cl
Ph
Ph
O
Me
SbCl2
18 19
222120
Ph Me
OPh
19
AcOH
H
Demark and coworkers reported an analogous transformation utilizing organosiloxanes as
the aryl source.9 Here, a fluoride additive was required to promote the transmetallation between
relatively unreactive organosiloxane reagents and the palladium catalyst, presumably by
formation of hypervalent silicon. Cyclohexenone 23 reacts with arylsiloxane 24 to furnish
conjugate addition adduct 25 with minimal Heck reaction side product 26 (Scheme 1.3a).
Adapting mechanistic insights from rhodium-catalyzed conjugate addition reactions developed by
Hayashi and Miyaura, Denmark suggested a redox-neutral palladium(II) based catalytic cycle,
and shows catalyst turnover via palladium enolate hydrolysis (Scheme 1.3b). Denmark shows the
antimony-assisted turnover mechanism suggested by Uemura, with alkylpalladium 30 undergoing
intramolecular depalladation to furnish the antimony enolate 31, but suggests that invoking
protonation of oxo-π-allyl enolate 28 to afford enol 29 is also a plausible mechanism of turnover.
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Scheme 1.3 Palladium-catalyzed conjugate addition of organosiloxanes and hypothesized
mechanisms of turnover
a. SbCl3-catalyzed addition of organosiloxanes
Pd(OAc)2 (5 mol%), 
SbCl3 (4 equiv), AcOH
TBAF•H2O (4 equiv)
CH3CN, 60 °C
b. Mechanistic proposals for catalyst turnover
O O
Ph
PhSi(OEt)3
O
Ph
73% yield 7% yield
23 24 25 26
O
Ph
[PdX]
O
Ph
2527 O
Ph
[PdX]
30
O
Ph
28
[PdX]
Cl2
Sb Cl
OH
Ph
29
O
Ph
31
SbCl2
AcOHSbCl3
AcOH
– Pd(X)OAc
– Pd(X)Cl
1.2.2 Addition of sulfinic acids to conjugate acceptors
In 2012, Duan and Li brought the use of acidic reaction medium as a way to promote
palladium-catalyzed conjugate addition to its logical conclusion, actually utilizing aryl sulfinic
acids as the phenyl donor source.10 They demonstrate the arylation of a number of conjugate
acceptors (32) using phenylsulfinic acid (33), and generate a wide array of products (Table 1.1).
Cyclic ketones bearing aryl tertiary (25) or quaternary (35) stereocenters could be furnished, as
well as tertiary stereocenters for acyclic ketones (19) and esters (36)
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Table 1.1 Substrate scope of aryl sulfinic acid conjugate addition
3619
Pd(OAc)2 (5 mol%), 
bpy (5 mol %)
50% H2SO4 (2 equiv)
CH3OH, 90 °C, air
X
O
X
O
Ph
32 33 34
S
O
OH
R
O
Ph
25
O
Ph
O Ph
Ph H3CO
O Ph
Ph
35
94% yield 60% yield 95% yield 82% yield
9:1 mixture
conjugate addition: Heck
The mechanistic explanation for the formation of the active arylpalladium species
involves expulsion of SO2 gas (Figure 1.3).  Invoking the sulfinic acid to coordinate the metal
center via Pd–O bonded intermediate 37, they suggest formation of arylpalladium 38 by β–carbon
elimination, effectively releasing SO2 while transferring the aryl moiety to the metal center. This
process is isoelectronic to the more commonly encountered β–hydride elimination. Arylpalladium
38 undergoes conjugate addition reaction to afford the observed array of products, suggesting that
β–carbon elimination is a viable entry into the conjugate addition reaction manifold beyond the
typical transmetallation sequence. Though conjugate arylations have not been disclosed with C–C
bond cleavage via β–carbon elimination, this mechanism of conjugate addition has been
demonstrated with β–carbon elimination of alkynes and their subsequent Rh-catalyzed
asymmetric conjugate addition. 11
Figure 1.3 Mechanistic hypothesis for generation of arylpalladium species
N
Pd
N
Ln O S
O
N
Pd
N
Ln
O
O
β-carbon
elimination
–SO2
253837
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1.3 Palladium-catalyzed conjugate addition of arylboronic acids
In the early 21st century, the popularity of palladium-catalyzed conjugate addition
reactions of arylboron reagents has risen. Unlike some early examples of palladium-catalyzed
conjugate addition, they utilized arylboronic acids as the aryl reagent instead of more reactive and
highly toxic tin and mercury reagents. These reactions often depend on the protic, Brønsted acid
solvents to assist in turnover of the palladium catalyst v i a  protonolysis of the latent
alkylpalladium species furnished by the C–C bond forming phenylpalladation step.
1.3.1 Triphenylphosphine as ligands for conjugate addition
Arylboron reagents are a highly desirable class of aryl reagent for organotransition metal
catalyzed reactions, as demonstrated by the ubiquitous Suzuki-Miyaura cross coupling reaction.
They are bench-stable, easily-handled, relatively non-toxic and their byproducts are easily
removed from reactions. Uemura’s application of these reagents to 1,4-addition reactions ushered
in a similar rapid expansion of palladium-catalyzed conjugate addition reactions. Ohta and
coworkers disclosed palladium-catalyzed 1,4-addition to cyclic and acyclic enones by a catalyst
derived from palladium(0) and chloroform (Scheme 1.4).12 They hypothesized that the reactive
species was palladium(II) species 39, generated from oxidative addition to the chloroform
additive. More recently, similar conditions have been adapted for conjugate additions employing
palladium(II) acetate with microwave catalysis while avoiding the need to oxidize palladium(0)
with chloroform.13
Scheme 1.4 Palladium(0) and chloroform catalyst system for conjugate addition of arylboronic acids
O
B(OH)2
OPd2(dba)3 (5 mol %)PPh3 (10 mol %), CHCl3
Cs2CO3 (1 equiv)
toluene/H2O, 60 °Cn n
R
39
predicted catalystAryl
Ph3P
Pd
HO
Cl
Cl
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Supporting Ohta’s hypothesized catalyst structure (39), Hartwig and corworkers proposed
that analogous palladium hydroxide complexes are the active catalysts in Suzuki coupling
reactions, and demonstrated that palladium(II) hydroxides are kinetically competent catalysts for
transmetallation with arylboronic acids while the corresponding palladium(II) halides were not.14
These result suggests that palladium(II) hydroxides are the active catalysts for reactions involving
transmetallation of boronic acids in aqueous media, even in reactions where the palladium(II)
halides are formed directly (as in Suzuki couplings via oxidative addition) or otherwise are
present in higher concentrations. Ohta proposes a similar ligand exchange, where oxidative
addition of phosphine-palladium(0) 40 to chloroform yields palladium chloride 41 (Scheme 1.5).
Ligand exchange with hydroxide in the basic reaction medium generates 16-electron complex 42,
which likely undergoes ligand dissociation to form the active, 14-electron catalyst (39).
Scheme 1.5 Proposed mechanism for formation of the active catalyst
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1.3.2 Bisphosphine ligands in palladium-catalyzed conjugate addition
Miyaura, having pioneered some early work in rhodium-catalyzed conjugate addition,
reported the first dicationic palladium(II) precatalyst (43) for conjugate addition utilizing 1,2-
bis(diphenylphosphino)ethane as the ligand (Scheme 1.6).15 Cationic arylpalladium(II) species are
known to coordinate and insert olefins significantly faster than their neutral counterparts; this
phenomenon has been applied to the copolymerization of carbon monoxide and olefins utilizing
cationic palladium catalysts and triarylboron reagents.16 Additionally, cationic palladium(II)
species are known to transmetallate rapidly with arylboron reagents, while neutral palladium(II)
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is slow or inert in the same transmetallation.17 Notably, these reactions proceed at ambient
temperature in aqueous tetrahydrofuran. Miyaura’s work tolerated a wide array of cyclic (e.g., 25)
and acyclic (e.g., 44) enone substrates.
Scheme 1.6 Dicationic palladium(II)-catalyzed conjugate addition of arylboronic acids
O PhB(OH)2 (1.5 equiv)
[Pd(dppe)NCPh2](SbF6)2 (5 mol%)
THF:H2O (10:1), 20 °C, 23 h
(87% yield)
O
Ph
Ph
O
OPh Ph
O
OPh
Ph
PhB(OH)2 (1.5 equiv)
[Pd(dppe)NCPh2](SbF6)2 (5 mol%)
THF:H2O (10:1), 20 °C, 23 h
(92% yield)
Ph2P Pd
PPh2
N N
Ph Ph
2SbF6
[Pd(dppe)NCPh2](SbF6)2
23 25
44 45
43
The tendency for the catalyst in Miyaura’s reactions to turn over via hydrolysis as
opposed to β–hydride elimination is rooted in the fact that cationic palladium(II) enolates
undergo facile hydrolysis.18 This phenomenon may be attributed to the increased Lewis acidity of
the palladium(II) cation, which may shift the enolate tautomer equilibrium such that it exists
primarily as the oxygen-bound enolate. Typically, carbon-bound enolates are observed for
intermediates in other palladium(II) catalytic cycles, such as α-arylations of ketone enolates.19
Oxygen-bound palladium(II) enolates cannot undergo β–hydride elimination, and must therefore
undergo hydrolysis to liberate the catalyst. Additionally, perhaps the cationic palladium(II) is less
nucleophilic than its neutral analog, and is slower to abstract β–hydrogens. Thus, the carbon-
bound enolate tautomer isomerizes on a time scale significantly fast enough to prevent
competitive β–hydride elimination from occurring.
Miyaura also demonstrated explicit transmetallation of arylboronic acids with precatalyst
43 (Scheme 1.7).20 A Hammett plot generated by varying the electronic nature of the para-X
substituent gave a negative ρ value, and supports the Wheland-type transmetallation intermediate
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46. This correlates with the observation that electron-rich arylboronic acids react readily under
these conditions. Isolated complex 47 proved to be chemically competent in 1,4-addition
reactions, though the stabilizing presence of triphenylphosphine required elevated reaction
temperatures, and suggests that the arylpalladium(II) species is the key intermediate in the  C–C
bond forming conjugate addition catalytic cycle.
Scheme 1.7 Isolation of arylpalladium(II) cationic complexes
X B
[Pd] O
OH
OH
Ph2P Pd
PPh2
N N
Ph Ph
2BF4
X B(OH)2
PPh3 (1.1 equiv)
acetone:H2O, 23 °C, 1 h
Ph2P Pd
PPh2
PPh3
X
BF4
43 46 47
chemically competent
for conjugate addition reactions
Wheland-type 
transmetallation intermediate
1.3.3 Diamine ligands in conjugate addition
Diamine ligands have seen extensive use in palladium-catalyzed conjugate addition
reactions. Unlike bulkier di- or triarylphosphine ligands, diamines have been employed in
catalysts that synthesize both tertiary and quaternary centers. Lu and coworkers reported a
bipyridine-based system that successfully catalyzed conjugate addition to cyclic and acyclic
enones (Scheme 1.8).21 Of a number of diamine ligands screened, bipyridine significantly
outperformed other diamines; a result consistent throughout much of the palladium-catalyzed 1,4-
addition literature entailing diamine ligands. Though a wide variety of cyclic (25) and acyclic
(49) β-aryl ketones could be synthesized, a large excess of arylboronic acid was required to drive
the reaction to full conversion. Furthermore, the large excess of bipyridine relative to palladium
was found to suppress formation of Heck products and biaryl homocoupling products. A follow-
up report detailed the use of phase transfer additives to facilitate the same reaction in aqueous
reaction media.22
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Scheme 1.8 Diamine ligands for palladium-catalyzed 1,4-addition
B(OH)2
R
O
O
RR
O
O
RR
Aryl
Aryl
Pd(OAc)2 (5 mol %)
bpy (20 mol %)
AcOH/THF/H2O, 40 °C
3 equiv
B(OH)2
R
Pd(OAc)2 (5 mol %)
bpy (20 mol %)
AcOH/THF/H2O, 40 °C
3 equiv
23 25
4948
Itami and coworkers employed unique diamine palladium complex 50, perhaps the first
unsymmetric diamine ligand to be employed in palladium-catalyzed 1,4-additions.23 Lu had
explored several unsymmetric ligands, including a number of chiral diamines, but found none to
be efficacious. Though Itami’s work is functional on both cyclic and acyclic enone substrates, it
is most notable for its ability to functionalize fullerenes via palladium-catalyzed hydroarylation
(Scheme 1.9).
Scheme 1.9 Hydroarylation of fullerenes
Pd catalyst 50 (5 mol %)
t-BuCO2H/toluene, 23 °C
N N
Pd
C6F5OCO OCOC6F5
catalyst 50
Aryl H
B(OH)2
R
1.5 equiv
In 2010, Lu and coworkers described the first reported palladium-catalyzed conjugate
addition forming quaternary stereocenters by using dimeric [(bpy)Pd(OH)]2 (5 1 ) as the
precatalyst.24 This catalyst system builds off the success of their Pd/bpy results, and employs
some of the observations made my Miyaura and others concerning the increased efficacy of
cationic palladium(II) hydroxide in transmetallation with arylboron reagents and the facile
hydrolysis of cationic palladium(II) enolates. Moving to the cationic diamine complex facilitated
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milder reaction conditions that do not require acetic acid as a cosolvent to assist in enolate
hydrolysis. This system tolerates a variety of cyclic enone ring sizes, including five- (52) and six-
membered (35) rings (Table 1.2), as well as acyclic ketones (53). β-aryl enones (54) are
unreactive, however electron-rich (55) and electron-poor (56) arylboronic acids are competent in
the reaction manifold. Minnaard detailed a similar system in 2013, however, they employed a
catalyst derived in situ from palladium(II) trifluoroacetate and bpy.25
Table 1.2 Cationic palladium(II)-bypridine catalysts forming quaternary stereocenters by 1,4-
addition
O
R
B(OH)2
O
R
Aryl
Catalyst 51 (0.5 mol%)
CH3OH, 23 °Cn n
R
Pd
O
H
H
O
2BF4
N
N
Pd
N
N
Catalyst 51
O
Ph
Me
O
Ph
Me Ph
O
O
Ph
Ph
96% yield 0% yield94% yield 70% yield
(5 mol % Pd, 80 °C)
MeMe
O
Me
OMe
O
Me
F82% yield 81% yield
35 52 53 54 55 56
1.4 “Ligand-free” conjugate addition reactions
While “ligand-free” reactions are not amenable to asymmetric catalysis, they do provide
a direct route to 1,4-addition products that may be difficult to synthesize by other means. These
“ligand-free” reactions, perhaps due to their sterically unencumbered ligand sphere, tolerate
highly substituted enone reactants. Lee and coworkers detailed a system using a catalyst derived
from palladium(II) acetate and triflic acid to catalyze arylation of hindered enones (e.g., 57) using
arylboroxine reagents (Scheme 1.10).26 The procedure details treatment of a solution of
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palladium(II) acetate with triflic acid, which forms dicationic palladium(II) triflate species in situ.
Another important advance promoted by Lee was the addition of sodium nitrate to the reaction
mixture, which they found to suppress the undesired homocoupling side reaction. This additive is
particularly necessary when utilizing sterically hindered enones, however, they observed it was
not useful for facile, sterically unencumbered substrates.
Scheme 1.10 “Ligand-free” conjugate addition of arylboroxines to hindered enones
Pd(OAc)2, TfOH
NaNO3
ClCH2CH2Cl 
ambient temperature
air atmosphere
O O
O
B
O
B
O
B
Aryl
ArylAryl
R1 R2
R3
R1 R2
R3
Aryl
in situ generation of
[LnPd(II)]•2(OTf)
57 58
Lee and coworkers next disclosed a link between oxidation chemistry and 1,4-addition
reactions, whereby choice of solvent determines the outcome of a β-arylation reaction.27 Using
coordinating solvents, such as dimethylsulfoxide, simple enone substrates could undergo facile
oxidative Heck reaction to form arylated enone (26). This reactivity was best suited to
arylboronic acid reagents. Conversely, employing non-coordinating solvents, such as
dichloroethane, and arylboroxine reagents could tune the reactivity toward 1,4-addition products
(25). Presumably, the more coordinating solvent must stabilize the cationic palladium(II)
intermediates and disfavor protonolysis of the enolate. Furthermore, because carbopalladation
proceeds in a syn-facial stereochemical relationship, the carbon-bound palladium enolate must
isomerizes to have a syn β-hydrogen to promote the elimination reaction. Coordinating solvent
must either slow protonolysis of these equilibrating enolates sufficiently such that the β-hydride
elimination reaction can out-compete the other turnover pathways, or the coordinating solvent
itself may somehow promote isomerization and β-hydride elimination to furnish the oxidative
Heck product.
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Figure 1.4 Solvent effects on products of “ligand-free” palladium-catalyzed arylations
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1.5 Direct β-arylation of cyclic ketones
Until recently, β-functionalization of carbonyl compounds required a chemical handle,
such as the traditionally-employed α,β-unsaturated carbonyl conjugate acceptor. In 2013, direct
β−arylation reactions of ketones was demonstrated. Building on the ketone to enone oxidation
work of Stahl and others, which reports the use of molecular oxygen as the stoichiometric oxidant
in palladium-catalyzed oxidation reactions,28 Dong and coworkers reported the first, direct β-
arylation of ketones in 2013.29 Reacting aryl iodides with ketones of a variety of ring sizes, Dong
and coworkers postulate the in situ formation of the cyclic enone, which in turn reacts via
palladium-catalyzed 1,4-addition to furnish the β-arylation products (Table 1.3). Successful
reactions are reported with 5- (60), 6- (59) and 7-membered (61) ring ketones, as well as an
isolated example of a heteoaromatic iodide reactant (62) and some linear ketones (63).
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Table 1.3 Direct β-arylation of ketones
O
I
O
Aryl
Pd(OCOCF3)2 (10 mol %)
P(i-Pr)3 (20 mol %)
Ag(OCOCF3) (2 equiv)
hexafluoroisopropanol/dioxane (1:1)
80 °C, 12 h
n n
R
O O O
72% yield 60% yield55% yield 44% yield 67% yield
59 60 61 62 63
O
n
O
N
Ts
O
CO2Me
CO2Me
CO2Me
CO2Me
2.5 equiv 1 equiv
The mechanism Dong proposes is a hybrid of the Stahl oxidation chemistry and
the catalytic cycle studied by Miyaura for palladium-catalyzed 1,4-addition. A
palladium(II) catalyst (65) reacts with an equivalent of ketone/enol substrate (66) to
afford the equilibrium mixture of carbon– (67) and oxygen–bound (68) palladium
enolates (Figure 1.5). The carbon–bound isomer undergoes β-hydride elimination to
afford the corresponding enone and palladium(II) hydride. Reduction of palladium via
loss of HX generates palladium(0) (70), which undergoes oxidative addition with the aryl
iodide to furnish arylpalladium(II) 71. The author of this review speculates that at this
point, the reaction pathway becomes cationic by silver-mediated halogen abstraction to
precipitate silver iodide and yield arylpalladium(II) 72, the purported reactive species for
enone arylation. Migratory insertion of the enone olefin into the aryl–palladium bond
furnishes equilibrating palladium mixture 73  and 74 . Turnover is mediated by
protonolysis by an equivalent of HX, formed by reduction of hydride 69 or from initial
formation of the palladium enolate to begin the catalytic cycle. HX serves to liberate
arylation product 75 and regenerate the catalyst (65). The author of this review proposes
that the 1,4-addition portion of the cycle is likely facilitated by cationic arylpalladium(II),
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and that the reaction may best be thought of as two half-cycles that must link together to
form a closed catalytic cycle: 1) a palladium(II)-catalyzed ketone oxidation, which
generates palladium(0); and 2) a palladium(0)-catalyzed 1,4-arylation, involving cationic
palladium(II) during enone arylation and palladium enolate protonolysis. Notably,
switching between neutral and cationic palladium(II) is likely required, however the
precise mechanistic details are yet unknown.
Figure 1.5 Proposed mechanism of direct β-arylation of ketones
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1.6 Asymmetric reactions forging tertiary stereocenters
The application of bidentate ligands to palladium-catalyzed 1,4-addition reactions quickly
facilitated the development of asymmetric variants. A comprehensive review of this area was
published in 2007.6 This section will briefly describe a number of approaches that were developed
before the advance of quaternary-stereocenter forging palladium-catalyzed conjugate additions.
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1.6.1 Dicationic palladium(II)-catalyzed systems
Miyaura and coworkers first reported the asymmetric conjugate addition of triarylbismuth
reagents to enones.30 A variety of cyclic enone ring sizes and acyclic enones were reacted using a
catalyst derived from chiral bidentate phosphine ligands, such as dipamp and chiraphos.
However, the requisite use of uncommon arylbismuth reagents failed to challenge the popularity
of rhodium- and copper-catalyzed systems that employed more common organometallic reagents.
Later, Miyaura’s group significantly expanded the scope of nucleophiles to include more
common reagents such as aryltrifluoroborate salts,31 and arylboronic acids (Scheme 1.1).32 In the
most general scheme, arylboronic acids are reacted with a dipamp-palladium catalyst (76) to
deliver phenylated ketone 25 in 95% yield and 93% ee. The catalyst is highly active, and requires
sub-zero temperatures to deliver high stereoselectivity. Switching to acetone as the cosolvent and
(S,S)-chiraphos as the ligand allowed high stereoselectivity to be obtain at ambient temperature,
and while aryltrifluoroborate reagents were found to react more rapidly at ambient temperature
than arylboronic acids the addition of catalytic AgBF4 induced significantly greater turnover
numbers for the arylboronic acids.33 This advance facilitated the delivery of 25 in 99% yield and
89% ee with catalyst loadings as low as 0.01 mol % on 5 mmol scale. Miyaura’s group continued
to be extremely productive in this field and has reported a number of further advances in substrate
scope, include aldehyde-based conjugate acceptors,34 nitrogen-containing acceptors,35 and
asymmetric tandem conjugate addition/aldol processes.36 The authors have since published a
retrospective account of their pursuits in the area of palladium-catalyzed conjugate addition.37
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Scheme 1.11 Chiral dicationic palladium(II) precatalysts based on bidentate bisphosphine ligands
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[Pd((S,S)–Dipamp)PhCN2](SbF6)2 (3 mol%)
MeOH:H2O (10:1), –15 °C, 20 h
(95% yield)
[Pd((S,S)–Dipamp)PhCN2](SbF6)2
93% ee
2523
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1.6.2 Palladium(II) trifluoroacetate-catalyzed systems and systems derived in situ
Minnaard and coworkers reported a system for asymmetric conjugate addition to cyclic
enones employing a catalyst derived in situ from palladium(II) trifluoroacetate and (R,R)-Me-
DuPhos as the chiral ligand.38 This system features a streamlined reaction procedure, as there is
no need to pre-form the precatalyst complex. However, because the precatalyst is not cationic or
dicationic, elevated temperatures are required to promote the reaction. Presumably, this is
because bidentate ligands require that arylpalladium(II) species must necessarily undergo ligand
dissociation to form cationic species in order to have an open coordination site for the substrate.
Minnaard and coworkers later extended the scope of the nucleophiles to include arylsiloxanes by
employing ZnF2 in conjunction with their Pd/DuPhos catalyst system.39 Notably, heteroatom-
containing substrates were successfully employed in these reactions, such as δ−lactones and 4-
piperidinone substrates.
Scheme 1.12 (R,R)-Me-DuPhos as ligand for asymmetric conjugate addition
O O
Ph
P P
PhB(OH)2 (3 equiv)
Pd(OCOCF3)2 (5 mol%)
(R,R)–Me-DuPHOS (5.5 mol%)
THF/H2O (10:1), 50 °C, 12 h
(99% yield)
(R,R)–Me-DuPHOS99% ee
23 25 77
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Shi and coworkers reported a bidentate ligand scaffold derived from BINAP and N-
heterocyclic carbene ligands (Scheme 1.13a, 78).40 Related development of bis-NHC ligands
derived from anthrocene has been reported recently by Viege.41 The advance of this work is that
the catalyst (80) can be derived in situ from palladium(II) acetate and the triflate salt of the NHC
precursor (Scheme 1.13b, 79).
Scheme 1.13 N-heterocyclic carbene ligand scaffolds for asymmetric 1,4-addition to cyclic enones
O O
Aryl
ArylB(OH)2 (1.5 equiv)
Catalyst 78 (3 mol%)
THF:H2O (10:1), 20 °C, 36h
(78–99% yield)
88–99% ee
N NMe
N NMe
Pd
OTFA
OTFA
Catalyst 78
23 25
N
N
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OTf Pd(OAc)2
– 2 HOAc
NN
RNRN
Pd
OTfTfO
79 80
a. Pre-formed NHC-Pd catalysts
a. NHC-Pd catalysts generated in situ
Bedford and Hu independently pioneered the application of palladacycle catalysts to 1,4-
addition reactions.42 These catalysts were suitable for use at loadings of 1 mol % or lower, and
functioned with both arylboronic acids and arylsiloxanes. Notably, reactions employing these
palladacycles do not facilitate homocoupling of the arylmetal reagent. Otha and coworkers
developed an asymmetric variant of these palladacycle-catalyzed reactions.43 They hypothesize a
palladium(II) hydroxide catalyst, presumably by a bromide/hydroxide ligand exchange similar to
that detailed in Scheme 1.5. Follow up work saw modest success applying the transformation to
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acyclic enones, reporting 42–52% ee with moderate chemical yields, and 1,2-addition to
aldehydes, albeit in poor ee.44
Scheme 1.14 Chiral ferrocene-based ligand designs for palladium-catalyzed conjugate addition
O O
Aryl
ArylB(OH)2 (1 equiv)
Catalyst 79 (5 mol%)
Cs2CO3
PhCH3, 20–80 °C, 24 h
(81–90% yield)
Pd
Br
PPh2
Me
42–74% ee
Catalyst 81
Fe
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1.7 Asymmetric reactions forging quaternary stereocenters
1.7.1 C1 symmetric ligands
In 2011, Stoltz reported the first palladium-catalyzed asymmetric conjugate addition of
arylboronic acids to cyclic enones to form quaternary stereocenters utilizing a catalyzed formed
in situ from palladium(II) trifluoroacetate and the (S)-tert-butylpyridinooxazoline ligand (Table
1.4).45 This reaction delivered arylated ketones of five- (52), six- (35), and seven-membered rings
(83) all in greater than 90% ee. Bulky β-substituents (86) and heteroatom-containing tethers (87)
were all tolerated. The reaction exhibited high functional group compatibility, and reactions of
esters (88), fluorinated groups (89) and even aryl bromides (90) proceeded in high yields.
Additionally, the ligand was easy to synthesize,46 and the process was found amenable to
heterocyclic conjugate acceptors (84, 85).47
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Table 1.4 Pd/PyOx-catalyzed asymmetric conjugate addition product scope
O
O
R
(S)-t-BuPyOx 82 (6 mol %)
Pd(OCOCF3)2 (5 mol %)
NH4PF6, H2O
ClCH2CH2Cl
40–60 °C, 12 h
O
O
Cy
Ph
O
Ph
O
Ph
O
Ph
BnO
84% yield
91% ee
85% yield
93% ee
99% yield
92% ee
65% yield
91% ee
 
86% yield
85% ee
Ph
n
n Aryl
R
R
B(OH)2
N
N
O
(S)-t-BuPyOx 82
O Ph
O
O
O
NH(OCOCF3)
OCH3
91% yield
94% ee
80% yield
95% ee
O
91% yield
95% ee
O
99% yield
96% ee
O
84% yield
84% ee
CO2Me Br
CF3
52 83 35 84 85
9089888786
Stoltz and Houk jointly reported a computational and experimental study of the
stereochemical model for induction of enantioselectivity and the mechanistic details of the
conjugate addition.48 Steric repulsion between the α-methylene protons of the enone substituent
and the tert-butyl group of the ligand was implicated as the interaction that determined the
preferred transition state geometry (Figure 1.6). Computational studies indicate a cationic
palladium(II) hydroxide catalyst, and experiments detailed the addition of water and non-
coordinating counterions increased the reaction rate, facilitating a lower reaction temperature and
a broader, more functional-group tolerant substrate scope.
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Figure 1.6 Stereochemical model for induction of asymmetry in Pd/PyOx conjugate addition
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1.7.2 C2 symmetric ligands
Minnaard and de Vries reported the asymmetric conjugate addition of boronic acids to
enones utilizing a dicationic palladium catalyzed derived in situ from (PhBOX)PdCl2 (91).49
Treatment of dichloride 91 with silver hexafluoroantimonate furnishes the active, dicationic
palladium(II) catalyst. The C2 symmetry of the ligand tolerates enones of five- (52), six- (35), and
seven-membered ring size (83), providing the corresponding β-aryl ketones all in greater than
93% ee. Lactone 92 serves as a selective substrate, with an 88% ee. This substrate provided only
50% ee in the Stoltz Pd/PyOx manifold, as the substrate lacks the α-methylene protons that are
implicated in the enantiodetermining steric interactions with the ligand. Linear ketones (e.g., 93)
react with modest to good yields, but poor ee. Additionally, the researchers demonstrated that
more functionally diverse arylboronic acids could react successfully, furnishing 94 in 93% yield
and 93% ee.
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Table 1.5 Dicationic palladium(II) asymmetric conjugate addition with bisoxazoline ligands
X
O
X
O
R
Complex 91 (8 mol %)
AgSbF6 (20 mol %)
CH3OH/H2O: 4/1
40 °C, 24–40 h
OO
Ph
O
Ph
93% yield
93% ee
80% yield
94% ee
93% yield
93% ee
Ph
n
n Aryl
R
R
B(OH)2
O
Ph
O
57% yield
88% ee
52 83 35
N
Pd
N
OO
Ph PhCl Cl
Complex 91
X = CH2, O
t-BuO
OPh
92
81% yield
25% ee
93
O
93% yield
93% ee
94
O
O
1.8 Conclusion and outlook
The study of palladium-catalyzed conjugate addition is significantly less developed than
systems employing rhodium or copper. These palladium catalysts provide an excellent contrast to
the other metals in several respects. For example, copper systems generally have lower functional
group tolerance due to the necessity of employing highly reactive organometallic reagents for
transmetallation with copper, and therefore these reactions also require rigorously anhydrous
reaction conditions. The rhodium catalysts can be impractical because they require expensive,
sensitive precursors, complicated and difficult to synthesize ligands, and must be run in
thoroughly degassed solvents. In contrast, the palladium-catalyzed reactions provide user-friendly
advantages in several key areas: 1) the use of bench-stable and easily-handled boron-based aryl
reagents, 2) high tolerance for aqueous reaction media and protic solvents, 3) insensitive to
oxygen atmosphere, 4) high functional group tolerance, 5) mild reaction conditions and
straightforward reaction procedure.
However, palladium-catalyzed conjugate addition significantly lags behind the rhodium and
copper manifolds in other areas, most notably the narrow substrate scope. To date, palladium
conjugate addition is specific to aryl organometallic reagents, and do not tolerate alkenyl or alkyl
Chapter 1 28
nucleophiles. Alkenyl reagents undergo rapid transmetallation, and may dimerize or polymerize
under typical reaction conditions. Likewise, alkylpalladium species are often subject to rapid, off-
cycle β-hydride elimination. This is particularly true of many of the putative alkylpalladium
species formed in the reactions catalyzed by chiral ligands because they frequently employ small
ligand-metal bite angles, a geometry that does not retard β-hydride elimination. Indeed,
generation of palladium hydrides and subsequent reduction to palladium(0) is one of the factors
that prevents lower catalyst loadings in several palladium conjugate addition systems discussed
herein. Despite some current drawbacks, the advantages conveyed by palladium-catalyzed
conjugate addition should continue to attract researchers to the subject, and perhaps this
continued study will enable the technological advance required to significantly expand the
substrate scope and synthetic utility of this reaction.
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CHAPTER 2
The development of a palladium-catalyzed asymmetric conjugate addition of
arylboronic acids to cyclic conjugate acceptors÷
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÷ This work was performed in collaboration with Dr. Kotaro Kikushima and Dr. Michele
Gatti, and was partially adapted from the publication: Kikushima, K.; Holder, J. C.; Gatti,
M. Stoltz, B. M. J. Am. Chem. Soc. 2011, 133, 6902–6905. Copyright 2011 American
Chemical Society.
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 available
The first enantioselective Pd-catalyzed, asymmetric construction of all-carbon
quaternary stereocenters via 1,4-addition of arylboronic acids to cyclic, β-substituted
enones is reported. A wide range of arylboronic acids and cyclic enones are reacted
utilizing a catalyst prepared from palladium(II) trifluoroacetate and a chiral
pyridinooxazoline ligand to yield enantioenriched products bearing benzylic
stereocenters. Notably, this transformation is insensitive to air or moisture, providing a
practical and operationally simple method of synthesizing enantioenriched all-carbon
quaternary stereocenters.
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2.1 Introduction
The catalytic enantioselective construction of all-carbon quaternary stereocenters
remains a difficult problem in synthetic chemistry.1  A reliable approach toward this
challenge has been the asymmetric conjugate addition of carbon-based nucleophiles to
suitable α,β-unsaturated carbonyl acceptors.2 Pioneered by the groups of Feringa,
Alexakis, and Hoveyda, the majority of asymmetric conjugate additions for the synthesis
of quaternary centers involve the use of highly reactive organometallic reagents (e.g.,
diorganozinc,3 triorganoaluminum,4 and organomagnesium reagents5) to a variety of
unsaturated electrophiles with copper catalysts.6  These reactions uniformly involve air
and moisture sensitive organometallic reagents that require rigorously anhydrous reaction
conditions.  Alternatively, Hayashi has championed the use of chiral rhodium catalysts in
combination with air stable, easily handled nucleophilic organoboron reagents to produce
a wide array of conjugate addition adducts in exceptional yield and ee.7,8  In contrast to
the copper systems, relatively few examples in the rhodium series lead to the formation
of products containing quaternary centers.9  Notably, Hayashi and Shintani have recently
developed a rhodium•diene-catalyzed conjugate addition of sodium tetraaryl borates
(Ar4BNa) and arylboroxines (ArBO)3) to β,β-disubstituted enones to provide ketone
products bearing b-chiral all-carbon quarternary stereocenters.10,11  Unfortunately, in these
examples commercially available arylboronic acids (ArB(OH)2) are not competent
nucleophiles.10,11,12
The conjugate addition of arylboronic acids and their derivatives to enones with
palladium catalysis has been investigated for some time and has resulted in the
development of addition reactions that produce enantioenriched tertiary β-substituted
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ketones.13  In 2010, Lu reported the use of a dicationic bipyridine-derived palladium
catalyst for additions to β-substituted enones that deliver racemic products containing the
quaternary center in high yield.14  Notably absent from the Lu report and from the work of
others in the area are examples of Pd-catalyzed enantioselective conjugate addition
reactions that forge a quaternary center.13  Herein, we report the first palladium-catalyzed
asymmetric conjugate addition of arylboronic acids to β-substituted cyclic enones
employing an easily accessible chiral pyridinooxazoline (PyOx) ligand.15  These reactions
generate a wide array of benzylic all-carbon quaternary stereocenters while exhibiting
extraordinary tolerance to both air and water.
2.2 Development and optimization of reaction conditions
2.2.1 Identification of chemically competent ligand and solvent conditions
To achieve the desired enantioselective conjugate addition, the reaction of 3-
methylcyclohexen-2-one (1) with phenylboronic acid (2) was investigated in the presence
of various palladium catalysts and chiral ligands (Table 2.1).  After a preliminary ligand
search that included an array of standard chiral ligand frameworks,16 we noted that bis-
nitrogen ligands were generally successful in the literature, and bipyridine (bpy, 96)
provided full conversion of enone 95 when treated with palladium(II) acetate and
phenylboronic acid in protic solvents. Unfortunately, a number of standard privileged
ligand scaffolds failed to afford any conversion to the desired conjugate addition product
under identical reaction conditions. Sparteine (98), PyBox (99), and a variety of bis-
oxazoline (101 and 102) and phosphinooxazoline (100) did not enable the transformation.
“Ligand-less” conditions (97) also failed to provide any product. Notably, pyridine (103,
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12 mol %) failed to deliver any product, insinuating that architechtural features of the
bidentate bpy scaffold enabled the desired reaction.
Table 2.1 diamine ligand screen a
O
B(OH)2
O
Pd(OAc)2 (5 mol %)
ligand (6 mo l%)
t-amylalcohol:H2O (2:1),
80 °C, 12 h
+
NN
N N No Ligand
N
N
O
PPh2 N
O
O
N
N N
O O
t-Bu t-Bu
NO
N N
O
t-Bu t-Bu
100% conversion no product detected no product detected no product detected
no product detectedno product detectedno product detectedno product detected
Ph
2 equiv
96 97 98 99
100 101 102 103
95 35
a Conditions: enone (0.25 mmol), phenylboronic acid (0.50 mmol), Pd(OAc)2 (5 mol %), ligand (6 mol %),
solvent (1 mL), 24 h.  NMR yield. ee determined by chiral HPLC.
Success with bpy and lack of success with chiral bis-oxazoline ligands led us to
hypothesize that a C1  symmetry chiral ligand based on the bpy scaffold would be a
suitable catalyst. The presence of a pyridine was required, however the small bite angle
and 5-membered metallocycle chelate seemed equally important. We reasoned that
modification of one pyridine moiety of bpy would allow the introduction of a chiral
group (Figure 2.1, 104), while still maintaining the 5-membered chelate and narrow bite-
angle. We quickly discovered that substituted PyOx ligands (105)15 provided high levels
of enantioselection.
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Figure 2.1 Motivating the use of pyridinooxazoline ligands
N
N
N
N *
N
N
O
R
Pyridinooxazoline (PyOx)
Ligand Scaffold
• 5-membered metallocycle chelate
• Narrow bite-angle
96 104
105
Identification of a functioning chiral ligand (82) prompted us to consider the
effects of solvent on the yield and enantioselectivity of the reaction. A preliminary
solvent screen led us to observe that polar, coordinating solvents hindered the reaction
(Table 2.2, entries 1–3). Moving toward non-polar solvents, such as toluene (entry 4),
encouraged higher conversions and modest enantioinduction, however, heating these
reactions (entries 6–7) failed to drive the reactions to full conversion. Fortuitously,
dichloromethane (entry 5) provided 87% isolated yield of the desired conjugate addition
adduct in 91% ee.
Table 2.2 Preliminary solvent screen a
temperature (°C)
40 
40 
40 
40 
40 
60 
60
solvent
t-amyl alcohol
dioxane
THF
toluene
CH2Cl2
toluene
hexane
yield (%)
14 (NMR)
17 (NMR)
31 (NMR)
65 (NMR)
87 (isolated)
63 (isolated)
68 (isolated)
ee (%)
--
--
--
82
91
77
62
entry
1
2
3
4
5
6
7
O
B(OH)2
O
Pd(OCOCF3)2 (5 mol %)
(S)-t-BuPyOx (6 mol %)
Conditions
+
Ph
95 35
a Conditions: enone (0.25 mmol), phenylboronic acid (0.50 mmol), Pd(OCOCF3)2 (5 mol %),
(S)-t-BuPyOx (6 mol %), solvent (1 mL), 24 h.  NMR yield. ee determined by chiral HPLC
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To further optimize the reaction, we next looked at palladium sources. The use of
palladium(II) halides afforded no reaction (Table 2.3, entry 1–2). The reactivity could be
rescued by treatment with AgOTf, presumably abstracting the halides and leading to a
dicationic palladium(II) catalyst (entry 3). However, this reaction produced ketone 35 in
low enantioselectivity. In the presence of ligand 82, palladium(II) carboxylate sources
were capable of catalyzing the desired reaction (entries 4–5). The acetate counterion
(entry 4) led to modest chemical yields of the desired conjugate addition adduct in 93%
ee.  A catalyst derived from palladium(II) trifluoroacetate and pyridinooxazoline 82
produced the desired ketone product 3517 in 87% yield and 91% ee (entry 5).18  By using
1,2-dichloroethane in place of dichloromethane as solvent, and increasing the reaction
temperature from 40 to 60 °C, ketone 35 was isolated in 99% yield and 93% ee (entry
6).19 The high yield and enantioselectivity were maintained even upon addition of 10
equiv of water (entry 7).  Furthermore, the amount of phenylboronic acid was reduced to
1.1 equiv with no detrimental effects (entry 8).
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Table 2.3 Optimization of palladium source a
O
Ph
O
Pd source
solvent
40-80 °C, 12 h
B(OH)2
95 35
entry Pd source temp (°C) yield (%)b ee (%)c
1
2
3d
4
5
6
7e
Pd(MeCN)2Cl2
Pd(MeCN)2Cl2, AgOTf
40 – –
40
40
40 65 92
40 87 91
60 99 93
60 99 91
PdCl2
Pd(OCOCF3)2
Pd(OCOCF3)2
Pd(OCOCF3)2
– –
69 17
8f Pd(OCOCF3)2 60 99 93
solvent
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
ClCH2CH2Cl
ClCH2CH2Cl
ClCH2CH2Cl
Pd(OAc)2
82
N N
O
t-Bu
a Conditions: Reactions were performed with phenylboronic acid (0.50 mmol), 3-
methylcyclohexen-2-one (0.25 mmol), Pd(OCOCF3)2 (5 mol%), and ligand 4  (6
mol%) in solvent (1 mL) for 12 h, unless otherwise noted.  b Isolated yield.  c ee was
determined by chiral HPLC.  d 12 mol% AgOTf.  e Reaction performed in the presence
of added H2O (2.5 mmol, 10 equiv). f Phenylboronic acid loading reduced to 1.1 equiv.
A final examination of solvent and palladium sources was undertaken to finalize
the reaction conditions before examining a wider range of pyridinooxazoline ligands.
Highly polar solvents (Table 2.4, entries 2–3) failed to produce product. Switching to
dicationic palladium by employing tetrakis acetonitrile palladium(II) tetrafluoroborate
facilitate no conversion in methanol at a variety of temperatures, or as a mixture with
dichloroethane as cosolvent (entries 4–6). Finally, we failed to generate a catalyst in situ
from isolated (PyOx)PdCl2 by treatment with sodium hexafluorophosphate (entry 7).
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Table 2.4 Screen of related conjugate addition conditions a
O
2 equiv
[Pd] (5 mol %)
(S)-t-BuPyOx (6 mol %)
O
entry solvent temp (°C) yield ee
1
2
3
4
5
metal source
DCE
Acetone
60
60
60
60
25
Low
---
---
Trace
---
--
--
--
--
--
6 DCE-MeOH 25 --- --
7 Acetone 25 --- --tBuPyOXPdCl2 - NaPF6
PhB(OH)2
DMF
MeOH
MeOH
Pd(OAc)2
Pd(TFA)2
Pd(TFA)2
Pd(CH3CN)4(BF4)2
Pd(CH3CN)4(BF4)2
Pd(CH3CN)4(BF4)2
95 35
a Conditions: Reactions were performed with phenylboronic acid (0.50
mmol), 3-methylcyclohexen-2-one (0.25 mmol), Pd(OCOCF3)2 (5 mol%),
and ligand 4 (6 mol%) in solvent (1 mL) for 12 h, unless otherwise noted.  b
Isolated yield.  c ee was determined by chiral HPLC.
2.2.2 Investigation of Other Ligands
Having successfully optimized the reaction conditions, we next examined the
reaction with other members of the PyOx or related quinolinooxazoline (QuinOx) and
isoquinolinooxazoline (IQuinOx) ligand series (Table 2.5, entries 9–16).  PyOx ligands
bearing isopropyl (106) or phenyl (107) substitution instead of tert-butyl at the 4-position
of the oxazoline resulted in low enantioselectivity, although the desired product was
obtained in nearly quantitative yield.  Similarly, it was found that the PyOx ligands with a
4,5-diphenyl oxazoline (108) or simply 5-phenyl substitution (109) resulted in poor
enantioselectivity.  Next, employing QuinOx ligands 110 or 111 resulted in a dramatic
decrease in both the reactivity and enantioselectivity, whereas IQuinOx ligands 112and
113 provided little difference in yield and enantioselectivity to t-BuPyOx 82.
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Table 2.5  PyOx, QuinOx, IQuinOx Ligand Screen a
N
N
O
i-Pr
N
N
O
Ph
N
N
O
Ph
Ph N
N
O
Ph
106
99% yield
40% ee
107
99% yield
52% ee
108
99% yield
41% ee
109
99% yield
2% ee
N
N
O
t-Bu
N
N
O
i-Pr
N
N
O
t-Bu
N
N
O
t-Bu110
13% yield
20% ee
111
14% yield
0% ee
112
99% yield
92% ee
113
99% yield
91% ee
O
B(OH)2
O
Pd(OCOCF3)2 (5 mol %)
ligand (6 mo l%)
ClCH2CH2Cl, 60 °C
12 h
+
Ph
2 equiv95 35
a Conditions: Reactions were performed with phenylboronic acid (0.50 mmol), 3-methylcyclohexen-2-one (0.25 mmol),
Pd(OCOCF3)2 (5 mol%), and ligand (6 mol%) in ClCH2CH2Cl (1 mL) for 12 h, unless otherwise noted.  Isolated yield.  ee was
determined by chiral HPLC.
However, later developments of improved reaction conditions encouraged us to
reconsider our initial ligand screen. The use of ammonium hexafluorophosphate and
water as additives greatly improved reaction rates. We re-screened a large number of
chiral and achiral ligands to determine if the new conditions facilitated an expanded class
of ligands to successfully catalyze the reaction. Unfortunately, all phosphine ligands we
tried failed to product appreciable conversion (Table 2.6, 114, 115 and 116). The drop in
conversion from dppe (115) to dppbz (114) led us to question whether ligand rigidity was
detrimental to conversion. However, the nearly identical results observed with bpy (96),
phenanthroline (117) and bathophenanthroline (118) suggest that rigidity of the ligand
scaffold has no effect on conversion.
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We screened a number of chiral diamine ligands under the optimized conditions
as well. The best conversion was observed with a bisoxazoline with a similar bite-angle
to bpy (Table 2.6, 125), followed by proline-derived 123, which also features a 5-
membered metallocycle chelate. Ligands forming 6-membered metallocycles (119 and
120) performed poorly, however those containin gem-dimethyl (122) or cyclopropyl
(126) substituted bridging methylene groups showed improved conversion. We believe
this to be the result of the fully substititued carbon on the ligand backbone enforcing a
smaller bite angle. Additionally, sparteine (98), PHOX (124) and PyBox (121) ligands
delivered no conversion to the desired product.
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Table 2.6 Expanded ligand screen a
O
B(OH)2
O
Ph
 ligand (3 mol%)
Pd(OCOCF3)2 (2.5 mol%)
NH4PF6 (30 mol%), H2O (5 equiv)
ClCH2CH2Cl, 40 °C, 12–48 h
+
Fe
PPh2
PPh2
Ph2P PPh2
Ph2P PPh2
N N
N N N N
Achiral Ligands
PhPh
0% conversion 22% conversion 2% conversion 100% conversion
99% yield
100% conversion
99% yield
98% conversion
97% yield
95 35
96116115114
117 118
PPh2 N
O
t-Bu
NN N
O
N
O
N N
O O
Ph Ph
NO
N N
O
Ph Ph
BnBn
N N
O O
t-Bu t-Bu
N N
O O
N HN
O O
Ph Ph
CN
N
Ph
OH
Ph
N
H
H
H
H
0% conversion 0% conversion 35% conversion 20% conversion
1% conversion11% conversion2% conversion
12% conversion 22% conversion
Chiral Ligands
119 120 121
123122
124 98 125 126
a Conditions: Reactions were performed with phenylboronic acid (0.50 mmol), 3-
methylcyclohexen-2-one (0.25 mmol), Pd(OCOCF3)2 (2.5 mol%), and ligand (3 mol%) in
ClCH2CH2Cl (1 mL) for 12 h, unless otherwise noted. Conversion was determined by 1H NMR.
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2.2.3 Investigation of Substrate Scope
To investigate the reaction scope, we explored various arylboronic acids as
nucleophiles for this process (Table 2.7). Generally, para-substituted arylboronic acids
are well tolerated (entries 1–9). Reactions with 4-methyl and 4-ethylboronic acid
proceeded well to give high yields of the desired products with good asymmetric
induction (entries 1 and 2).  While electron-rich nucleophiles tend to be reliable reaction
partners, they often furnish products in moderate enantioselectivity (entries 3–5).
Electron-deficient nucleophiles fared particularly well, producing ketone products in
excellent ee (entries 6–9).  Specifically, these electron-poor nucleophiles can possess a
wide range of functional groups, such as ketone (entry 6), halide (entries 7 and 8) and a
trifluoromethyl group (entry 9). Reactions involving meta-substituted arylboronic acids
were also broadly successful with alkyl (entry 10), halide (entries 11 and 12), ester (entry
13) and even nitro (entry 14) groups on the nucleophile.20
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Table 2.7 Scope of Arylboronic Acids a
O
Aryl
O
B(OH)2
1
entry R = temp (°C) yield (%)b ee (%)c
1
2
3
5
4
6
7
8
9
10
11
12
13
4-Me– (127)
4-Et– (128)
4-MeO– (129)
4-TBSO– (131)
4-BnO– (130)
4-Ac– (132)
4-F– (134)
4-F3C– (89)
60 99 87
60 90 85
40 58 69
40 52 82
60 96 74
60 99 96
80 84 92
60 99 96
4-Cl– (133) 60 94 95
3-Me– (135)
3-Cl– (136)
3-Br– (90)
3-MeO2C– (88)
14 3-O2N– (137)
60 99 91
60 55 96
60 44 85
60 91 95
60 40 92
R
4 (6 mol%)
Pd(OCOCF3)2 
(5 mol%)
ClCH2CH2Cl
40–80 °C, 12–24 h
time (h)
12
12
24
24
18
18
12
12
12
24
18
24
24
18
a Conditions: Reactions were performed with phenylboronic acid (0.50
mmol), 3-methylcyclohexen-2-one (0.25 mmol), Pd(OCOCF3)2 (5 mol%),
and ligand 4 (6 mol%) in (ClCH2)2 (1 mL) at 40–80 °C for 12–24 h.  b
Isolated yield.  c ee was determined by chiral HPLC,
We sought to further examine the scope of the reaction by exploring cyclic enones
of different ring sizes and with a range of β-substitution (Table 2.8). Importantly, altering
the ring size to the 5- or 7-membered ring series had no deleterious effect on the
transformation and fashioned ketones 52 and 83 in high yield and ee. To the best of our
knowledge this represents the first time that quaternary centers have been constructed by
asymmetric conjugate addition of boronic acids to these differing ring sized enones using
a single catalyst.2 Cyclohexenones bearing other β-alkyl substituents, such as ethyl, n-
butyl, and benzyl furnished ketone products (i.e., 138–140) in good yield and excellent ee
as well. In addition to linear alkyl substitution, ketones with branched β-alkyl substituents
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such as iso-propyl (141) and cyclopropyl (142) and cyclohexyl (86) are produced in good
yield and enantioselectivity. Finally, products containing functionalized side-chains, such
as benzyl ether 88, are readily obtained, providing a useful chemical handle for further
transformations.
Table 2.8 Asymmetric synthesis of β,β-disubstituted cyclic ketones a
O
R
Ph
O
R
Ph–B(OH)2 (2 equiv)82 (6 mol %)
Pd(OCOCF3)2 (5 mol %)
ClCH2CH2Cl
60 °C, 12 h
O
Ph
O
Ph
O
O
O
Ph
O
Me
Ph
O
Me
Ph
O
Ph
Ph
O
Ph
BnO
52
84% yield
91% ee
83
85% yield
93% ee
138
96% yield
92% ee
141
86% yield
79% ee
142
68% yield
88% ee
139
95% yield
91% ee
140
74% yield
91% ee
88
90% yield
91% ee
86 
86% yield
85% ee
Et
Ph
n n
Ph
a Conditions: Reactions were performed with phenylboronic acid (0.50 mmol),
cycloalkenone (0.25 mmol), Pd(OCOCF3)2 (5 mol%), and ligand 82 (6 mol%) in
(ClCH2)2 (1 mL) at 60 °C for 12 h.
2.2.4 Substrate Limitations
Despite the many substrates that undergo facile conjugate addition, a number of
substrates proved incompatible with the newly developed methodology (Figure 2.2).
Pyridine 143 presumably coordinates Pd and inhibits the catalyst, yielding no conjugate
addition product.  Allyl enone 144 also did not react, nor did enyneone 145.  β-aromoatic
enones also failed, such as thiopene 146 and chloroarene 147.  Each of these substrates
has functionality that can potentially interact with palladium; such interactions are likely
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detrimental to the catalytic cycle. Curiously, β−aryl enones are problematic for many
conjugate addition systems, including other palladium-catalyzed systems.
Figure 2.2 Unsuccessful enone substrates
O O O O
S
Cl
O
N
143 144 145 146 147
A broader representation of enone substrate scope leads to some observations
about the limitations of the catalyst (Figure 2.3). First, linear substrates are generally less
reactive, and lead to lower ee than their cyclic counterparts (row 1). Second, lactones of
varying ring sizes, and other electron donating substituents that mitigate the
electrophilicity of the carbonyl are less reactive and lead to low ee (row 2). Third, steric
modification of the substrate backbone generally leads to low conversion, if any (row
3–4). Finally, nitrogen-containing substrates are tolerated, though they require electron-
withdrawing carbamate protecting groups (row 4–5). Lactams and imides with less
electron-withdrawing groups are unreactive (row 4–5).
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Figure 2.3 Steric considerations of enone substrates
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82 (6 mol %)
Pd(OCOCF3)2 (5 mol %)
NH4PF6, H2O
ClCH2CH2Cl
60 °C, 12 h
n n
B(OH)2
2 equiv
Some arylboronic acids also proved to be poor nucleophiles. Ortho-substituted
arylboronic acids were generally poor substrates; 2-chlorophenylboronic acid (Figure 2.4,
1 4 8 ) yielded only 2% of its corresponding product in 37% ee, while 2-
methylphenylphenylboronic acid (149) yielded 13% product in 25% ee. Arylboronic
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acids with reactive groups, such as iodide 151 and furan 152, were all not reactive. Other
heterocycles such as indole 153 failed, as did the very electron poor fluoroarene 154,
though steric congestion likely contributes to its poor performance.  Interestingly, styrene
moieties 155 and 156 also did not undergo addition. Additionally, it should be noted that
electron-rich arylboronic acids (e.g., dimethoxyphenylboronic acid 150) undergo rapid
homocoupling and proteodeborylation under the optimized reaction conditions. Thus, it is
difficult to achieve synthetically useful yields of these electron-rich adducts.
Additionally, the enantioselectivity seems to be lower these electron-rich arylboronic
acids. We hypothesize that this may be attributed to the lower energy barrier in
transmetallation for electron-rich arylboronic acids.
Figure 2.4  Unreactive arylboronic acid nucleophiles
O
Ph
O Aryl–B(OH)2 (2 equiv)82 (6 mol %)
Pd(OCOCF3)2 (5 mol %)
ClCH2CH2Cl
60 °C, 12 h
B(OH)2 B(OH)2
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B(OH)2
B(OH)2
Cl Me
F
FF
I
B(OH)2
O B(OH)2
Boc
N
MeO
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B(OH)2
153
no reaction
154
no reaction
155
no reaction
156
no reaction
148
2% yield
37% ee
149
13% yield
22% ee
150
trace product
significant homocoupling
151
no reaction
152
no reaction
MeO
OMe
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2.2.5 Identification of new substrates
The discovery that reaction rates were dramatically increased by the addition of
hexafluorophosphate salts and additional water represented a major opportunity to
expand the substrate scope.21 The additives promoted successful reaction at 40 °C or
lower, and thus substantially facilitated the reaction of substrates with temperature-
sensitive functionalities (such as silyl ethers), or groups that may react with trace
palladium(0) that is formed by off-cycle pathways (such as arylbromides). We next
turned our attention to two other broad substrate classes: 1) enones bearing β-substituents
that are not merely alkyl chains, and 2) arylboronic acids containing nitrogen and other
heteroatoms.
The synthesis of 1,4-dicarbonyl compounds is a nontrivial transformation. This
motif is significantly less common that 1,3-dicarbonyl (made from aldol reactions) or 1,5-
dicarbonyl (often made through Michael additions) stereochemical relationships.
Furthermore, asymmetric synthesis of 1,4-dicarbonyl compounds is exceedingly rare. We
considered that our β-arylation reaction constituted a synthetically useful means of
synthesizing asymmetric 1,4-dicarbonyl compounds. Beginning with β-acyl cyclic
enones (157), we were able to react a variety of arylboronic acids to synthesize
asymmetric 1,4-dicarbonyl compounds (Table 2. 9, 158a–g).
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Table 2.9 β-arylation of cyclic β-acyl enones
NH(COCF3)
O
O
O
O
(S)-t-BuPyOX (6 mol%)
Pd(OCOCF3)2 (5 mol%)
H2O, NH4PF6
ClCH2CH2Cl, 40 °C
85% yield
96% ee
B(OH)2
O
O
Cl
RR
157 158
n n
158a
92% yield
90% ee
O
O
F
158b
66% yield
92% ee
O
O
158c
73% yield
91% ee
O
O
158d
O
O
O
O
O
O
72% yield
93% ee
158e
72% yield
90% ee
158f
57% yield
92% ee
158g
F
a Conditions: Reactions were performed with phenylboronic acid (0.50 mmol), cycloalkenone (0.25
mmol), Pd(OCOCF3)2 (5 mol%), and ligand 4 (6 mol%) in (ClCH2)2 (1 mL) at 60 °C for 12 h.
Next, we strived to demonstrate that the reaction was tolerant of heteroatom substitution
on the arylboronic acid. Having demonstrated that nitrogen atoms bearing electron-withdrawing
groups were competent enone substrates (Figure 2.3, rows 4–5), we proposed that aniline-derived
boronic acids could be reacted when protected with electron-withdrawing functional groups. Cbz-
protected aniline boronic acid 160 reacted with modest yield (Table 2.10), but a promising 76%
ee. Modification to the pivalyl protected boronic acid 161, facilitated higher yields, but minimal
effect on enantioselectivity. Finally, trifluoroacetyl-protected 162 afforded clean conversion to
afford 98% of the conjugate addition adduct in 89% ee. The trifluroacetyl group facilitated the
reaction on a number of aniline-derived arylboronic acids, including methoxyphenyl aniline 163,
trisubstituted aniline 164, and m-anilines 165 and 166. Their successful reactions demonstrate the
broad utility of these substrates.
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Table 2.10 Trifluoroacetamide boronic acid nucleophiles
NH
B(OH)2
O
O
F3C
NH
B(OH)2
O
F3C
NH
B(OH)2
O
F3C NH
O
F3C
B(OH)2
NH
O
F3C
B(OH)2
NH
B(OH)2
O
O NH
B(OH)2
O
Ph
O
O(S)-t-BuPyOX (6 mol%)
Pd(OCOCF3)2 (5 mol%)
arylboronic acid (1.5 equiv)
H2O,  NH4PF6
ClCH2CH2Cl  60 °C
72% yield
78% ee
NHR
45% yield
76% ee
98% yield
89% ee
75% yield
88% ee
93% yield
90% ee
60% yield
92% ee
77% yield
88% ee
15935
160 161 162
166165164163
2.2.6 Catalytic Cycle
Computational and experimental work by Stoltz and Houk suggests that the
reaction is catalyzed by a palladium(II) cationic species (Figure 2.5, 167).22 We propose
that the active catalyst is likely a palladium(II) hydroxide cation, which is known to
undergo rapid transmetallation with arylboronic acids to afford cationic arylpalladium(II)
168. Ligand substitution and substrate coordination, likely through the oxygen of the
enone to make complex 170, leads to insertion of the aryl-palladium bond when
coordination via the enone olefin occurs (169). Insertion affords palladium enolate 171,
formed from its tautomer, carbon–bound palladium enolate 172. Hydrolysis of this latent
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cationic palladium enolate affords the product ketone (35) and regenerates the catalyst
(167).
Figure 2.5 Plausible catalytic cycle
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2.3 Conclusion
In summary, we report the first palladium-catalyzed enantioselective conjugate
addition of arylboronic acids to β-substituted cyclic enones to deliver products containing
an all-carbon quaternary stereocenter.  Critically, 5-, 6-, and 7-membered ring enones
function well in the process, delivering products of uniformly high ee using a single
catalyst.  A wide variety of commercially available arylboronic acids and substituted
enones can be employed in the asymmetric transformation, while exhibiting broad
functional group tolerance.  Furthermore, the reaction displays a remarkable tolerance to
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water and oxygen, and reactions are typically performed open to air in screw-top vials
and without the need for purification or distillation of any commercially obtained
materials.  Finally, the optimal chiral ligand, (S)-t-BuPyOx (82), is expediently prepared,
rendering this process an experimentally simple, practical method for enantioselective
construction of all-carbon quaternary stereocenters.  Continuing investigations of this
method and application of this chemistry in the context of natural product synthesis are
currently underway and will be reported in due course.
2.4 Experimental Procedures
2.4.1 Materials and Methods
Unless otherwise stated, reactions were performed with no extra precautions taken to
exclude air or moisture.  Commercially available reagents were used as received from
Sigma Aldrich unless otherwise stated.  Enone substrates (Table 3) were prepared
according to literature procedure.23  Reaction temperatures were controlled by an
IKAmag temperature modulator.  Thin-layer chromatography (TLC) was performed
using E. Merck silica gel 60 F254 precoated plates (250 nm) and visualized by UV
fluorescence quenching, potassium permanganate, or p-anisaldehyde staining.  Silicycle
SiliaFlash P60 Academic Silica gel (particle size 40-63 nm) was used for flash
chromatography.  Analytical chiral HPLC was performed with an Agilent 1100 Series
HPLC utilizing a Chiralcel OJ column (4.6 mm x 25 cm) obtained from Daicel Chemical
Industries, Ltd with visualization at 254 nm and flow rate of 1 mL/min, unless otherwise
stated.  1H and 13C NMR spectra were recorded on a Varian Inova 500 (500 MHz and 125
MHz, respectively) and a Varian Mercury 300 spectrometer (300 MHz and 75 MHz,
respectively).  Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm)
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(multiplicity, coupling constant (Hz), integration).  Data for 1H NMR spectra are
referenced to the centerline of CDCl3 (δ 7.26)  as the internal standard and are reported in
terms of chemical shift relative to Me4Si (δ  0.00).  Data for 13C NMR spectra are
referenced to the centerline of CDCl3 (δ 77.0) and are reported in terms of chemical shift
relative to Me4Si (δ 0.00).  Infrared spectra were recorded on a Perkin Elmer Paragon
1000 Spectrometer and are reported in frequency of absorption (cm-1).  High resolution
mass spectra (HRMS) were obtained on an Agilent 6200 Series TOF with an Agilent
G1978A Multimode source in electrospray ionization (ESI), atmospheric pressure
chemical ionization (APCI) or mixed (MultiMode ESI/APCI) ionization mode.  Optical
rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell
at 589 nm.
 2.4.2 Synthesis of Compounds
N
N
O
t-Bu
(S)-4-(tert-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole  (82).
The ligand was prepared according to literature procedures.24  All characterization data
matches previously reported data. We have recently reported alternative conditions, see
Chapter 5 for modified synthetic procedures and references.
Representative General Procedure for the Enantioselective 1,4-Addition of
Arylboronic Acids to β-Substituted Cyclic Enones
A screw-top 1 dram vial was charged with a stir bar, Pd(OCOCF3)2 (4.2 mg, 0.0125
mmol, 5 mol%), (S)-t-BuPyOx (3.1 mg, 0.015 mmol, 6 mol%), and PhB(OH)2 (61 mg,
0.50 mmol, 2.0 equiv).  The solids were dissolved in dichloroethane (0.5 mL) and 3-
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methyl-2-cyclohexenone (29 µL, 0.25 mmol) was added.  The walls of the vial were
rinsed with an additional portion of dichloroethane (0.5 mL).  The vial was capped with a
Teflon/silicone septum and stirred at 60 °C in an oil bath for 12 h.  Upon complete
consumption of the starting material (monitored by TLC, 4:1 hexanes/EtOAc, p-
anisaldehyde stain) the reaction was purified directly by column chromatography
(CH2Cl2) to afford a clear colorless oil (47 mg, 99% yield).
General Procedure for the Synthesis of Racemic Products
Racemic products were synthesized in a manner analogous to the general procedure using
bipyridine (2.1 mg, 0.015 mmol, 6 mol%) as an achiral ligand.
Spectroscopic Data for Enantioenriched β,β-Disubstituted Cyclic Ketones
O
(R)-3-phenyl-3-methylcyclohexanone (35)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2) to afford a colorless oil (93% yield).  [α]25D –56.1° (c 1.36, CHCl3, 92% ee). All
characterization data matches previously reported data.25, 26, 27, 28, 29, 30, 31
O
Me
(R)-3-(4-methylphenyl)-3-methylcyclohexanone (127)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2) to afford a colorless oil (99% yield). [α]25D –60.9° (c 1.11, CH2Cl2, 87% ee). All
characterization data matches previously reported data.25, 27, 29
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O
Et
(R)-3-(4-ethylphenyl)-3-methylcyclohexanone (128)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (90% yield). 1H NMR (500
MHz, CDCl3) δ 7.23 (ddd, J = 2.0, 8.5 Hz, 2H), 7.16 (ddd, J = 2.0, 8.5 Hz, 2H), 2.87 (d, J
= 14.0 Hz, 1H), 2.62 (q, J = 7.5, 2H), 2.42 (d, J = 14.0 Hz, 1H), 2.35–2.26 (m, 2H),
2.20–2.15 (m, 1H), 1.93–1.83 (m, 2H), 1.73–1.64 (m, 1H), 1.31 (s, 3H), 1.23 (t, J = 7.5
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 211.6, 144.7, 142.0, 127.9, 125.5, 53.2, 42.5,
40.8, 38.0, 29.8, 28.2, 22.0, 15.4; IR (Neat Film, NaCl): 2957, 2933, 2863, 1710, 1513,
1453, 1416, 1315, 1288, 1226, 1078 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C15H21O [M+H]+: 217.1587, found 217.1592; [α]25D –56.8° (c 1.61, CHCl3, 85% ee).
O
OMe
(R)-3-(4-methoxyphenyl)-3-methylcyclohexanone (129)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 90:10) as colorless oil (58% yield). [α]25D –47.9° (c 1.05,
CHCl3, 69% ee). All characterization data matches previously reported data.26, 27, 28, 29, 30
O
O
(R)-3-(4-benzyloxylphenyl)-3-methylcyclohexanone (130)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (96% yield). 1H NMR (500
MHz, CDCl3) δ  7.43 (ddd, J = 1.5, 2.0, 7.5 Hz, 2H), 7.39 (ddd, J = 1.0, 7.0, 7.5, 2H),
7.33 (tt, J = 1.5, 7.0 Hz, 1H), 7.22 (ddd, J = 2.0, 3.5, 10.0 Hz, 2H), 6.93 (ddd, J = 2.0,
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3.5, 10.0 Hz, 2H), 5.04 (s, 2H), 2.85 (d, J = 14.0 Hz, 1H), 2.42 (d, J = 14.0 Hz, 1H), 2.30
(t, J = 7.0 Hz, 2H), 2.18–2.13 (m, 1H), 1.92–1.83 (m, 2H), 1.71–1.62 (m, 1H), 1.30 (s,
3H), 0.97 (s, 9H), 0.19 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 211.6, 157.0, 139.7,
137.0, 128.6, 127.9, 127.5, 126.7, 114.7, 70.0, 53.3, 42.3, 40.8, 38.0, 30.0, 22.0; IR (Neat
Film, NaCl) 3066, 3027, 2947, 2873, 1710, 1609, 1579, 1510, 1453, 1426, 1379, 1312,
1290, 1246, 1181, 1021 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C20H23O2
[M+H]+: 295.1693, found 295.1673; [α]25D –26.8° (c 4.90, CHCl3, 74% ee).
O
OTBS
(R)-3-(4-tert-butyldimethylsiloxylphenyl)-3-methylcyclohexanone (131)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (52% yield). 1H NMR (500
MHz, CDCl3) δ 7.15 (ddd, J = 2.0, 3.0, 9.0 Hz, 2H), 6.71 (ddd, J = 2.0, 3.0, 9.0 Hz, 2H),
2.83 (d, J = 14.0 Hz, 1H), 2.40 (d, J = 14.0 Hz, 1H), 2.30 (t, J = 7.0 Hz, 2H), 2.16–2.10
(m, 1H), 1.90–1.81 (m, 2H), 1.70–1.61 (m, 1H), 1.29 (s, 3H), 0.97 (s, 9H), 0.19 (s, 6H);
13C NMR (125 MHz, CDCl3) δ 211.7, 153.8, 140.1, 126.5, 119.8, 53.3, 42.3, 40.8, 38.1,
29.9, 25.6, 22.0, 18.1, –4.4; IR (Neat Film, NaCl) 2952, 2933, 2858, 1713, 1607, 1510,
1473, 1458, 1263, 1181 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C19H31O2Si
[M+H]+: 319.2088, found 319.2090; [α]25D –36.4° (c 1.11, CHCl3, 82% ee).
O
O
(R)-3-(4-acetylphenyl)-3-methylcyclohexanone (132)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2/EtOAc = 100:0 to 98:2) to afford colorless oil (99% yield). 1H NMR (500 MHz,
CDCl3) δ  7.92 (ddd, J = 2.0, 9.0 Hz, 2H), 7.42 (ddd, J = 2.0, 9.0 Hz, 2H), 2.90 (d, J =
14.0 Hz, 1H), 2.58 (s, 1H), 2.47 (d, J = 14.0 Hz, 1H), 2.38–2.26 (m, 2H), 2.25–2.20 (m,
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1H), 1.98–1.88 (m, 2H), 1.68–1.59 (m, 1H), 1.34 (s, 3H); 13C NMR (125 MHz, CDCl3) δ
210.8, 197.6, 152.9, 135.2, 128.6, 125.9, 52.8, 43.2, 40.7, 37.8, 29.7, 26.5, 22.0; IR (Neat
Film, NaCl) 2957, 2868, 1708, 1683, 1607, 1569, 1456, 1421, 1404, 1359, 1312, 1268,
1228, 1194 cm-1; HRMS (MultiMode ESI/APCI) m/z  calc’d for C15H19O [M+H]+:
231.1379, found 231.1380; [α]25D  –58.9° (c 1.39, CHCl3, 96% ee).
O
Cl
(R)-3-(4-chlorophenyl)-3-methylcyclohexanone (133)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a white solid (94% yield). [α]25D –69.4° (c
0.56, CHCl3, 95%ee).  All characterization data matches previously reported data.26
O
F
(R)-3-(4-fluorophenyl)-3-methylcyclohexanone (134)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (84% yield). [α]25D –59.5° (c
1.00, CHCl3, 92%ee). All characterization data matches previously reported data.25, 26
O
CF3
(R)-3-(4-trifluoromethylphenyl)-3-methylcyclohexanone (89) Synthesized according
to the general procedure and purified by flash chromatography (hexanes/EtOAc = 100:0
to 95:5) to afford a colorless oil (99% yield). [α]25D –58.5° (c 0.92, CHCl3, 96% ee). All
characterization data matches previously reported data.27, 28, 29
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O
Me
(R)-3-methyl-3-(m-tolyl)cyclohexanone (135)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2) to afford a colorless oil (99% yield). [α]25D –59.8° (c 2.95, CH2Cl2, 91% ee). All
characterization data matches previously reported data.25, 27, 29
O
Cl
(R)-3-(3-chlorophenyl)-3-methylcyclohexanone (136)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (55% yield). [α]25D –56.7° (c
1.48, CHCl3, 96% ee). All characterization data matches previously reported data.25, 26
O
Br
(R)-3-(3-bromophenyl)-3-methylcyclohexanone (90)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2) to afford a colorless oil (44% yield). [α]25D –56.7° (c 0.68, CHCl3, 85% ee). All
characterization data matches previously reported data.29
O O
OMe
(R)-3-(3-methoxycarbonylphenyl)-3-methylcyclohexanone (88)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2/EtOAc 100:0 to 98:2) to afford a white solid (91% yield).  1H NMR (500 MHz,
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CDCl3) δ 8.03 (dd, J = 1.5, 2.0 Hz, 1H), 7.88 (dd, J = 1.5, 9.0 Hz, 1H), 7.51 (dd, J = 2.0,
9.0 Hz, 1H), 7.39 (dd, J = 9.0 Hz, 1H), 3.91 (s, 3H), 2.88 (d, J = 14.0 Hz, 1H), 2.47 (d, J
= 14.0 Hz, 1H), 2.37–2.28 (m, 2H), 2.24-2.19 (m, 1H), 1.98–1.86 (m, 2H), 1.73–1.65 (m,
1H), 1.33 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 210.9, 167.1, 147.9, 130.4, 130.2,
128.6, 127.5, 126.7, 53.0, 52.1, 42.8, 40.7, 37.7, 29.3, 22.0; IR (Neat Film, NaCl) 2952,
2878, 1720, 1604, 1582, 1438, 1350, 1310, 1273, 1243, 1209, 1194, 1120, 1085 cm-1;
HRMS (MultiMode ESI/APCI) m/z calc’d for C15H19O3 [M+H]+: 247.1329, found
247.1334; [α]25D –58.9° (c 1.39, CHCl3, 95% ee).
O
NO2
(R)-3-(3-nitrophenyl)-3-methylcyclohexanone (137)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2) to afford a colorless oil (40% yield).  1H NMR (500 MHz, CDCl3) δ 8.22 (t, J =
2.0 Hz, 1H), 8.08 (ddd, J = 1.0, 2.0, 8.0 Hz, 1H), 7.66 (ddd, J = 1.0, 2.0, 8.0 Hz, 1H),
7.50 (t, J = 8.0 Hz, 1H), 2.88 (d, J = 14.0 Hz, 1H), 2.53 (ddd, J = 1.0, 1.5, 14.0 Hz, 1H),
2.41–2.31 (m, 2H), 2.26–2.20 (m, 1H), 2.03–1.90 (m, 2H), 1.74–1.66 (m, 1H), 1.37 (s,
3H); 13C NMR (125 MHz, CDCl3) δ 210.1, 149.7, 148.6, 131.9, 129.5, 121.4, 120.7, 52.8,
43.1, 40.6, 37.6, 29.4, 22.0; IR (Neat Film, NaCl) 2957, 2873, 1713, 1525, 1480, 1453,
1426, 1347, 1298, 1226, 1107, 1075 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C13H15O3N [M]: 233.1052, found 233.1055; [α]25D –61.5° (c 0.96, CHCl3, 92% ee)
O
F
(R)-3-(2-fluorophenyl)-3-methylcyclohexanone (134a)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (32% yield). 1H NMR (500
MHz, CDCl3) d 7.25–7.19 (m, 2H), 7.07 (ddd, J = 1.5, 2.0, 7.5 Hz, 2H), 7.39 (ddd, J =
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1.0, 7.0, 7.5, 2H), 7.33 (tt, J = 1.5, 7.0 Hz, 1H), 7.22 (ddd, J = 1.5, 7.5 Hz, 1H), 7.02
(ddd, J = 1.5, 8.0, 13.0 Hz, 1H), 2.94 (d, J = 14.5 Hz, 1H), 2.44 (d, J = 14.5 Hz, 1H),
2.48–2.44 (m, 1H), 2.37–2.28 (m, 2H), 1.96–1.87 (m, 2H), 1.67-1.60 (m, 1H), 1.41 (s,
3H), 13C NMR (125 MHz, CDCl3) d 211.3, 128.3, 128.0, 127.9, 124.1, 116.7, 53.2, 42.4,
40.9, 35.7, 27.1; IR (Neat Film, NaCl) 2957, 2933, 2873, 1710, 1611, 1577, 1488, 1443,
1315, 1290, 1214, 1117, 1083 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C13H16OF [M+H]+: 207.1180, found 207.1188; [a]25D –41.0° (c 0.64, CHCl3, 77% ee).
O
(R)-3-phenyl-3-methylcyclopentanone (52)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (84% yield).  [α]25D +21.3° (c
1.51, CHCl3, 91% ee). All characterization data matches previously reported data.27, 28, 29
O
(R)-3-phenyl-3-methylcycloheptanone (83)
This product was synthesized according to the general procedure and purified by flash
chromatography (hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (85% yield).
[α]25D –75.1° (c 1.34, CHCl3, 93% ee). All characterization data matches previously
reported data.25, 27, 29
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O
Et
(R)-3-phenyl-3-ethylcyclohexanone (138)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (96% yield). [α]25D –74.5° (c
3.39, CHCl3, 92% ee). All characterization data matches previously reported data.25, 27, 29, 30
O
(R)-3-phenyl-3-n-butylcyclohexanone (139)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford colorless oil (95% yield). [α]25D –56.7° (c
1.48, CHCl3. 91% ee).  All characterization data matches previously reported data.30
 
O
Ph
(R)-3-benzyl-3-phenylcyclohexanone (140)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (74% yield). [α]25D +01.0°(c
3.83, CHCl3, 91% ee). All characterization data matches previously reported data.31
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O
(R)-3-phenyl-3-iso-propylcyclohexanone (141)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (86% yield). [α]25D –79.4° (c
3.24, CHCl3, 79% ee). All characterization data matches previously reported data.31
O
(R)-3-phenyl-3-methylcyclohexanone (142)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2) to afford a colorless oil (68% yield). 1H NMR (500 MHz, CDCl3) δ 7.30–7.28
(m, 4H), 7.21–7.17 (m, 1H), 2.90 (dt, J = 2.0, 14.5 Hz, 1H), 2.48 (d, J = 14.5 Hz, 1H),
2.31–2.19 (m, 3H), 1.94–1.86 (m, 2H), 1.60–1.51 (m, 1H), 0.99 (tt, J = 5.5, 8.5, 1H),
0.45–0.39 (m, 1H), 0.35–0.29 (m, 1H), 0.24–0.19 (m, 1H), 0.17–0.12 (m, 1H); 13C NMR
(125 MHz, CDCl3) δ 210.8, 143.2, 127.6, 126.5, 125.7, 50.0, 44.9, 40.3, 34.1, 23.1, 20.8,
1.1, 0.0; IR (Neat Film, NaCl) 3081, 3057, 3007, 2947, 2873, 1708, 1498, 1443, 1421,
1315, 1285, 1226, 1046, 1023 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C15H19O [M+H]+: 215.1430, found 215.1425; [α]25D –83.1° (c 1.39, CHCl3, 88% ee).
O
(R)-3-phenyl-3-cyclohexylcyclohexanone (86)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (86% yield).  1H NMR (500
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MHz, CDCl3) δ 7.29 (ddd, J = 2.0, 7.0, 8.0 Hz, 2H), 7.23 (ddd, J = 1.0, 2.0, 8.0 Hz, 2H),
7.18 (tt, J = 1.0, 7.0 Hz, 1H), 2.97 (dd, J = 2.0, 15.0 Hz, 1H), 2.46 (d, J = 15.0 Hz, 1H),
2.26–2.17 (m, 3H), 2.07 (ddd, J = 3.5, 12.5, 13.5 Hz, 1H), 1.94–1.88 (m, 1H), 1.84–1.75
(m, 2H), 1.68–1.56 (m, 2H), 1.52–1.45 (m, 1H), 1.44–1.38 (m, 1H), 1.37–1.31 (m, 1H),
1.26–1.17 (m, 1H), 1.11–0.95 (m, 2H), 0.88–0.75 (m, 2H); 13C NMR (125 MHz, CDCl3)
δ 212.0, 143.8, 128.1, 127.4, 125.9, 49.5, 49.0, 47.2, 41.0, 33.6, 27.5, 27.4, 26.9, 26.5,
21.4; IR (Neat Film, NaCl) 2928, 2853, 1713, 1495, 1443, 1315, 1285, 1228 cm-1; HRMS
(MultiMode ESI/APCI) m/z calc’d for C18H24O [M+H]+: 257.1900, found 257.1888;
[α]25D –52.4° (c 3.87, CHCl3, 85% ee).
O
O
(S)-3-(3-(benzyloxy)propyl)-3-phenylcyclohexanone (88)
Synthesized according to the general procedure and purified by flash chromatography
(hexanes/EtOAc = 100:0 to 95:5) to afford a colorless oil (65% yield).  1H NMR (500
MHz, CDCl3) δ 7.33–7.28 (m, 4H), 7.27–7.24 (m, 5H), 7.18 (tt, J = 1.5, 7.0 Hz, 1H), 4.37
(s, 2H), 3.30 (dt, J = 1.5, 6.5 Hz, 2H), 2.93 (d, J = 14.5 Hz, 1H), 2.43 (d, J = 14.5 Hz,
1H), 2.33–2.26 (m, 2H), 2.22–2.16 (m, 1H), 1.98 (ddd, J = 3.0, 10.0, 13.5 Hz, 1H),
1.86–1.77 (m, 2H), 1.68 (ddd, J = 4.5, 12.0 Hz, 1H), 1.61–1.53 (m, 1H), 1.43–1.32 (m,
1H), 1.23–1.14 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 211.2, 144.8, 138.4, 128.5,
128.3, 127.6, 127.5, 126.4, 126.2, 72.7, 70.4, 51.0, 45.9, 41.0, 39.7, 36.6, 23.9, 21.4; IR
(Neat Film, NaCl) 3057, 3027, 2947, 2858, 1710, 1602, 1495, 1451, 1359, 1312, 1280,
1228, 1100, 1075, 1026 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C22H26O2
[M+H]+: 323.2006, found 323.1993; [α]25D –42.9° (c 4.25, CHCl3, 91% ee).
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Representative procedure for the synthesis of N-trifluoroacetamide boronic acids
NH2 NH
O
F3C1. DMAP, NEt3, (CF3CO)2O, CH2Cl2, 0 °C
2. n-BuLi, THF, –78 °C
3. B(Oi-Pr)3
4. HCl (aq)
Br B(OH)2
N-(3-bromophenyl)-2,2,2-trifluoroacetamide.
In a 100 ml round bottom flask were added consecutively 3-bromoaniline (1.7 g, 10.0
mmol, 1 eq), DMAP (0.12 g, 1.0 mmol, 0.1 eq), 20 mL of CH2Cl2 and Et3N (1.7 ml, 12.0
mmol, 1.2 eq). The solution was cooled to 0 °C and trifluoroacetic anhydride (2.1 ml,
15.0 mmol, 1.5 eq) was added dropwise. The obtained mixture was stirred at room
temperature until all the starting material was consumed (TLC Hexane-EtOAc 4:1) and
then it was extracted with CH2Cl2 (3 x 20 mL) and washed with brine (2 x 20 mL). The
combined organic phases were dried with MgSO4 and the solvent was evaporated to give
an off-white solid that was purified via silica gel column chromatography (2.35 g, 88 %
yield). 1H NMR (300 MHz, CDCl3) δ 7.84 (t, J = 2.0 Hz, 1H), 7.80 (bs, 1H), 7.51 (dd, J =
8.1, 1.2 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.30-7.24 (m, 1H); 13C NMR (125 MHz,
CDCl3) δ 155.1 (q, JC-F = 37.7 Hz), 136.3, 130.7, 129.7, 123.8, 123.0, 119.3, 115.6 (q, JC-F
= 288.5 Hz); 19F NMR (282 MHz, CDCl3) δ −75.72, −75.73; FTIR (Neat  Film,  NaCl)
3288, 1709, 1593, 1538, 1470, 1429, 1338, 1263, 1251, 1171, 1153, 1069, 997, 975, 925,
873, 865, 785, 739 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C8H5BrF3NO [M-
H]-: 265.9434, found: 295.9426.
3-(2,2,2-trifluroacetamide)-phenylboronic acid.
A flame dried one neck round bottom flask was charged with the required
trifluoroacetanilide (1.0 g, 3.7 mmol, 1 eq). The flask was sealed, evacuated and
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backfilled with argon. THF (20 ml) was added via syringe and the obtained mixture was
cooled to -78 °C. nBuLi (2.3 M solution in hexane, 3.6 ml, 8.2 mmol, 2.2 eq) was added
dropwise and the obtained mixture was stirred for 2 h at this temperature.
Triisopropylborate (2.7 ml, 11.7 mmol, 3 eq) was then added via syringe and the mixture
was stirred for 10 minutes at -78 °C and for one hour at room temperature. A solution of
HCl (2 M in water, 10 ml) was added and the biphasic mixture was vigorously stirred for
another hour and then extracted with EtOAc (3 x 30 mL). The combined organic phases
where washed with brine (2 x 20 ml) and dried over MgSO4. Upon evaporation of the
solvent under reduced pressure an off-white solid was obtained. It was suspended in
hexane and stirred until a fine powder was formed. It was filtered and dried in high
vacuum for 30 minutes (0.58 g, 67 % yield). If the obtained product is not perfectly clean
from NMR analysis a 10:1 mixture of hexane-Et2O or hexane-CH2Cl2 can be used instead
of hexanes to suspend the compound. In some cases the desired aryl boronic acid is
obtained as an oil and does not solidify. This is usually due to the presence of a large
amount of byproducts. In these cases it is necessary to add ether, water and a 1 M
solution of NaOH (4 to 5 equivalents are normally enough) to the crude mixture. After
extraction, the isolated water phase can be acidified with a 1 M aqueous HCl solution and
extracted with EtOAc. It is important to wash this organic phase with water to eliminate
possible residual salt. Upon evaporation of the solvent and trituration with pentane or
hexane the desired product should be obtained as an off-white solid in 66% yield. 1H
NMR (300 MHz, acetone-d6) δ 8.11 (bs, 1H), 7.81 (m, 1H), 7.74 (dt, J = 7.4, 1.0 Hz 1H),
7.40 (t, J = 7.7 Hz, 1H), 7.28 (s, 1H); (The obtained 13C NMR is complex due to the
presence of two rotamers in solution) 13C NMR (125 MHz, CDCl3) δ 154.8 (q, J = 36.9
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Hz), 154.7 (q, J = 36.8 Hz), 135.8, 135.7, 131.5, 128.2, 126.7, 126.6, 123.0, 122.9, 116.2
(q, J = 288.1 Hz); 19F NMR (282 MHz, CDCl3) δ − 76.22, −76.25;   FTIR (Neat Film,
, NaCl): 3305, 1701, 1585, 1554, 1437, 1334, 1264, 1182, 1031, 780 cm-1; HRMS
(MultiMode ESI/APCI) m/z calc’d for C8H7BrF3NO [M-H]-: 231.0435, found: 231.0433.
HN
O
CF3
B(OH)2
4-(2,2,2-trifluroacetamide)-phenylboronic acid   
Obtained using the representative procedure in 65% yield. 1H NMR (300 MHz, acetone-
d6) δ 10.22 (bs, 1H), 7.91 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 8.4 Hz, 1H), 7.20 (s, 1H); 13C
NMR (125 MHz, acetone-d6) d 155.6 (q, JC-F = 37.2 Hz), 136.3, 139.2, 135.9, 120.5,
119.2 (q, JC-F = 288.3 Hz); 19F NMR (282 MHz, acetone-d6) δ  –76.21,  –76.24; FTIR
(Neat Film, NaCl) 3297, 1714, 1595, 1539, 1408, 1275, 1244, 1183, 1113, 1008, 832,
798 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C8H7BrF3NO [M-H]-: 231.0435,
found: 231.0443.
HN
O
CF3
O
B(OH)2
3-(2,2,2-trifluroacetamide)-4-methylphenylboronic acid
Obtained as an off-white solid in 35 % yield following the general procedure and using
the required trifluoroacetanilide (1.4 g, 4.9 mmol, 1 eq), nBuLi (4.4 ml of a 2.4M
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solution, 10.7 mmol, 2.2 eq) and triisopropylborate (3.4 mL, 14.6 mmol, 3 eq). 1H NMR
(300 MHz, acetone-d6) δ 9.34 (s, 1H), 8.05 (dd, J = 3.0, 6.9 Hz, 1H), 7.58 (s 1H), 7.54
(dd, J = 7.9, 1.0 Hz, 1H) 7.29 (s, 1H), 3.93 (s, 3H); 13C NMR (125 MHz, acetone-d6) δ
154.3 (q, JC-F = 150 Hz), 149.3, 126.8, 126.6, 120.5, 116.1, 115.8 (q, JC-F = 288 Hz),
112.5, 55.4; IR (Neat Film, NaCl): 3298, 1708, 1591, 1537, 1503, 1465, 1404, 1342,
1294, 1273, 1224, 1161, 1123, 1015; HRMS (MultiMode ESI/APCI) m/z calc’d for
C9H8BO4NF3 [M-H]-: 261.0590, found: 261.0497.
HN
O
CF3
B(OH)2
4-(2,2,2-trifluroacetamide)-2,6-dimethyl-phenylboronic acid
Obtained as an off-white solid in 66 % yield following the general procedure and using
the required trifluoroacetanilide (1.0 g, 3.4 mmol, 1 eq), nBuLi (3.2 ml of a 2.3M
solution, 7.44 mmol, 2.2 eq) and triisopropylborate (2.3 mL, 10.1 mmol, 3 eq). 1H NMR
(300 MHz, acetone-d6) δ 7.62 (s, 2H), 7.20 (s, 1H), 2.25 (s, 6H); 13C NMR (125 MHz,
acetone-d6) δ 155.1 (q, J = 36.5 Hz), 134.2, 134.2, 134.1, 133.9, 116.5 (q, J = 286.0 Hz),
17.1; 19F NMR (282 MHz, acetone-d6) δ − 75.97, −75.99;  FTIR (Neat Film, NaCl): 3233,
1705, 1602, 1533, 1340, 1219, 1192, 1160 cm-1; HRMS (MultiMode ESI/APCI) m/z
calc’d for C10H11NBrF3O [M-H]-: 259.0748, found 259.0749.
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HN
O
CF3
B(OH)2
3-(2,2,2-trifluroacetamide)-phenylboronic acid
Obtained as an off-white solid in 66 % yield following the general procedure and using
the proper trifluoroacetanilide (1.0 g, 3.7 mmol, 1 eq), nBuLi (3.6 ml of a 2.3M solution,
8.2 mmol, 2.2 eq) and triisopropylborate (2.6 mL, 11.2 mmol, 3 eq). 1H NMR (300 MHz,
acetone-d6) δ 8.11 (bs, 1H), 7.81 (m, 1H), 7.74 (dt, J = 7.4, 1.0 Hz 1H), 7.40 (t, J = 7.7
Hz, 1H), 7.28 (s, 1H); (The obtained 13C NMR is complex due to the presence of two
rotamers in solution) 13C NMR (125 MHz, acetone-d6) δ 154.8 (q, J = 36.9 Hz), 154.7 (q,
J = 36.8 Hz), 135.8, 135.7, 131.5, 128.2, 126.7, 126.6, 123.0, 122.9, 116.2 (q, J = 288.1
Hz); 19F NMR (282 MHz, acetone-d6) δ − 76.22, −76.25;  FTIR (Neat Film, NaCl): 3305,
1701, 1585, 1554, 1437, 1334, 1264, 1182, 1031, 780 cm-1; HRMS (MultiMode
ESI/APCI) m/z calc’d for C8H7BrF3NO [M-H]-: 231.0435, found: 231.0433.
HN
O
CF3
B(OH)2
3-(2,2,2-trifluroacetamide)-4-methylphenylboronic acid
Obtained as an off-white solid in 66 % yield following the general procedure and using
the required trifluoroacetanilide (2.0 g, 3.7 mmol, 1 eq), nBuLi (3.6 ml of a 2.3M
solution, 8.2 mmol, 2.2 eq) and triisopropylborate (2.6 mL, 11.2 mmol, 3 eq). 1H NMR
(300 MHz, acetone-d6) δ 7.82 (s, 1H), 7.75 (dd, J = 6.5, 10 Hz, 1H), 7.32 (d, J = 7.5 Hz,
1H) 7.24 (s, 1H);  13C NMR (125 MHz, acetone-d6) δ 155.4 (q, J = 37.5 Hz), 136.2,
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133.5, 132.9, 132.1, 130.1, 116.4 (q, J = 288.0 Hz); FTIR (Neat  Film, NaCl) 3270, 1708,
1617, 1533, 1406, 1351, 1259, 1180, 1162, 1092, 1036, 898, 825 cm-1; HRMS
(MultiMode ESI/APCI) m/z calc’d for C9H8BF3NO3 [M-H]-: 245.0477, found 245.0591.
Representative General Procedure for the Enantioselective 1,4-Addition of
Arylboronic Acids to β-Substituted Cyclic Enones.
O
N
H
O
CF3
(R)-3-(4-(2,2,2-trifluoroacetamide)phenyl)-3-methylcyclohexanone (162a)
A screw-top 5 ml vial was charged with a stir bar, Pd(OCOF3)2 (4.5 mg, 0.014 mmol,
0.05 eq), (S)-t-BuPyOx (3.3 mg, 0.016 mmol, 0.06 eq), boronic acid (95 mg, 0.41 mmol,
1.5 eq) and NH4PF6 (13 mg, 0.08 mmol, 0.3 eq). Dichloroethane (1 mL) was added and
the mixture was stirred until a homogeneous suspension was formed (around 1 minute).
3-methyl-2-cyclohexenone (30 mg, 0.27 mmol, 1 eq) was then added dissolved in 1.7 mL
of dichloroethane (yields are improved with the addition of enone as a solution). Water
(25 µl, 1.3 mmol, 5 eq) was added, and the vial was sealed and the reaction was stirred at
60 °C for 3h. After this time almost all the solid in the vial was consumed and from TLC
(Hexane- EtOAc 4:1) all the starting enone disappeared. The mixture was cooled to
ambient temperature and it was charged directly into a silica gel column for purification.
The desired product was isolated as white powder (80 mg, 98 % yield, 89 % ee SFC
column 6 (IC) 5 ml/min 4 % MeOH). 1H NMR (300 MHz, CDCl3) δ 7.91 (bs, 1H), 7.53
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(m, 2H), 7.36 (m, 2H), 2.85 (d, J = 14.2 Hz, 1H), 2.45 (d, J = 14.0 Hz, 1H), 2.32 (m, 2H),
2.25 - 2.12 (m, 1H), 1.98 - 1.82 (m, 2H), 1.71 - 1.57 (m , 1H), 1.32 (s, 3H); 13C NMR
(125 MHz, CDCl3) δ 211.8, 154.9 (q, J = 37.4 Hz), 145.2, 133.5, 126.7, 120.6, 115.7 (q, J
= 289.0 Hz), 52.9, 42.9, 40.7, 37.9, 30.4, 22.0; FTIR (Neat Film,  NaCl) 3292, 2958,
1706, 1609, 1545, 1517, 1412, 1285, 1252, 1193, 1155, 901, 835 cm-1; HRMS
(MultiMode ESI/APCI) m/z calc’d for C15H16F3NO [M-H]-: 298.106, found 289.1049;
[α]D25 – 47.5° (c 2.10, CHCl3, 89% ee).
O
N
H
O
O Ph
(R)-3-(4-(N-carbobenzyloxy)phenyl)-3-methylcyclohexanone (160)
Following the general procedure the desired product was obtained as a clear oil (35 mg,
45 % yield, 76 % ee, SFC column 6 (IC) 5 ml/min 15 % MeOH). 1H NMR (300 MHz,
CDCl3) δ 7.44-7.30 (m, 6H), 7.25-7.22 (m, 3H), 6.63 (bs, 1H), 5.20 (s, 2H), 2.84 (d, J =
14.2 Hz, 1H), 2.42 (d, J = 14.1 Hz, 1H), 2.31 (m, 2H), 2.21–2.10 (m, 1H), 1.95–1.80 (m,
2H), 1.73–1.60 (m, 1H), 1.30 (s, 3H); 13C NMR (125 MHz, CDCl3)
δ 211.6, 153.5, 142.7, 136.1, 135.9, 128.7, 128.5, 128.4, 126.5, 118.9, 67.2, 53.3, 42.6, 40
.9, 38.0, 30.1, 22.1; FTIR (Neat  Film, NaCl) 3306, 2953, 1705, 1597, 1534, 1454, 1409,
1323, 1220, 1052 cm-1;  HRMS (MultiMode ESI/APCI) m/z calc’d for C21H24NO3
[M+H]+: 338.1756, found 338.1760; [α]D25 – 26.8° (c 1.40, CHCl3, 76% ee).
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N
H
O
(R)-3-(4-(N-pyvaloyl)phenyl)-3-methylcyclohexanone (161)
 Following the general procedure the desired product was obtained as a white solid (56
mg, 72% yield, 76% ee SFC column 5 (OB-H) 5 ml/min 10 % MeOH). 1H NMR (300
MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 2H), 7.33-7.24 (m, 3H), 2.85 (d, J = 14.2 Hz, 1H),
2.42 (d, J = 14.2 Hz, 1H), 2.31 (m, 2H), 2.21–2.11 (m, 1H), 1.95–1.80 (m, 2H),
1.72–1.58 (m, 1H), 1.30 (s, 9H); 13C NMR (125 MHz, CDCl3)
δ 211.6, 176.7, 143.4, 136.2, 126.3, 120.1, 53.2, 42.7, 40.9, 39.7, 38.1, 30.1, 27.8, 22.1; F
TIR(Neat  Film ,NaCl) 3379, 2961, 1685, 1594, 1518, 1400, 1318, 1301, 1255, 1189 cm-
1;  HRMS (MultiMode ESI/APCI) m/z calc’d for C18H26NO2 [M+H]+: 2881964, found
288.1969; [α]D25 – 52.5° (c 1.01, CHCl3, 76% ee).
O
N
H
O
CF3
O
(R)-3-(4-(2,2,2-trifluoroacetamide)-3-methoxyphenyl)-3-methylcyclohexanone
(163)
Following the general procedure the desired product was obtained as white solid (67 mg,
75 % yield). 1H NMR (300 MHz, CDCl3) δ 8.50 (bs, 1H), 8.24 (d, J = 8.5 Hz, 2H), 6.96
(dd, J = 8.5, 2.1 Hz, 1H), 6.87 (d, J = 2.1 Hz, 1H), 3.93 (s, 3H), 2.87 (d, J = 14.1 Hz, 1H),
2.45 (d, J = 14.2 Hz, 1H), 2.32 (m, 2H), 2.24-2.14 (m, 1H), 2.0-1.8 (m, 2H), 1.68-2.5 (m,
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1H), 1.32 (s, 3H); FTIR (neat, NaCl): 3362, 2960, 2871, 1706, 1665, 1594, 1515, 1479,
1402, 1321, 1228, 1193, 1164 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C16H17F3NO3 [M-OH]: 328.1161, found: 328.1167; [α]D25 – 61.3° (c 1.25, CHCl3, 88%
ee).
O
N
H
O
CF3
(R)-3-(4-(2,2,2-trifluoroacetamide)-2,6-dimethylphenyl)-3-methylcyclohexanone
(164)
Following the general procedure the desired product was obtained in 93 % yield as a
white solid (90 % ee, SFC column 1 (AD-H) 5ml/min 5 % MeOH). 1H NMR (300 MHz,
CDCl3) δ 7.41 (bs, 1H), 7.05 (s, 2H), 2.84 (d, J = 14.2 Hz, 1H), 2.42 (d, J = 14.1 Hz, 1H),
2.32 (m, 2H), 2.24 (s, 6H), 2.21–2.10 (m, 1H), 1.96–1.80 (m, 2H), 1.76–1.60 (m, 1H),
1.30 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 211.8, 156.2 (q, J = 36.4 Hz), 147.6, 135.1,
128.9, 125.7, 118.2 (q, J = 279.9 Hz), 52.8, 42.4, 40.6, 37.6, 29.4, 21.9, 18.2; FTIR (Neat
 Film, NaCl) 2958, 2863, 1715, 1651, 1583, 1568, 1538, 1479, 1441, 1359, 1314, 1228,
1198, 1157, 1101 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C17H20F3NO2 [M-
H]-: 326.1373, found 326.1370; [α]D25 – 54.3° (c 2.10, CHCl3, 90% ee).
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(R)-3-(3-(2,2,2-trifluoroacetamide)phenyl)-3-methylcyclohexanone (165)
Following the general procedure the desired product was obtained in 60 % yield as
transparent oil (92 % ee, SFC column 1 (AD-H) 5ml/min 5 % MeOH). 1H NMR (300
MHz, CDCl3) δ 7.91 (bs, 1H), 7.55–7.45 (m, 2H), 7.36 (t, J = 7.9 Hz,, 1H), 7.20 (m , 1H),
2.87 (d, J = 14.2 Hz, 1H), 2.46 (d, J = 14.2 Hz, 1H), 2.32 (m, 2H), 2.27–2.17 (m, 1H),
1.98–1.82 (m, 2H), 1.71–1.57 (m , 1H), 1.33 (s, 3H); 1 3C NMR (125 MHz, CDCl3)
δ 211.5, 154.9 (q, J = 37.0 Hz), 148.9, 135.5, 129.5, 123.6, 118.5, 118.0, 115.6 (q, J =
289.2 Hz), 52.9, 43.0, 40.7, 37.8, 30.0, 22.0; FTIR (Neat  Film, NaCl) 3298, 3157, 3111,
2959, 2876, 1713, 1616, 1595, 1563, 1493, 1442, 1421, 1291, 1239, 1201, 1156.  cm-1;
HRMS (MultiMode ESI/APCI) m/z calc’d for C15H16F3NO2 [M-H]-: 298.1055, found:
298.1050; [α]D25 – 28.9° (c 2.10, CHCl3, 92 % ee).
O
H
N
O
CF3
(R)-3-(3-(2,2,2-trifluoroacetamide)-4-methylpheny)-3-methylcyclohexanone (166).
Following the general procedure the desired product was obtained in 77 % yield as a
white solid (91% ee, OD-H column, 5 mL/min, 5% MeOH). 1H NMR (300 MHz,
CDCl3) δ 7.94 (bs, 1H), 7.66 (s, 1H), 7.16 (d, J = 8.1 Hz, 1H), 7.11 (dd, J = 8.1, 1.9 Hz,
1H), 2.85 (d, J = 14.1 Hz, 1H), 2.44 (d, J = 14.1 Hz, 1H), 2.32 (m, 2H), 2.26 (s, 3H),
2.24–2.07 (m, 1H), 1.97–1.80 (m, 2H), 1.78–1.60 (m, 1H), 1.31 (s, 3H). 13C NMR (125
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MHz, CDCl3) δ 211.3, 156.2 (q, J = 36.4 Hz), 146.6, 132.9, 131.4, 130.9, 128.3, 124.4,
118.1 (q, J = 279.8 Hz), 53.0, 42.7, 40.7, 37.7, 29.6, 22.0, 16.9; FTIR (Neat  Film, NaCl)
3277, 3060, 2959, 2873, 1711, 1617, 1577, 1540, 1507, 1452, 1420, 1316, 1281, 1257,
1200, 1162 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C16H18F3NO2 [M+H]+:
314.1362, found: 314.1370. [α]D25 – 45.6° (c 5.3, CHCl3, 88% ee).
O
Cl
O
(R)-3-(4-chloropheny)-3-acetylcyclohexanone (158)
Following the general procedure and using 3-acetylcyclohexenone (34 mg, 0.25 mmol, 1
eq), 4-chlorophenyl boronic acid (78 mg, 0.5 mmol, 2 eq), water (25 µL, 1.25 mmol, 5
eq), tBuPyOX (3 mg, 0,015 mmol, 0.06 eq), Pd(OCOF3)2 (4.1 mg, 0.012 mmol, 0.05 eq),
NH4PF6 (12 mg, 0.075 mmol, 0.3 eq) and ClCH2CH2Cl (2 mL) the desired product were
isolated as a white solid (53 mg, 85 % yield, 96 % ee, SFC column 3 (OJ-H) 5 ml/min 15
% MeOH). 1H NMR (300 MHz, CDCl3) δ 7.35 (m, 2H), 7.18 (m, 2H), 2.85 (dt, J = 1.4,
14.8 Hz, 1H), 2.63 (dt, J =1.1, 14.8 Hz, 1H), 2.48–2.20 (m, 4H), 1.87 (s, 3H), 1.80–1.69
(m, 2H); 13C NMR (125 MHz, CDCl3) 208.3, 208.1, 139.3, 133.8, 129.5, 127.8, 59.6,
48.6, 40.3, 31.5, 25.3, 21.1; FTIR (Neat  Film , NaCl) 3397, 2951, 2875, 1708, 1490,
1455, 1420, 1402, 1356, 1319, 1235, 1183, 1140, 1097, 1012, 970, 829, 717 cm-1; HRMS
(MultiMode ESI/APCI) m/z calc’d for C14H15ClO2 [M+H]+: 251.0833, found: 251.0829;
[α]D25 – 6.74° (c 3.2, CHCl3, 96 % ee).
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Table 2.11 Chiral assays
entry product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
HPLC
conditions
O
1
O
O
O
O
O
O
Me
OMe
OBn
Cl
F
2
4
5
6
7
8
9
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
15.3 19.6 92
O
Et
Ac
3
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
15.2 17.1 87
Chiralcel
OJ-H
0.5% IPA/Hexanes
isocratic 1 mL/min
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
25.9 34.4 85
29.5 37.1 69
Chiralpak
AD-H
5% IPA/Hexanes
isocratic 1 mL/min
37.9 35.3 74
Chiralpak
AD-H
5% IPA/Hexanes
isocratic 1 mL/min
30.4 29.5 96
Chiralpak
AD-H
1% IPA/Hexanes
isocratic 1 mL/min
12.8 11.7 95
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
13.9 16.9 92
O
OTBS
Chiralcel
OJ-H
0.5% IPA/Hexanes
isocratic 1 mL/min
16.6 24.9 82
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entry product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
HPLC
conditions
10
11
12
13
14
15
16
17
O
O
CF3
O
Me
O
Cl
O
Br
O
CO2Me
O
NO2
O
Chiralcel
OJ-H
0.5% IPA/Hexanes
isocratic 1 mL/min
35.0 41.1 96
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
11.0 13.0 91
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
17.2 20.4 96
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
14.7 16.9 85
Chiralpak
AD-H
5% IPA/Hexanes
Isocratic 1mL/min
11.1 10.4 95
Chiralpak
AD-H
1% IPA/Hexanes
Isocratic 1mL/min
29.0 30.6 92
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
9.3 10.9 77
Chiralpak
AD-H
1% IPA/Hexanes
Isocratic 1mL/min
12.6 10.2 91
F
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entry product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
HPLC
conditions
18
O
Et
O
O
O
19
20
21
22
23
24
25
Ph
O
O
O
BnO
O
Me
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
14.5 19.8 93
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
15.5 18.0 92
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
8.2 9.2 91
Chiralpak
AD-H
5% IPA/Hexanes
isocratic 1 mL/min
7.3 9.4 91
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
13.1 14.7 79
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
18.7 20.6 88
Chiralpak
AD-H
1% IPA/Hexanes
isocratic 1 mL/min
8.9 8.2 85
Chiralpak
AD-H
1% IPA/Hexanes
isocratic 1 mL/min
28.3 26.8 91
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The development of a palladium-catalyzed asymmetric conjugate 
addition of arylboronic acids to cyclic conjugate acceptors 
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Figure A1.2 13C NMR (126 MHz, CDCl3) of compound 35 
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Figure A1.4 13C NMR (126 MHz, CDCl3) of compound 127 
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Figure A1.7 13C NMR (126 MHz, CDCl3) of compound 128 
 
 Figure A1.6 Infrared spectrum (Thin Film, NaCl) of compound 128 
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Figure A1.9 13C NMR (126 MHz, CDCl3) of compound 129 
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Figure A1.12 13C NMR (126 MHz, CDCl3) of compound 130 
 
 Figure A1.11 Infrared spectrum (Thin Film, NaCl) of compound 130 
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Figure A1.15 13C NMR (126 MHz, CDCl3) of compound 131 
 
 Figure A1.14 Infrared spectrum (Thin Film, NaCl) of compound 131 
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Figure A1.18 13C NMR (126 MHz, CDCl3) of compound 132 
 
 Figure A1.17 Infrared spectrum (Thin Film, NaCl) of compound 132 
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Figure A1.20 13C NMR (126 MHz, CDCl3) of compound 133 
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Figure A1.22 13C NMR (126 MHz, CDCl3) of compound 134 
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Figure A1.25 13C NMR (126 MHz, CDCl3) of compound 89 
 
 Figure A1.24 Infrared spectrum (Thin Film, NaCl) of compound 89 
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Figure A1.27 13C NMR (126 MHz, CDCl3) of compound 135 
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Figure A1.29 13C NMR (126 MHz, CDCl3) of compound 136 
 
 Figure A1.24 Infrared spectrum (Thin Film, NaCl) of compound 89 
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Figure A1.32 13C NMR (126 MHz, CDCl3) of compound 90 
 
 Figure A1.31 Infrared spectrum (Thin Film, NaCl) of compound 90 
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Figure A1.35 13C NMR (126 MHz, CDCl3) of compound 88 
 
 Figure A1.34 Infrared spectrum (Thin Film, NaCl) of compound 88 
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Figure A1.38 13C NMR (126 MHz, CDCl3) of compound 137 
 
 Figure A1.37 Infrared spectrum (Thin Film, NaCl) of compound 137 
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Figure A1.41 13C NMR (126 MHz, CDCl3) of compound 134a 
 
 Figure A1.40 Infrared spectrum (Thin Film, NaCl) of compound 134a 
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Figure A1.43 13C NMR (126 MHz, CDCl3) of compound 52 
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Figure A1.45 13C NMR (126 MHz, CDCl3) of compound 83 
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Figure A1.47 13C NMR (126 MHz, CDCl3) of compound 138 
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Figure A1.49 13C NMR (126 MHz, CDCl3) of compound 139 
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Figure A1.51 13C NMR (126 MHz, CDCl3) of compound 140 
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Figure A1.54 13C NMR (126 MHz, CDCl3) of compound 141 
 
 Figure A1.53 Infrared spectrum (Thin Film, NaCl) of compound 141 
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Figure A1.57 13C NMR (126 MHz, CDCl3) of compound 142 
 
 Figure A1.56 Infrared spectrum (Thin Film, NaCl) of compound 142 
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Figure A1.60 13C NMR (126 MHz, CDCl3) of compound 86 
 
 Figure A1.59 Infrared spectrum (Thin Film, NaCl) of compound 86 
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Figure A1.63 13C NMR (126 MHz, CDCl3) of compound 88 
 
 Figure A1.62 Infrared spectrum (Thin Film, NaCl) of compound 88 
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Figure A1.66 13C NMR (126 MHz, CDCl3) of compound 160 
 
 Figure A1.65 Infrared spectrum (Thin Film, NaCl) of compound 160 
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Figure A1.69 13C NMR (126 MHz, CDCl3) of compound 161 
 
 Figure A1.68 Infrared spectrum (Thin Film, NaCl) of compound 161 
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Figure A1.72 13C NMR (126 MHz, CDCl3) of compound 162 
 
 Figure A1.71 Infrared spectrum (Thin Film, NaCl) of compound 162 
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Figure A1.75 13C NMR (126 MHz, CDCl3) of compound 164 
 
 Figure A1.74 Infrared spectrum (Thin Film, NaCl) of compound 164 
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Figure A1.78 13C NMR (126 MHz, CDCl3) of compound 165 
 
 Figure A1.77 Infrared spectrum (Thin Film, NaCl) of compound 165 
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Figure A1.81 13C NMR (126 MHz, CDCl3) of compound 166 
 
 Figure A1.80 Infrared spectrum (Thin Film, NaCl) of compound 166 
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CHAPTER 3
Palladium-catalyzed asymmetric conjugate addition
of arylboronic acids to heterocyclic acceptors±
N N
O
t-Bu
Single Catalyst System
X
O
Pd(OCOCF3)2, NH4PF6
B(OH)2
R2+
ClCH2CH2Cl, H2O, 60 °C
Range of Heterocyclic Products
X
O
R2
X = O, NCbz
38 examples
up to 98% yield
up to 98% ee
R1 R1
                                                 
± This work was performed in collaboration with Dr. Alexander N. Marziale (notebooks
AM), Michele Gatti (notebooks MG), and Bin Mao (notebooks BM). It was adapted from
the publication: Holder, J. C.; Marziale, A. N.; Gatti, M.; Mao, B.; Stoltz, B. M. Chem.
Eur. J. 2013, 19, 74–77. Copyright John Wiley & Sons 2013.
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Abstract
N N
O
t-Bu
Single Catalyst System
X
O
Pd(OCOCF3)2, NH4PF6
B(OH)2
R2+
ClCH2CH2Cl, H2O, 60 °C
Range of Heterocyclic Products
X
O
R2
X = O, NCbz
38 examples
up to 98% yield
up to 98% ee
R1 R1
Asymmetric conjugate additions to chromones and 4-quinolones are reported
utilizing a single catalyst system formed in situ from Pd(OCOCF3)2 and (S)-t-BuPyOx.
Notably, these reactions are performed in wet solvent under ambient atmosphere, and
utilize readily available arylboronic acids as the nucleophile, thus providing ready access
to these asymmetric heterocycles.
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3.1 Introduction
Palladium-catalyzed asymmetric conjugate additions are an increasingly versatile
class of enantioselective reactions that allow for stereoselective alkylation and arylation
of α,β-unsaturated conjugate acceptors.[1] These processes often utilize easily-handled,
air- and water-stable boron nucleophiles that render these reactions highly tolerant of
oxygen and moisture.[2]  Recently, our group disclosed the asymmetric conjugate addition
of arylboronic acids to cyclic enones facilitated by a palladium catalyst derived in situ
from palladium(II) trifluoroacetate and a chiral pyridinooxazoline (PyOx) ligand (82).[3]
Notably, our catalyst system was generally applicable for 5-, 6-, and 7-membered
carbocyclic enones.
The numerous advantages of this system encouraged us to seek application to
heterocyclic molecules, in order to demonstrate the broad utility of this reaction for the
synthesis of pharmaceutically relevant molecules. Herein, we report the first general
enantioselective conjugate addition of arylboronic acids to heterocyclic conjugate
acceptors derived from chromones and 4-quinolones utilizing the Pd/PyOx catalyst
system. These reactions are performed under an atmosphere of air and deliver a large
variety of asymmetric products with high enantioselectivity in moderate to excellent
yields. The stereoselective conversion of chromones through conjugate addition renders
access to flavanones, a class of heterocyclic molecules that have demonstrated numerous
medicinal properties.[4] Recent literature suggests that intramolecular oxa-Michael
additions are among the best-studied synthetic methods for asymmetric flavanone
synthesis.[5] However, examples for the retrosynthetic disconnection of flavanones via
conjugate addition of an aryl moiety to a chromone derivative remain scarce.[6,7]
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3.2 Results and discussion
3.2.1 Identification of chromones as substrates for Pd/PyOx asymmetric 1,4-
addition
While chromones have been successfully employed in rhodium-catalyzed
conjugate addition,[7] to the best of our knowledge, no palladium-catalyzed asymmetric
conjugate addition syntheses of flavanones have been reported.[8] We identified chromone
as a functioning conjugate acceptor with our Pd/PyOx system during a screen developed
to analyze the effect of a β-substituent on reactivity and enantioselectivity (Table 3.1). As
reported in our initial communication,[3] 3-methylcyclohexenone reacts with
phenylboronic acid to give nearly quantitative yield of the conjugate addition adduct in
93% ee (entry 2). With only hydrogen in the β-position, enantioselectivity drops
precipitously to 18% ee (entry 1). Interestingly, 2-methyl-4-chromone reacts poorly, with
only trace conjugate addition adduct detected by 1H NMR spectroscopy (entry 4), yet
chromone reacts with high yield and excellent enantioselectivity (94% ee, entry 3).
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Table 3.1 Comparison of asymmetric conjugate additions to various enone substrates a
O
O
R
R
product yield (%)b ee (%)c
25 (R = H)
35 (R = Me)
84 (R = H)
173 (R = Me)
87d
99
18
93
91
trace
94
--
O
productentry
1
2
3
4
X
O B(OH)2
X
O
X = CH2, O
R
R
+
Pd(OCOCF3)2,
ClCH2CH2Cl, 60 °C
(S)-t-BuPyOX
N N
O
t-Bu
82
NH4PF6, H2O
[a] Conditions: chromone (0.25 mmol), arylboronic acid (0.50 mmol), Pd(OCOCF3)2 (5 mol %), Ligand (6
mol %), NH4PF6 (30 mol %), H2O (5 equiv), ClCH2CH2Cl (1 mL), 60 °C, 12 h; [b] isolated yield; [c] ee
determined by chiral SFC or HPLC; [d] no NH4PF6 was used.
3.2.1 Application of Pd/PyOx conjugate addition to asymmetric flavanone
syntheses
We sought to explore the scope of the asymmetric conjugate addition of
arylboronic acids to chromones with respect to the range of substrates and functional
groups tolerated. Moderate yields and enantioselectivity were realized with sterically
challenging 2-fluorophenylboronic acid (Table 3.2, entry 2). Arylboronic acid
substitution at the meta position is generally tolerated with high enantioselectivity and
moderate to good yields (entries 3–7).  Notably, arylboronic acids with halogen
substitutents in the para position (entry 10) and 3-carbomethoxyphenylboronic acid
undergo conjugate addition with high enantioselectivity (entry 4). Furthermore, nitrogen-
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containing substitution was well tolerated when protected as a trifluoroacetamide,
producing the flavanone in 77% yield and 98% ee (entry 6). Other para-substituted
arylboronic acids also reacted with high enantioselectivity: alkyl substituents on the
phenylboronic acid yielded 94% and 85% ee (entries 8 and 9, respectively). With 3,5-
dimethoxyphenylboronic acid, bearing multiple substituents, high enantioselectivity
(95% ee) was obtained (entry 11). Remarkably, a heteroarylboronic acid was successfully
reacted with chromone as the conjugate acceptor for the first time (entry 12), as 4-
dibenzofuranboronic acid was converted with 64% yield and 77% ee in this case.
Table 3.2 Asymmetric conjugate addition of arylboronic acids to chromone a
O
O B(OH)2 Pd(OCOCF3)2 
(S)-t-BuPyOX (82)
NH4PF6, H2O
ClCH2CH2Cl, 60 °C
R
O
O
R
entry R = yield (%)b ee (%)c
1
2-F-C6H4 (174) 50 762
3 3-Me-C6H4 (175) 66 90
4 3-CO2Me-C6H4 (176) 72 93
5 3-Br-C6H4 (177) 40 89
6 3-NH(CO)CF3-C6H4 (178) 77 98
8 4-Me-C6H4 (180) 64 94
9 4-Et-C6H4 (181) 36 85
10 4-F-C6H4 (182) 51 90
11
12
3,5-OMe-C6H3 (183) 69 95
4-dibenzofuran (184) 64 77
H (84) 91 94
+
7 3-Cl-C6H4 (179) 52 94
[a] Conditions: chromone (0.25 mmol), arylboronic acid (0.50 mmol), Pd(OCOCF3)2 (5 mol %), Ligand (6 mol %),
NH4PF6 (30 mol %), H2O (5 equiv), ClCH2CH2Cl (1 mL), 60 °C, 12 h; [b] isolated yield; [c] ee determined by
chiral SFC.
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Substituted chromones were also found to perform well with the PyOx/Pd
catalytic system. 5,7-dimethyl-6-acetylchromone was successfully converted with a
variety of arylboronic acids (Table 3.3, i.e., 185–187). Addition of phenylboronic acid
gave nearly quantitative yield and 90% ee (185), while 3-methylphenylboronic acid saw
diminished yield with comparable ee of 88% (186), and 4-ethylphenylboronic acid
reacted with modest yield and 86% ee (187).  Furthermore, a variety of para- and meta-
substituted arylboronic acids were successfully converted with the corresponding 5,7-
dimethyl-8-acetylchromone as well (i.e., 188–193). Nucleophiles bearing functional
group handles such as 3-carbomethoxy-phenylboronic acid and 3-bromophenylboronic
acid reacted to yield flavanone products 192 and 190, respectively, with good to
moderate yield (60% and 65%) and high ee (i.e., 86% and 95%). Notably, with the
present catalytic protocol 7-hydroxychromone could be successfully applied, yielding
flavanones 196, 197,  and 198 without protection of the phenol (Table 3.3). To our
knowledge, this is the first example of an unprotected phenol reacted in asymmetric
conjugate additions and serves to highlight the high functional group tolerance as
compared to other systems.[7] 7-hydroxychromone underwent smooth conjugate addition
with a range of boronic acids in good yield and enantioselectivity: phenylboronic acid
(196, 77% yield, 93% ee), 3-methylphenylboronic acid (197, 66% yield, 90% ee), and 4-
fluorophenylboronic acid (198, 50% yield, 93% ee). Finally, we found reaction of
phenylboronic acids with substituted chromones to be general for a number of other
substituted chromones including 5,7-dimethylchromone (flavanones 194 and 85, 92% ee
and 95% ee), 7-acetoxychromone (flavanone 195, 93% ee) and 7-methoxychromone
(flavanones 199 and 200, 94% ee and 96% ee).
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Table 3.3 Asymmetric conjugate addition of arylboronic acids to substituted chromones a
O
O B(OH)2 Pd(OCOCF3)2 
(S)-t-BuPyOX (82)
NH4PF6, H2O
ClCH2CH2Cl, 60 °C
R2
O
O
O
OMe
Me
Ac
O
OMe
Me
O
OMe
Me
Ac
F
Et
O
OMe
Me
O
OMe
Me
Ac
185
98% yield
90% ee
O
OMe
Me
O
O
OMe
Me O
O
AcO
O
O
HO
R1 R1
O
O
HO
Me
Me
CO2Me
O
OMe
Me
Ac
O
OMe
Me
Ac
Me
Ac Ac Ac
O
O
HO
F
O
O
MeO O
O
MeO
CO2Me
O
O
Me
Me
NH(COCF3)
OMe
O
O
Br
Me
Me
Ac
+
186
76% yield
88% ee
187
45% yield
86% ee
188
79% yield
95% ee
189
84% yield
86% ee
191
68% yield
91% ee
190
65% yield
95% ee
192
60% yield
86% ee
193
70% yield
83% ee
194
84% yield
92% ee
85
80% yield
95% ee
195
77% yield
93% ee
196
77% yield
93% ee
197
66% yield
90% ee
198
50% yield
93% ee
199
96% yield
94% ee
200
81% yield
96% ee
R2
[a] Conditions: chromone (0.25 mmol), arylboronic acid (0.50 mmol), Pd(OCOCF3)2 (5 mol %), Ligand (6 mol %),
NH4PF6 (30 mol %), H2O (5 equiv), ClCH2CH2Cl (1 mL), 60 °C, 12 h, yields given are isolated yields, ee determined
by chiral SFC.
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3.2.2 Application of Pd/PyOx conjugate addition to 4-quinolone acceptors
We next turned our attention to 4-quinolones as a class of potential substrates.
Like flavanones, 4-quinolones have been reported as potential pharmaceutical agents.[9]
Yet, despite their promising antimitotic and antitumor activity, the enantioselective
synthesis of 2-aryl-2,3-dihydro-4-quinolones remains a challenge in asymmetric
conjugate addition. Hayashi and coworkers reported a rhodium-catalyzed asymmetric
conjugate addition, which utilized 3 equivalents of arylzinc chloride nucleophiles and
superstoichiometric chlorotrimethylsilane to react with Cbz-protected 4-quinolones.[10]
While Hayashi notes that phenylboronic acid is a particularly poor nucleophile in
reactions with protected 4-quinolones, giving the desired conjugate addition adduct in
only 10% yield, Liao and coworkers reported rhodium-catalyzed asymmetric 1,4-addition
of sodium tetraarylborate reagents to N-substituted 4-quinolones.[11]  To the best of our
knowledge, there are no literature reports of palladium-catalyzed conjugate additions to
4-quinolones, nor are there any robust examples of additions to the latter utilizing simple
boronic acid nucleophiles
To our delight, Carboxybenzyl-protected (Cbz) 4-quinolone reacted with
phenylboronic acid to yield conjugate addition adduct 201 in modest yield and 80% ee
(Table 3.4). Investigation of further N-protecting groups demonstrated that the
Carboxybenzyl-protected substrates gave the best results in terms of reactivity and
stereoselectivity. Gratifyingly, a range of addition products could be prepared in yields up
to 65% yield and 89% ee (Table 3.4). Nitrogen-containing, heteroaromatic and simpler
boronic acid derivatives were successfully employed as nucleophiles in the 1,4-addition
to 4-quinolones. For the corresponding alkyl- and halogen-substituted boronic acids,
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reasonable yields (45–65%) and enantioselectivities (67–89% ee) were observed in the
conjugate addition of 4-quinolones. Disubstituted boronic acids were well tolerated and
gave similar results (202 and 204). Both compounds were obtained in 85% ee. For
addition products 205, 208, and 209 yields and enantioselectivities ranging from 31% to
36% and 40% to 60% ee were achieved (Table 4). While the decreased yield of quinolone
209 can be rationalized by the sterically demanding nature of the boronic acid, the lower
ee could not be readily explained.
Table 3.4 Asymmetric conjugate addition of arylboronic acids to 4-quinolones a
N
Cbz
O B(OH)2 Pd(OCOCF3)2 
(S)-t-BuPyOX (5)
NH4PF6, H2O
ClCH2CH2Cl, 60 °C
R
N
Cbz
O
R
N
Cbz
O
201 
50% yield
80% ee
N
Cbz
O
203 
51% yield
85% ee
N
Cbz
O
206
65% yield
89% ee
F
N
Cbz
O
204 
50% yield
85% ee
N
Cbz
O
202 
45% yield
85% ee
OMe
OMe
N
Cbz
O
205
34% yield
60% ee
CO2Me
Me
NH(COCF3)
N
Cbz
O
207
45% yield
67% ee
Me
N
Cbz
O
208
36% yield
54% ee
OMe
N
Cbz
O
209
31% yield
40% ee
O
+
Me
[a] Conditions: 4-quinolone (0.25 mmol), arylboronic acid (0.50 mmol), Pd(OCOCF3)2 (5 mol %), Ligand (6 mol %), NH4PF6
(30 mol %), H2O (5 equiv), ClCH2CH2Cl (1 mL), 60 °C, 12 h, yields given are isolated yields, ee determined by chiral SFC.
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3.2.3 Experiments excluding Pd(0) nanoparticles as heterogeneous catalysts
To confirm the homogenous nature of our catalyst system and exclude the
possibility of erosion of enantiomeric excess due to the presence of catalytically active,
achiral Pd nanoparticles, a mercury drop test was performed. The addition of mercury to
a catalytic reaction is widely used to exclude catalysis by Pd- nanoparticles as the
amalgamation should only deactivate heterogeneous metal particles.[12] For the
conversion of chromone with phenylboronic acid in presence of 200 equiv of mercury,
with respect to the catalyst, only a slight drop of the yield from 91% to 80% was
observed, while the ee of 94% remained unaltered. Addition of mercury to the reaction of
3-Me-cyclohexenone and phenylboronic acid resulted in quantitative yield and a slightly
reduced ee of 90% for addition product 2, which is within error margins. Hence, the
formation of zerovalent Pd-nanoparticles could be excluded.
3.3 Summary and Concluding Remarks
In conclusion, we report the palladium-catalyzed conjugate addition of
arylboronic acids to chromones and 4-quinolones using a single, easily prepared catalyst
system. To our knowledge this is the first report of a palladium-catalyzed asymmetric
conjugate addition to chromones and 4-quinolones using either palladium catalysis or
arylboronic acid nucleophiles. Overall, a total of 38 addition products could be
synthesized in moderate to excellent yield and generally high enantioselectivity. The
present catalytic protocol exhibits particularly mild reaction conditions and renders the
use of silver salts for catalyst activation obsolete. Furthermore, moisture and air are well
tolerated; this results in an unprecedented functional group tolerance. Hence, the direct
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synthesis of flavanones bearing free hydroxyl-groups via conjugate addition and the
application of N-substituted, as well as heterocyclic boronic acids, is realized. Kinetic and
computational studies to elucidate the present catalytic reaction mechanism are presented
in Chapter 4. Furthermore, continued study of the substrate scope of the Pd/PyOx system
and its reactivity, as well as the application of these operationally simple asymmetric
conjugate addition reactions to total synthesis are underway in our laboratory
3.4 Experimental procedures
3.4.1 Materials and methods
Unless otherwise stated, reactions were performed with no extra precautions taken
to exclude air or moisture. Commercially available reagents were used as received from
Sigma Aldrich unless otherwise stated.  Enone substrates were purchased from Sigma
Aldrich (3-methylcyclohexenone, 2-cyclohexene-1-one, chromone) or prepared
according to literature procedure.10  Reaction temperatures were controlled by an
IKAmag temperature modulator.  Thin-layer chromatography (TLC) was performed
using E. Merck silica gel 60 F254 precoated plates (250 nm) and visualized by UV
fluorescence quenching, potassium permanganate, or p-anisaldehyde staining. Silicycle
SiliaFlash P60 Academic silica gel (particle size 40-63 nm) was used for flash
chromatography.  Analytical chiral HPLC was performed with an Agilent 1100 Series
HPLC utilizing a Chiralcel OJ column (4.6 mm x 25 cm) obtained from Daicel Chemical
Industries, Ltd with visualization at 254 nm and flow rate of 1 mL/min, unless otherwise
stated. Analytical chiral SFC was performed with a JASCO 2000 series instrument
utilizing Chiralpak (AD-H or AS-H) or Chiralcel (OD-H, OJ-H, or OB-H) columns (4.6
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mm x 25 cm), or a Chiralpak IC column (4.6 mm x 10 cm) obtained from Daicel
Chemical Industries, Ltd with visualization at 210 or 254 nm. 1H and 13C NMR spectra
were recorded on a Varian Inova 500 (500 MHz and 125 MHz, respectively) and a
Varian Mercury 300 spectrometer (300 MHz and 75 MHz, respectively). Data for 1H
NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling
constant (Hz), integration). Data for 1H NMR spectra are referenced to the centerline of
CHCl3 (δ 7.26) or (CH3)2CO (δ 2.05)  as the internal standard and are reported in terms of
chemical shift relative to Me4Si (δ 0.00).  Data for 13C NMR spectra are referenced to the
centerline of CDCl3 (δ 77.0) or (CD3)2CO (δ 29.8, 206.3) and are reported in terms of
chemical shift relative to Me4Si (δ 0.00). Infrared spectra were recorded on a Perkin
Elmer Paragon 1000 Spectrometer and are reported in frequency of absorption (cm-1).
High resolution mass spectra (HRMS) were obtained on an Agilent 6200 Series TOF
with an Agilent G1978A Multimode source in electrospray ionization (ESI), atmospheric
pressure chemical ionization (APCI) or mixed (MultiMode ESI/APCI) ionization mode.
Optical rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-
length cell at 589 nm.
3.4.2 Experimental procedures
N
N
O
t-Bu
(S)-4-(tert-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole  (82)
Adapted from: Brunner, H.; Obermann., U. Chem. Ber. 1989, 122, 499–507.
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A flame-dried round bottom flask was charged with a stir bar and MeOH (110 mL).
Sodium metal ingot (295 mg, 12.8 mmol, 0.1 equiv) was cut with a razor into small
portions, washed in a beaker of hexanes, and added in five portions over 5 min to the
stirring flask of MeOH.  The reaction mixture was stirred vigorously at ambient
temperature until no sodium metal remained, at which time it was cooled to 0 °C in an
ice/water bath.  At this time, 2-cyanopyridine (13.0 g, 125 mmol, 1.0 equiv) was added
dropwise, and the clear, colorless reaction mixture was allowed to warm to ambient
temperature with stirring.  When all the starting material was consumed as indicated by
TLC analysis (50% EtOAc/Hexanes, p-anisaldehyde stain), the reaction was cooled to 0
°C in an ice/water bath and quenched by dropwise addition of glacial AcOH (1 mL).  The
crude reaction mixture was evaporated in vacuo, redissolved in CH2Cl2 (100 mL) and
washed with brine (2 x 50 mL).  The organic phase was dried (MgSO4), concentrated in
vacuo, and dried under high vacuum for 1 h.  The resulting crude methoxyimidate (light
yellow oil) was suitable for use in the next step without further purification.
To a flame-dried round bottom flask charged with a stir bar was added crude
methoxyimidate (2.55 g, 18.7 mmol, 1.0 equiv), (S)–tert-leucinol (2.10 g, 17.9 mmol,
0.96 equiv), and toluene (100 mL), and p-TsOH•H2O (167 mg, 0.88 mmol, 5 mol%).
The mixture was stirred at 80 °C in an oil bath for 3 h, at which time the starting material
was consumed as indicated by TLC analysis (20% acetone/hexanes, p-anisaldehyde
stain).  The reaction was cooled to ambient temperature and quenched with sat. NaHCO3
(60 mL).  The reaction was partitioned with EtOAc and water, and the aqueous phase was
extracted with EtOAc (3 x 50 mL).  The combined organic extracts were washed with
water (2 x 50 mL), brine (1 x 25 mL), dried (MgSO4) and concentrated in vacuo.  The
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crude mixture was purified by flash column chromatography (eluent: 20%
acetone/hexanes) to afford 1.85 g (9.06 mmol, 51%) (S)-t-BuPyOX as an off-white solid.
Rf = 0.44 with 3:2 hexanes/acetone; mp 70.2 - 71.0 ºC; 1H NMR (500 MHz, CDCl3) δ
8.71 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.08 (dt, J = 7.9, 1.1 Hz, 1H), 7.77 (dt, J = 7.7, 1.7
Hz, 1H), 7.37 (ddd, J = 7.0, 4.5, 1.0 Hz, 1H), 4.45 (dd, J = 10.2, 8.7 Hz, 1H), 4.31 (t, J =
8.5 Hz, 1H), 4.12 (dd, J = 10.2, 8.5 Hz, 1H), 0.98 (s, 9H);  13C NMR (125 MHz, CDCl3) δ
162.4, 149.6, 147.0, 136.5, 125.4, 124.0, 76.5, 69.3, 34.0, 26.0;  IR (Neat film, NaCl):
2981, 2960, 2863, 1641, 1587, 1466, 1442, 1358, 1273, 1097, 1038, 968 cm-1;  HRMS
(MultiMode ESI/APCI) m/z calc’d for C12H17ON2 [M+H]+: 205.1335, found 205.1327;
[α]25D –90.5º (c 1.15, CHCl3).
Representative General Procedure for the Enantioselective 1,4-Addition of
Arylboronic Acids to Heteroaromatic Conjugate Acceptors
A screw-top 1 dram vial was charged with a stir bar, Pd(OCOCF3)2 (4.2 mg, 0.0125
mmol, 5 mol%), (S)-t-BuPyOX (3.1 mg, 0.015 mmol, 6 mol%), NH4PF6 (12.5 mg, 0.075
mmol, 30 mol%) and PhB(OH)2 (61 mg, 0.50 mmol, 2.0 equiv).  The solids were
suspended in dichloroethane (0.5 mL) and stirred for 2 min at ambient temperature, at
which time a yellow color was observed.  Not all solids were dissolved at this time.
Conjugate acceptor substrate (0.25 mmol) and water (0.025 mL, 1.25 mmol, 5.0 equiv)
were added.  The walls of the vial were rinsed with an additional portion of
dichloroethane (0.5 mL), and the vial was capped with a Teflon/silicone septum and
stirred at 60 °C in an oil bath for 12 h.  Upon complete consumption of the starting
material (monitored by TLC, 4:1 hexanes/EtOAc, p-anisaldehyde or iodine/silica gel
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stain) the reaction mixture was filtered through a pipet plug of silica gel using CH2Cl2 as
the eluent and concentrated in vacuo. The crude residue was purified by column
chromatography (gradient: 9:1 hexanes/EtOAc to 7:3 hexanes/EtOAc) to afford the title
compound.
General Procedure for the Synthesis of Racemic Products
Racemic products were synthesized in a manner analogous to the general procedure using
PyOX synthesized from racemic tert-leucinol (3.1 mg, 0.015 mmol, 6 mol%) as an
achiral ligand.
General Procedure for the synthesis of N-trifluoroacetamide Boronic Acids from
Bromo-trifluoroacetanilides
A flame round bottom flask was charged with bromo-trifluoroacetanilide (3.7 mmol, 1
equiv). The flask was sealed, evacuated and backfilled with argon. THF (20 ml) was
added via syringe and the obtained mixture was cooled to -78 °C.  n-BuLi (2.3 M
solution in hexane, 3.6 mL, 8.2 mmol, 2.2 equiv) was added dropwise and the reaction
was stirred for 2 h.  Triisopropylborate (2.7 mL, 11.7 mmol, 3 equiv) was then added via
syringe and the mixture was stirred for 10 minutes, at which time the cooling bath was
removed and the reaction was allowed to stir and warm to room temperature for 1 h.  A
solution of HCl (2 M in water, 10 mL) was added and the biphasic mixture was
vigorously stirred for 1 and then extracted with EtOAc (3 x 30 mL).  The combined
organic extracts where washed with brine (2 x 20 ml) and dried over MgSO4.  Upon
concentration in vacuo an off-white solid was obtained.  The solid was suspended in
Chapter 3 165
hexane and stirred until a fine powder was formed, filtered, and dried in high vacuum for
30 minutes to obtain the title boronic acid.
HN
O
CF3
O
B(OH)2
3-(2,2,2-trifluroacetamide)-4-methylphenylboronic acid
 Obtained as an off-white solid in 35% yield following the general procedure. 1H NMR
(300 MHz, acetone) δ 9.34 (s, 1H), 8.05 (dd, J = 3.0, 6.9 Hz, 1H), 7.58 (s 1H), 7.54 (dd, J
= 7.9, 1.0 Hz, 1H) 7.29 (s, 1H), 3.93 (s, 3H); 13C NMR (125 MHz, acetone) δ 154.3 (q,
JC-F = 150 Hz), 149.3, 126.8, 126.6, 120.5, 116.1, 115.8 (q, JC-F = 288 Hz), 112.5, 55.4;
IR (Neat Film, NaCl): 3298, 1708, 1591, 1537, 1503, 1465, 1404, 1342, 1294, 1273,
1224, 1161, 1123, 1015; HRMS (MultiMode ESI/APCI) m/z calc’d for C9H8BO4NF3 [M-
H]-: 261.0590, found: 261.0497.
HN
O
CF3
B(OH)2
3-(2,2,2-trifluroacetamide)-phenylboronic acid
Obtained as an off-white solid in 66 % yield following the general procedure.  1H NMR
(300 MHz, acetone-d6) δ 8.11 (bs, 1H), 7.81 (m, 1H), 7.74 (dt, J = 7.4, 1.0 Hz 1H), 7.40
(t, J = 7.7 Hz, 1H), 7.28 (s, 1H); (The obtained 13C NMR is complex due to the presence
of two rotamers in solution) 13C NMR (125 MHz, CDCl3) δ 154.8 (q, J = 36.9 Hz), 135.8,
135.7, 131.5, 128.2, 126.7, 126.6, 123.0, 122.9, 116.2 (q, J = 288.1 Hz); IR (Neat
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Film, NaCl): 3305, 1701, 1585, 1554, 1437, 1334, 1264, 1182, 1031, 780 cm-1; HRMS
(MultiMode ESI/APCI) m/z calc’d for C8H7BrF3NO [M-H]-: 231.0435, found: 231.0433.
HN
O
CF3
B(OH)2
3-(2,2,2-trifluroacetamide)-4-methylphenylboronic acid.
Obtained as an off-white solid in 66% yield following the general procedure.  1H NMR
(300 MHz, acetone) δ 9.91 (bs, 1H), 7.82 (s, 1H), 7.75 (dd, J = 6.5, 10 Hz, 1H), 7.32 (d, J
= 7.5 Hz, 1H) 7.24 (s, 1H), 2.29 (s, 3H);  13C NMR (125 MHz, acetone-d6) δ 155.4 (q, J =
37.5 Hz), 136.2, 133.5, 132.9, 132.1, 130.1, 116.4 (q, J = 288.0 Hz), 16.8; FTIR (Neat
Film, NaCl) 3270, 1708, 1617, 1533, 1406, 1351, 1259, 1180, 1162, 1092, 1036, 898,
825 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C9H8BF3NO3 [M-H]-: 245.0477,
found 245.0591.
General Procedure for the Synthesis of Substituted Chromones
A known literature procedure was used.13 An Erlenmeyer flask charged with the
corresponding hydroxy acetophenone (26.2 mmol, 1 equiv) was suspended in
triethylorthoformate (12 mL).  A 70 % aqueous solution of HClO4 was added rapidly via
syringe (1.3 mL) and the obtained mixture was stirred for 30 minutes at room
temperature.  A moderate increase in temperature is observed.  Et2O was added to
precipitate a red-brown solid that was filtered and transferred into a flask.  Water (10 mL)
was added and the flask was warmed to 100 °C for 10 minutes.  The solid rapidly
dissolve and re-precipitate.  The mixture is cooled to room temperature and filtered.  The
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obtained solid can be purified via crystallization from ethanol (17 mL EtOH/ 4 mL H2O,
80 °C) and the obtained powder is pure by NMR analysis, but often contains colored
impurities.  This compound is typically further purified by flash chromatography to
obtain off-white powders.  All characterization data for the following chromones matches
previously reported data: 7-hydroxychromone,2 7-methoxychromone,14 7-acetoxy-
chromone,15 5,7-dimethylchromone,16
O
Me
Me
O
Ac
7-acetoxy-chromen-4-one
Synthesized from 1,1'-(4-hydroxy-2,6-dimethyl-1,3-phenylene)diethanone in 82% yield
by the general procedure, obtained as an off-white powder solid.  1H NMR (500 MHz,
CDCl3) δ 7.68–7.62 (m, 1H), 7.06 (d, J = 3.5 Hz, 1H), 6.18–6.13 (m, 1H), 2.71–2.65 (m,
3H), 2.44 (q, J = 1.4 Hz, 3H), 2.28–2.23 (m, 3H);13C NMR (125 MHz, CDCl3) δ 207.3,
179.3, 157.4, 153.4, 140.8, 138.5, 135.4, 121.1, 117.5, 114.4, 32.5, 19.5, 18.8; IR (Neat
Film, NaCl): 3086, 2987, 2918, 1701, 1649, 1604, 1443, 1354, 1339, 1245, 1221, 1182,
1060 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C13H13O3 [M+H]+: 217.0859,
found: 217.0858.
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3.4.3 Spectroscopic Data for Enantioenriched Products
O
(R)-3-phenyl-3-methylcyclohexanone (35)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford a pale yellow oil (99% yield).  [α]25D –56.1° (c 1.36,
CHCl3, 93% ee). All characterization data matches previously reported data.17, 18, 19, 20, 21, 22,
23
O
H
(R)-3-phenylcyclohexanone (25)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford a pale yellow oil (89% yield).  [α]25D –2.93° (c 1.01,
CHCl3, 18% ee). All characterization data matches previously reported data.24
O
O
(R)-2-phenylchroman-4-one (84)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford an off-white solid (91% yield).  [α ]25D 67.3° (c 0.95,
CHCl3, 92% ee). All characterization data matches previously reported data.7
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O
O
F
(R)-2-(2-fluorophenyl)chroman-4-one (174)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford an off-white solid (50% yield). 1H NMR (500 MHz,
CDCl3) δ 7.97 (dd, J = 1.5, 7.5 Hz, 1H), 7.67 (dt, J = 1.7, 7.6 Hz, 1H), 7.54 (ddd, J = 1.8,
7.1, 8.2 Hz, 1H), 7.39 (ddt. J = 1.7, 5.4, 7.8 Hz, 1H), 7.25–7.28 (m, 1H), 7.07–7.16 (m,
3H), 5.81 (dd, J = 2.9, 13.4 Hz, 1H), 3.08 (dd, J = 13.4, 16.9 Hz, 1H), 2.93 (dd, J = 2.9,
16.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 191.5, 161.5, 160.6, 158.6, 136.2, 130.6,
130.2, 127.5, 127.4, 126.2, 126.1, 124.5, 124.5, 121.8, 120.9, 118.9, 118.0, 115.8, 115.6,
73.8, 73.8, 43.7; IR (Neat Film, NaCl): 1698, 1609, 1577, 1493, 1463, 1370, 1305, 1224,
1149, 1116, 1068 c m-1; HRMS (MultiMode ESI/APCI) m /z calc’d for C15H12FO2
[M+H]+: 243.0816, found 243.0814; [α]25D 63.6° (c 3.0, CHCl3, 76% ee).
O
O
(R)-2-(m-tolyl)chroman-4-one (175)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford an off-white solid (66% yield).  [α]25D 45.5° (c 6.9, CHCl3,
90% ee). All characterization data matches previously reported data.,25
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O
O
CO2Me
(R)-methyl 3-(4-oxochroman-2-yl)benzoate (176)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford an off-white solid (72% yield). 1H NMR (500 MHz,
CDCl3) δ  8.18 (t, J = 1.8 Hz, 1H), 8.06 (dt, J = 1.4, 7.8 Hz, 1H), 7.93 (dd, J = 1.7, 8.1
Hz, 1H), 7.68 (dq, J = 1.2, 7.8 Hz, 1H), 7.57–7.44 (m, 2H), 7.10–6.93 (m, 2H), 5.53 (dd,
J = 2.8, 13.4 Hz, 1H), 3.93 (s, 3H), 3.07 (dd, J = 13.4, 16.8, Hz, 1H), 2.91 (dd, J = 2.9,
16.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ  191.6, 166.7, 161.4, 139.4, 136.4, 130.9,
130.6, 130.0, 129.1, 127.4, 127.2, 121.9, 121.0, 118.2, 79.00, 52.4, 44.8; IR (Neat Film,
NaCl): 2951, 1720, 1691, 1606, 1577, 1463, 1431, 1359, 1304, 1225, 1214, 1149, 1114,
1068 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C17H15O4 [M+H]+: 283.0965,
found 285.0967; [α]25D 66.5° (c 1.00, CHCl3, 93% ee).
O
O
Br
(R)-2-(3-bromophenyl)chroman-4-one (177)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford an off-white solid (40% yield). 1H NMR (500 MHz,
CDCl3) δ 7.94 (dd, J = 2.0, 8.5 Hz, 1H), 7.68 (bs, 1H), 7.53 (dt, J = 1.7, 7.8 Hz, 2H), 7.39
(d, J = 7.6 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.08 (t, J = 7.6 Hz, 2H), 5.46 (dd, J = 2.9,
13.2 Hz, 1H), 3.04 (dd, J = 13.2, 16.9 Hz, 1H), 2.89 (dd, J = 2.9, 16.9 Hz, 1H); 13C NMR
(125 MHz, CDCl3) δ 191.3, 161.2, 140.9, 136.3, 131.7, 130.3, 129.2, 127.0, 124.6, 122.9,
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121.8, 121.6, 118.1, 78.6, 44.6; IR (Neat Film, NaCl): 1691, 1605, 1575, 1463, 1362,
1304, 1226, 1152, 1115, 1067 c m-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C15H12BrO2 [M+H]+: 300.9871, found 300.9870; [α]25D 53.5° (c 3.0, CHCl3, 89% ee).
O
O
NH(COCF3)
(R)-2,2,2-trifluoro-N-(3-(4-oxochroman-2-yl)phenyl)acetamide (178)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 8:2 hexanes/EtOAc to 7:3 hexanes/EtOAc) to afford an off-white solid (40%
yield). 1H NMR (500 MHz, CDCl3) δ  8.07 (bs, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.79 (s,
1H), 7.67–7.58 (m, 1H), 7.54 (t, J = 7.8 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H), 7.35 (d, J = 7.7
Hz, 1H), 7.08 (t, J = 8.9 Hz, 2H), 5.51 (dd, J = 3.1, 13.3 Hz, 1H), 3.06 (dd, J = 13.1, 16.9
Hz, 1H), 2.92 (dd, J = 3.1, 16.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ  191.5, 161.2,
154.6–154.9 (m), 140.4, 136.4, 135.7, 129.9, 127.1, 123.9, 121.9, 120.9, 120.6, 118.1,
118.1, 114.4–116.7 (m), 78.9, 44.7; IR (Neat Film, NaCl): 3304, 1718, 1684, 1607, 1565,
1465, 1307, 1208, 1148, 1116 c m-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C17H13O3F3N [M+H]+: 336.0847, found 336.0854; [α]25D 74.4° (c 1.02, CHCl3, 98% ee).
O
O
(R)-2-(p-tolyl)chroman-4-one (179)
Synthesized according to the general procedure and purified by flash chromatography
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(9:1 hexanes/EtOAc) to afford an off-white solid (64% yield). [α]25D 30.0° (c 1.85,
CHCl3, 94% ee). All characterization data matches previously reported data.Error! Bookmark not
defined.
O
O
(R)-2-(4-ethylphenyl)chroman-4-one (180)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford an off-white solid (36% yield). 1H NMR (500 MHz,
CDCl3) δ 7.94 (dd, J = 1.8, 8.2 Hz, 1H), 7.51 (ddd, J = 1.7, 7.1, 8.3 Hz, 1H), 7.45–7.34
(m, 2H), 7.32–7.21 (m, 2H), 7.12 –6.92 (m, 2H), 5.46 (dd, J = 2.8, 13.4 Hz, 1H), 3.11
(dd, J = 13.5, 16.9 Hz, 1H), 2.88 (dd, J = 2.8, 16.9 Hz, 1H), 2.69 (q, J = 7.7 Hz, 2H), 1.26
(t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 192.1, 161.6, 145.0, 136.1, 135.8,
128.3, 126.9, 126.2, 121.5, 120.8, 118.1, 79.5, 44.5, 28.6, 15.5; IR (Neat Film, NaCl):
2964, 2930, 2896, 2872, 1691, 1605, 1576, 1516, 1472, 1463, 1420, 1367, 1319, 1304,
1225, 1148, 1114, 1068 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C17H17O2
[M+H]+: 253.1223, found 253.1225; [α]25D 20.7° (c 0.4, CHCl3, 95% ee).
O
O
F
(R)-2-(4-fluorophenyl)chroman-4-one (182)
Synthesized according to the general procedure and purified by flash chromatography
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(9:1 hexanes/EtOAc) to afford an off-white solid (51% yield). [α]25D 29.6° (c 3.4, CHCl3,
90% ee). All characterization data matches previously reported data.25
O
O
OMe
OMe
(R)-2-(3,5-dimethoxyphenyl)chroman-4-one (183)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 8:2 hexanes/EtOAc to 7:3 hexanes/EtOAc) to afford an off-white solid (69%
yield). 1H NMR (500 MHz, CDCl3) δ  7.93 (ddd, J = 0.7, 1.8, 7.5 Hz, 1H), 7.52 (ddd, J =
1.8, 7.3, 8.3Hz, 1H), 7.15–6.93 (m, 2H), 6.63 (dd, J = 0.6, 2.2 Hz, 2H), 6.47 (t, J = 2.3
Hz, 1H), 5.51–5.30 (m, 1H), 3.82 (s, 6H), 3.07 (dd, J = 13.3, 16.9 Hz, 1H), 2.89 (dd, J =
2.9, 16.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ  191.9, 161.4, 161.1, 141.0, 136.2,
127.0, 121.6, 120.9, 118.1, 104.1, 100.4, 79.6, 55.4, 44.8; IR (Neat Film, NaCl): 3852,
3744, 3674, 3648, 2933, 1695, 1606, 1464, 1362, 1303, 1205, 1157, 1115, 1063 cm-1;
HRMS (MultiMode ESI/APCI) m/z calc’d for C17H17O4 [M+H]+: 285.1127, found
285.1127; [α]25D 46.7° (c 0.98, CHCl3, 95% ee).
O
O
O
(R)-2-(dibenzo[b,d]furan-4-yl)chroman-4-one (184)
Synthesized according to the general procedure and purified by flash chromatography
(8:2 hexanes/EtOAc) to afford an off-white solid (64% yield). 1H NMR (500 MHz,
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CDCl3) δ  8.08–7.92 (m, 3H), 7.70 (dd, J = 1.2, 7.7 Hz, 1H), 7.62–7.52 (m, 2H), 7.49
(ddt, J = 1.1, 7.2, 8.4 Hz, 1H), 7.44 (td, J = 0.9, 7.6 Hz, 1H), 7.40–7.34 (m, 1H),
7.16–7.07 (m, 2H), 6.11 (dd, J = 2.9, 13.5 Hz, 1H), 3.35 (ddd, J = 1.0, 13.4, 17.0 Hz,
1H), 3.17 (ddd, J = 1.0, 3.0, 17.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ  192.0, 161.7,
156.1, 152.8, 136.2, 127.5, 127.6, 124.8, 124.4, 123.9, 123.1, 123.1, 122.9, 121.7, 121.1,
120.9, 120.8, 118.2, 111.9, 75.3, 43.4; IR (Neat Film, NaCl): 3060, 1690, 1604, 1576,
1471, 1463, 1450, 1428, 1303, 1223, 1187, 1118 1066 c m-1; HRMS (MultiMode
ESI/APCI) m/z calc’d for C21H15O3 [M+H]+: 315.1016, found 315.1017; [α]25D 74.1° (c
0.77, CHCl3, 77% ee).
O
OMe
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(R)-6-acetyl-5,7-dimethyl-2-phenylchroman-4-one (185)
Synthesized according to the general procedure and purified by flash chromatography
(8:2 hexanes/EtOAc) to afford a colorless solid (98% yield). 1H NMR (500 MHz, CDCl3)
δ 7.47–7.37 (m, 5H), 6.79 (s, 1H), 5.43 (dd, J = 2.9, 13.1 Hz, 1H), 3.07 (dd, J = 13.2,
16.5 Hz, 1H), 2.87 (dd, J = 3.0, 16.5 Hz, 1H), 2.56 (s, 3H), 2.47 (s, 3H), 2.23 (s, 3H); 13C
NMR (125 MHz, CDCl3) δ 207.7, 192.9, 162.3, 140.8, 138.6, 138.0, 136.5, 128.8, 128.7,
126.0, 117.7, 117.3, 78.8, 46.2, 32.8, 19.8, 18.9; IR (Neat Film, NaCl): 3034, 2974, 2916,
1700, 1696, 1684, 1559, 1425, 1354, 1314, 1278, 1258, 1211, 1182, 1074, 1029, 895,
856, 766 c m-1; HRMS (MultiMode ESI/APCI) m /z  calc’d for C19H19O3 [M+H]+:
295.1329, found 295.1320; [α]25D 22.2° (c 1.14, CHCl3, 90% ee).
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(R)-6-acetyl-5,7-dimethyl-2-(m-tolyl)chroman-4-one (186)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc to 8:2 hexanes/EtOAc) to afford a colorless solid (76% yield). 1H
NMR (500 MHz, CDCl3) δ 7.38–7.18 (m, 4H), 6.79 (m, 1H), 5.38 (dd, J = 2.8, 13.3 Hz,
1H), 3.07 (dd, J = 13.3, 16.5 Hz, 1H), 2.85 (dd, J = 2.9, 16.5 Hz, 1H), 2.56 (s, 3H), 2.48
(s, 3H), 2.40 (s, 3H), 2.22 (d, J  = 0.6 Hz, 3H); 13C NMR (125 MHz, CDCl3)
δ 207.8,  193.0, 162.3, 140.8, 138.6, 138.5, 138.0, 136.5, 129.5, 128.7, 126.7, 123.1,
117.7, 117.3, 78.9, 46.2, 32.8, 21.5, 19.8, 18.9; IR (Neat Film, NaCl): 2918, 1701, 1683,
1600, 1558, 1464, 1427, 1354, 1313, 1278, 1258, 1216, 1182, 1072, 969, 876, 786, 705
cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C20H21O3 [M+H]+: 309.1485, found
309.1483; [α]25D 22.2° (c 1.14, CHCl3, 88% ee).
O
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(R)-6-acetyl-2-(3-ethylphenyl)-5,7-dimethylchroman-4-one (187)
Synthesized according to the general procedure and purified by flash chromatography
(8:2 hexanes/EtOAc to 6:1 hexanes/EtOAc) to afford a colorless solid (45% yield). 1H
NMR (500 MHz, CDCl3) δ 7.38–7.36 (m, 2H), 7.27–7.25 (m, 2H), 6.77 (s, 1H), 5.40 (dd,
J = 2.8, 13.2 Hz, 1H), 3.09 (dd, J = 13.2, 16.5 Hz, 1H), 2.86 (dd, J = 2.9, 16.5 Hz, 1H),
2.68 (q, J = 7.6 Hz, 2H), 2.56 (s, 3H), 2.47 (s, 3H), 2.22 (s, 3H), 1.25 (t, J = 7.6 Hz, 3H);
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13C NMR (125 MHz, CDCl3) δ 207.7, 193.1, 162.4, 145.0, 140.7, 138.0, 136.5, 135.8,
128.3, 126.2, 117.7, 117.3, 78.8, 46.1, 32.8, 28.6, 19.8, 19.0, 15.6; IR (Neat Film, NaCl):
3379, 2965, 2930, 2873, 1910, 1685, 1601, 1559, 1517, 1465, 1427, 1379, 1354, 1313,
1278, 1258, 1212, 1182, 1117, 1073, 1021, 988, 969, 895, 858, 831, 777, 736 cm-1;
HRMS (MultiMode ESI/APCI) m/z calc’d for C21H23O3 [M+H]+: 323.1642, found
323.1627; [α]25D 8.8° (c 1.00, CHCl3, 86% ee).
O
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(R)-8-acetyl-5,7-dimethyl-2-phenylchroman-4-one (188)
Synthesized according to the general procedure and purified by flash chromatography
(8:2 hexanes/EtOAc) to afford a colorless solid (79% yield). 1H NMR (500 MHz, CDCl3)
δ 7.44–7.36 (m, 5H), 6.72 (s, 1H), 5.48 (dd, J = 2.9, 13.2 Hz, 1H), 3.06 (dd, J = 13.2,
16.6 Hz, 1H), 2.89 (dd, J = 2.9, 16.6 Hz, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.26 (s, 3H); 13C
NMR (125 MHz, CDCl3) δ 203.7, 192.4, 159.4, 143.1, 142.2, 138.5, 128.9, 128.7, 127.5,
125.8, 117.6, 110.0, 79.4, 46.1, 32.3, 22.7, 19.7; IR (Neat Film, NaCl): 2946, 2924, 1684,
1599, 1559, 1473, 1444, 1352, 1317, 1281, 1163, 1079, 763 cm-1; HRMS (MultiMode
ESI/APCI) m/z calc’d for C19H17O3 [M-H]-: 293.1183, found 293.1178; [α]25D 65.5° (c
1.02, CHCl3, 95% ee).
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(R)-8-acetyl-5,7-dimethyl-2-(m-tolyl)chroman-4-one (189)
Synthesized according to the general procedure and purified by flash chromatography
(5:1 hexanes/EtOAc) to afford a colorless solid (84% yield). 1H NMR (500 MHz, CDCl3)
δ 7.33–7.17 (m, 4H), 6.71 (s, 1H), 5.44 (dd, J = 2.9, 13.1 Hz, 1H), 3.05 (dd, J = 13.2,
16.6 Hz, 1H), 2.86 (dd, J = 3.0, 16.6 Hz, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.39 (s, 3H),
2.26 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 203.7, 192.5, 159.4, 143.1, 142.2, 138.6,
138.4, 129.4, 129.3, 128.7, 127.4, 126.5, 122.9, 117.6, 79.5, 46.2, 32.3, 22.7, 21.5, 19.7;
IR (Neat Film, NaCl): 2945, 2923,1684, 1599, 1558, 1472, 1447, 1353, 1316, 1281,
1173, 1085, 960, 892, 811, 789, 757 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C20H21O3 [M+H]+: 309.1485, found 309.1494; [α]25D 60.6° (c 1.03, CHCl3, 86% ee).
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(R)-8-acetyl-2-(4-fluorophenyl)-5,7-dimethylchroman-4-one (191)
Synthesized according to the general procedure and purified by flash chromatography
(1:1 hexanes/EtOAc) to afford a colorless solid (68% yield). 1H NMR (500 MHz, CDCl3)
δ 7.40–7.38 (m, 2H), 7.26 (s, 1H), 7.12–7.09 (m, 2H), 5.45 (dd, J = 2.9, 13.1 Hz, 1H),
3.03 (dd, J = 13.1, 16.6 Hz, 1H), 2.87 (dd, J = 2.9, 16.6 Hz, 1H), 2.63 (s, 3H), 2.46 (s,
3H), 2.26 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 203.6, 192.1, 162.8 (d, 1J(C,F) = 247.8
Hz), 159.1, 143.1, 142.2, 134.3 (d, 4J(C,F) = 3.3 Hz), 129.3, 127.7 (d, 3J(C,F) = 8.4 Hz) ,
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127.5, 117.5, 115.8 (d, 2J(C,F) = 21.7 Hz), 78.7, 46.0, 32.3, 22.7, 19.7; IR (Neat Film,
NaCl): 3354, 3073, 2967, 2925, 1895, 1685, 1603, 1560, 1513, 1474, 1445, 1353, 1316,
1283, 1265, 1254, 1227, 1187, 1161, 1087, 1041, 1014, 992, 961, 897, 880, 837, 811,
731, 727 c m-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C19H18FO3 [M+H]+:
313.1234, found 313.1240; [α]25D 53.4° (c 1.05, CHCl3, 91% ee).
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(R)-methyl 3-(8-acetyl-5,7-dimethyl-4-oxochroman-2-yl) benzoate (192)
Synthesized according to the general procedure and purified by flash chromatography
(5:1 hexanes/EtOAc) to afford a colorless solid (60% yield). 1H NMR (500 MHz, CDCl3)
δ 8.10 (t, J = 1.7 Hz, 1H), 8.06–8.04 (m, 1H), 7.64–7.62 (m, 1H), d 7.51 (t, J = 7.7 Hz,
1H), 6.73 (s, 1H), 5.52 (dd, J = 2.9, 13.1 Hz, 1H), 3.94 (s, 3H), 3.07 (dd, J = 13.3, 16.6
Hz, 1H), 2.90 (dd, J = 2.9, 16.6 Hz, 1H), 2.64 (s, 3H), 2.48 (s, 3H), 2.26 (s, 3H); 13C
NMR (125 MHz, CDCl3) δ 203.5, 191.9, 166.5, 159.1, 143.1, 142.3, 138.9, 130.8, 130.2,
129.9, 129.3, 129.1, 127.7, 127.0, 117.5, 78.9, 52.3, 46.0, 32.3, 22.7, 19.7; IR (Neat Film,
NaCl): 2953, 2924, 2360, 1722, 1684, 1600, 1559, 1473, 1436, 1354, 1316, 1283, 1210.
1163, 1084, 961, 892, 860, 822, 755 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C21H21O5 [M+H]+: 353.1384, found 353.1385; [α]25D 83.5° (c 1.53, CHCl3, 86% ee).
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(R)-8-acetyl-2-(3-bromophenyl)-5,7-dimethylchroman-4-one (190)
Synthesized according to the general procedure and purified by flash chromatography
(8:2 hexanes/EtOAc) to afford a colorless solid (65% yield). 1H NMR (500 MHz, CDCl3)
δ 7.56 (t, J = 1.6 Hz, 1H), 7.53–7.48 (m, 1H), 7.35–7.28 (m, 2H), 6.73 (s, 1H), 5.44 (dd, J
= 2.9, 13.2 Hz, 1H), 3.02 (dd, J = 13.2, 16.6 Hz, 1H), 2.87 (dd, J = 3.0, 16.6 Hz, 1H),
2.64 (s, 3H), 2.48 (s, 3H), 2.26 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 203.5, 191.7,
158.9, 143.1, 142.3, 140.7, 131.8, 130.5, 129.3, 128.9, 127.7, 124.4, 122.9, 117.5, 78.6,
46.0, 32.3, 22.7, 19.7; IR (Neat Film, NaCl): 3583, 2919, 1685, 1597, 1559, 1473, 1444,
1355, 1316, 1282, 1263, 1163, 1084, 959, 891, 789 cm-1; HRMS (MultiMode ESI/APCI)
m/z calc’d for C19H18BrO3 [M+H]+: 373.0434, found 373.0435; [α]25D 97.6° (c 0.81,
CHCl3, 95% ee).
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(R)-8-acetyl-2-(dibenzo[b,d]furan-4-yl)-5,7-dimethylchroman-4-one (194)
Synthesized according to the general procedure and purified by flash chromatography
(8:2 hexanes/EtOAc) to afford a colorless solid (70% yield). 1H NMR (500 MHz, CDCl3)
δ 7.97 (d, J = 7.7 Hz, 2H), 7.60–7.55 (m, 2H), 7.48 (dt, J = 0.9, 7.8 Hz, 1H), 7.46–7.35
(m, 2H), 6.75 (s, 1H), 6.09 (dd, J = 3.1, 12.9 Hz, 1H), 3.30 (dd, J = 13.0, 16.6 Hz, 1H),
3.16 (dd, J = 3.3, 16.7 Hz, 1H), 2.69 (s, 3H), 2.48 (s, 3H), 2.28 (s, 3H); 13C NMR (125
MHz, CDCl3) δ 203.7,  192.4, 159.4, 156.1, 152.8, 143.2, 142.2, 129.3, 127.6, 127.5,
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124.8, 124.0, 123.8, 123.1, 123.0, 122.6, 121.0, 120.8, 117.7, 111.8, 75.2, 45.0, 32.3,
22.8, 19.7; IR (Neat Film, NaCl): 3583, 3017, 2963, 2923, 1683, 1600, 1557, 1474, 1450,
1428, 1378, 1352, 1317, 1282, 1188, 1171, 1078, 961, 893, 843, 800, 754 cm-1; HRMS
(MultiMode ESI/APCI) m/z calc’d for C25H21O4 [M+H]+: 385.1438, found 385.1440,
found; [α]25D 52.4° (c 0.75, CHCl3, 83% ee).
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(R)-5,7-dimethyl-2-phenylchroman-4-one (195)
Synthesized according to the general procedure and purified by flash chromatography
(6:1 hexanes/EtOAc) to afford a colorless solid (84% yield). 1H NMR (500 MHz, CDCl3)
δ 7.48–7.38 (m, 5H), 6.75 (s, 1H), 6.66 (s, 1H), 5.42 (dd, J = 2.8, 13.3 Hz, 1H), 3.05 (dd,
J = 13.3, 16.5 Hz, 1H), 2.84 (dd, J = 2.9, 16.5 Hz, 1H), 2.64 (s, 3H), 2.31 (s, 3H); 13C
NMR (125 MHz, CDCl3) δ 193.0, 162.7, 146.1, 141.9, 139.1, 128.8, 128.6, 126.1, 126.0,
117.2, 116.2, 78.8, 46.1, 22.8, 21.7; IR (Neat Film, NaCl): 3650, 3586, 2916, 2360, 1675,
1616, 1559, 1320, 1279, 1159, 1072, 843, 763 cm-1; HRMS (MultiMode ESI/APCI) m/z
calc’d for C17H17O2 [M+H]+: 253.1223, found 253.1217; [α ]25D 46.8° (c 1.00, CHCl3,
92% ee).
O
O
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Me
NH(COCF3)
OMe
(R)-N-(4-(5,7-dimethyl-4-oxochroman-2-yl)-2-methoxyphenyl)-2,2,2-
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trifluoroacetamide (85)
Synthesized according to the general procedure and purified by flash chromatography
(8:2 hexanes/EtOAc) to afford a colorless solid (80% yield). 1H NMR (500 MHz, CDCl3)
d 8.57 (s, 1H), 8.35 (d, J = 8.7 Hz, 1H), 7.11-7.07 (m, 2H), 6.75 (s, 1H), 6.67 (s, 1H),
5.40 (dd, J = 2.8, 13.1 Hz, 1H), 3.97 (s, 3H), 3.02 (dd, J = 13.2, 16.5 Hz, 1H), 2.83 (dd, J
= 2.9, 16.5 Hz, 1H), 2.63 (s, 3H), 2.32 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 192.6,
162.4, 152.42 (q, 2J(C,F) = 37.3 Hz), 148.5, 146.2, 142.0, 137.1, 126.3, 125.1, 120.3, 118.8,
117.2, 116.1, 112.6 (m, 1J(C,F) = 211.0 Hz), 107.9, 78.4, 56.1, 46.1, 22.7, 21.7; IR (Neat
Film, NaCl): 3401, 2917, 2848, 1721, 1682, 1613, 1545, 1499, 1464, 1425, 1362, 1322,
1302, 1291, 1266, 1226, 1156, 1119, 1078, 1033, 901, 864, 846, 826, 790, 733 cm-1;
HRMS (MultiMode ESI/APCI) m/z calc’d for C20H19F3NO4 [M]+: 393.1261, found
393.1269; [α]25D 46.8° (c 0.93, CHCl3, 95% ee).
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(R)-4-oxo-2-phenylchroman-7-yl acetate (196)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc to 8:2 hexanes/EtOAc) to afford a colorless solid (77% yield). 1H
NMR (500 MHz, CDCl3) δ 7.96 (d, J = 8.6 Hz, 1H), 7.49–7.38 (m, 5H), 6.85 (d, J = 2.1
Hz, 1H), 6.81 (dd, J = 2.2, 8.6 Hz, 1H), 5.51 (dd, J = 2.9, 13.4 Hz, 1H), 3.08 (dd, J =
13.4, 16.9 Hz, 1H), 2.89 (dd, J = 2.9, 16.9 Hz, 1H), 2.32 (s, 3H); 13C NMR (125 MHz,
CDCl3) δ 190.8, 168.5, 162.3, 156.5, 138.3, 128.8, 128.7, 128.4, 126.0, 118.7, 115.6,
111.1, 79.9, 44.3, 21.1; IR (Neat Film, NaCl): 3034, 1768, 1691, 1611, 1580, 1481, 1437,
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1369, 1340, 1286, 1243, 1192, 1140, 1117, 1062, 1012, 965, 905, 884, 843, 819, 758 cm-
1; HRMS (MultiMode ESI/APCI) m/z calc’d for C17H15O4 [M+H]+: 283.0965, found
283.0969; [α]25D 41.7° (c 1.00, CHCl3, 93% ee).
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(R)-7-methoxy-2-phenylchroman-4-one (199)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford a colorless solid (96% yield). 1H NMR (500 MHz, CDCl3)
δ 7.87 (d, J = 8.8 Hz, 1H), 7.49–7.39 (m, 5H), 6.62 (dd, J = 2.4, 8.8 Hz, 1H), 6.50 (d, J =
2.4 Hz, 1H), 5.47 (dd, J = 2.9, 13.3 Hz, 1H), 3.83 (s, 3H), 3.04 (dd, J = 13.3, 16.9 Hz,
1H), 2.83 (dd, J = 2.9, 16.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 190.6, 166.2, 163.5,
138.8, 128.9, 128.8, 128.7, 126.2, 114.8, 110.3, 100.9, 80.0, 55.7, 44.3; IR (Neat Film,
NaCl): 3583, 2915, 1677, 1602, 1496, 1437, 1355, 1255, 1198, 1156, 1113, 1058, 1022,
996, 953, 835, 764 c m-1; HRMS (MultiMode ESI/APCI) m /z  calc’d for C16H15O3
[M+H]+: 255.1016, found 255.1017; [α]25D 63.5° (c 0.97, CHCl3, 94% ee).
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(R)-methyl 3-(7-methoxy-4-oxochroman-2-yl)benzoate (200)
Synthesized according to the general procedure and purified by flash chromatography
(2:1 hexanes/EtOAc) to afford a colorless solid (81% yield). 1H NMR (500 MHz, CDCl3)
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δ 8.18 (s, 1H), 8.06 (dt, J = 1.3, 7.7 Hz, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 7.7 Hz,
1H), 7.52 (t, J = 7.7 Hz, 1H), 6.64 (dd, J = 2.4, 8.8 Hz, 1H), 6.52 (d, J = 2.4 Hz, 1H),
5.52 (dd, J = 3.0, 13.2 Hz, 1H), 3.95 (s, 3H), 3.85 (s, 3H), 3.03 (dd, J = 13.2, 16.8 Hz,
1H), 2.85 (dd, J = 3.1, 16.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 190.1, 166.6, 166.3,
163.3, 139.3, 130.8, 130.5, 129.9, 129.0, 128.8, 127.3, 114.8, 110.5, 100.9, 79.4, 55.7,
52.3, 44.3; IR (Neat Film, NaCl): 3431, 2951, 2841, 1721, 1683, 1608, 1575, 1496, 1443,
1353, 1335, 1289, 1258, 1210, 1159, 1132, 1114, 1060, 1023, 1000, 953, 838, 824, 752
cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C18H17O5 [M+H]+: 313.1071, found
313.1067; [α]25D 86.8° (c 0.89, CHCl3, 96% ee).
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(R)-7-hydroxy-2-phenylchroman-4-one (196)
Synthesized according to the general procedure and purified by flash chromatography
(6:4 hexanes/EtOAc) to afford a colorless solid (77% yield). 1H NMR (500 MHz,
(CD3)2CO) δ  9.46 (s, 1Η), 7.74 (d, J = 8.7 Hz, 1H), 7.62–7.54 (m, 2H), 7.48–7.42 (m,
2H), 7.41–7.36 (m, 1H), 6.60 (dd, J = 2.3, 8.7 Hz, 1H), 6.46 (d, J = 2.3 Hz, 1H), 5.57 (dd,
J = 2.9, 12.9 Hz, 1H), 3.04 (dd, J = 12.9, 16.7 Hz, 1H), 2.75 (dd, J = 3.0, 16.7 Hz, 1H);
13C NMR (125 MHz, (CD3)2CO) δ 190.1, 165.2, 164.3, 140.5, 129.5, 129.4, 129.3, 127.3,
115.2, 111.3, 103.7, 80.6, 44.8; IR (Neat Film, NaCl): 3376, 1657, 1601, 1464, 1332,
1279, 1255, 1219, 1156, 1121, 1062, 1002, 963, 850, 752 cm-1; HRMS (MultiMode
ESI/APCI) m/z calc’d for C15H13O3 [M+H]+: 241.0859, found 241.0858; [α]25D 76.9° (c
0.98, CHCl3, 93% ee).
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(R)-7-hydroxy-2-(m-tolyl)chroman-4-one (197)
Synthesized according to the general procedure and purified by flash chromatography
(6:4 hexanes/EtOAc) to afford a colorless solid (66% yield). 1H NMR (500 MHz,
(CD3)2CO) δ 9.47 (s, 1H), 7.74 (d, J = 8.6 Hz, 1H), 7.43–7.28 (m, 3H), 7.20 (d, J = 7.2
Hz, 1H), 6.59 (dd, J = 0.9, 8.7 Hz, 1H), 6.46 (d, J = 1.4 Hz, 1H), 5.51 (dd, J = 2.4, 13.0
Hz, 1H), 3.03 (dd, J = 13.0, 16.7 Hz, 1H), 2.72 (dd, J = 2.6, 16.7 Hz, 1H), 2.37 (s, 3H);
13C NMR (125 MHz, (CD3)2CO) δ 189.4, 164.4, 163.5, 139.6, 138.1, 129.1, 128.6, 128.5,
127.0, 123.5, 114.4, 110.4, 102.8, 79.8, 44.0, 20.6; IR (Neat Film, NaCl): 3207, 2918,
2360, 1657, 1601, 1575, 1464, 1332, 1279, 1244, 1221, 1189, 1155, 1121, 1065, 1000,
964, 851, 819, 785, 731 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C16H15O3
[M+H]+: 255.1016, found 255.1012; [α]25D 58.5° (c 1.15, CHCl3, 90% ee).
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(R)-2-(4-fluorophenyl)-7-hydroxychroman-4-one (198)
Synthesized according to the general procedure and purified by flash chromatography
(1:1 hexanes/EtOAc) to afford a colorless solid (50% yield). 1H NMR (500 MHz,
(CD3)2CO) δ 9.47 (s, 1H), 7.74 (d, J = 8.7 Hz, 1H), 7.69–7.55 (m, 2H), 7.28-7.09 (m,
2H), 6.60 (dd, J = 2.9, 8.7 Hz, 1H), 6.46 (d, J = 2.3 Hz, 1H), 5.59 (dd, J = 2.9, 13.0 Hz,
1H), 3.04 (dd, J = 13.0, 16.7 Hz, 1H), 2.75 (dd, J = 2.9, 16.7 Hz, 1H); 13C NMR (125
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MHz, (CD3)2CO) δ 189.1, 164.3, 163.3, 162.6 (d, 1J(C,F) = 245.0 Hz), 135.8 (d, 4J(C,F) = 3.0
Hz), 128.7, 128.6 (d, 3J(C,F) = 8.3 Hz), 115.3 (d, 2J(C,F) = 21.7 Hz), 114.3, 110.5, 102.8,
79.0, 43.8; IR (Neat Film, NaCl): 3256, 2922, 2852, 1661, 1602, 1511, 1464, 1331, 1280,
1225, 1156, 1125, 1003, 853 c m-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C15H10FO3 [M-H]-: 257.0619, found 257.0623; [α]25D 54.1° (c 1.54, CHCl3, 93% ee).
N
Cbz
O
(R)-benzyl 4-oxo-2-phenyl-3,4-dihydroquinoline-1(2H)-carboxylate (201)
Synthesized according to the general procedure and purified by flash chromatography
(8:2 hexanes/EtOAc) to afford an off-white solid (50% yield). [α]25D 110.9° (c 0.98,
CHCl3, 80% ee). All characterization data matches previously reported data.10,11
N
Cbz
O
NH(COCF3)
(R)–benzyl 2-(4-methyl-3-(2,2,2-trifluoroacetamido)phenyl)-4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate (202)
Synthesized according to the general procedure and purified by flash chromatography
(7:3 hexanes/EtOAc) to afford an off-white solid (45% yield). 1H NMR (500 MHz,
CDCl3) δ 7.86 (dd, J = 1.5, 7.8 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.75 (bs, 1H), 7.64 (s,
1H), 7.45–7.47 (m, 1H), 7.35–7.42 (m, 5H), 7.07 (dd, J = 5.6, 7.6 Hz, 2H), 6.98 (dd, J =
1.1, 7.9 Hz, 1H), 6.20 (t, J = 3.5 Hz, 1H), 5.39 (d, J = 12.0 Hz, 1H), 5.33 (d, J = 12.0 Hz,
1H), 3.27 (d, J = 3.9 Hz, 2H), 2.15 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 192.4, 155.0,
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154.9 (q, J = 37.2 Hz), 154.2, 141.3, 137.4, 135.4, 134.6, 133.2, 131.1, 129.6, 128.7,
128.5, 128.4, 128.1, 126.8, 124.9, 124.8, 124.5, 124.3, 121.7, 115.8 (m), 68.6, 55.7, 42.1,
16.9; IR (Neat Film, NaCl): 3281, 1719, 1711, 1683, 1600, 1480, 1460, 1390, 1320,
1303, 1268, 1222, 1162, 1041 cm-1; HRMS (FAB+) m/z calc’d for C26H22O4N2F3
[M+H]+: 483.1532, found 481.1545; [α]25D 65.3° (c 1.0, CHCl3, 79% ee).
N
Cbz
O
(R)-benzyl 4-oxo-2-(m-tolyl)-3,4-dihydroquinoline-1(2H)-carboxylate (203)
Synthesized according to the general procedure and purified by flash chromatography
(2:1 hexanes/EtOAc) to afford an off-white solid (51% yield).  [α]25D 116.5° (c 1.05,
CHCl3, 87% ee). All characterization data matches previously reported data.Error! Bookmark
not defined.
N
Cbz
O
OMe
OMe
(R)-benzyl 2-(3,5-dimethoxyphenyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
(204)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 9:1 hexanes/EtOAc to 7:3 hexanes/EtOAc) to afford a pale yellow solid (50%
yield). 1H NMR (500 MHz, CDCl3) δ 7.90 (dd, J = 1.7, 7.8 Hz, 1H), 7.82 (d, J = 8.3 Hz,
1H), 7.47 (ddd, J = 1.7, 7.2, 8.4 Hz, 1H) 7.35–7.42 (m, 5H), 7.1–7.2 (m, 1H), 6.31 (dd, J
Chapter 3 187
= 0.7, 2.2 Hz, 2H), 6.24 (t, J = 2.1 Hz, 1H), 6.16 (t, J = 3.8 Hz, 1H), 5.38 (d, J = 12.2,
1H), 5.33 (d, J = 12.2, 1H), 3.64 (s, 6H), 3.26–3.27 (m, 2H); 13C NMR (125 MHz,
CDCl3) δ 192.4, 160.9, 154.2, 141.5, 140.5, 135.6, 134.5, 128.7, 128.6, 128.5, 128.4,
128.1, 126.9, 125.3, 125.0, 124.2, 105.0, 99.1, 68.4, 56.2, 55.2, 42.4; IR (Neat Film,
NaCl): 2958, 1708, 1686, 1598, 1479, 1460, 1427, 1389, 1315, 1286, 1221, 1159, 1041
cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C25H23NO5 [M-H]-: 416.1500, found
416.1520; [α]25D 116.8° (c 1.4, CHCl3, 85% ee).
N
Cbz
O
CO2Me
(R)-benzyl 2-(3-(methoxycarbonyl)phenyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate (205)
Synthesized according to the general procedure and purified by flash chromatography
(gradient 9:1 hexanes/EtOAc to 7:3 hexanes/EtOAc) to afford a pale yellow solid (34%
yield). 1H NMR (500 MHz, CDCl3) δ 7.91 (q, J = 1.2 Hz, 1H), 7.89 (ddd, J = 0.5, 1.7, 7.8
Hz, 1H), 7.81–7.86 (m, 2H), 7.47 (ddd, J = 1.8, 7.3, 8.4 Hz, 1H), 7.35–7.40 (m, 6H), 7.29
(d, J = 7.8 Hz, 1H), 7.09 (ddd, J = 1.1, 7.6, 7.6 Hz, 1H), 6.27 (t, J = 3.8 Hz, 1H), 5.41 (d,
J = 12.2 Hz, 1H), 5.34 (d, J = 12.2 Hz, 1H), 3.87 (s, 3H), 3.34–3.35 (m, 2H); 13C NMR
(125 MHz, CDCl3) δ 192.1, 166.5, 154.2, 141.2, 138.5, 134.6, 130.7, 130.6, 128.7, 128.6,
128.5, 128.4, 128.3, 128.1, 127.8, 126.9, 124.9, 124.4, 124.3, 68.6, 55.9, 52.4, 42.2; IR
(Neat Film, NaCl): 2950, 1720, 1688, 1600, 1479, 1460, 1389, 1298, 1281, 1221, 1130,
1041 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C25H21NO5 [M-H]-: 415.1420,
found 415.1419; [α]25D 109.7° (c 0.9, CHCl3, 69% ee).
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N
Cbz
O
F
(R)-benzyl 2-(4-fluorophenyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (206)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 2:1 hexanes/EtOAc) to afford a colorless solid (65% yield).  [α]25D 96.4° (c
1.19, CHCl3, 89% ee). All characterization data matches previously reported data.
N
Cbz
O
(R)-benzyl 4-oxo-2-(p-tolyl)-3,4-dihydroquinoline-1(2H)-carboxylate (207)
Synthesized according to the general procedure and purified by flash chromatography
(gradient 9:1 hexanes/EtOAc to 8:2 hexanes/EtOAc) to afford a colorless solid (65%
yield).  [α]25D 71.2° (c 0.5, CHCl3, 67% ee). All characterization data matches previously
reported data.
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N
Cbz
O
OMe
(R)-benzyl 2-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
(208)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 9:1 hexanes/EtOAc to 8:2 hexanes/EtOAc) to afford a colorless solid (36%
yield). 1H NMR (500 MHz, CDCl3) δ 7.91 (dd, J = 1.5, 7.8 Hz, 1H), 7.78 (d, J = 8.5 Hz,
1H), 7.37–7.46 (m, 6H), 7.07–7.12 (m, 3H), 6.72–6.74 (m, 2H), 6.20 (t, J = 3.9 Hz, 1H),
5.41 (d, J = 12.2 Hz, 1H), 5.34 (d, J = 12.2 Hz, 1H), 3.71 (s, 3H), 3.28 (d, J = 3.9 Hz,
2H); 13C NMR (125 MHz, CDCl3) δ192.9, 158.8, 154.2, 141.3, 135.6, 134.5, 130.0,
128.7, 128.4, 128.1, 127.8, 126.8, 125.0, 124.4, 124.1, 113.9, 68.4, 55.7, 55.1, 42.4; IR
(Neat Film, NaCl): 2957, 1705, 1683, 1601, 1513, 1479, 1460, 1380, 1320, 1302, 1252,
1224, 1181, 1128, 1035 cm-1; HRMS (FAB+) m /z calc’d for C24H22O4N [M+H]+:
388.1549, found 388.1548; [α]25D 54.8° (c 2.5, CHCl3, 53% ee).
N
Cbz
O
O
(R)-benzyl 2-(dibenzo[b,d]furan-4-yl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
(209)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 9:1 hexanes/EtOAc to 8:2 hexanes/EtOAc) to afford a colorless solid (31%
yield). 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.5 Hz, 1H), 7.92 (dd, J = 1.7, 7.8 Hz,
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1H), 7.89–7.90 (m, 1H), 7.77–7.79 (m, 1H), 7.44–7.50 (m, 3H), 7.32–7.41 (m, 6H),
7.09–7.13 (m, 2H), 7.05 (td, J = 1.1, 7.8 Hz, 1H), 6.76 (dd, J = 0.9, 5.3 Hz, 1H), 5.44 (d,
J = 12.5 Hz, 1H), 5.34 (d, J = 12.2 Hz, 1H), 3.63 (dd, J = 2.0, 17.9 Hz, 1H), 3.44 (dd, J =
6.4, 17.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 192.9, 155.9, 153.9, 153.3, 142.1,
135.7, 134.6, 128.6, 128.3, 128.1, 127.3, 126.9, 124.9, 124.8, 124.7, 124.1, 123.9, 123.7,
122.9, 122.7, 122.6, 120.6, 120.3, 111.7, 68.4, 53.4, 42.3; IR (Neat Film, NaCl): 3032,
1710, 1683, 1600, 1459, 1479, 1420, 1388, 1344, 1319, 1298, 1269, 1223, 1186, 1133,
1041, 1027 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C29H20NO4 [M-H]-: ,
found 446.1393; [α]25D 27.4° (c 2.2, CHCl3, 40% ee).
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Table 3.5 Chiral assays
Compound product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
SFC or HPLC
conditions
Table 1
Entry 1
O
Me
O
O
O
O
O
O
O
O
Table 1
Entry 2
Table 2
Entry 2
Table 2
Entry 3
Table 2
Entry 4
Table 2
Entry 5
Table 2
Entry 6
Chiralcel HPLC
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
O
O
Table 1
Entry 3
Chiralcel HPLC
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
15.3 19.6 93
Chiralcel SFC
OB-H
4% MeOH/CO2
isocratic 5 mL/min
Chiralcel SFC
OJ-H
1% MeOH/CO2
isocratic 5 mL/min
2.71 2.51 94
4.57 4.21 76
Chiralcel SFC
OD-H
20% MeOH/CO2
isocratic 5 mL/min
2.09 1.85 93
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 5 mL/min
4.59 3.55 89
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 5 mL/min
3.21 2.68 98
O
O
Chiralcel SFC
OJ-H
3% MeOH/CO2
isocratic 5 mL/min
2.53 2.29 90
17.0 19.1 18
F
Me
CO2Me
Br
NH(COCF3)
O
O
O
Table 2
Entry 7
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 4 mL/min
4.02 4.96 94Cl
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O
O
Table 2
Entry 8
O
O
O
O
O
O
Table 2
Entry 9
Table 2
Entry 11
Table 2
Entry 12
Table 3
Entry 1
Table 3
Entry 2
Table 3
Entry 3
Chiralcel SFC
OB-H
3% MeOH/CO2
isocratic 5 mL/min
O
O
Table 2
Entry 10
Chiralcel HPLC
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
15.3 19.6 85
Chiralpak HPLC
AD-H
10% IPA/Hexanes
isocratic 1 mL/min
22.7 27.2 90
Chiralcel SFC
OD-H
20% MeOH/CO2
isocratic 5 mL/min
2.33 1.98 95
Chiralcel SFC
OD-H
15% MeOH/CO2isocratic 4 mL/min
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 5 mL/min
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 5 mL/min
O
O
Chiralcel SFC
OD-H
25% MeOH/CO2
isocratic 4 mL/min
9.92 5.69 77
3.70 3.44 94
Me
Et
F
OMe
OMe
O
Me
Me
Ac
O
OMe
Me
Ac
O
OMe
Me
Ac
4.64 3.37 88
3.67 3.17 86
4.93 3.87 90
Compound product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
SFC or HPLC
conditions
Et
Me
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Compound product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
SFC or HPLC
conditions
Table 3
Entry 4
O
O
Table 3
Entry 5
Table 3
Entry 7
Table 3
Entry 8
Table 3
Entry 9
Table 3
Entry 10
Table 3
Entry 11
Table 3
Entry 12
Chiralcel SFC
AS-H
4% IPA/CO2
isocratic 5 mL/min
Table 3
Entry 6
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 4 mL/min
4.07 3.76 86
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 4 mL/min
5.89 5.42 91
Chiralcel SFC
OJ-H
5% MeOH/CO2
isocratic 5 mL/min
4.13 3.67 92
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 4 mL/min
4.30 5.38 95
Chiralcel SFC
OJ-H
5% MeOH/CO2
isocratic 5 mL/min
5.45 5.00 93
Chiralcel SFC
OD-H
25% MeOH/CO2
isocratic 4 mL/min
9.19 6.31 83
3.49 4.19 95
Me
Me
O
O
Me
O
O
AcO
O
OMe
Me
O
OMe
Me
O
OMe
Me
O
O
Me
Ac
Ac
Me
F
Ac
Me
Ac
O
Me
NH(COCF3)
OMe
O
O
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 4 mL/min
6.87 5.83 95
Me
Me
Ac
Br
Chiralcel SFC
OD-H
15% MeOH/CO2
isocratic 4 mL/min
3.68 4.13 86
O
OMe
Me
COOMe
Ac
Chapter 3 194
Compound product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
SFC or HPLC
conditions
Table 3
Entry 13
O
O
Table 3
Entry 14
Table 3
Entry 16
Table 3
Entry 17
Table 3
Entry 15*
Chiralcel HPLC
OD-H
10% IPA/Hexanes
isocratic 1 mL/min
Chiralcel SFC
OD-H
10% MeOH/CO2
isocratic 4 mL/min
18.30 16.63 93
9.01 8.44 90
Chiralcel SFC
OD-H
5% MeOH/CO2
isocratic 4 mL/min
6.71 6.23 93
O
O
HO
O
O
HO
MeO
Me
F
Chiralcel SFC
OJ-H
5% MeOH/CO2
isocratic 5 mL/min
Chiralcel SFC
OD-H
15% MeOH/CO2
isocratic 4 mL/min
5.81 4.70 96
5.88 5.07 94
O
O
MeO
O
O
MeO
COOMe
* The free-OH compound from Table 3 Entry 15 was unsuccessfully separated by analytical SFC or HPLC.  The 
compound was methylated under standard conditions, and the methyl ether was used to determine the ee.
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Compound product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
SFC or HPLC
conditions
Table 4
Entry 1
Table 4
Entry 2
Table 4
Entry 4
Table 4
Entry 5
Table 4
Entry 6
Table 4
Entry 7
Table 4
Entry 8
Table 4
Entry 9
Chiralpak
AS-H
5% MeOH/CO2
isocratic 5 mL/min
Table 4
Entry 3
Chiralcel SFC
OB-H
10% MeOH/CO2
isocratic 5 mL/min
3.28 3.67 85
Chiralcel SFC
AS-H
5% MeOH/CO2
isocratic 5 mL/min
Chiralpak SFC
IC
10% MeOH/CO2
isocratic 5 mL/min
4.93 4.43 85
4.87 3.71 85
Chiralpak SFC
AD-H
10% MeOH/CO2
isocratic 5 mL/min
5.47 6.07 60
Chiralpak SFC
IC
10% MeOH/CO2
isocratic 5 mL/min
2.91 2.53
Chiralpak SFC
IC
10% MeOH/CO2
isocratic 5 mL/min
Chiralpak
AS-H
10% MeOH/CO2
isocratic 5 mL/min
Chiralcel SFC
AS-H
5% MeOH/CO2
isocratic 5 mL/min
4.44 3.91 89
4.65 4.19 80
N
Cbz
O
N
Cbz
O
N
Cbz
O
N
Cbz
O
N
Cbz
O
N
Cbz
O
N
Cbz
O
N
Cbz
O
N
Cbz
O
NH(COCF3)
Me
Me
OMe
OMe
CO2Me
F
Me
OMe
O
67
3.87 3.36 54
6.24 5.24 40
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Spectra relevant to Chapter 3: Palladium-catalyzed addition of 
arylboronic acids to heterocyclic conjugate acceptors 
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Figure A2.3 13C NMR (126 MHz, CDCl3) of compound 84 
 
 
Figure A2.2 Infrared spectrum (Thin Film, NaCl) of compound 84 
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Figure A2.6 13C NMR (126 MHz, CDCl3) of compound 174 
 
 
Figure A2.5 Infrared spectrum (Thin Film, NaCl) of compound 174 
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Figure A2.9 13C NMR (126 MHz, CDCl3) of compound 175 
 
 
Figure A2.8 Infrared spectrum (Thin Film, NaCl) of compound 175 
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Figure A2.12 13C NMR (126 MHz, CDCl3) of compound 176 
 
 
Figure A2.11 Infrared spectrum (Thin Film, NaCl) of compound 176 
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Figure A2.15 13C NMR (126 MHz, CDCl3) of compound 177 
 
 
Figure A2.14 Infrared spectrum (Thin Film, NaCl) of compound 177 
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Figure A2.18 13C NMR (126 MHz, CDCl3) of compound 178 
 
 
Figure A2.17 Infrared spectrum (Thin Film, NaCl) of compound 178 
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Figure A2.21 13C NMR (126 MHz, CDCl3) of compound 181 
 
 
Figure A2.20 Infrared spectrum (Thin Film, NaCl) of compound 181 
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Figure A2.24 13C NMR (126 MHz, CDCl3) of compound 183 
 
 
Figure A2.23 Infrared spectrum (Thin Film, NaCl) of compound 183 
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Figure A2.27 13C NMR (126 MHz, CDCl3) of compound 184 
 
 
Figure A2.26 Infrared spectrum (Thin Film, NaCl) of compound 184 
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Figure A2.30 13C NMR (126 MHz, CDCl3) of compound 185 
 
 
Figure A2.29 Infrared spectrum (Thin Film, NaCl) of compound 185 
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Figure A2.33 13C NMR (126 MHz, CDCl3) of compound 186 
 
 
Figure A2.32 Infrared spectrum (Thin Film, NaCl) of compound 186 
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Figure A2.36 13C NMR (126 MHz, CDCl3) of compound 187 
 
 
Figure A2.35 Infrared spectrum (Thin Film, NaCl) of compound 187 
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Figure A2.39 13C NMR (126 MHz, CDCl3) of compound 188 
 
 
Figure A2.38 Infrared spectrum (Thin Film, NaCl) of compound 188 
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Figure A2.42 13C NMR (126 MHz, CDCl3) of compound 189 
 
 
Figure A2.41 Infrared spectrum (Thin Film, NaCl) of compound 189 
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Figure A2.45 13C NMR (126 MHz, CDCl3) of compound 190 
 
 
Figure A2.44 Infrared spectrum (Thin Film, NaCl) of compound 190 
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Figure A2.48 13C NMR (126 MHz, CDCl3) of compound 191 
 
 
Figure A2.47 Infrared spectrum (Thin Film, NaCl) of compound 191 
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Figure A2.51 13C NMR (126 MHz, CDCl3) of compound 192 
 
 
Figure A2.50 Infrared spectrum (Thin Film, NaCl) of compound 192 
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Figure A2.54 13C NMR (126 MHz, CDCl3) of compound 194 
 
 
Figure A2.53 Infrared spectrum (Thin Film, NaCl) of compound 194 
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Figure A2.57 13C NMR (126 MHz, CDCl3) of compound 195 
 
 
Figure A2.56 Infrared spectrum (Thin Film, NaCl) of compound 195 
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Figure A2.60 13C NMR (126 MHz, CDCl3) of compound 85 
 
 
Figure A2.59 Infrared spectrum (Thin Film, NaCl) of compound 85 
 
Appendix 2: Spectra Relevant to Chapter 3  241 
 
 
?
?
?
?
?
?
?
?
?
?
??
??
?
  
Fi
gu
re
 A
2.
61
 1
H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3
) o
f c
om
po
un
d 
19
6 
 
Appendix 2: Spectra Relevant to Chapter 3  242 
 
 
??????????????????????????????
???
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2.63 13C NMR (126 MHz, CDCl3) of compound 196 
 
 
Figure A2.62 Infrared spectrum (Thin Film, NaCl) of compound 196 
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Figure A2.66 13C NMR (126 MHz, CDCl3) of compound 196 
 
 
Figure A2.65 Infrared spectrum (Thin Film, NaCl) of compound 196 
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Figure A2.67 13C NMR (126 MHz, CDCl3) of compound 197 
 
 
Figure A2.68 Infrared spectrum (Thin Film, NaCl) of compound 197 
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Figure A2.72 13C NMR (126 MHz, CDCl3) of compound 198 
 
 
Figure A2.71 Infrared spectrum (Thin Film, NaCl) of compound 198 
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Figure A2.75 13C NMR (126 MHz, CDCl3) of compound 199 
 
 
Figure A2.74 Infrared spectrum (Thin Film, NaCl) of compound 199 
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Figure A2.78 13C NMR (126 MHz, CDCl3) of compound 200 
 
 
Figure A2.77 Infrared spectrum (Thin Film, NaCl) of compound 200 
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Figure A2.81 13C NMR (126 MHz, CDCl3) of compound 202 
 
 
Figure A2.80 Infrared spectrum (Thin Film, NaCl) of compound 202 
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Figure A2.84 13C NMR (126 MHz, CDCl3) of compound 204 
 
 
Figure A2.83 Infrared spectrum (Thin Film, NaCl) of compound 204 
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Figure A2.87 13C NMR (126 MHz, CDCl3) of compound 205 
 
 
Figure A2.86 Infrared spectrum (Thin Film, NaCl) of compound 205 
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Figure A2.90 13C NMR (126 MHz, CDCl3) of compound 207 
 
 
Figure A2.89 Infrared spectrum (Thin Film, NaCl) of compound 207 
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Figure A2.93 13C NMR (126 MHz, CDCl3) of compound 208 
 
 
Figure A2.92 Infrared spectrum (Thin Film, NaCl) of compound 208 
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Figure A2.96 13C NMR (126 MHz, CDCl3) of compound 209 
 
 
Figure A2.95 Infrared spectrum (Thin Film, NaCl) of compound 209 
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CHAPTER 4
Mechanism and Enantioselectivity in Palladium-Catalyzed Conjugate
Addition of Arylboronic Acids to β-Substituted Cyclic Enones: Insights
from Computation and Experiment÷
R1
O O
B(OH)2
N N
O
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÷ This work was completed in collaboration with Dr. Alexander N. Marziale, Dr. Michele
Gatti, Dr. Kotaro Kikushima,  as well as computational collaboration with Lufeng Zou,
Dr. Peng Liu, and Dr. Yu Lan from the laboratory of Prof. K. N. Houk at UCLA. It was
published: Holder, J. C.; Zou, L.; Marziale, A. N., Liu, P.; Lan, Y.; Gatti, M.; Kikushima,
K.; Houk, K. N.; Stoltz, B. M. J. Am. Chem. Soc. 2013, 135, 14996. Copyright American
Chemical Society 2013.
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Abstract
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Enantioselective conjugate additions of arylboronic acids to β-substituted cyclic enones
have been reported previously from our laboratories. Air and moisture tolerant conditions
were achieved with a catalyst derived in situ from palladium(II) trifluoroacetate and the
chiral ligand (S)-t-BuPyOx. We now report a combined experimental and computational
investigation on the mechanism, the nature of the active catalyst, the origins of the
enantioselectivity, and the stereoelectronic effects of the ligand and the substrates of this
transformation. Enantioselectivity is controlled primarily by steric repulsions between the
t-Bu group of the chiral ligand and the α-methylene hydrogens of the enone substrate in
the enantiodetermining carbopalladation step. Computations indicate that the reaction
occurs via formation of a cationic arylpalladium(II) species, and subsequent
carbopalladation of the enone olefin forms the key carbon-carbon bond. Studies of non-
linear effects and stoichiometric and catalytic reactions of isolated (PyOx)Pd(Ph)I
complexes show that a monomeric arylpalladium-ligand complex is the active species in
the selectivity-determining step. The addition of water and ammonium
hexafluorophosphate synergistically increases the rate of the reaction. These additives
also allow the reaction to be performed at 40 °C and facilitate an expanded substrate
scope.
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4.1 Introduction
Asymmetric conjugate addition has become a familiar reaction manifold in the
synthetic chemists’ repertoire.1 Though seminal reports involved highly reactive
organometallic nucleophiles,2 systems were rapidly developed that involved functional-
group-tolerant organoboron nucleophiles. Namely, Hayashi pioneered the use of
rhodium/BINAP catalysts for the asymmetric conjugate addition of a number of boron-
derived nucleophiles.3 As an economical alternative to the rhodium systems, Miyaura
pioneered the use of chiral palladium-phosphine catalysts to address similar
transformations4 and Minnaard reported a palladium-catalyzed asymmetric conjugate
addition using a catalyst formed in situ from palladium trifluoroacetate and commercially
available (S,S)-Me-DuPhos.5
More recently, asymmetric conjugate addition has become a useful strategy for the
challenge of constructing asymmetric quaternary stereocenters.6 Again, many earlier
developed methods involved highly reactive diorganozinc,7 triorganoaluminum,8 and
organomagnesium9 nucleophiles, however, more recently chiral rhodium/diene systems
have been shown to construct asymmetric quaternary stereocenters with functional group-
tolerant organoboron nucleophiles.10 While rhodium systems are highly developed and
exhibit a wide substrate scope, the high cost of the catalyst precursors and oxygen
sensitivity of the reactions are undesirable. Despite progress in palladium-catalyzed
conjugate additions for the formation of tertiary stereocenters,11 no conditions were
amenable to the synthesis of even racemic quaternary centers until Lu and coworkers
disclosed a dicationic, dimeric palladium/bipyridine catalyst in 2010.12 However, it was
not until our recent report that a palladium-derived catalyst was employed to generate an
Chapter 4 270
asymmetric quaternary stereocenter via conjugate addition chemistry.13 We employed a
catalyst derived in situ from Pd(OCOCF3)2 and a chiral pyridinooxazoline (PyOx)
ligand,14 (S)-t-BuPyOx (ligand 82, Scheme 4.1). This catalyst facilitates the asymmetric
conjugate addition of arylboronic acids to β-substituted enones in high yield and good
enantioselectivity.
Scheme 4.1  Asymmetric conjugate addition with (S)-t-BuPyOx ligand
N N
O
t-Bu
O
R
OPd(OCOCF3)2 (5 mol %)
Ligand 82 (6 mol %)
ArB(OH)2 (2 equiv.)
ClCH2CH2Cl, 60 °C, 12 h ArR
Up to 99% yield
Up to 96% ee
82
(S)–t-BuPyOx
Importantly, this reaction is highly tolerant of air and moisture, and the chiral
ligand, while not yet commercially available, is easily prepared.15 Initial results with the
Pd/PyOx system were reported rapidly due to concerns over competition in the field.
Indeed, recent publications prove palladium-catalyzed conjugate addition to be a
burgeoning field of research.16 After the initial disclosure, we observed that in addition to
catalyzing conjugate additions to 5-, 6-, and 7-membered enones, the Pd/PyOx catalyst
successfully reacted with chromones and 4-quinolones.17 Intrigued by the broad substrate
scope and operational simplicity of this highly asymmetric process, we conducted a
thorough study to optimize the reaction conditions, including measures to reduce the
catalyst loading, lower the reaction temperature, and further generalize the substrate
scope. We also performed mechanistic and computational investigations toward
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elucidating the catalytic cycle, active catalyst species, and the stereoelectronic effects on
enantioselectivity of this reaction.
4.2 Results
4.2.1 Effects of Water on Catalyst Turnover
In our initial report,13 we were able to demonstrate that the addition of up to 10
equivalents of water had no deleterious effect.  Despite this, water was not considered as
an important additive in the initially reported conditions because the stoichiometric
arylboronic acid was believed to be a sufficient proton source to turn over the catalyst. In
considering the overall reaction scheme, a more precise analysis of the mass balance of
the reaction led us to reconsider the importance of water as an participant in the overall
transformation (Scheme 4.2a). These considerations proved to be essential during the
scale up of the reaction. Attempts to use the original conditions (with no water added)
failed to convert enone 95 efficiently, generating the desired ketone (35) only in moderate
yield (Scheme 4.2b). We reasoned that when the reaction is performed on a small scale
under ambient atmosphere the moisture present in the air and on the glassware could be
sufficient to drive the reaction to completion. On a larger scale, however, where a more
significant quantity of water was necessary, this was no longer true. Gratifyingly, upon
the addition of as little as 1.5 equivalents of water to the reaction mixture, both reactivity
and the enantioselectivity were restored (Scheme 4.2c), affording ketone 35 in high yield
and ee.
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Scheme 4.2  (a) Examination of reaction mass balance (b) Absence of water prohibits scale-up (c)
Addition of water facilitates larger scale reactions
O
Ph
O
H
HO B(OH)2PhB(OH)2 H2O
OO (S)-t-BuPyOx (6 mol %)
Pd(OCOCF3)2 (5 mol %)
PhB(OH)2 (2 equiv)
ClCH2CH2Cl, 60 °C, 12 h
5 equiv H2O
Ph
97% yield, 91% ee
22 mmol scale
OO (S)-t-BuPyOx (6 mol %)
Pd(OCOCF3)2 (5 mol %)
PhB(OH)2 (2 equiv)
ClCH2CH2Cl, 60 °C, 12 h
No Added H2O
Ph
Incomplete Conversion
on 1 g scale (9 mmol)
95
95
95 35
35
35
(a)
(b)
(c)
We next sought to measure deuterium incorporation at the carbonyl α-position as
a method to determine the source of the proton utilized in reaction turnover. Reactions
were performed substituting deuterium oxide for water and observed by 1H and 2H NMR
analysis (Figure 4.1).  Using phenylboronic acid, the reaction afforded ketone 35 in
similar yield and enantioselectivity (Figure 4.1a). Likewise, substitution of
phenylboroxine ((PhBO)3) for phenylboronic acid and deuterium oxide for water (Figure
4.1b) resulted in identical yield, albeit with slightly depressed ee observed in ketone 35.
Analysis of ketone 3 5  by 1H NMR (Figure 4.1c) showed significant deuterium
incorporation at the α-position of the carbonyl, even in the presence of phenylboronic
acid.18 As expected, a higher degree of deuterium incorporation was observed in the
reaction where phenyl boroxine was substituted for the boronic acid, however, the similar
level of incorporation in both experiments suggested that the deuterium oxide was the
agent assisting reaction turnover regardless of the use of protic or aprotic boron reagent.
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Figure 4.1 (a) deuterium incorporation using PhB(OH)2 (b) deuterium incorporation using (PhBO)3
(c) 1H NMR data measuring deuterium incorporation by integral comparison of α-protons relative to
H5, control: treatment of ketone 35 to deuterium incorporation conditions
OO (S)-t-BuPyOx (6 mol %)Pd(OCOCF3)2 (5 mol %)
NH4PF6 (30 mol %)
ClCH2CH2Cl, 60 °C, 12 h
D2O
Ph
B(OH)2
OO (S)-t-BuPyOx (6 mol %)
Pd(OCOCF3)2 (5 mol %)
NH4PF6 (30 mol %)
ClCH2CH2Cl, 60 °C, 12 h
D2O
Ph
B
O
B
O
B
O PhPh
Ph
(99% yield)
(96% yield)
Ph
O
H1
H2
H3
H4
entry
boronic acid
boroxine
0.67 0.52 0.88 1.00
0.52 0.41 0.66 1.00
H2 H3 + H4 H5H1
integral relative to H5
(a)
(b)
(c)
95
95
35
35
D
D
H5
control 0.94 0.90 1.67 1.00
4.2.2. Effects of Salt Additives on Reaction Rate
Satisfied with our ability to perform the reaction on scale, we turned our attention
toward improving the catalyst activity. We observed that nearly all previous literature
reports regarding palladium-catalyzed conjugate addition utilized cationic precatalysts
featuring weakly-coordinative anions (PF6–, SbF6–, BF4– etc.). We reasoned that the
substitution of the trifluoroacetate counterion with a less coordinative species could lead
to an increase in reaction rate. With this goal in mind, we examined a series of salt
additives containing weakly coordinative counterions. We viewed the strategy for the in
situ generation of the catalyst as the more practical and operationally simple alternative to
the design, synthesis, and isolation of a new dicationic palladium precatalyst.
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We investigated a number of salt additives to test this mechanistic hypothesis
(Table 4.1).  Coordinating counterions like chloride (entry 1) shut down reactivity.
Pleasingly, as per our hypothesis, weakly coordinating counterions with sodium cations
(entries 2–4) facilitated swift reaction, albeit with depressed ee. Tetrabutylammonium
salts (entries 5–6) encountered slow reaction times, but good enantioselectivity. Sodium
tetraphenylborate (entry 7), however, failed to deliver appreciable quantities of the
quaternary ketone 35, as rapid formation of biphenyl was observed. Ammonium salts
(entries 8–9) provided the desired blend of reaction rate and enantioselectivity. We
concluded that the hexafluorophosphate anion (entry 9) gave the optimal combination of
short reaction time with minimized loss of enantioselectivity. Perhaps the influence/effect
of the salt on the polarity of the medium also effects the enantioselectivity.
Table 4.1 Effect of salt additives on reaction rate a
entrya time (h) yield (%)b ee (%)c
1
2
3
24 trace ---
24 trace ---
6 97 87
4
5
6
7
24 98 90
5 99 81
24 95 88
additive
n-(Bu)4PF6
8 81d 88
NaCl
NaBPh4
NaPF6
NaSbF6
NaBF4
n-(Bu)4BF4
O O
Ph
(S)-t-BuPyOX, PhB(OH)2
Pd(OCOCF3)2
additive
ClCH2CH2Cl, 40 °C
95 35
15 93 898 NH4BF4
12 96 919 NH4PF6
aConditions: phenylboronic acid (0.5 mmol), 3-methylcyclohexen-2-one (0.25 mmol),
water (5 equiv), additive (30 mol %), Pd(OCOCF3)2 (5 mol %) and (S)-t-BuPyOx (6
mol %) in ClCH2CH2Cl (1 mL) at 40 °C . bGC yield utilizng tridecane standard. cee was
determined by chiral HPLC.  dReaction checked at 83% conversion as determined by
GC analysis.
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Based on our previous observations regarding the beneficial nature of water as an
additive, we next explored the combined effect of water and hexafluorophosphate
counterions.  We found addition of both water and ammonium hexafluorophosphate were
the most successful for increasing reactivity (Table 4.2).  Water alone is insufficient to
alter reactivity (entry 1), though the use of water with 30 mol % ammonium
hexafluorophosphate greatly reduced the reaction time (entry 2) to only 1.5 hours with
minimal effect on yield or ee. Furthermore, this combination of additives allowed the
reaction to proceed at temperatures as low as 25 °C with 5 mol % palladium and 6 mol %
ligand, and lowering of catalyst loadings to only 2.5 mol % of palladium and 3 mol %
ligand at 40 °C (entry 3). We determined that optimal conditions for the reaction with
lower catalyst loading to be 5 equivalents of water, 30 mol % ammonium
hexafluorophosphate at 40 °C (entry 4), conditions that reproduce the original result at
milder temperature and lower catalyst loadings. The reaction was extraordinarily tolerant
of the amount of water, with both 10 (entry 5) and 20 (entry 6) equivalents of water
having minimal effect on the yield or ee.  Loadings of ammonium hexafluorophosphate
can be as low as 5 mol % (entry 7) or 10 mol % (entry 8) with reactions completed in 24
hours. Stoichiometric additive (entry 9) gave no additional benefit (entry 4). Thus, we
optimized the additive amounts to be 30 mol % ammonium hexafluorophosphate and 5
equivalents of water
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Table 4.2 Effect of water and NH4PF6 on reaction rate
 a
O O
entrya time (h) yield (%)b ee (%)c
1
2
3
10
5
12 99 91
temp 
(°C)
60
1.5 93 8860
12 95 9140
Pd 
(mol %)
5
4
5
6
7
36 98 9125
12 96 8940
12 95 9040
8
5 24 93 9040
H2O 
(equiv.)
NH4PF6 
(mol %)
---
30
5 30
5 30
10 30
20 30
5
9
5 24 93 924010
5 12 97 8840100
Ph
ligand 
(mol %)
5
5
6
6
6
2.5 3
2.5 3
2.5 3
2.5 3
2.5 3
2.5 3
(S)-t-BuPyOx, PhB(OH)2
Pd(OCOCF3)2
H2O,  NH4PF6
ClCH2CH2Cl
95 35
aConditions: phenylboronic acid (1.0 mmol), 3-methylcyclohexen-2-one (0.5 mmol), water, NH4PF6,
Pd(OCOCF3)2 and (S)-t-BuPyOx in ClCH2CH2Cl (2 mL). bIsolated yield. cee was determined by chiral HPLC.
Though increased rates were observed at 60 °C, the newly-found ability to
perform reactions at 40 °C promoted superior reactivity of many substrates (Table 4.3).
In fact, many substrates that exhibited high enantioselectivities under the original 60 °C
reaction conditions suffered from poor yields. Reacting these substrates at 40 °C with the
addition of ammonium hexafluorophosphate and water promoted significantly higher
isolated yields. Arylboronic acids containing halides, such as m-chloro- (210a) and m-
bromophenylboronic acid (210b) reacted with good enantioselectivity, but each substrate
was originally marred by low yield using our original conditions. However, when reacted
under the newly optimized reaction conditions, the isolated yield for the addition of
chlorophenylboronic acid increased from 55% to 96% and for bromophenylboronic acid
from 44% to 86%. Even m-nitroboronic acid (210c) reacted with higher isolated yield.
Notably, some ortho-substituted boronic acids, such as o-fluorophenylboronic acid
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(210d), reacted more successfully under the milder reaction conditions, leading to
increased isolated yield of 70%.
Table 4.3 Increased reaction yields with different arylboronic acid substrates under new reaction
conditions a
210d210c
Br NO2
55 % Yield 97 % ee
(HO)2B (HO)2B (HO)2BCl (HO)2B
96 % Yield 96 % ee
44 % Yield 86 % ee
84 % Yield 84 % ee
40 % Yield 92 % ee
81 % Yield 91 % ee
32 % Yield 77 % ee
70 % Yield 77 % ee
F
210a 210b
O O(S)-t-BuPyOx (6 mol %)Pd(OCOCF3)3 (5 mol %)
NH4PF6, H2O
ClCH2CH2Cl
40 °C, 12 hB(OH)2
R
R
95 210 211
aBlue font: reported yield and ee of 211 in the absence of NH4PF6 and water with reactions performed at 60
°C; red font: yield and ee of 211 with additives.  Conditions: boronic acid (1.0 mmol), 3-
methylcyclohexen-2-one (0.5 mmol), NH4PF6 (30 mol %), water (5 equiv.), Pd(OCOCF3)2 (5 mol %) and
(S)-t-BuPyOx (6 mol %) in ClCH2CH2Cl (2 mL) at 40 °C . Isolated yield reported, ee was determined by
chiral HPLC.
4.2.3 Determination of active catalyst as monomeric (ML)-system
Despite optimization of catalytic conditions for this highly enantioselective
process, we were unsure of the nature of the active catalyst. For example, some rhodium
conjugate addition systems have been shown to involve trimeric ligand/metal
complexes.19  Furthermore, Lu and coworkers reported the use of the palladium dimer
[(bpy)Pd(OH)]2•2BF4 as a precatalyst for conjugate addition.12 We aimed to rule out the
in situ formation and kinetic relevance of such dimers in our system. In seeking to
support our hypothesized monomeric ligand-metal complex, we performed a non-linear
effect study to determine the relationship between the ee of the ligand and the ee of the
generated product.20 The endeavor was to exclude dimeric (ML)2 complexes from kinetic
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relevance, clarifying the monomeric nature of the active catalyst.21 Five reactions were
performed using a catalyst with different level of enantiopurity (racemic, 20%, 40%, 60%
and 80% ee), and the obtained enantioselectivities were plotted against ee of the catalyst
mixture (Figure 4.2). The obtained data clearly demonstrates that a non-linear effect is
not present, and this observation strongly supports the action of a single, monomeric
(ML)-type Pd/PyOx catalyst as the kinetically relevant species.21  While the precise nature
of the active catalyst species is unknown, isolated (PyOx)Pd(OCOCF3)2 serves as an
identically useful precatalyst, delivering ketone 35 in 99% yield and 92% ee.22
Figure 4.2  Determination of linearity between catalyst ee and product ee
We aimed to augment the result of our non-linear experiment with a qualitative
measurement of the molecular weight of the catalyst in solution (Table 4.4). Diffusion
oriented spectroscopy (DOSY) NMR studies are a common method of correlating the
molecular weight of a solution complex with its diffusion rate, which can be determined
by NMR observation.23 We used the pre-formed complex (PyOx)Pd(OCOCF3)2 as
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standards for molecular weight (entry 1). As a high molecular weight standard for the
hypothetical dimer, we measured the diffusion of (dppf)PdCl2 (entry 2). Next, we mixed
the PyOx ligand with a Pd(OCOCF3)2, ammonium hexafluorophosphate, and water in
CD2Cl2 and observed the diffusion rate of the major species formed in situ (entry 3). The
major solution species for the complex formed in entry 3 matched the 1H and 13C solution
structure of synthesized and isolated (PyOx)Pd(OCOCF3)2 (entry 1), and produced a very
reasonable match for diffusion coefficient in the DOSY NMR studies when the value of
the solvent’s diffusion coefficient (CD2Cl2) is taken into account as a standardization
parameter. Furthermore, the high molecular weight standard (entry 2) was observed to
diffuse slower than both these complexes, suggesting no change in speciation occurs
when (PyOx)Pd(OCOCF3)2 is in solution. Taken together, these data suggest that the
major palladium species formed in solution is a monomeric ligand-metal complex. We
cannot definitively rule that (PyOx)Pd(OCOCF3)2 is the active catalyst; in fact, this
author hypotheses that cationic [(PyOx)Pd(OH)]+ is the likely active catalyst. However,
our data does suggest that, initially, the monomeric ligand-metal complex is the major
species formed under the reaction conditions. Furthermore, the isolated
(PyOx)Pd(OCOCF3)2 complex is chemically competent as a catalyst for the reaction, and
delivers ketone 3 according to the general procedure in 99% yield and 92% ee.
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Table 4.4 DOSY NMR Values for palladium complexes
entry Pd species molecular weight (g/mol) diffusion coefficent (d) CD2Cl2 diffusion coefficient (d)
1
2
3
(PyOx)Pd(OCOCF3)2 536.72
(dppf)PdCl2
Pd(OCOCF3)2 + PyOx + NH4PF6 + H2O
731.70
unknown
1.1 x 10-4 3.3 x 10-4
0.9 x 10-4 3.2 x 10-4
1.1 x 10-4 3.2 x 10-4
Conditions: Spectra acquired utilizing complex (0.015 mmol) dissolved in CD2Cl2 (700 mL) at 25 °C.  Pulse sequence:Varian 2D DOSY with convection
compensation (gradient stimulated echo), with the 90-Grad-90 option and 1.5 ms diffusion gradient length pules (called “DgsteSL_cc” in VnmrJ).  Data
processed in VnmrJ and corrected for non-uniform gradients.  Attached spectra are processed in Mestrenova for clarity, and do not match the numbers
shown in the above table.
4.2.4 Computational Investigations of the Reaction Mechanism
Despite the results of the non-linear effect study agreeing with the proposed
monomeric Pd/PyOx catalyst, no formal exploration of the mechanism of this
transformation has been reported. Our initial hypothesis concerning the mechanism of the
Pd/PyOx-catalyzed asymmetric conjugate addition were well informed by the seminal
work of Miyaura,24 however, the heterogeneous nature of the reaction medium, undefined
nature of the precise catalyst,25 and complicating equilibrium of organoboron species
make kinetic analysis and thorough mechanistic study extremely challenging.26
Previously, Houk performed density functional theory (DFT) calculations to
investigate the mechanism of palladium-catalyzed conjugate addition of arylboronic acids
to enones, explicitly studying a catalytic palladium(II)/bipyridine system in MeOH
solvent similar to that developed by Lu.12,27,28  Calculations indicated that the mechanism
involves three steps: transmetallation, carbopalladation (i.e., alkene insertion), and
protonation with MeOH. Monomeric cationic palladium complexes are the active species
in the catalytic cycle. The carbopalladation is calculated to be the rate- and
stereoselectivity-determining step (Scheme 4.3). Now, Houk and coworkers performed
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DFT investigations on the catalytic cycle of reactions with the Pd/PyOx manifold and the
effects of substituents and ligand on reactivity and enantioselectivity. The calculations
were performed at the theoretical level found satisfactory in their previous study of the
Pd/bipyridine system. Geometries were optimized with BP8629 and a standard 6-31G(d)
basis set (SDD basis set for palladium). Solvent effects were calculated with single point
calculations on the gas phase geometries with the CPCM solvation model in
dichloroethane. All calculations were performed with Gaussian 03.30
Scheme 4.3 Enantioselectivity-determining step in asymmetric conjugate addition of arylboronic
acids to cyclic enones
82O OB(OH)2
N N
O
t-Bu
Pd(OCOCF3)2
ClCH2CH2Cl, 60 °C
95
Enantioselectivity-Determining Step
35
N
Pd
N
O O
H
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The computed potential energy surface for the catalytic cycle is shown in Figure
4.3. To simplify the computations of the mechanisms, a model ligand, in which the t-Bu
group on the t-BuPyOx ligand was replaced by H, was used in the calculations of the
mechanisms and the full ligand was used in the calculations of enantioselectivities which
will be discussed below. Calculations on the reaction mechanism with the full ligand
scaffold, however, generated a similar reaction diagram, and the rate- and stereo-
determining steps were unchanged. The first step involves transmetallation of cationic
Pd(II)-phenylborate complex 212  to generate a phenyl palladium complex.
Transmetallation requires a relatively low free energy barrier of 15.6 kcal/mol (213-ts)
with respect to complex 212 and leads to a phenyl palladium complex (214). Complex
214 undergoes ligand exchange to form a more stable phenyl palladium-enone complex
218, in which the palladium binds to the enone oxygen atom. Complex 218 isomerizes to
a less stable π complex 219 and then undergoes carbopalladation of the enone (220-ts) to
form the new carbon–carbon bond. The carbopalladation step requires an activation free
energy of 21.3 kcal/mol (219 → 220-ts), and is the stereoselectivity-determining step.
The regioisomeric carbopalladation transition state 222-ts requires 5.6 kcal/mol higher
activation free energy than 220-ts, indicating the formation of the α-addition compound
223 is unlikely to occur. Coordination of one water molecule to 221 leads to a water-
palladium enolate complex 224, and finally facile hydrolysis of 224 via 225-ts affords
product complex 226. Liberation of the product 35 from 226 and coordination with
another molecule of phenyl boronic acid regenerates complex 212 to complete the
catalytic cycle. The computed catalytic cycle demonstrates some similarities with the
Pd/bipyridine system in our previous computational investigation, which also involves
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monomeric cationic palladium as the active species and a catalytic cycle of
transmetallation, carbopalladation, and protonation (with MeOH instead of H2O). Houk
also considered an alternative pathway involving direct nucleophilic attack of the phenyl
boronic acid at the enone while the Pd catalyst is acting as a Lewis acid to activate the
enone and directs the attack of the nucleophile (215-ts, Figure 3). This alternative
pathway requires an activation free energy of 58.9 kcal/mol, 43.3 kcal/mol higher than
the transmetallation transition state 213-ts. Thus, this alternative pathway was excluded
by calculations.
Figure 4.3  Computed potential energy surface of the catalytic cycle (shown in black), the
alternative direct nucleophilic addition pathway (via 9-ts, shown in blue), and the isomeric
carbopalladation pathway (via 16-ts, shown in green)
OH
HO Pd
NN
B
OH
O
(-21.2)
0.0
15.6
58.9
0.8
-17.4
212
213-ts
214
215-ts
216
-9.0
217
-25.6
218
-11.0
219
-4.3
220-ts
-19.0
221
1.3
222-ts
-13.9
223
-12.4
224
-10.6
225-ts
-22.7
226
ΔGsol
(ΔHsol)
220-ts 225-ts
kcal/mol
HO OH
Pd
B
HO
NN
O
HO
HO Pd
NN
B OH
O
O
215-ts
213-ts
212
214
217
HO
OH
Pd
B
OH
NN
O
Pd
NN
O
Pd
NN
O
O
218
Pd
NN
O
O
Pd
NN
O
O
213-ts
215-ts
220-ts
222-ts
Pd
NN
O
O
222-ts
Pd
NN
O
O
Ph
221
Pd
NN
O
O
Ph
O
H
H
224
225-ts
Pd
NN
O
O
Ph
O
H
H
Pd
NN
O
O
Ph
HO
226
219
(0.0)
(42.6)
(14.4)
(-12.9)
(-15.3)
(5.1)
(-24.2)
(-11.3)
(-0.4)
(-6.8)
(-15.3) (-24.0)
(-23.7)
(-33.2)
95
O
B(OH)3
-22.3
212
(-35.0)
35
O
Ph
B(OH)2
Pd
NN
O
O
223
HO
HO Pd
NN
B
HO
O
O
216
H2O
Chapter 4 284
4.2.5 Experimental and Computational Investigations of the Enantioselectivities
With the aforementioned optimized reaction conditions and computational
elucidation of the mechanism and stereoselectivity-determining transition states, Houk
explored the effects of ligand and substrate on enantioselectivities by both experiment
and computations. The enantioselectivity-determining alkene insertion step involves a
four-membered cyclic transition state, which adopts a square-planar geometry. When a
chiral bidentate ligand, such as (S)-t-BuPyOx, is employed, there are four possible
isomeric alkene insertion transition states. The 3D structures of the alkene insertion
transition states in the reaction of 3-methyl-2-cyclohexenone with (S)–t-BuPyOx ligand
are shown in Figure 4.4. In 1-TS-A and 1-TS-B, the phenyl group is trans to the chiral
oxazoline on the ligand, and in 1-TS-C and 1-TS-D, the phenyl group is cis to the
oxazoline. 1-TS-A, which leads to the predorminant (R)-product, is the most stable as the
t-Bu group is pointing away from other bulky groups. 1-TS-C leads to the same
enantiomer, but with an activation enthalpy 2.6 kcal/mol higher than 1-TS-A. The
difference is likely to result from steric effects between the t-Bu on the ligand and the
phenyl group, as indicated by the C-H and C-C distances labeled in Figure 4. 1-TS-B and
1-TS-D lead to the minor (S)-product, which are ~ 3 kcal/mol less stable than 1-TS-A as
a result of the repulsions between the t-Bu on the ligand and the phenyl group. In 1-TS-B,
the cyclohexenone ring is syn to the t-Bu group on the ligand. The shortest H–H distance
between the ligand and the enone is 2.30 Å, suggesting some steric repulsions. In
contrast, no ligand-substrate steric repulsions are observed in 1-TS-A, in which the
cyclohexenone is anti to the t-Bu. 1-TS-A is also stabilized by a weak hydrogen bond
between the carbonyl oxygen and the hydrogen geminal to the t-Bu group on the
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oxazoline. The O–H distance is 2.16Å. Therefore, the enthalpy of 1-TS-B is 2.3 kcal/mol
higher than that of 1-TS-A. This corresponds to an ee of 94%, which is very similar to
the experimental observation (93%). Enantioselectivities were computed from relative
enthalpies of the transition states. The selectivities computed from Gibbs free energies
are very similar and are given in the experimental procedures section.
Figure 4.4  The optimized geometries of transition states in the enantioselectivity-determining alkene
insertion step of the reaction of 3-methyl-2-cyclohexenone and phenyl boronic acid with (S)–t-
BuPyOx ligand. Selected H–H, C–H, and O–H distances are labeled in Å
1-TS-A
ΔH‡ = 19.2 kcal/mol
1-TS-B
ΔH‡ = 21.5 kcal/mol
1-TS-C
ΔH‡ = 21.8 kcal/mol
1-TS-D
ΔH‡ = 22.2 kcal/mol
Houk then investigated the effects of substituents on the ligand, in particular, at
the 4 position of the oxazoline. The activation enthalpies of four alkene insertion
pathways and the computed and experimental ee for the reaction of 3-methyl-2-
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cyclohexenone and phenyl boronic acid are summarized in Table 4.5. The t-Bu
substituted PyOx ligand is found to be the optimum ligand experimentally (Table 4.5,
entry 1). Replacing t-Bu with smaller groups, such as i-Pr, i-Bu, or Ph, dramatically
reduces the ee.
Table 4.5 Activation energies and enantioselectivities of alkene insertion with (S)-t-BuPyOx, (S)-i-
PrPyOx, (S)-i-BuPyOx, and (S)-PhPyOx ligands
N
Pd
N
O O
R1
H N
Pd
N
O
R1
H
O
N
Pd
N
O
O
R1
HN
Pd
N
O
R1
H
O
n-TS-A n-TS-B n-TS-C n-TS-D
TS R1 ΔH‡ a ee b
TS-A TS-B TS-C TS-D
1 t-Bu 19.2 21.5 21.8 22.2 94%[93%]
2 i-Pr 18.6 19.7 20.1 20.0 67%[40%]
3 i-Bu 18.5 19.3 20.4 20.4 52%[24%]
4 Ph 18.0 19.0 19.6 20.2 65%[52%]
aThe values are activation enthalpies in kcal/mol calculated at the BP86/6-31G(d)–SDD
level and the CPCM solvation model in dichloroethane. bExperimental ee were obtained
under standard conditions and are given in square brackets.
The bulky t-Bu substituent on the ligand is essential not only to discriminate the
diastereomeric transition states 1-TS-A and 1-TS-B, but also fix the orientation of the
ligand to point the chiral center cis to the cyclohexenone. The energy difference between
1-TS-C  and 1-TS-D , in which the chiral center on the ligand is trans  to the
cyclohexenone, is diminished. When the (S)-i-PrPyOx ligand is used, the alkene insertion
transition states with phenyl trans to the oxazoline (2-TS-A and 2-TS-B) are also
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preferred. Thus, the enantioselectivity is determined by the energy difference between 2-
TS-A and 2-TS-B. The (R)-product (via 2-TS-A) is favored with a computed ee of 67%,
slightly higher than the experimental ee (40%). The optimized geometries of 2-TS-A and
2-TS-B are shown in Figure 4.5 and the activation energies of all four transition states are
shown in Table 4.5, entry 2. The i-Pr substituted ligand manifests via similar steric
effects to (S)-t-BuPyOx, with, as expected, slightly weaker steric control. The lower
enantioselectivity is attributed to the weaker steric repulsions between the i-Pr and the
cyclohexenone in 2-TS-B than those with the t-Bu in 1-TS-B. The shortest distance
between the hydrogen atoms on the ligand and the cyclohexenone is 2.35 Å in 2-TS-B,
slightly longer than the H–H distance in 1-TS-B (2.30 Å). Less steric repulsions with the
(S)-i-PrPyOx lead to 2.8 kcal/mol lower activation barriers for 2-TS-B compared to 1-
TS-B. The ligand steric effects on the activation energies of the major pathway TS-A are
smaller; the i-Pr substituted 2-TS-A is only 0.6 kcal/mol more stable than the t-Bu
substituted 1-TS-A.
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Figure 4.5 The optimized geometries of transition states in the enantioselectivity-determining alkene
insertion step of the reaction of (a) 3-methyl-2-cyclohexenone and phenyl boronic acid with (S)-i-
PrPyOx ligand; (b) 3-methyl-δ-2-pentenolide and phenyl boronic acid with (S)-t-BuPyOx ligand.
Selected H–H, C–H, and O–H distances are labeled in Å
2-TS-A
ΔH‡ = 18.6 kcal/mol
2-TS-B
ΔH‡ = 19.7 kcal/mol
7-TS-A
ΔH‡ = 16.7 kcal/mol
7-TS-B
ΔH‡ = 18.6 kcal/mol
(a)
(b)
Electronically differentiated PyOx ligands were also studied, and the results are
summarized in Table 4.6. Electron-withdrawing or donating groups at the 4-position of
the PyOx ligand showed minimal effects on the activation barriers, and were calculated to
have minimal effect on product ee.  With the electron-withdrawing CF3 and the electron-
donating OCH3 on the 4-position of the ligand, the activation enthalpies of alkene
insertion increase by only 0.3 kcal/mol and 0.1 kcal/mol, respectively. The calculated ee
are essentially identical among these three ligands. Experimentally, depressed ee was
observed with both the 4-CF3 and the 4-OCH3 substituted ligands (entries 5 and 6). This
Chapter 4 289
confirms that the enantioselectivity is mainly attributed to the ligand/substrate steric
repulsions.
Table 4.6 Remote ligand substituent effects on activation energies and enantioselectivities of alkene
insertion
N
Pd
N
O O
H N
Pd
N
O
H
O
N
Pd
N
O
O HN
Pd
N
O
H
O
n-TS-A n-TS-B n-TS-C n-TS-D
R2 R2 R2 R2
TS R2 ΔH‡ a ee b
TS-A TS-B TS-C TS-D
1 H 19.2 21.5 21.8 22.2 94%[93%]
5 CF3 19.5 21.7 21.8 22.3 93%[81%]
6 OCH3 19.3 21.5 21.5 22.2 93%[78%]
aThe values are activation enthalpies in kcal/mol calculated at the BP86/6-31G(d)-SDD
level and the CPCM solvation model in dichloroethane. bExperimental ee are given in
square brackets.
The transition state structures shown in Figure 4.5 indicate that the steric control
mainly arises from the repulsion of the Cα' hydrogens on the cyclohexenone with the
ligand. Houk then investigated the effects of substitution at the α ' position and
replacement of the CH2 group with O. The reactivity and enantioselectivity of the
reactions of lactone (Table 4.7, entry 7) and α',α'-dimethylcyclohexenone (entry 8) with
the (S)-t-BuPyOx ligand were computed. The enantioselectivity of lactone is predicted to
be lower than cyclohexenone. The enthalpy of 7-TS-B is 1.8 kcal/mol higher than that of
7-TS-A, corresponding to an ee of 88%. Experimentally, the ee of the lactone product is
59%, also significantly lower than that with cyclohexenone. The optimized geometries of
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7-TS-A and 7-TS-B are shown in Figure 4.5b. Replacing the CH2 group with O decreases
the ligand–substrate steric repulsion in 7-TS-B is smaller than that in 1-TS-B. This
results in decreased enantioselectivity.
Methyl substitution at the α ' position of cyclohexenone increases the steric
repulsion with the t-Bu group on the ligand. Computations predicted increased
enantioselectivity with α',α'−dimethylcyclohexenone (99% ee, Table 4.7, entry 8).31
However, experimentally, the ee is comparable with the reaction of 3-
methylcyclohexenone.
Table 4.7  Activation energies and enantioselectivities of alkene insertion with substrates varying at
the α'-position
N
Pd
N
OX O
H N
Pd
N
O
H
X
O
N
Pd
N
O
XO HN
Pd
N
O
H
X
O
n-TS-A n-TS-B n-TS-C n-TS-D
TS X ΔH‡ a ee b
TS-A TS-B TS-C TS-D
1 CH2 19.2 21.5 21.8 22.2 94%[93%]
7 O 16.7 18.6 19.4 19.6 88%[57%]
8 C(CH3)2 17.9 22.0 20.0 20.8 99%[90%]
aThe values are activation enthalpies in kcal/mol calculated at the BP86/6-31G(d)-SDD
level and the CPCM solvation model in dichloroethane.  bExperimental ee are given in
square brackets.  Experimental isolated yields: TS-1: 99%, TS-7: 49%, TS-8: 9%.
Houk also considered the electronic effects of arylboronic acids on
enantioselectivity (Table 4.8). Computations predicted that para-electron-withdrawing
substituents lead to increases in the activation barrier in alkene insertion, probably due to
the electrophilicity of the β-carbon of the enone, and thus are predicted to afford slightly
decreased enantioselectivities. Both para-acetylphenylboronic acid (9-TS-A) and para-
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trifluoromethylphenylboronic acid (10-TS-A) are predicted to react with 92% ee.
However, both excellent enantioselectivities (96% ee) and excellent yields (99% isolated
yield) are observed experimentally. Thus, the electronic effects of phenyl substituents on
enantioselectivities are minimal, though slightly increased enantioselectivities are
observed experimentally with the use of electron-withdrawing substituents.
Table 4.8 Activation energies and enantioselectivities of alkene insertion with various boronic acids
N
Pd
N
O O
H N
Pd
N
O
H
O
N
Pd
N
O
O HN
Pd
N
O
H
O
n-TS-A n-TS-B n-TS-C n-TS-D
R3 R3 R3 R3
TS R3 ΔH‡ a ee b
TS-A TS-B TS-C TS-D
1 H 19.2 21.5 21.8 22.2 94%[93%]
9 CH3CO 21.6 23.7 24.5 24.8 92%[96%]
10 CF3 21.3 23.4 23.6 24.2 92%[96%]
aThe values are activation enthalpies in kcal/mol calculated at the BP86/6-31G(d)-SDD
level and the CPCM solvation model in dichloroethane. bExperimental ee are given in
square brackets. Experimental isolated yields: TS-1: 99%, TS-9: 1%, TS-10: 99%, TS-
11: 99%.
Permutations of the pyridinooxazoline ligand framework corroborate the
calculated data and suggest that a number of factors affect enantioselectivity. First, the
steric demand of the chiral group on the oxazoline greatly impacts the observed
enantioselectivity in the reaction (Table 4.9). Only t-BuPyOx (82) yields synthetically
tractable levels of enantioselectivity, while the less sterically demanding i-PrPyOx (227),
PhPyOx (228), and i-BuPyOx (229) all exhibit greatly diminished selectivity. Oxazoline
substitution patterns also affect enantioselectivity. Substitution at the 4-position appears
to be required for high selectivity, as substitution at the 5-position yields practically no
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enantioselectivity (ligand 230). Electronic variation in the PyOx framework was observed
to have a large effect on the rate of the reaction but, disappointingly, led to depressed
stereoselectivity. CF3-t-BuPyOx (231) afforded the conjugate addition product in 99%
yield and 81% ee. Surprisingly, MeO-t-BuPyOx (232) afforded the product in similar
yield and only 78% ee. Finally, substitution at the 6-position of the pyridine (ligands 233
and 234) greatly diminished both reactivity and selectivity, perhaps due to hindered
ligand chelation to palladium.
Table 4.9  Enantioselectivity trends in pyridinooxazoline and related ligand frameworks a
N
N
O
i-Pr
N
N
O
Ph
N
N
O
Ph
227
99% yield
40% ee
228
99% yield
52% ee
230
99% yield
2% ee
N
N
O
t-Bu
N
N
O
i-Pr23313% yield
20% ee
234
14% yield
0% ee
O
B(OH)2
O
 ligand (6 mol %)
Pd(OCOCF3)2 (5 mol %)
ClCH2CH2Cl, 60 °C, 12 h
+
N
N
O
i-Bu
229
95% yield
24% ee
N
N
O
t-Bu
82
99% yield
93% ee
N
N
O
t-Bu
231
99% yield
81% ee
N
N
O
t-Bu
232
96% yield
78% ee
H CF3 OMe
Ph
95 35
aConditions: 3-methylcyclohexen-2-one (0.25 mmol), phenylboronic acid (0.5 mmol),
ClCH2CH2Cl (1 mL).  Yields are isolated yields, ee determined by chiral HPLC.
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Thus, we have concluded that enantioselectivity is controlled by the steric
repulsion between the substituent on the chiral pyridinooxazoline ligand and the
cyclohexyl ring. The bulkier t-Bu substituent on the (S)-t-BuPyOx ligand leads to greater
enantioselectivity than the reactions with (S)-i-PrPyOx or (S)-PhPyOx. Similarly,
substrates with less steric demand adjacent the carbonyl exhibit lower
enantioselectivities; for example the reaction of a lactone substrate (Table 4.7, TS-7)
yields lower enantioselectivity due to smaller repulsions between the lactone oxygen and
the t-Bu group.
4.2.6 Experimental Investigation of Arylpalladium(II) Intermediates and Formation
of the Key C–C Bond
Experiments aiming to corroborate the calculated mechanism have been
performed.  We sought to observe the formation of the key C–C bond between an
arylpalladium(II) species and the enone substrate in the absence of exogenous
phenylboronic acid. Complexes 235 were synthesized as an intractable mixture of
isomers, and were treated with AgPF6 in situ to generate the [(PyOx)Pd(Ph)]+ cation.
Gratifyingly, complexes 235 serve as a competent precatalyst at 5 mol % loading, and
affords ketone 35 in 96% yield and 90% ee (Table 4.10, entry 1). Varying the amount of
complex utilized in proportion with phenylboronic acid, however, leads to significant
production of biphenyl above 5 mol % (entries 2–5). Utilizing even 25 mol % (entry 2)
resulted in significant increase in biphenyl production (16% yield), and reduction in yield
of the desired ketone 35 to 79%. Increasing complex loadings to 45 and 65 mol %
(entries 3 and 4) leads to negligible production of ketone 35, and nearly quantitative
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formation of biphenyl relative to catalyst loading. Furthermore, attempts to use the
complex as a stoichiometric reagent in the place of PhB(OH)2 lead to no observed
product (entry 5), and exclusive formation of biphenyl. We hypothesize that quantitative
generation of the reactive arylpalladium cation intermediate in high relative concentration
leads quickly to disproportionation and formation of biphenyl and palladium(0).
Omission of the AgPF6 in favor of 30 mol % NH4PF6 leads to isolation of only 22% yield
of the conjugate addition product (entry 6). Finally, a control experiment demonstrates
that AgPF6 is incapable of catalyzing the reaction itself (entry 7).32 This control further
supports the computational results, which indicate a transmetallation-based mechanism as
opposed to a Lewis acid-catalyzed pathway.
Table 4.10  Arylpalladium(II) catalyzed conjugate addition a
OO
Complex 235, AgPF6
H2O (5 equiv.)
ClCH2CH2Cl, 40 °C, 12 h Ph
B(OH)2
entry complex 29 (mol %) AgPF6 (mol %) PhB(OH)2 (mol %)
yield (%)
3 biphenyl
1
2
3
4
5
5
25
45
65
105
10
50
90
130
210
7 0 20 200
0
40
60
80
100 96
79
11
5
0
3
16
53
58
87
0 0
95 35
6b 5 0 22 0200
a Conditions: 3-methylcyclohexen-2-one (0.25 mmol), pheylboronic acid (equiv as stated),
ClCH2CH2Cl (1 mL).  Yields are isolated yields, ee determined by chiral HPLC.  bReaction
performed with 30 mol % NH4PF6
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Concerned by our inability to observe consistent product formation at 40 °C, we
sought alternative experimental verification that a putative cationic arylpalladium(II)
species is capable of reacting to form conjugate addition products. Thus, we performed
the stoichiometric reaction of the isomeric phenyl palladium iodide complexes (235) with
AgPF6 and 3-methylcyclohexenone at cryogenic temperatures, allowing the mixture to
warm slowly to room temperature before quenching with trifluoroethanol.33 We observed
both conjugate addition product and biphenyl, with the desired adduct (35) isolated in
30% yield (Scheme 4.4a).  Curiously, the conjugate addition adduct was isolated in only
55% ee. We considered that the isomeric mixture of phenyl palladium iodide isomers
formed configurationally stable cationic species at cryogenic temperature.34, Repeating
the experiment, we substituted triphenylphosphine for methylcyclohexenone and
observed the reaction at low temperature utilizing 1H and 31P NMR (Scheme 4.4b).
Indeed, two 31P signals corresponding to phosphine-bound palladium(II) species (236)
were observed at 28 and 34 ppm.  No isomerization was observed upon warming the
isomeric mixture to room temperature.35  Indeed, we were able to isolate and characterize
the mixture of arylpalladiumphosphine cations. With evidence for the configurationally
stable arylpalladium cation, we rationalized the observed 55% ee for the direct reaction of
mixture 234 with methylcyclohexenone corresponds directly to the isomeric ratio of the
complex: a ratio of 1.3:1 represents a 56:44 ratio of isomers. Assuming that the major
isomer reacts with 92% ee, and the minor isomer reacts with no stereoselectivity to give
racemic products,36 a net stereoselectivity of 53.7% ee would be predicted for the
product. Presuming configurational stability of the arylpalladium(II) cation as suggested
by the triphenylphosphine trapping experiment, the diminished enantioselectivity
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observed in this result is unsurprising. Thus, we have obtained experimental verification
of the key C–C bond forming event of the Pd/PyOx asymmetric conjugate addition
occurring from a quantitative generated arylpalladium(II) cation in the presence of enone
substrate and absence of an exogenous arylboronic acid.
Scheme 4.4 (a) Direct formation of C–C bond from arylpalladium(II) cation. (b) Triphenylphosphine
trapping experiments demonstrates configurational stability of arylpalladium cation
N
Pd
I
N
O
t-Bu
1. 3-methylcyclohexenone,
    AgPF6, CH2Cl2, –78 °C
2. CF3CH2OH, 20 °C
O
Ph
35
30% yield
55% ee
N
Pd
I
N
O
t-Bu
N
Pd
PPh3
N
O
t-Bu
AgPF6, PPh3
CD2Cl2, –78 °C
+  PF6–
(a)
(b)
235
mix of isomers
236
Two 31P Signals Observed
N
I
Pd
N
O
t-Bu
235
mix of isomers
N
I
Pd
N
O
t-Bu
N
Ph3P
Pd
N
O
t-Bu
+  PF6–
Attempts to optimize the transition state of the isomerization of the tricoordinated
cationic phenylpalladium(II) complexes 217 and 217’ failed. Houk then performed a scan
of the reaction coordinates by calculating structures with fixed N-Pd-C angle. The results
are summarized in Figure 4.6. Based on the scan of the reaction coordinate (i.e., N-Pd-C
angle), they estimated the activation barrier for the isomerization of 217 to 217’ is higher
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than 10 kcal/mol with respect to 217. Thus, the isomerization has higher activation
energy than subsequent alkene insertion (220-ts is only 1.7 kcal/mol less stable than 217).
Figure 4.6 Scan of the reaction coordinate of the interconversion between 217 and 217’. The
energies in kcal/mol are calculated at the BP86/6-31G(d)-SDD level without solvent corrections
217 217'
Houk attempted to compute the activation energies of transmetallation leading to
cis and trans cationic phenylpalladium(II) complexes (217 and 217’) with the (S)-t-
BuPyOx ligand. However, the geometry optimizations cannot locate the transmetallation
transition states. We then performed a scan of the forming Pd–C(phenyl) bond in the cis
and trans pathway (Table 4.11). In 237-ts, the phenyl is trans to the oxazoline on the
ligand. In 238-ts, the phenyl is cis to oxazoline. We fixed the forming Ph-C bond distance
in both structures to 2.20, 2.35, 2.40, 2.45, 2.50, 2.55 and 2.60 Å, respectively. In all
distances, the cis structure 238-ts are at least 2.0 kcal/mol less stable than the trans
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isomer 237-ts. This indicates the formation of the trans product is favored in
transmetallation. In the cis pathway, the phenyl is adjacent to the bulky t-Bu group on the
ligand, and the transition state 238-ts is destabilized by the steric repulsions between t-Bu
and Ph.
Table 4.11 Scan of the forming Pd–C(phenyl) bond in pathways 237-ts and 238-ts
a 237-ts 238-ts
RPd-C E237-ts E238-ts ΔE
2.20 5.6 9.5 3.9
2.35 8.3 11.3 3.0
2.40 8.8 11.9 3.0
2.45 9.5 12.5 3.0
2.50 10.1 13.1 3.0
2.55 10.8 13.6 2.7
2.60 11.6 14.0 2.4
aThe values are energies in kcal/mol calculated at the BP86/6-31G(d)-SDD level without solvent corrections
4.2.7 Attempts to rationalize the importance of arylboronic acid additives
A small screen of alternative boron species was undertaken to explore the scope of
the boron nucleophile beyond the known reactivity of arylboronic acids and their
dehydrated forms, triarylboroxines (Table 4.12). Tetraarylborates (entry 1) were poor
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substrates, and afforded trace product and rapid precipitation of palladium black.
Potassium trifluoroborates also performed poorly (entry 2), though their efficacy could be
increased by addition of additional equivalents of water (entry 3), though not by the
presence of other proton sources, such as ortho-methylphenylboronic acid (entry 4).
Additionally, an experiment was performed utilizing the cationic arylpalladium(II)
species generated from the treatment of complex 235 with AgPF6 under dilute conditions
designed to mimic the catalytic reaction.  Trace yield of the product was observed in the
absence of boronic acid. Curiously, a comparable concentration of 235 in solution with
enone and AgPF6 produces high yield of ketone 35 in the presence of phenylboronic acid
(Table 4.10, entry 1). Other phenyl sources, such as n-Bu3SnPh or NaOSiMe2Ph,
produced no observable conjugate addition reaction, even at elevated temperature or in
the presence of an unreactive boronic acid (entries 6–9). Presumably, these other
organometallic phenyl reagents require additional activation to undergo transmetallation
with palladium, such as fluoride additives in the case of dimethylphenyl sodium
silanolate. Brief efforts to identify these conditions and additives yielded little more than
trace conversion to the desired product.
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Table 4.12 Alternative Boron Sources Screen
OO
phenyl source
boronic acid
NH4PF6, H2O
ClCH2CH2Cl, 40 °C, 12 h
Ph
entry phenyl source boronic acid H2O (equiv.) yield (%)
1
2
3
4
5a
NaBPh4
(PyOx)Pd(Ph)(I)/AgPF6
--
--
--
o-methylphenyl
-- 5
5
25
5
5 trace
19
46
15
trace
95 35
KPhBF3
KPhBF3
KPhBF3
ee (%)
--
91
90
91
--
6b
7b
8b
9b
--
o-methylphenyl
--
o-methylphenyl 0
0
0
0 trace
trace
--
--
n-Bu3SnPh
n-Bu3SnPh
NaOSiMe2Ph
--
--
--
--NaOSiMe2Ph
Conditions: enone (0.25 mmol), phenyl source (0.50 mmol), NH4PF6 (0.075 mmol),
H2O (1.25 mmol), ClCH2CH2Cl (1 mL).  aReaction performed with Pd complex 29
(0.125 mmol), AgPF6 (0.250 mmol), ClCH2CH2Cl (10 mL).  bReactions performed at
80 °C.
Next, Houk investigated if coordination of phenylboronic acid will activate the
enone in the alkene insertion step (220-ts, Figure 4.3). Two different binding modes
between the alkene insertion transition state 220-ts and phenylboronic acid are
considered in the calculations (Figure 4.7): the boronic acid acting as a hydrogen bonding
donor (239-ts-B) and as a Lewis acid that the B atom is coordinated with the enone
oxygen (239-ts-C). 239-ts-B is 9.1 kcal/mol less stable than the uncoordinated 220-ts in
terms of Gibbs free energy. The structure of 239-ts-B is shown in Figure 4.7. Geometry
optimization of 239-ts-C was not successful and always leading to dissociation of the B–
O bond, indicating the interaction between B and O is not stabilizing. These results
suggest that binding with boronic acid does not accelerate the alkene insertion, and are
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not particularly surprising given that cationic organometallic palladium complexes are
known to rapidly bind and insert olefins at ambient temperature. Furthermore, these
calculations support our hypothesis that the boronic acid serves a secondary role in
stabilizing the cationic palladium(II) intermediates along the hypothetical catalytic cycle,
and prevent rapid disproportionation and formation of biphenyl as is observed with
reactions seeking to use isolated arylpalladium(II) complex 235 as the only aryl source in
the reaction medium (Table 4.10, entry 5).
Figure 4.7 Activation free energies of alkene insertion with boronic acid coordination. Energies are
with respect to the Pd(PyOx)Ph–enone complex 219
220-ts 239-ts-b 239-ts-c
4.3 Summary and discussion
Several experimental results have been described that support the DFT-calculated
mechanism for the Pd/PyOx-catalyzed asymmetric conjugate addition of arylboronic
acids to cyclic enone (Figure 4.4); specifically, the role of the palladium catalyst has been
addressed. Calculations and previous experimental work by Miyaura on palladium-
catalyzed conjugate addition suggest that a transmetallation event occurs to transfer the
aryl moiety from the boronic acid species to the palladium catalyst.4 Houk’s calculations
indicated that the Pd/PyOx system operates under a similar manifold, and demonstrated a
significant energy difference (transmetallation is favored by over 40 kcal/mol, Figure 4.4)
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between the potential roles of the palladium catalyst, suggesting that the role of the
palladium species is not simply that of a Lewis acid. Furthermore, it is difficult to
rationalize the high degree of enantioselectivity imparted by the chiral palladium catalyst
if it is assumed that the metal acts only as a Lewis acid and is not directly mediating the
key C–C bond-forming step.37 Finally, a number of Lewis- and π−acidic metal salts were
substituted for palladium with no product observed, further indicating that palladium-
catalyzed conjugate addition is likely not a Lewis acid-catalyzed process.38
While highly Lewis-acidic, the role of cationic palladium(II) is to provide a
vacant coordination site for the enone substrate to approach the catalyst. The presence of
a cationic intermediate is further supported by the observed rate acceleration of non-
coordinating anionic additives such as PF6– and BF4– salts (Table 4.1). Conversely, the
addition of coordinating anions, such as chloride, inhibited the reaction (Table 4.1, entry
1). This counterion effect was evident even from choice of palladium(II) precatalysts.13
For instance, Pd(MeCN)2Cl2 was not a suitable precatalyst, nor were any palladium(II)
halides.  Additionally, Pd(OAc)2 only afforded modest yield of conjugate adducts,
whereas the less coordinating counterion present in Pd(OCOCF3)2 afforded complete
conversion.
Satisfied that the palladium catalyst was not acting as a Lewis acid, we next
sought to demonstrate the viability of the hypothesized arylpalladium(II) species as a
catalyst (Table 4.10, entries 1–5). While serving as a suitable precatalyst under reaction
conditions, arylpalladium(II) mixture 235 failed to facilitate the conjugate addition
reaction when used in stoichiometric quantities in the presence of AgPF6 (entry 5). We
rationalize this outcome to be the result of the highly reactive nature of the quantitatively
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generated arylpalladium(II) cation. Significant biphenyl formation– occurring even under
dilute conditions representative of the catalytic reaction itself– suggest that alternative
reaction pathways, such as disproportionation, readily out compete the desired insertion
reaction. This reactive nature of the arylpalladium(II) cation led us to propose performing
the stoichiometric reactions at low temperatures (Scheme 4.4). Successfully
demonstrating that the key C–C bond could be generated, albeit in modest yield, from
(PyOx)Pd(Ph)(I) (235) corroborates both the precise role of the arylpalladium(II) cation
in the calculated mechanism as well as the transition state put forth in the calculations.
However, the modest yield of this process and requisite cryogenic temperatures
prompted, again, consideration of the role of the arylboronic acid.39 Calculations suggest
that the presence of boronic acids as Lewis basic entities may serve to stabilize these
reactive intermediates under the reaction conditions (Figure 4.3, cationic arylpalladium
217).40 This suggestion is consistent with the successful use of arylpalladium(II) mixture
235  as a precatalyst in the presence of arylboronic acids (Table 4.10, entry 1).
Calculations rule out the use of boronic acid further activating the enone, either as a
hydrogen bond donor or Lewis acid (Figure 4.6).
Lastly, water (or another proton source) is required for efficient turnover of the
reaction. Considerations of reaction scale (Scheme 4.2) and deuterium incorporation
experiments (Figure 4.1) suggest that water is the likely protonation agent, despite
numerous other protic sources in the heterogenous reaction mixture. Attempts to use
other, miscible proton sources (MeOH, phenol, t-BuOH, etc.) typically resulted in
10–15% less enantioselectivity observed.41 2,2,2-Trifluoroethanol can be successfully
substituted for water with minimal loss of enantioselectivity, however it affords no
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supplementary benefit and water is the preferred additive for all reactions.26 Water in
combination with NH4PF6 serves to facilitate milder reaction conditions (Table 4.2),
which in turn greatly increases the synthetic scope with respect to challenging
arylboronic acid nucleophiles (Table 4.3). Synthetic yields were observed to double in
many cases, greatly increasing the utility of these transformations. The functional group
tolerance of the Pd/PyOx system is unprecedented for asymmetric conjugate addition; it
encompasses a wide array of halides, carbonyl functional groups, protected phenols,
acetamides, free hydroxyl groups, and even nitro groups. Many of these groups are
incompatible with traditional rhodium- and copper-catalyzed conjugate additions due to
the reactivity with the nucleophiles used or the strong coordination of the functional
group to the metal catalyst.
The combined results described herein have allowed us to put forth the following
catalytic cycle (Figure 4.8). The cationic catalyst, represented as (PyOx)Pd(X)(L) (240),
undergoes transmetallation with an arylboronic acid to yield cationic (PyOx)Pd(Ar)(L)
(241).  Substrate coordination forms cationic arylpalladium(II) 242, which undergoes rate
and enantioselectivity-determining insertion of the aryl moiety into the enone π-system to
afford C-bound palladium enolate 243. Tautomerization to the O-bound palladium
enolate (244), or direct protonolysis of the C-bound enolate (243), liberates the conjugate
addition product (35) and regenerates a cationic palladium(II) species for reentry into the
catalytic cycle.
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Figure 4.8  Proposed catalytic cycle for Pd/PyOx-catalyzed conjugate addition of arylboronic acids
to cyclic enones
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4.4 Conclusions
In conclusion, we have reported experimental and computational results that
corroborate a single PyOx ligand/metal complex as the active catalytic species in the
palladium-catalyzed asymmetric conjugate addition of arylboronic acids to enones for the
construction of quaternary stereocenters. Houk has used computational models to rule out
a suggested alternative mechanism in which the palladium catalyst is acting as a Lewis
acid to activate the enone. The preferred mechanism involves formal transmetallation
from boron to palladium, rate- and enantioselectivity-determining carbopalladation of the
enone olefin by a cationic palladium species, and protonolysis of the resulting palladium-
enolate. We have taken advantage of these mechanistic insights to develop a modified
reaction system whereby the addition of water and ammonium hexafluorophosphate
increase reaction rates, and can facilitate lower catalyst loadings. The modified
conditions have opened the door to new substrate classes that were inaccessible by the
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initially published reaction conditions. Furthermore, we have demonstrated that this
operationally simple reaction is tolerant of ambient atmosphere and capable of producing
enantioenriched, β-quaternary ketones on multi-gram scale. The steric and electronic
effects of the boronic acid and enone substrates and the ligand on enantioselectivities
were elucidated by a combined experimental and computational investigation. The
enantioselectivity is mainly controlled by the steric repulsion of the t-Bu substituent of
the oxazoline on the ligand and the Cα' position hydrogens of the cyclohexenone substrate
in the alkene insertion transition state. Further investigations of both the scope of this
transformation and its application toward natural product synthesis are current underway
in our laboratories.
4.5 Experimental Procedures
4.5.1 Materials and Methods
Unless otherwise stated, reactions were performed with no extra precautions taken to
exclude air or moisture. Air and moisture sensitive reactions were carried out under an
atmosphere of argon using Schlenk and glovebox techniques. Diethyl ether, hexanes,
benzene and toluene were dried and deoxygenated by passing through columns packed
with activated alumina and Q5, respectively. Deionized water was purified with a
Barnstead NANOpure Infinity UV/UF system. Dichloroethane was dried by stirring over
CaH2 and subsequent distillation, followed by deoxygenation by three freeze–pump–thaw
cycles. Deuterated solvents were dried by distillation from CaH2 (CD2Cl2) and
deoxygenated by three freeze-pump-thaw cycles.  Commercially available reagents were
used as received from Sigma Aldrich unless otherwise stated. Enone substrates were
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purchased from Sigma Aldrich (3-methylcyclohexenone, 2-cyclohexene-1-one,
chromone) or prepared according to literature procedure.42  Pyridinooxazoline ligands
were synthesized according to literature procedures.43 Iodobenzene was obtained from
Sigma Aldrich and purified by distillation and deoxygenated by three freeze–pump–thaw
cycles. AgPF6 was obtained from ABCR and used without further purification. Reaction
temperatures were controlled by an IKAmag temperature modulator.  Thin-layer
chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated
plates (250 nm) and visualized by UV fluorescence quenching, potassium permanganate,
or p-anisaldehyde staining. Silicycle SiliaFlash P60 Academic Silica gel (particle size 40-
63 nm) was used for flash chromatography. Analytical chiral HPLC was performed with
an Agilent 1100 Series HPLC utilizing a Chiralcel OJ column (4.6 mm x 25 cm) obtained
from Daicel Chemical Industries, Ltd with visualization at 254 nm and flow rate of 1
mL/min, unless otherwise stated. Analytical chiral SFC was performed with a JASCO
2000 series instrument utilizing Chiralpak (AD-H or AS-H) or Chiralcel (OD-H, OJ-H, or
OB-H) columns (4.6 mm x 25 cm), or a Chiralpak IC column (4.6 mm x 10 cm) obtained
from Daicel Chemical Industries, Ltd with visualization at 210 or 254 nm. 1H and 13C
NMR spectra were recorded on a Varian Inova 500 (500 MHz and 125 MHz,
respectively) and a Varian Mercury 300 spectrometer (300 MHz and 75 MHz,
respectively). Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm)
(multiplicity, coupling constant (Hz), integration). Data for 1H NMR spectra are
referenced to the centerline of CHCl3 (δ 7.26), CD2Cl2 (δ 5.32), or C2D4Cl2 (δ 3.72) as the
internal standard and were reported in terms of chemical shift relative to Me4Si (δ 0.00).
Data for 13C NMR spectra were referenced to the centerline of CDCl3 (δ 77.0), CD2Cl2
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(δ 53.8), or C2D4Cl2 (δ 43.6) and were reported in terms of chemical shift relative to
Me4Si (δ  0.00). Infrared spectra were recorded on a Perkin Elmer Paragon 1000
Spectrometer and are reported in frequency of absorption (cm-1). High resolution mass
spectra (HRMS) were obtained on an Agilent 6200 Series TOF with an Agilent G1978A
MultiMode source in electrospray ionization (ESI), atmospheric pressure chemical
ionization (APCI) or mixed (MultiMode ESI/APCI) ionization mode. Optical rotations
were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589
nm.
4.5.2 Preparation of compounds
(S)-4-(tert-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole  (82).
N
N
O
t-Bu
N CN
1. NaOMe, MeOH, 0 °C
2. (S)-2-amino-1-tertbutylethanol,
    cat. p-TsOH, PhMe, 80 °C
        (50% yield, two steps) 82
This route is amenable to smaller batches of ligand synthesis.  Adapted from Brunner. H.;
Obermann. U. Chem. Ber. 1989, 122, 499–507.
A flame-dried round bottom flask was charged with a stir bar and MeOH (110
mL).  Sodium metal ingot (295 mg, 12.8 mmol, 0.1 equiv) was cut with a razor into small
portions, washed in a beaker of hexanes and added in 5 portions over 5 min. The reaction
mixture was stirred vigorously until no sodium metal remained, at which time it was
cooled to 0 °C in an ice/water bath. At this time, 2-cyanopyridine (13.0 g, 125 mmol, 1.0
equv) was added dropwise, and the clear, colorless reaction mixture was allowed to warm
to ambient temperature and stir. When all the starting material is consumed as indicated
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by TLC analysis (50% EtOAc/Hexanes, p-anisaldehyde stain), the reaction was cooled to
0 °C in an ice/water bath and quenched by dropwise addition of glacial AcOH (1 mL).
The crude reaction mixture was concentrated in vacuo, redissolved in CH2Cl2 (100 mL)
and washed with brine (2 x 50 mL). The organic phase was dried (MgSO4), concentrated
in vacuo, and dried under high vacuum for 1 h. The resulting crude methoxyimidate (light
yellow oil) was suitable for use in the next step without further purification. To a flame-
dried round bottom flask charged with a stir bar was added crude methoxyimidate (2.55
g, 18.7 mmol, 1.0 equiv), (S)-tert-leucinol (2.10 g, 17.9 mmol, 0.96 equiv) toluene (100
mL), and p-TsOH•H2O (167 mg, 0.88 mmol, 5 mol %). The mixture was stirred at 80 °C
in an oil bath for 3 h, at which time the starting material was consumed as indicated by
TLC analysis (20% acetone/hexanes, p-anisaldehyde stain). The reaction was cooled to
ambient temperature and quenched with sat. aq. NaHCO3 (60 mL). The reaction was
partitioned between EtOAc and water, and the aqueous phase extracted with EtOAc (3 x
50 mL). The combined organic extracts were washed with water (2 x 50 mL), brine (1 x
25 mL), dried (MgSO4), and concentrated in vacuo. The crude mixture was purified by
flash column chromatography (eluent: 20% acetone/hexanes) to afford 1.85 g (9.06
mmol, 51%) (S)-t-BuPyOx as an off-white solid. Rf = 0.44 with 3:2 hexanes/acetone; mp
70.2 – 71.0 ºC; 1H NMR (500 MHz, CDCl3) δ 8.71 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.08
(dt, J = 7.9, 1.1 Hz, 1H), 7.77 (dt, J = 7.7, 1.7 Hz, 1H), 7.37 (ddd, J = 7.0, 4.5, 1.0 Hz,
1H), 4.45 (dd, J = 10.2, 8.7 Hz, 1H), 4.31 (t, J = 8.5 Hz, 1H), 4.12 (dd, J = 10.2, 8.5 Hz,
1H), 0.98 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 162.4, 149.6, 147.0, 136.5, 125.4,
124.0, 76.5, 69.3, 34.0, 26.0; IR (Neat film, NaCl): 2981, 2960, 2863, 1641, 1587, 1466,
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1442, 1358, 1273, 1097, 1038, 968 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C12H17N2O [M+H]+: 205.1335, found 205.1327; [α]25D –90.5º (c 1.15, CHCl3).
Representative General Procedure for the Enantioselective 1,4-Addition of
Arylboronic Acids to Conjugate Acceptors.
A screw-top 1 dram vial was charged with a stir bar, Pd(OCOCF3)2 (4.2 mg, 0.0125
mmol, 5 mol %), (S)-t-BuPyOX (3.1 mg, 0.015 mmol, 6 mo l%), NH4PF6 (12.5 mg, 0.075
mmol, 30 mol %) and PhB(OH)2 (61 mg, 0.50 mmol, 2.0 equiv).  The solids were
dissolved in dichloroethane (0.5 mL) and stirred for 2 min at ambient temperature, at
which time a yellow color was observed.  Not all solids were dissolved at this time.
Conjugate acceptor substrate (0.25 mmol) and water (0.025 mL, 1.25 mmol, 5.0 equiv)
were added.  The walls of the vial were rinsed with an additional portion of
dichloroethane (0.5 mL).  The vial was capped with a Teflon/silicone septum and stirred
at 40 °C in an oil bath for 12 h.  Upon complete consumption of the starting material
(monitored by TLC, 4:1 hexanes/EtOAc, p-anisaldehyde or iodine/silica gel stain) the
reaction mixture was filtered through a pipet plug of silica gel, using CH2Cl2 as the
eluent, and concentrated in vacuo. The crude residue was purified by column
chromatography (gradient: 9:1 hexanes/EtOAc to 7:3 hexanes/EtOAc) to afford a
colorless solid.
Representative General Procedure for Additive Screening for the Enantioselective
1,4-Addition of Arylboronic Acids to Conjugate Acceptors.
A screw-top 1 dram vial was charged with a stir bar, Pd(OCOCF3)2 (4.2 mg, 0.0125
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mmol, 2.5 mol%), (S)-t-BuPyOX (3.1 mg, 0.015 mmol, 3 mol %), salt additive (0.15
mmol, 30 mol %) and PhB(OH)2 (122 mg, 1.0 mmol, 2.0 equiv).  The solids were
dissolved in dichloroethane (1 mL) and stirred for 2 min at ambient temperature, at which
time a yellow color was observed.  Not all solids were dissolved at this time.  Conjugate
acceptor substrate (0.5 mmol) and water (0.025 mL, 1.25 mmol, 5.0 equiv) were added.
The walls of the vial were rinsed with an additional portion of dichloroethane (1 mL).
The vial was capped with a Teflon/silicone septum and stirred at the indicated
temperature in an oil bath for 12 h.  Upon complete consumption of the starting material
(monitored by TLC, 4:1 hexanes/EtOAc, p-anisaldehyde or iodine/silica gel stain) the
reaction mixture was filtered through a pipet plug of silica gel, using CH2Cl2 as the
eluent, and concentrated in vacuo. The crude residue was purified by column
chromatography (gradient: 9:1 hexanes/EtOAc to 7:3 hexanes/EtOAc) to afford a
colorless solid.
General Procedure for the Synthesis of Racemic Products
Racemic products were synthesized in a manner analogous to the general procedure using
PyOx synthesized from racemic tert-leucinol (3.1 mg, 0.015 mmol, 6 mol %) as a ligand.
Experimental Procedure for the Mercury Drop Experiment
This experiment was conducted following the general procedure for the enantioselective
1,4-addition of phenylboronic acid and 3-methylcyclohex-2-enone. Immediately
following the addition of the conjugate acceptor substrate and water, mercury (501.5 mg,
37 µL, 2.50 mmol, 200 equiv. with respect to the catalyst) was added to the reaction.
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Following completion, the reaction was filtered and the filtrate was concentrated under
reduced pressure. The resulting yellow oil was purified by flash chromatography (9:1
hexanes/EtOAc) to afford 46.5 mg of (R)-3-phenyl-3-methylcyclohexanone 35 as a
colorless oil (99% yield, 90% ee).
Experimental Procedure for the Deuteration Experiments
A flame-dried 1 dram vial with a septum-fitted screw-top was cycled into a glove box
and charged with a stir bar, Pd(OCOCF3)2 (4.2 mg, 0.0125 mmol, 5 mol %), (S)-t-
BuPyOX (3.1 mg, 0.015 mmol, 6 mol %), NH4PF6 (12.5 mg, 0.075 mmol, 30 mol %) and
either PhB(OH)2 (61 mg, 0.50 mmol, 2.0 equiv.) or triphenyl boroxine (103.9 mg, 0.33
mmol, 4 equiv.).  The solids were dissolved in dry dichloroethane (0.5 mL) and stirred
for 2 min at ambient temperature, at which time a yellow color was observed.  Not all
solids were dissolved at this time. Freshly distilled 3-methylcyclohexenone (0.25 mmol)
was added.  The walls of the vial were rinsed with an additional portion of dichloroethane
(0.5 mL).  The vial was capped with a Teflon/silicone septum and removed from the
glove-box.  Deuterium oxide (23 µL, 25.0 mg, 1.25 mmol, 5.0 equiv) was added and the
reaction was stirred at 40 °C in an oil bath for 12 h.  The reaction mixture was
concentrated in vacuo and the crude residue was purified by column chromatography
(gradient: 9:1 hexanes/EtOAc to 7:3 hexanes/EtOAc) to afford 44.2 mg of a colorless oil
(94% yield, 92% ee) for phenylboronic acid and 46.8 mg (99% yield, 91% ee) for
triphenyl boroxine, respectively.  For the control experiment, ketone 3 was synthesized
according to the general procedure and was then subjected to the above described
conditions for the deuteration experiments.
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General Procedure for Low Temperature NMR Experiments:
A J. Young NMR tube was charged with complex 235 (26 mg, 0.05 mmol, 1.0 equiv.),
AgPF6 (25 mg, 0.10 mmol, 2.0 equiv.), and either 3-methylcyclohexenone (5.5 mg, 5.7
µL, 0.05 mmol, 1.0 equiv.) or PPh3 (26 mg, 0.10 mmol, 2.0 equiv).  The NMR tube was
attached to a vacuum transfer bridge and dry CD2Cl2 was condensed into the J. Young
tube at –78 °C by trap-to-trap condensation.  The J. Young tube was sealed and removed
from the vacuum transfer bridge and maintained at –78 °C in a dry ice/iso-propanol bath.
The NMR tube was quickly transferred to a pre-cooled (–60 °C) NMR probe.  The
sample was observed at 20 °C intervals before being quenched with 2,2,2-trifluoroethanol
(17 µL) at 20 °C.
Attempts to React or Isomerize Complex 236
A solution of complex 236 (13 mg, 0.025 mmol, 1.0 equiv.) in dichloroethane (700 µL)
was observed by 31P NMR spectroscopy at 60 °C over the course of 2 h.  No observable
change in the ratio or intensity of the phosphorus signals was noted.  Subsequently, 3-
methylcyclohexenone (28 µL, 0.25 mmol, 1.0 equiv.) was added to the NMR sample
tube.  The sample was observed by 31P NMR spectroscopy at 60 °C over the course of 2
h.  No observable change in the ratio or intensity of the phosphorus signals was observed.
No product ketone 35 was observed by LCMS or TLC analysis of the sample.
Procedure for Non-Linear Effect Experiments (Figure 4.2)
Stock solutions of both racemic t-BuPyOx and of (S)-t-BuPyOx were made (60 mg
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ligand, 10 mL DCE) in separate 20 mL vials.  Portions of each stock solution were
transferred to a 4 mL vial by syringe and concentrated in vacuo to afford ligand mixtures
of the desired enantiopurity. The vials with the ligand mixture were used in accordance
with the general procedure to afford ketone 35 as a colorless oil.  The various ligand
mixtures were made as follows:
0% ee: 500 µL racemic t-BuPyOx (afforded ketone 35 in 0% ee)
20% ee: 400 µL racemic t-BuPyOx, 100 µL (S)- t-BuPyOx (afforded ketone 35 in 16% ee)
40% ee: 300 µL racemic t-BuPyOx, 200 µL (S)- t-BuPyOx (afforded ketone 35 in 34% ee)
60% ee: 200 µL racemic t-BuPyOx, 300 µL (S)- t-BuPyOx (afforded ketone 35 in 52% ee)
80% ee: 100 µL racemic t-BuPyOx, 400 µL (S)- t-BuPyOx (afforded ketone 35 in 68% ee)
100% ee: 500 µL (S)- t-BuPyOx (afforded ketone 35 in 92% ee)
4.5.3 Spectroscopic Data for Compounds
Synthesis of [PdIPh(PyOx)] (complex 235)
Pd(dba)2 (288.0 mg, 0.50 mmol, 1.0 equiv) was dissolved in benzene (20 mL). (S)-t-
BuPyOX (108.0 mg, 0.52 mmol, 1.05 equiv) and iodobenzene (83.0 µL, 0.75 mmol, 1.50
equiv) were added and the mixture was slowly heated to 50 °C and stirred overnight.
Upon completion the crude product was filtered and the filtrate was concentrated under
reduced pressure.  The resulting brown oil was triturated with diethyl ether and washed
several times with diethylether and hot hexanes. The resulting orange solid was dried in
vacuo to yield 103 mg of the desired product (0.20 mmol, 40% yield). Two different
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stereoisomers were visible in 1H NMR in a 1:1.3 ratio. 1H NMR (500 MHz, CDCl3)
Major isomer: δ 0.63 (s, 9H), 3.90 (dd, J = 9.0, 3.2 Hz, 1H), 4.62 (t, J = 9.2 Hz, 1H), 4.82
(dd, J = 3.3, 9.3 Hz, 1H), 6.83 (t, J = 6.6 Hz, 1H), 6.89 (m, 2H), 7.28-7.33 (m, 2H), 7.62-
7.65 (m, 1H), 7.87 (d, J = 7.7 Hz, 1H), 8.05 (td, J = 7.8, 1.5 Hz, 1H), 9.39 (d, J = 5.1 Hz,
1H); Minor isomer: δ 1.09 (s, 9H), 4.37 (dd, J = 3.6, 9.2 Hz, 1H), 4.54 (t, J = 9.2 Hz,
1H), 4.79 (dd, J = 3.6, 9.2 Hz, 1H), 6.98 (dt, J = 7.1, 8.7 Hz, 1H), 7.06-7.11 (m, 2H),
7.43-7.48 (m, 2H), 7.50 (d, J = 4.5 Hz, 1H), 7.84 (d, J = 7.6 Hz, 1H), 8.00-8.03 (m, J =
7.8, 1H), 9.70 (d, J = 4.2 Hz, 1H); 13C NMR (500 MHz, CDCl3) Major isomer: δ 25.6,
35.0, 70.0, 73.3, 123.3, 124.3, 126.5, 129.0, 138.7, 138.8, 143.8, 144.0, 153.4, 168.6;
Minor isomer: δ 26.9, 35.4, 72.0, 73.5, 123.4, 124.4, 126.5, 128.8, 138.5, 138.7, 143.5,
144.9, 150.2, 166.6; IR (cm-1) ν = 3050, 2961, 1636, 1587, 1560, 1490, 1467, 1405, 1395,
1368, 1297, 1251, 1209, 1159, 1094, 1062, 1018, 927, 791, 750, 732; Anal. Calc. for
C18H21ON2IPd1: C, 41.11; H, 4.04; N, 5.42%. Found: C, 41.09; H, 3.91; N, 4.87%; ESI-
MS m/z = 436.8 ([M-Ph]+)
Synthesis of [PdIPh(bpy)] (complex S1)
Referring to a known procedure,44 Pd(dba)2 (115.0 mg, 0.20 mmol, 1.0 equiv) was
dissolved in benzene (5 mL). 2,2’-bipyridyl (40.3 mg, 0.26 mmol, 1.30 equiv) and
iodobenzene (32.0 _L, 0.286 mmol, 1.43 equiv) were added and the mixture was slowly
                                                 
1 Isolation of X-ray quality crystals shows 5 mol % contamination with (PyOx)Pd(I)2.
This elemental analysis is consistent with that observed impurity, i.e. C, 42.00; H, 4.11;
N, 5.44 x 0.05 (C, 25.53; H, 2.86; N, 4.96) = C, 41.11; H, 4.04; N, 5.42.
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heated to 50 °C and stirred overnight. Upon completion the crude product was filtered
and the filtrate was concentrated under reduced pressure.  The resulting orange oil was
triturated with diethyl ether and washed several times with diethyl ether and hot hexanes.
The resulting yellow solid was dried in vacuo to yield the title compound (41 mg, 0.09
mmol, 45% yield). All characterization data matches previously reported data.44,45
N
NPd
I
Synthesis of [PdIPh(TMEDA)] (complex S2)
Referring to a known procedure,44 Pd(dba)2 (80.0 mg, 0.14 mmol, 1.0 equiv) was
dissolved in benzene (5 mL). Freshly distilled TMEDA (27.0 µL, 0.18 mmol, 1.30 equiv)
and iodobenzene (22.0 _L, 0.20 mmol, 1.43 equiv) were added and the mixture was
slowly heated to 50 °C and stirred overnight. Upon completion the crude product was
filtered and the filtrate was concentrated under reduced pressure.  The resulting orange oil
was triturated with diethyl ether and washed several times with diethyl ether and hot
hexanes. The resulting yellow solid was dried in vacuo to yield the title compound (30
mg, 0.07 mmol, 51% yield). All characterization data matches previously reported data.44
N
N
O
t-Bu
Pd
OCOCF3
F3COCO
Synthesis of (PyOx)Pd(OCOCF3)2 (complex S3, thesis compound number 245)
Pd(MeCN)2Cl2- (362 mg, 1.40 mmol, 1 equiv.) and (S)-t-BuPyOX (321, 1.57 mmol, 1.12
equiv.) were dissolved in CH2Cl2 (6 mL) and stirred for 1 h at ambient temperature.  The
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reaction mixture was filtered through a plug of celite, and concentrated in vacuo until 1
mL of solution remained.  The solution was triturated with hexanes to precipitate an
orange powder.  The powder was collected by filtration and dried under high vacuum to
afford (PyOx)PdCl2 as a pale orange solid (507 mg, 1.33 mmol, 95% yield).  A portion of
this solid (200 mg, 0.52 mmol, 1 equiv.) was dissolved in CH2Cl2 (10 mL) and
Ag(OCOCF3)2 (290 mg, 1.09 mmol, 2.2 equiv.) was added at ambient temperature.  The
reaction was stirred for 1 h, filtered through a plug of celite and concentrated in vacuo,
and was triturated with hexanes to afford a pale yellow solid (198 mg, 0.37 mmol, 72%).
1H NMR (500 MHz, CD2Cl2) δ 8.26–8.18 (m, 2H), 7.87–7.80 (m, 1H), 7.75 (ddt, J = 7.8,
5.7, 1.5 Hz, 1H), 4.93 (dd, J = 9.5, 3.4 Hz, 1H), 4.86 (td, J = 9.4, 1.6 Hz, 1H), 3.92 (dt, J
= 9.3, 2.7 Hz, 1H), 1.00 (d, J = 1.6 Hz, 9H), 13C NMR (126 MHz, CD2Cl2) δ 171.9, 164.4
(q, JC-F = 36 Hz), 164.3 (q, JC-F = 37 Hz), 152.3, 145.9, 143.6, 131.7, 127.9, 116.3 (q, JC-F
= 295 Hz), 116.1 (q, JC-F = 292 Hz), 76.5, 74.0, 36.8, 27.1; 19F NMR (282 MHz, CD2Cl2)
–74.7, -74.6; IR (Neat film, NaCl) ν = 2916, 1684, 1595, 1424, 1210, 1140 cm–1; Anal.
Calc. for C16H16O5N2F6Pd: C, 35.80; H, 3.00; N, 5.22%. Found: C, 35.52; H, 3.29; N,
4.65%; HRMS (EI+) m/z calc’d for C14H16F3N2O3Pd [M–(OCOCF3)]+: 423.0147, found
423.0163.
N
N
O
Pd
PPh3
+
 PF6 -
Synthesis of [PdPh(PPh3)(PyOx)][PF6] (complex 236)
Complex 29 (52.0 mg, 0.10 mmol, 1.0 equiv) and PPh3 (25.0 mg, 0.10 mmol, 1.0 equiv)
were dissolved in THF (10 mL) and the solution was cooled to –78 °C. A solution of
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AgPF6 (26.2 mg, 0.10 mmol, 1.0 equiv) in 10 mL of THF was added at –78 °C and the
reaction was stirred for 30 min at this temperature. The reaction was allowed to come to
ambient temperature and the resulting suspension was filtered. The solvent was removed
under reduced pressure and the resulting yellow oil was dissolved in CH2CL2 and filtrated
again. A white powder was precipitated from solution upon addition of diethyl ether and
hexanes. The solid was washed with hexanes and dried in vacuo to yield the title
compound (62 mg, 0.079 mmol, 79% yield). Two different stereoisomers were visible in
1H NMR and 31P NMR in a 1:1.35 ratio.  1H NMR (500 MHz, CD2Cl2) Major isomer: δ
0.59 (s, 9H), 1.88 (dd, J = 8.9, 2.8 Hz, 1H), 4.25 (t, J = 9.2 Hz, 1H), 4.61 (dd, J = 2.6, 9.4
Hz, 1H), 6.48 (m, 1H), 6.60 (t, J = 8.0 Hz, 1H), 6.89 (t, J = 7.2 Hz, 1H), 6.98 (t, J = 7.1
Hz, 1H), 7.32 (t, J = 6.7 Hz, 2H), 7.55 (d, J = 7.7 Hz, 1H), 7.96 (d, J = 7.7 Hz, 1H), 8.10
(dt, J = 7.7, 1.2 Hz, 1H). Minor isomer: δ 0.63 (s, 9H), 3.68 (dd, J = 3.4, 8.9 Hz, 1H),
4.77 (t, J = 9.3 Hz, 1H), 4.90 (dd, J = 2.4, 11.9 Hz, 1H), 6.54 (m, 1H), 6.72 (m, 1H), 6.79
(m, 1H), 7.03 (d, J = 4.8 Hz, 1H), 7.16 (d, J = 4.8 Hz, 2H), 7.26 (m, 1H), 7.98 (m, 1H),
8.03 (dt, J = 7.7, 1.3 Hz, 1H); 13C NMR (500 MHz, CD2Cl2) Major isomer: δ 25.6, 35.0,
70.0, 73.3, 123.3, 124.3, 126.5, 129.0, 138.7, 138.8, 143.8, 144.0, 153.4, 168.6.  Minor
isomer: δ 26.9, 35.4, 72.0, 73.5, 123.4, 124.4, 126.5, 128.8, 138.5, 138.7, 143.5, 144.9,
150.2, 166.6. 31P NMR (161.8 MHz, CD2Cl2): δ 28.3 (major isomer), 33.5 (minor
isomer), –166.5 (PF6–, septuplet, J = 712.9 Hz); IR (cm-1) ν = 3050, 2961, 1636, 1587,
1560, 1490, 1467, 1405, 1395, 1368, 1297, 1251, 1209, 1159, 1094, 1062, 1018, 927,
791, 750, 732; Anal. Calc. for C36H36F6N2OP2Pd: C, 54.39; H, 4.56; N, 3.52%. Found: C,
53.81; H, 4.94; N, 3.44%; HRMS (ESI+) m/z calc’d for C36H36N2OPPd [M]+: 649.1600,
found 649.1598.
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(R)-3-phenyl-3-methylcyclohexanone (35)
Synthesized according to the general procedure and purified by flash chromatography
(9:1 hexanes/EtOAc) to afford a colorless oil (99% yield).  [α]25D –56.1° (c 1.36, CHCl3,
92% ee). All characterization data matches previously reported data.46, 47, 48, 49, 50, 51, 52
(R)-3-(3-chlorophenyl)-3-methylcyclohexanone (211a, Table 4.3)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 100:0 hexanes/EtOAc to 95:5 hexanes/EtOAc) to afford a colorless oil (96%
yield).  [α]25D –56.7° (c 1.48, CHCl3, 96% ee). All characterization data matches
previously reported data.42,46
(R)-3-(3-bromophenyl)-3-methylcyclohexanone (211b, Table 4.3)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 100:0 hexanes/EtOAc to 95:5 hexanes/EtOAc) to afford a colorless solid (84%
yield).  [α]25D –56.7° (c 0.68, CHCl3, 84% ee). All characterization data matches
previously reported data.48
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(R)-3-methyl-3-(3-nitrophenyl)cyclohexanone (211c, Table 3)
Synthesized according to the general procedure and purified by flash chromatography
(CH2Cl2) to afford a colorless solid (81% yield).  [α]25D –61.5° (c 0.96, CHCl3, 91% ee).
All characterization data matches previously reported data.53
(R)-3-(2-fluorophenyl)-3-methylcyclohexanone (211d, Table 3)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 100:0 hexanes/EtOAc to 95:5 hexanes/EtOAc) to afford a colorless oil (70%
yield). [α]25D –41.0° (c 0.64, CHCl3, 77% ee)All characterization data matches previously
reported data.53
O
O
(R)-4-methyl-4-phenyltetrahydro-2H-pyran-2-one (Table 4.6, Entry 7)
Synthesized according to the general procedure and purified by flash chromatography
(gradient 100:0 hexanes/EtOAc to 90:10 hexanes/EtOAc) to afford a colorless solid (49%
yield).  [α ]25D –87.2 (c 0.99, CHCl3, 57% ee).  All characterization data matches
previously reported data.54
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(R)-2,2,5-trimethyl-5-phenylcyclohexanone (Table 4.6, Entry 8, thesis comound 246)
Enone substrate was synthesized by known procedure.55  Synthesized according to the
general procedure and purified by flash chromatography (gradient: 100:0 hexanes/EtOAc
to 90:10 hexanes/EtOAc) to afford a colorless oil (9% yield). 1H NMR (500 MHz,
CDCl3) δ 7.32 (d, J = 4.8 Hz, 4H), 7.24–7.16 (m, 1H), 2.92 (dd, J = 14.4, 1.5 Hz, 1H),
2.52 (dd, J = 14.4, 1.2 Hz, 1H), 2.18 (dddd, J = 14.0, 8.4, 4.1, 1.5 Hz, 1H), 1.97 (dddd, J
= 13.8, 8.5, 3.9, 1.2 Hz, 1H), 1.74–1.59 (m, 1H), 1.51 (ddd, J = 14.1, 8.6, 4.1 Hz, 1H),
1.29 (s, 3H), 1.15 (s, 3H), 1.06 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 215.8, 147.8,
128.5, 128.4, 126.1, 125.5, 49.4, 44.1, 43.3, 36.4, 34.5, 29.6, 25.5, 25.1; IR (Neat film,
NaCl) ν = 2961, 2923, 2863, 1704, 1666, 1496, 1444, 1384, 1302, 1030 cm–1; HRMS
(EI+) m/z calc’d for C15H21O [M+H)+: 216.1514, found 216.1506; [α]25D –58.3° (c 0.48,
CHCl3, 90% ee).
O
O
(R)-3-(4-acetylphenyl)-3-methylcyclohexanone (Table 4.7, Entry 9)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 95:5 hexanes/EtOAc to 85:15 hexanes/EtOAc) to afford colorless oil (99%
yield). [α]25D –58.9° (c 1.39, CHCl3, 96% ee). All characterization data matches
previously reported data.53
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CF3
(R)-3-methyl-3-(4-(trifluoromethyl)phenyl)cyclohexanone (Table 4.7, Entry 10)
Synthesized according to the general procedure and purified by flash chromatography
(gradient: 95:5 hexanes/EtOAc to 85:15 hexanes/EtOAc) to afford colorless oil (99%
yield). [α]25D –58.5° (c 0.92, CHCl3, 96% ee). All characterization data matches
previously reported data.53
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Table 4.13 Chiral Assays
compound product
retention time
of major
isomer (min)
% ee
retention time
of minor
isomer (min)
HPLC
conditions
O
35
O
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
15.3 19.6 92
Chiralpak
AD-H
5% IPA/Hexanes
isocratic 1 mL/min
30.4 29.5 96
O
CF3
Chiralcel
OJ-H
0.5% IPA/Hexanes
isocratic 1 mL/min
35.0 41.1 96
211a
(Table 3)
211b
(Table 3)
211c
(Table 3)
O
Cl
O
Br
O
NO2
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
17.2 20.4 96
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
14.7 16.9 85
Chiralpak
AD-H
1% IPA/Hexanes
Isocratic 1mL/min
29.0 30.6 92
Table 7
Entry 9
O
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
9.3 10.9 77
F
O
O
O
O
Chiralcel
OJ-H
1% IPA/Hexanes
isocratic 1 mL/min
Chiralcel
OJ-H
5% IPA/Hexanes
isocratic 1 mL/min
13.7 17.8 57
7.8 9.9 90
211d
(Table 3)
Table 6
Entry 7
Table 6
Entry 8
Table 7
Entry 10
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Spectra relevant to Chapter 4:  
Mechanism and enantioselectivity in palladium-catalyzed conjugate  
addition of arylboronic acids to β−substituted cyclic enones:  
Insights from computation and experiment 
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Figure A3.3 13C NMR (126 MHz, CDCl3) of compound 235 
 
 Figure A3.2 Infrared spectrum (Thin Film, NaCl) of compound 235 
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Figure A3.6 13C NMR (126 MHz, CDCl3) of compound 236 
 
 
Figure A3.5 31P NMR (121 MHz, CDCl3) of compound 236 
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Figure A3.9 13C NMR (126 MHz, CDCl3) of compound 245 
 
 
Figure A3.8 19F NMR (272 MHz, CDCl3) of compound 245 
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Figure A3.12 13C NMR (126 MHz, CDCl3) of compound 246 
 
 
Figure A3.11 Infrared spectrum (Thin Film, NaCl) of compound 246 
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Figure A3.13 DOSY Spectrum Entry 1 
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Figure A3.14 DOSY Spectrum Entry 2 
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Figure A3.15 DOSY Spectrum Entry 3 
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Figure A4.1 X-ray Structure for Complex  235, CCDC 953854 
 
X-Ray Structure Determination 
 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker 
Kappa four-circle diffractometer coupled to a Bruker APEX-II CCD detector with 
graphite-monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of 
compound anm02.  The structure was solved by direct methods using SHELXSi and 
refined against F2 on all data by full-matrix least squares with SHELXL-2013ii using 
established refinement techniques. iii   All non-hydrogen atoms were refined 
anisotropically.  All hydrogen atoms were included into the model at geometrically 
calculated positions and refined using a riding model.  The isotropic displacement 
parameters of all hydrogen atoms were fixed to 1.2 times the U value of the atoms they 
are linked to (1.5 times for methyl groups).   
Compound anm02 crystallizes in the monoclinic space group C2 with one molecule 
in the asymmetric unit.  The phenyl ligand is disordered with a partially occupied iodide 
ligand.  A mixture of cis- and trans- isomers is identified in solution and the other 
position is probably also a mixture of phenyl and iodide.  Refinement of a partially 
occupied phenyl ligand in the second position is not stable and the phenyl collides with a 
neighboring molecule.  Because of this the second of the two iodide positions was refined 
fully occupied.  The disordered iodine was refined with the help of similarity restraints on 
the Pd-I distance.   
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Table A4.1  Crystal data and structure refinement for anm02. 
Identification code  anm02, CCDC 953854 
Empirical formula  C17.80 H20.83 I1.03 N2 O Pd 
Formula weight  516.47 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 2 
Unit cell dimensions a = 18.4571(12) Å α= 90°. 
 b = 9.9004(6) Å β= 101.240(4)°. 
 c = 10.5480(7) Å γ = 90°. 
Volume 1890.5(2) Å3 
Z 4 
Density (calculated) 1.815 Mg/m3 
Absorption coefficient 2.677 mm-1 
F(000) 1002 
Crystal size 0.150 x 0.050 x 0.050 mm3 
Theta range for data collection 1.968 to 30.600°. 
Index ranges -26<=h<=26, -14<=k<=14, -15<=l<=15 
Reflections collected 24103 
Independent reflections 5762 [R(int) = 0.0380] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.746 and 0.665 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5762 / 2 / 221 
Goodness-of-fit on F2 1.027 
Final R indices [I>2sigma(I)] R1 = 0.0226, wR2 = 0.0403 
R indices (all data) R1 = 0.0269, wR2 = 0.0414 
Absolute structure parameter 0.023(10) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.568 and -0.578 e.Å-3 
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Table A4.2  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for anm02.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
I(1) 1111(1) 1537(1) 8477(1) 26(1) 
Pd(1) 2229(1) 299(1) 7918(1) 15(1) 
I(2A) 1528(8) -1898(12) 7873(15) 39(4) 
C(1) 1681(3) -1422(6) 7810(6) 18(1) 
C(2) 1048(2) -1720(4) 6897(4) 27(1) 
C(3) 736(2) -3011(5) 6822(4) 33(1) 
C(4) 1041(2) -4014(4) 7665(5) 30(1) 
C(5) 1653(2) -3742(4) 8593(4) 24(1) 
C(6) 1975(2) -2458(4) 8672(4) 19(1) 
N(1) 2975(2) 2025(3) 8127(3) 19(1) 
C(7) 2837(2) 3340(4) 8273(4) 25(1) 
C(8) 3397(3) 4273(4) 8546(4) 32(1) 
C(9) 4114(3) 3889(5) 8663(4) 36(1) 
C(10) 4270(2) 2532(4) 8515(4) 29(1) 
C(11) 3682(2) 1648(4) 8243(3) 21(1) 
C(12) 3766(2) 197(4) 8018(3) 20(1) 
N(2) 3211(2) -581(3) 7649(3) 16(1) 
O(1) 4442(2) -330(3) 8174(3) 29(1) 
C(13) 4313(2) -1793(4) 8025(4) 28(1) 
C(14) 3507(2) -1924(3) 7364(3) 18(1) 
C(15) 3378(2) -2221(4) 5897(3) 24(1) 
C(16) 2554(2) -2265(5) 5352(4) 34(1) 
C(17) 3745(3) -1142(4) 5188(4) 36(1) 
C(18) 3710(3) -3608(4) 5714(4) 36(1) 
________________________________________________________________________________ 
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Table A4.3   Bond lengths [Å] and angles [°] for  anm02. 
_____________________________________________________  
I(1)-Pd(1)  2.5655(3) 
Pd(1)-C(1)  1.973(6) 
Pd(1)-N(2)  2.080(3) 
Pd(1)-N(1)  2.178(3) 
Pd(1)-I(2A)  2.526(10) 
C(1)-C(2)  1.393(7) 
C(1)-C(6)  1.407(7) 
C(2)-C(3)  1.397(6) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.379(6) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.370(6) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.399(5) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
N(1)-C(11)  1.341(5) 
N(1)-C(7)  1.342(4) 
C(7)-C(8)  1.373(6) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.360(7) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.389(7) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.380(5) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.470(6) 
C(12)-N(2)  1.280(5) 
C(12)-O(1)  1.332(4) 
N(2)-C(14)  1.489(4) 
O(1)-C(13)  1.471(5) 
C(13)-C(14)  1.521(5) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
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C(14)-C(15)  1.548(5) 
C(14)-H(14)  1.0000 
C(15)-C(16)  1.519(6) 
C(15)-C(18)  1.531(6) 
C(15)-C(17)  1.534(6) 
C(16)-H(16A)  0.9800 
C(16)-H(16B)  0.9800 
C(16)-H(16C)  0.9800 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
 
C(1)-Pd(1)-N(2) 94.67(18) 
C(1)-Pd(1)-N(1) 171.83(18) 
N(2)-Pd(1)-N(1) 78.00(11) 
N(2)-Pd(1)-I(2A) 95.4(3) 
N(1)-Pd(1)-I(2A) 171.3(4) 
C(1)-Pd(1)-I(1) 89.97(16) 
N(2)-Pd(1)-I(1) 173.14(8) 
N(1)-Pd(1)-I(1) 97.02(8) 
I(2A)-Pd(1)-I(1) 89.1(3) 
C(2)-C(1)-C(6) 117.3(5) 
C(2)-C(1)-Pd(1) 125.0(4) 
C(6)-C(1)-Pd(1) 117.6(4) 
C(1)-C(2)-C(3) 120.9(4) 
C(1)-C(2)-H(2) 119.5 
C(3)-C(2)-H(2) 119.5 
C(4)-C(3)-C(2) 120.7(4) 
C(4)-C(3)-H(3) 119.6 
C(2)-C(3)-H(3) 119.6 
C(5)-C(4)-C(3) 119.7(4) 
C(5)-C(4)-H(4) 120.2 
C(3)-C(4)-H(4) 120.2 
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C(4)-C(5)-C(6) 120.2(4) 
C(4)-C(5)-H(5) 119.9 
C(6)-C(5)-H(5) 119.9 
C(5)-C(6)-C(1) 121.2(4) 
C(5)-C(6)-H(6) 119.4 
C(1)-C(6)-H(6) 119.4 
C(11)-N(1)-C(7) 117.5(4) 
C(11)-N(1)-Pd(1) 112.1(2) 
C(7)-N(1)-Pd(1) 130.0(3) 
N(1)-C(7)-C(8) 121.7(4) 
N(1)-C(7)-H(7) 119.1 
C(8)-C(7)-H(7) 119.1 
C(9)-C(8)-C(7) 120.7(4) 
C(9)-C(8)-H(8) 119.7 
C(7)-C(8)-H(8) 119.7 
C(8)-C(9)-C(10) 118.7(4) 
C(8)-C(9)-H(9) 120.7 
C(10)-C(9)-H(9) 120.7 
C(11)-C(10)-C(9) 117.7(4) 
C(11)-C(10)-H(10) 121.1 
C(9)-C(10)-H(10) 121.1 
N(1)-C(11)-C(10) 123.7(4) 
N(1)-C(11)-C(12) 112.9(3) 
C(10)-C(11)-C(12) 123.4(4) 
N(2)-C(12)-O(1) 118.4(4) 
N(2)-C(12)-C(11) 122.3(3) 
O(1)-C(12)-C(11) 119.2(3) 
C(12)-N(2)-C(14) 107.2(3) 
C(12)-N(2)-Pd(1) 111.9(2) 
C(14)-N(2)-Pd(1) 139.9(2) 
C(12)-O(1)-C(13) 104.1(3) 
O(1)-C(13)-C(14) 104.9(3) 
O(1)-C(13)-H(13A) 110.8 
C(14)-C(13)-H(13A) 110.8 
O(1)-C(13)-H(13B) 110.8 
C(14)-C(13)-H(13B) 110.8 
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H(13A)-C(13)-H(13B) 108.8 
N(2)-C(14)-C(13) 101.3(3) 
N(2)-C(14)-C(15) 112.3(3) 
C(13)-C(14)-C(15) 114.8(3) 
N(2)-C(14)-H(14) 109.4 
C(13)-C(14)-H(14) 109.4 
C(15)-C(14)-H(14) 109.4 
C(16)-C(15)-C(18) 108.8(4) 
C(16)-C(15)-C(17) 109.9(3) 
C(18)-C(15)-C(17) 109.8(3) 
C(16)-C(15)-C(14) 109.3(3) 
C(18)-C(15)-C(14) 108.0(3) 
C(17)-C(15)-C(14) 111.0(3) 
C(15)-C(16)-H(16A) 109.5 
C(15)-C(16)-H(16B) 109.5 
H(16A)-C(16)-H(16B) 109.5 
C(15)-C(16)-H(16C) 109.5 
H(16A)-C(16)-H(16C) 109.5 
H(16B)-C(16)-H(16C) 109.5 
C(15)-C(17)-H(17A) 109.5 
C(15)-C(17)-H(17B) 109.5 
H(17A)-C(17)-H(17B) 109.5 
C(15)-C(17)-H(17C) 109.5 
H(17A)-C(17)-H(17C) 109.5 
H(17B)-C(17)-H(17C) 109.5 
C(15)-C(18)-H(18A) 109.5 
C(15)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(15)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table A4.4.   Anisotropic displacement parameters  (Å2x 103) for anm02.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
I(1) 21(1)  28(1) 29(1)  3(1) 8(1)  12(1) 
Pd(1) 15(1)  15(1) 16(1)  0(1) 4(1)  4(1) 
I(2A) 37(7)  32(8) 52(7)  -14(6) 20(5)  -17(5) 
C(1) 17(3)  19(3) 21(2)  -4(2) 8(2)  0(2) 
C(2) 21(2)  37(2) 24(2)  0(2) 5(2)  0(2) 
C(3) 25(2)  47(3) 27(2)  -14(2) 7(2)  -14(2) 
C(4) 30(2)  27(2) 41(2)  -10(2) 21(2)  -11(2) 
C(5) 31(2)  22(2) 25(2)  -2(2) 17(2)  1(2) 
C(6) 19(2)  22(2) 18(2)  -4(2) 9(2)  0(2) 
N(1) 26(2)  17(2) 15(1)  0(1) 6(1)  0(1) 
C(7) 37(2)  19(2) 19(2)  2(2) 7(2)  3(2) 
C(8) 56(3)  18(2) 23(2)  -2(2) 11(2)  -8(2) 
C(9) 49(3)  32(2) 28(2)  -5(2) 11(2)  -18(2) 
C(10) 30(2)  31(2) 28(2)  -5(2) 9(2)  -10(2) 
C(11) 24(2)  23(2) 17(2)  -4(2) 7(1)  -2(2) 
C(12) 16(2)  25(2) 20(2)  2(2) 7(1)  3(2) 
N(2) 17(1)  16(1) 18(1)  0(1) 6(1)  4(1) 
O(1) 16(1)  35(2) 36(2)  -4(1) 7(1)  1(1) 
C(13) 21(2)  31(2) 34(2)  2(2) 7(2)  9(2) 
C(14) 22(2)  16(2) 19(2)  3(1) 10(1)  5(1) 
C(15) 34(2)  21(2) 21(2)  2(2) 16(2)  6(2) 
C(16) 41(2)  38(2) 21(2)  -10(2) 3(2)  4(2) 
C(17) 58(3)  28(2) 29(2)  5(2) 25(2)  0(2) 
C(18) 56(3)  27(2) 29(2)  -4(2) 21(2)  9(2) 
______________________________________________________________________________ 
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Table A4.5   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for anm02. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 825 -1036 6319 33 
H(3) 310 -3199 6182 39 
H(4) 827 -4891 7604 36 
H(5) 1859 -4427 9185 29 
H(6) 2401 -2283 9318 23 
H(7) 2340 3634 8186 29 
H(8) 3281 5196 8654 38 
H(9) 4501 4536 8842 43 
H(10) 4765 2224 8599 35 
H(13A) 4403 -2247 8878 34 
H(13B) 4640 -2197 7488 34 
H(14) 3266 -2646 7802 22 
H(16A) 2318 -2915 5844 50 
H(16B) 2470 -2540 4443 50 
H(16C) 2341 -1367 5418 50 
H(17A) 3532 -255 5310 54 
H(17B) 3660 -1356 4264 54 
H(17C) 4277 -1124 5539 54 
H(18A) 4238 -3603 6100 54 
H(18B) 3645 -3809 4789 54 
H(18C) 3460 -4299 6136 54 
________________________________________________________________________________  
                                                
i	  Sheldrick,	  G.	  M.	  Acta	  Cryst.	  1990,	  A46,	  467-­‐473.	  
ii	  Sheldrick,	  G.	  M.	  Acta	  Cryst.	  2008,	  A64,	  112-­‐122.	  
iii	  Müller,	  P.	  Crystallography	  Reviews	  2009,	  15,	  57-­‐83.	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CHAPTER 5
Development of a Scalable Synthesis of the (S)-4-(tert-butyl)-2-
(pyridin-2-yl)-4,5-dihydrooxazole ((S)–t-BuPyOx) Ligand÷
N
N
O
t-Bu
N
O
OH
Three Steps
Multi-Gram Scale$0.43 per gram
                                                 
÷ This work was done in collaboration with Dr. Hideki Shimizu (notebooks HS-I and HS-
II), and was adapted from the publication: Shimizu, H.; Holder, J. C.; Stoltz, B. M.
Beilstein J. Org. Chem. 2013, 9, 1637–1642.
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Abstract
N
N
O
t-Bu
N
O
OH
Three Steps
Multi-Gram Scale$0.43 per gram
An efficient method for the synthesis of the (S)-4-(tert-butyl)-2-(pyridin-2-yl)-
4,5-dihydrooxazole ((S)–t-BuPyOx) ligand has been developed. Inconsistent yields and
tedious purification in known routes to (S)–t-BuPyOx suggested the need for an efficient,
dependable, and scalable synthetic route. Furthermore, a route suitable for the synthesis
of PyOx derivatives is desirable. Herein, we describe the development of a three-step
route from inexpensive and commercially available 2-picolinic acid. This short procedure
is amenable to multi-gram scale synthesis and provides the target ligand in 64% overall
yield.
Chapter 5 358
5.1 Introduction
Pyridinooxazoline (PyOx) ligands represent a growing class of bidentate
dinitrogen ligands used in asymmetric catalysis.1 Recently, our laboratory reported the
catalytic asymmetric conjugate addition of arylboronic acids to cyclic, β,β1-disubstituted
enones utilizing (S)–t-BuPyOx (82) as the chiral ligand (Figure 1).2  This robust reaction
is insensitive to oxygen atmosphere, highly tolerant of water,3 and provides cyclic
ketones bearing β -benzylic quaternary stereocenters in high yields and
enantioselectivities.  While the reaction itself proved to be amenable to multi-gram scale,
the ligand is not yet commercially available and no reliable method for the large-scale
synthesis of (S)–t-BuPyOx was known.4  We sought to address this shortcoming by
developing an efficient route starting from a cheap, commercially available precursor to
pyridinooxazoline ligands (Scheme 5.1).
Scheme 5.1 Picolinic acid as a precursor for the synthesis of pyridinooxazoline ligands
N
N
O
t-Bu
N
O
OH
Three Steps
Multi-Gram Scale$0.43 per gram
Inconsistent yields and tedious purification in known routes to (S)–t-BuPyOx
suggested the need for an efficient, dependable, and scalable synthetic route.
Furthermore, a route suitable for the synthesis of PyOx derivatives is desirable.  Herein,
we describe the development of a three-step route from inexpensive and commercially
available 2-picolinic acid.  This short procedure is amenable to multi-gram scale
synthesis and provides the target ligand in 64% overall yield.
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5.2 Results and Discussion
5.2.1 Revised Retrosynthetic Analysis of (S)-t-BuPyOx
Initially, (S)–t-BuPyOx (82) was synthesized by methanolysis of 2-cyanopyridine
(247) to afford methoxyimidate 248, and subsequent acid-catalyzed cyclization to afford
the (S)–t-BuPyOx ligand (Figure 5.1).5 We found the yields of this reaction sequence to
be highly variable, and the purification by silica gel chromatography to be tedious. In the
revised retrosynthesis, 2-picolinic acid (250) was identified as a comparably priced,
commonly available surrogate for cyanopyridine 247. Amidation of (S)-tert-leucinol
(251) and picolinic acid (250) would generate amide 249, which upon cyclization would
generate the ligand framework.
Figure 5.1  Initial PyOx synthesis and revised plan
N CN
N
OMe
NH
N
N
O
t-Bu
NaOMe,
MeOH
0 °C → 20 °C
85% yield
pTsOH•H2O
(S)-tert-leucinol
toluene, 80 °C
40% yield
N
N
O
t-Bu
N CO2H
H2N OH
t-Bu
+
Initial Route to (S)–t-BuPyOx:
Revised Retrosynthetic Plan:
N
O
H
N
t-Bu
OH
Asymmetric conjugate addition with (S)–t-BuPyOx
R
O
Ar
O
R
Pd(OCOCF3)2 (5 mol%) 
(S)-t-BuPyOx (6 mol%)
ClCH2CH2Cl (wet), 60 °C
B(OH)2
R
+
247 248 82
82 249 250 251
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5.2.2 Amidation of 2-picolinic acid and (S)-tert-leucinol
Initial efforts focused on the amidation reaction between (S)-tert-leucinol and 2-
picolinic acid (250) via acid chloride 252 (Table 5.1), which was generated in situ by
treatment of acid 250 with a number of chlorinating agents. Oxalyl chloride (entries 1, 2)
provided reasonable yields of amide 249, however bis-acylation of (S)-tert-leucinol was
observed as a common side product. Importantly, temperature control of this reaction
(entry 2) allowed isolation of 75% of desired alcohol 249 in acceptable purity without the
use of column chromatography. Use of diphenyl chlorophosphate (entries 3, 5-6) also
resulted in noticeable quantities of over acylation product, as well as the generation of a
small amount of phosphorylation of amide 249. These results encouraged us to explore
alternative activation strategies to generate the desired amide bond. Adapting a procedure
from Sigman, activation of acid 250 by treatment with iso-butylchloroformate and N-
methylmorpholine (anhydride 253) facilitated the desired transformation with the highest
overall yield, with amide 249 being isolated in 91% yield, albeit requiring column
chromatography.6
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Table 5.1  Amidation reactions of picolinic acid
N
O
H
N
t-Bu
OHN
O
OH
temp. (°C)solvent 1 / 2 time (h) yield (%)b
1
2
3
4
5
6
7
THF/THF
THF/THF
THF
toluene/THF
THF
THF/THF
CH2Cl2/CH2Cl2
50
0 → rt
0 → rt
rt
50
0 → rt
0 → rt
1 
7 
6 
5 
2 
3 
3
55
75c
72
trace
30
65c
92
reagent
(COCl)2
(COCl)2
DPCP
SOCl2
DPCP
DPCP
i-BuOCOCl, NMM
N
O
X
reagent
solvent 1
base
Et3N
Et3N
Et3N
none
none
Et3N
NMM
entry
250 249252   X = Cl
(S)-tert-leucinol
base
solvent 2
253   X = OCOi-Bu
DPCP = diphenyl chlorophosphate,  NMM = N-methylmorpholine.  a Conditions: b Isolated
yield.  c Purification by flash chromatography not required.
5.2.3 Cyclization to form oxazoline ring
Satisfied with our ability to generate amide 249 on gram-scale with good yield,
we turned our attention to the completion of the synthesis. The cyclization of amide 249
to (S)–t-BuPyOx (82) proved more challenging than anticipated. Activation of alcohol
249 as mesylate 254 (Table 5.2, entries 1-2) and tosylate 255 (entry 3) followed by in situ
cyclization gave the desired product in low yield and incomplete conversion. This could
potentially result from ligand hydrolysis under the reaction conditions.7 As an alternative
to in situ cyclization of an activated intermediate, alcohol 249 was reacted with thionyl
chloride (entries 4–10) to yield chloride 256, which was isolated as the hydrochloric acid
salt and dried under vacuum. This compound proved to be bench stable and was
spectroscopically unchanged after being left open to oxygen atmosphere and adventitious
moisture for more than one week. Furthermore, chloride 256 proved to be a superior
cyclization substrate. A series of bases were screened. Organic amine bases (entries 4-5)
and sodium hydride (entry 6) provided inadequate conversion and low yields, whereas
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hydroxide and alkoxide bases proved superior (entries 7-10). Finally, sodium methoxide
was chosen to be optimal, as slower rates of hydrolysis of chloride 256 were observed
when compared to the use of potassium hydroxide.
Table 5.2 Cyclization screen
N
O
H
N
t-Bu
OH N
O
H
N
t-Bu
R
N
N
O
t-Bu
conditions base, temp
time
entry conditions R base temp (°C) time (h) yield (%)a
1
2
3
4
5
7
8
MsCl, Et3N, CH2Cl2 OMs Et3N 0 → 40 12 N.D.c
MsCl, Et3N, ClCH2CH2Cl OMs Et3N 0 → 80 12 N.D.c
TsCl, DMAP, Et3N, ClCH2CH2Cl OTs Et3N 0 → 80 12 N.D.c
SOCl2, CH2Cl2 Clb DABCO rt 18 38
SOCl2, CH2Cl2 Clb DBU 50 12 59
SOCl2, CH2Cl2 Clb 5% KOH/EtOH 50 11 58
SOCl2, CH2Cl2 Clb 5% KOH/MeOH 50 11 62
9 SOCl2, CH2Cl2 Clb 25% NaOMe/MeOH 50 10 71
10 SOCl2, CH2Cl2 Clb 25% NaOMe/MeOH 50 3 72
6 SOCl2, CH2Cl2 Clb NaH, THF 0 → 50 18 60
249 82R = OMs 254R = OTs 255
R = Cl • HCl 256
MsCl = methanesulfonyl chloride, TsCl = 4-toluenesulfonyl chloride, DMAP = 4-dimethylaminopyridine,
DABCO = 1,4-diazabicyclo[2.2.2]octane, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene.  a isolated yield.
bIntermediate 256 isolated as HCl salt and dried under high vacuum before use in cyclization reactions.
cIncomplete conversion.
5.2.4 Attempts to purify the ligand by salt formation
Attempts to purify ligand 82 via salt formation failed due to instability of the generated
products. Treatment with a number of carboxylic acids resulted in no salt formation, or a
mixture of products as observed by 1H NMR analysis (Table 5.3, entries 1–5). Treatment
with stronger acids, such as HCl (entry 6), resulted in decomposition. While purification
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via formation of the HBF4 salt is successful (entry 7, 82b), the salt is unstable in open air
and decomposes to the amide alcohol 249. Although salt formation is perhaps useful in
the purification of the crude reaction mixture of 82, further studies were suspended due to
the instability of salt.
Table 5.3 Attempts to form HX salts of PyOx ligand
N
N
O
t-Bu
acid (1.0 eq)
solvent, 
ambient temperature
N
H N
O
t-Bu
X
Result
1
2
3
4
5
6
7
THF
THF
THF
THF
THF
ether
ether
maleic acid
fumaric acid
malonic acid
DL-malic acid
2-ethylhexanoic acid
HCl in ether
HBF4 etherate
AcidEntry Solvent
peak shifted (mixture)
not formed
peak shifted (mixture)
not formed
not formed
decomposed
salt formed*
HO OH
O O
HO
O OH
OH
O
malonic acid DL-malic acid
HO
O
2-ethylhexanoic acid
OH
OH
O
O
maleic acid
OH
O
HO
O
fumaric acid
8 h
8 h
8 h
8 h
8 h
12 h
12 h
Time
*
5.1 mg
5.1 mg
5.1 mg
5.1 mg
5.1 mg
10 mg
10 mg
Scale
5.2.5 Purification by conventional column chromatography
Purification by silica gel chromatography also proved challenging as up to 10% of
crude ligand 82 was observed to decompose, even with the addition of triethylamine to
the eluent.  Finally, the use of neutral silica gel (American International Chemical
ZEOprep ECO silica gel, 40–63 micron, $18/kg) allowed isolation of ligand 82 in high
purity and with no observed decomposition.
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5.3 Conclusion and completed synthesis of (S)-t-BuPyOx
In conclusion, we have developed a concise, highly efficient and scalable
synthesis of the chiral ligand (S)–t-BuPyOx (82) (Figure 5.2). Efforts to further refine the
synthesis by telescoping the procedure and removing chromatographic purifications are
currently underway.
Figure 5.2  Scale-up synthesis of (S)–t-BuPyOx
N CO2H
N
O
H
N
t-Bu
OH N
O
H
N
t-Bu
Cl •HCl
1. i-BuOCOCl, NMM
    CH2Cl2, 0 °C
2. (S)-tert-leucinol, 
    NMM, CH2Cl2,
    0 °C → 20 °C
SOCl2
40 °C
(91% yield) (98% yield)
25 wt% NaOMe
MeOH, 50 °C
(72% yield)
N
N
O
t-Bu
250 249 256
82
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5.4 Experimental Procedures
5.4.1 Materials and Methods
All reactions were run under a nitrogen atmosphere.  Solvents and reagents were
obtained by commercial sources and used without further purification. Thin-layer
chromatography (TLC) was visualized by UV fluorescence quenching, and p-
anisaldehyde staining.  American International Chemical ZEOprep® 60 ECO 40-63
micron silica gel was used for flash chromatography.  Analytical chiral SFC was
performed utilizing an OB-H column (4.6 mm x 25 cm) with visualization at 254 nm and
flow rate of 5.0 mL/min, unless otherwise stated.  1H and 13C NMR spectra were recorded
at 500 MHz and 125 MHz, respectively.  Data for 1H NMR spectra are referenced to the
centerline of CHCl3 (δ 7.26) as the internal standard and are reported in terms of
chemical shift relative to Me4Si (δ 0.00).  Data for 13C NMR spectra are referenced to the
centerline of CDCl3 (δ  77.16) and are reported in terms of chemical shift relative to
Me4Si (δ 0.00).  Infrared spectra are reported in frequency of absorption (cm-1).
5.4.2 Experimental Procedures
OH
t-Bu
H2N
OH
t-Bu
H2N
O
(S)–tert-leucinol(S)–tert-leucine
(S)-tert-Leucinol (251)
This procedure was adapted from: Krout, M. R.; Mohr, J. T.; Stoltz, B. M.  Org.
Synth.  2009, 86, 181.  A 1000 mL separable flask equipped with a three-pitched curved
blade, an internal thermometer, and a reflux condenser equipped with a two-tap Schlenk
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adapter connected to a bubbler and a nitrogen/vacuum manifold was assembled hot and
cooled under a steam of N2.  The flask was charged with (L)-tert-leucine (15.08 g, 115.0
mmol, 1.00 equiv, 99% ee) and THF (360 mL) under a positive pressure of nitrogen.  The
resulting slurry was cooled to 0 ºC in a dry ice-acetone bath and NaBH4 (10.44 g, 276.0
mmol, 2.40 equiv) was added in one portion.  A solution of I2 (29.19 g, 115.0 mmol, 1.00
equiv) in THF (50 mL) was transferred dropwise over 2 hours by using a syringe pump.
After the addition was complete, the cooling bath and the thermometer were removed and
replaced by a condenser and the reaction was heat to reflux (80 ºC oil bath).  After 20 h
the reaction was allowed to cool to ambient temperature and methanol (150 mL) was
added slowly, resulting in an almost clear solution.  After stirring for 30 min the solution
was quantitatively transferred to a 1000 mL round bottom flask with MeOH (100 mL)
and concentrated on a rotary evaporator under reduced pressure (40 ºC) to a white semi-
solid.  The resulting material was dissolved in 20 wt% aqueous KOH (250 g) and stirred
for 12 h at ambient temperature.  The aqueous phase was extracted with CH2Cl2 (5 x 180
mL) and the combined organic extracts were dried over Na2SO4 (ca 25 g), filtered, and
concentrated on a rotary evaporator under reduced pressure (40 ºC) and dried under
vacuum to give crude (S)-tert-leucinol (14.00 g, quantitative yield) as a colorless oil.
This material was used in the following step without further purification.
Alternative Route to (S)–t-BuPyOx*
N CN
N OMe
NH
N
N
O
t-Bu
NaOMe,
MeOH
0 °C → 20 °C
pTsOH•H2O
(S)-tert-leucinol
toluene, 80 °C
(50% yield, two steps)
*This route is amenable to smaller batches of ligand synthesis.
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Adapted from: Brunner. H.; Obermann. U. Chem. Ber. 1989, 122, 499–507.
A flame-dried round bottom flask was charged with a stir bar and MeOH (110
mL).  Sodium metal ingot (295 mg, 12.8 mmol, 0.1 equiv) was cut with a razor into small
pieces, washed in a beaker of hexanes, and added in five portions over 5 min.  The
reaction mixture was stirred vigorously until no sodium metal remained, at which time it
was cooled to 0 °C in an ice/water bath.  Subsequently, 2-cyanopyridine (13.0 g, 125
mmol, 1.0 equiv) was added drop wise, and the clear, colorless reaction mixture was
allowed to warm to ambient temperature and stir.  When all the starting material was
consumed as indicated by TLC analysis (1:1 EtOAc/Hexanes, p-anisaldehyde stain), the
reaction was cooled to 0 °C in an ice/water bath and quenched dropwise with glacial
AcOH (1 mL).  The crude reaction mixture was concentrated in vacuo, redissolved in
CH2Cl2 (100 mL) and washed with brine (2 x 50 mL).  The organic phase was dried
(MgSO4), concentrated in vacuo, and dried under high vacuum for 1 h.  The resulting
crude methoxyimidate (light yellow oil) was suitable for use in the next step without
further purification.
To a flame-dried round bottom flask charged with a stir bar was added crude
methoxyimidate (2.55 g, 18.7 mmol, 1.0 equiv), (S)–tert-leucinol (2.10 g, 17.9 mmol,
0.96 equiv), toluene (100 mL), and p-TsOH•H2O (167 mg, 0.88 mmol, 5 mol%).  The
mixture was stirred at 80 °C in an oil bath for 3 h, at which time the starting material was
consumed as indicated by TLC analysis (1:4 acetone/hexanes, p-anisaldehyde stain).  The
reaction was cooled to ambient temperature and quenched with sat. NaHCO3 (60 mL).
The reaction was partitioned with EtOAc and water, and the aqueous phase was extracted
with EtOAc (3 x 50 mL).  The combined organic extracts were washed with water (2 x
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50mL), brine (1 x 25 mL), dried (MgSO4) and concentrated in vacuo.  The crude mixture
was purified by flash column chromatography using American International Chemical
ZEOprep® 60 ECO 40-63 micron silica gel (1:4 acetone/hexanes) to afford 1.85 g (9.06
mmol, 50%) (S)–t-BuPyOx as an off-white solid.  Characterization data matches the data
previously reported in this document.
N
O
H
N
t-Bu
OH
(S)-N-(1-hydroxy-3,3’-dimethylbutan-2-yl)picolinamide (249)
To a 200 mL round bottom flask was added 2-picolinic acid (2.46 g, 20.0 mmol, 1.00
equiv), 50 mL CH2Cl2, and N-methylmorpholine (3.03 g, 30.0 mmol, 1.50 equiv).  The
reaction mixture was cooled to 0 ºC in an ice bath and iso-butyl chloroformate (3.14 g,
23.0 mmol, 1.15 equiv) was added dropwise over 30 min.  Following complete addition,
the reaction mixture was stirred for 30 min at 0 ºC.  In a separate flask, (S)-tert-leucinol
(2.58 g, 22.0 mmol, 1.10 equiv) was dissolved in CH2Cl2 (25 mL), and N -
methylmorpholine (2.43 g, 24.0 mmol, 1.20 equiv) was added.  This solution was
transferred dropwise over the course of 1 h to the cooled reaction mixture using a syringe
pump.  The cooling bath was removed and the reaction mixture was allowed to warm to
room temperature and stirred for 2 h.  The mixture was quenched with an aqueous
solution of NH4Cl (10 g in 50 mL H2O) and the aqueous phase was extracted with CH2Cl2
(20 mL).   The combined organic phase was dried over Na2SO4 (5 g), filtered, and
concentrated under reduced pressure.  The residue was purified with flash silica gel
column chromatography (4:1 hexanes/acetone) to afford amide alcohol 249 as a white
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solid (4.10 g, 92% yield). Rf = 0.32 with 3:2 hexanes/acetone;  M.P. 79.6–79.9ºC;  1H
NMR (500 MHz, CDCl3) δ 8.56 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.32 (br d, J = 8.9 Hz, -
NH), 8.19 (dt, J = 7.8, 1.1 Hz, 1H), 7.85 (td, J = 7.7, 1.7 Hz, 1H), 7.43 (ddd, J = 7.6, 4.8,
1.2 Hz, 1H), 4.02–3.96 (m, 2H), 3.69 (m, 1H), 2.72 (br t, J = 6.5 Hz, -OH), 1.05 (s, 9H);
13C NMR (125 MHz, CDCl3) δ 165.6, 149.7, 148.2, 137.6, 126.4, 122.6, 63.7, 60.6, 33.9,
27.1;  IR (Neat Film, NaCl): 3375, 2962, 1669, 1591, 1570, 1528, 1465, 1434, 1366,
1289, 1244, 1088, 1053, 998 cm-1;  HRMS (MultiMode ESI/APCI) m/z calc’d for
C12H19N2O2 [M+H]+: 223.1447, found 223.1448; [α]25D –8.68° (c 1.17, CHCl3, > 99% ee).
N
O
H
N
t-Bu
Cl
•HCl
(S)-N-(1-chloro-3,3’-dimethylbutan-2-yl)picolinamide hydrochloride (256)
A 500 mL 3-neck round bottom flask was charged with a stir bar, amide alcohol 249
(8.89 g, 40.0 mmol, 1.00 equiv) and toluene (140 mL).  The resulting clear solution was
warmed to 60 ºC.  In a separate flask, SOCl2 (9.25 g, 80.0 mmol, 2.00 equiv) was diluted
with toluene (20 mL).  This solution was transferred slowly, dropwise, over 20 min to the
vigorously stirring reaction mixture at 60 ºC.  The reaction mixture was stirred at 60 ºC
for 4 h, at which time the slurry was cooled to ambient temperature, concentrated on a
rotary evaporator under reduced pressure (40 ºC, 40 mmHg), and dried under vacuum
(0.15 mmHg) to give a white powder of amide chloride hydrochloric salt 256 (10.80 g,
98% yield).  This material was used in the following step without purification.  1H NMR
(500 MHz, DMSO-d6) δ 8.70 (ddd, J = 4.8, 2.0, 1.0 Hz, 1H), 8.66 (br d, J = 9.9 Hz, -NH),
8.10 (dt, J = 8.0, 1.0 Hz, 1H), 8.06 (td, J = 7.5, 1.4 Hz, 1H), 7.66 (ddd, J = 7.4, 4.8, 1.4
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Hz, 1H), 4.08 (td, J = 9.9, 3.7 Hz, 1H), 3.97–3.90 (m, 2H), 0.93 (s, 9H); 13C NMR (125
MHz, DMSO-d6) δ 163.6, 149.0, 147.8, 138.1, 126.5, 122.0, 59.0, 44.9, 35.0, 26.3; IR
(Neat film, NaCl): 3368, 2963, 1680, 1520, 1465, 1434, 1369, 1285, 1239, 1087, 998 cm-
1; HRMS (MultiMode ESI/APCI) m/z calc’d for C12H18ClN2O [M+H]+: 241.1108, found
241.1092; [α]25D +39.40° (c 0.96, MeOH, > 99% ee).
N
N
O
t-Bu
(S)-4-(tert-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole (82)
A 500 mL 3-neck round bottom flask was charged with a stir bar, amide chloride
hydrochloric acid salt 256 (10.26 g, 37.0 mmol, 1.00 equiv) and MeOH (100 mL).  To the
clear solution was added powdered NaOMe (9.99 g, 185.0 mmol, 5.00 equiv), and the
resulting mixture was heat to 55 ºC in the oil bath.  The slurry was stirred for 3 h until the
free amide chloride was fully consumed, according to TLC analysis (4:1
hexanes/acetone).  After removing the oil bath, toluene (100 mL) was added and the
mixture was concentrated on a rotary evaporator (40 ºC, 60 mmHg) to remove MeOH.
The residual mixture was extracted with H2O (100 mL) and the aqueous phase was back
extracted with toluene (40 mL x 2).  The combined organic extracts were dried over
Na2SO4 (10 g), filtered, and concentrated under reduced pressure.  The residue was
purified by flash column chromatography using American International Chemical
ZEOprep® 60 ECO 40-63 micron silica gel (4:1 hexanes/acetone) to yield (S)-t-BuPyOx
(82) as a white solid (5.44 g, 72% yield).  Rf = 0.44 with 3:2 hexanes/acetone;  M.P.
70.2–71.0 ºC;  1H NMR (500 MHz, CDCl3) δ 8.71 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.08
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(dt, J = 7.9, 1.1 Hz, 1H), 7.77 (dt, J = 7.7, 1.7 Hz, 1H), 7.37 (ddd, J = 7.0, 4.5, 1.0 Hz,
1H), 4.45 (dd, J = 10.2, 8.7 Hz, 1H), 4.31 (t, J = 8.5 Hz, 1H), 4.12 (dd, J = 10.2, 8.5 Hz,
1H), 0.98 (s, 9H);  13C NMR (125 MHz, CDCl3) δ  162.4, 149.6, 147.0, 136.5, 125.4,
124.0, 76.5, 69.3, 34.0, 26.0;  IR (Neat film, NaCl): 2981, 2960, 2863, 1641, 1587, 1466,
1442, 1358, 1273, 1097, 1038, 968 cm-1;  HRMS (MultiMode ESI/APCI) m/z calc’d for
C12H17ON2 [M+H]+: 205.1335, found 205.1327; [α]25D –90.5º (c 1.15, CHCl3, > 99% ee).
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Figure A5.3 13C NMR (126 MHz, CDCl3) of compound 249 
 
 
Figure A5.2 Infrared spectrum (Thin Film, NaCl) of compound 249 
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Figure A5.6 13C NMR (126 MHz, CDCl3) of compound 256 
 
 
Figure A5.5 Infrared spectrum (Thin Film, NaCl) of compound 256 
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Figure A5.9 13C NMR (126 MHz, CDCl3) of compound 82 
 
 
Figure A5.8 Infrared spectrum (Thin Film, NaCl) of compound 82 
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Figure A5.12 13C NMR (126 MHz, CDCl3) of compound 82b 
 
 
Figure A5.11 Infrared spectrum (Thin Film, NaCl) of compound 82b 
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CHAPTER 6
Progress toward the catalytic asymmetric total synthesis of
(+)–taiwaniaquinone H and other taiwaniaquinoid natural products÷
H3CO
O
O
(+)-taiwaniaquinone H
OPiv
PivO
X O
Asymmetric Conjugate Addition
                                                 
÷ This work was performed in collaboration with Samantha E. Shockley and Emmett D.
Goodman
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Abstract
H3CO
O
O
(+)-taiwaniaquinone H
OPiv
PivO
X O
Asymmetric Conjugate Addition
Work toward the catalytic, asymmetric total synthesis of (+)–taiwaniaquinone H
is presented. This route features an expedient, highly convergent retrosynthetic analysis
whereby 13 of the total 20 core scaffold carbon atoms are brought together by
asymmetric palladium-catalyzed conjugate addition. The rational design of a highly
enantioselective and high yielding conjugate addition substrate is discussed. Additionally,
steps toward the synthesis of the B-ring are disclosed, including a highly surprising
arene/ketone ene-type cyclization to afford a [3.2.1] bicyclic scaffold.
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6.1 A biological and chemical introduction to the taiwaniaquinoids
6.1.1 Isolation and biological activity of taiwaniaquinoids
Isolated first in 1995, the taiwaniaquinoid family of natural products are a set of
tricyclic diterpenoids obtained from the flowing sage Salvia dichroantha Stapf and the
Taiwanese pine tree Taiwania cryptomerioldes Hayata (Figure 6.1).12 Relatively little is
known about the biological activity of these norditerpenoids, however, significant
cytotoxicity is observed for many of the isolated natural products.2 Furthermore, some
have demonstrated aromatase inhibitory activity, which has potential therapeutic
application in the treatment of carcinoma cancers.3 Though their purported biological
activity make these norditerpenoids an enticing target for natural product total synthesis,
we were drawn to the unique architecture of these molecules. In particular, we thought
that the challenge of installing the benzylic quaternary stereocenter would be well-suited
to our recently developed asymmetric conjugate addition methodology. We believe that
the high degree of oxidation on the C-ring will test the limitations of our methodology,
and that the successful implementation of our strategy would yield a significant wealth of
knowledge about the scope of the newly developed chemistry, specifically the tolerance
for high degrees of substitution and oxidation on the arylboronic acid coupling partner.
Finally, we were keen to demonstrate that we could synthesize tricyclic scaffolds from
our aryl 1,4-addition products.
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Figure 6.1 (a) flowing sage Salvia dichroantha Stapf, (b) Taiwania cryptomerioldes Hayata
(a) (b)
Unique to these diterpenoids is their [6.5.6]-abeo-abietane scaffold. Furthermore,
much of the diversity comes from functionality of the central 5-membered B-ring, which
can be found fully saturated (taiwaniaquinone G, Figure 6.2, 257), unsaturated
(taiwaniaquinone H 258, dichroanone 259, and dichroanal 260), oxidized as a ketone
(taiwaniaquinol B, 262) or even with the full carbon count of a norditerpenoid
(taiwaniaquinones A and F, 261). Additionally, the oxidation state of the aromatic C-ring
varies from quinone to quinol. Aside from these major factors, a number of structural
motifs are highly conserved among all members of the class, including: gem-dimethyl
functionality on the A-ring, benzylic quanternary stereocenter at the A/B-ring fusion, iso-
propyl group on the C-ring, and high degree of oxygenation on the C-ring.
Figure 6.2 Taiwaniaquinoid natural products
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6.1.2 Previous Synthetic Work
No shortage of synthetic literature exists for the taiwaniaquinones. A number of
total syntheses, semi-syntheses, and asymmetric total syntheses have been reported.
Banerjee and coworkers reported the first synthesis of racemic dichroanal B (260),
utilizing a reductive palladum-catalyzed 5-exo-trig cyclization.4 A number of more
efficient routes have been accomplished in more recent years (Figure 6.3). Notable
strategies include acylation/alkylation reactions,5 intramolecular aldol condensations,6
cationic olefin cyclizations,7 electrocyclizations,8 Friedel-Crafts acylations,9 and Heck
cyclizations,10 among others.11 While significant work has been published regarding
synthetic efforts toward these natural products, only three catalytic asymmetric
approaches have been disclosed. Indeed, the installation of the benzylic quaternary
stereocenter has proved to be the major challenge in these synthetic works.
Figure 6.3 Retrosynthetic disconnections of taiwaniaquinoids
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Trauner and coworkers reported a strategy centered around a Nazarov cyclization
of ketone 263 in 2006.12 This is the most convergent approach to date, and demonstrates
the efficiency of a late-stage B-ring synthesis. However, the electrocyclization is racemic.
This approach benefited from the commercial availability of citral-derived aldehyde 269,
and expedient the preparation of recorsinol 268, which were combined via 1,2-addition.
Redox manipulations provided ketone 270, which was the substrate for a TMSOTf-
catalyzed Nazarov cyclization. This approach installs the benzylic quaternary
stereocenter as the final bond in the tricyclic core, presumably reacting via cationic
intermediate 271 to afford cyclization product 272 upon hydrolytic work up. Trauner and
coworkers were able to quickly advance the core to taiwaniaquinol B (262) and
taiwaniaquione H (258) by deprotection and oxidation of the C-ring arene.
Scheme 6.1 Trauner synthesis of taiwaniaquinoids
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While Stoltz and McFadden reported the first catalytic, asymmetric total synthesis
of a taiwaniaquinoid natural product,13 it was Node who first installed the benzylic
quaternary stereocenter in an asymmetric fashion, employing an enantioselective
intramolecular Heck.14,10c Working with a disconnection similar to that employed by
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Trauner, Node begins with bromide 274 and citral-derivative 269. Addition product of
the aryl lithium of 274 affords alcohol 275, which is advanced to the cyclization
precursor (as an inconsequential mixture of olefin isomers) in a few steps. Triflate 276
serves as a precursor, whereby 5-exo-trig palladium migratory insertion affords diene
277. Selective hydrogenation of the 1,2-cis-olefin and oxidation of the arene affords
taiwaniaquinone H (258) in short order. This route effectively turns Trauner’s synthetic
disconnection into an asymmetric synthesis, however, significant functional group
manipulations are required to adjust oxidation states and protecting groups to suit the
chosen route.
Scheme 6.2 Node synthesis with asymmetric Heck
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In what features the first truly convergent, catalytic, asymmetric synthesis of the
quaternary stereocenter, Hartwig and coworkers utilized asymmetric α-arylation to
directly furnish the benzylic quaternary stereocenter from two separate synthetic
fragments in their syntheses of taiwaniaquinone H (258) and taiwaniaquinol B (Scheme
6.3, 262).15 Ketone 278 is treated with aryl bromide 279 in the presence of a catalyst
derived from palladium(0) and (R)-difluorophos to afford arylated ketone 267 in 80%
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yield and excellent enantioselectivity. Removal of the benzylidene blocking group,
methylations, and Corey-Chaykovsky epoxidation affords epoxide 280 as a mixture of
diastereomers. Lewis-acid mediated epoxy-keto rearrangement affords the corresponding
aldehyde, which undergoes in situ nucleophilic attack by the electron-rich arene ring.
Subsequent dehydration under the reaction conditions (or during the work up) affords
styrenyl olefin product 281. Deprotection of the flanking methoxy ethers on the C-ring
and facile oxidation to the quinol and quinone readily affords (+)-taiwaniaquinone H
(258). They are also able to furnish taiwaniaquinol B from the common intermediate,
olefin 281. Hartwig’s route uniquely installs the benzylic quaternary stereocenter, and
cleverly builds the tricyclic core scaffold. However, the necessary installation of the
benzylidene blocking group (2 steps), and its subsequent removal (also 2 steps) reduces
the efficiency of the α-arylation approach, although these steps are all reported in high
chemical yield.
Scheme 6.3 Hartwig asymmetric α-arylation approach to taiwaniaquinoids
O
N
Ph
H3CO OCH3
Br
Pd2(dba)3 (10 mol %)
(R)-Difluorophos (20 mol %)
NaOt-Bu (2 equiv)
toluene, 80 °C
(80% yied, 94% ee)
O
N
Ph
OCH3
H3CO
PPh2
PPh2
(R)-Synphos
O
O
O
O
F
F
F
F
278 279 267
OCH3
H3CO
280
O
OCH3
H3CO
O
H3CO
O
281 (+)-258
BF3•OEt2
CH2Cl2, –20 °C
(75% yield)
Lewis acid-promoted
epoxy-keto rearrangement/
aldol condensation
catalytic asymmetric α-arylation
Chapter 6 391
Thus far, considerable effort has been placed on the synthesis of the bond joining
the A-ring and C-ring. The installation of this bond, and requisite completion of the
benzylic quaternary stereocenter, are the most challenging aspects of synthesizing
taiwaniaquinoid natural products.
6.2 Stoltz-McFadden Synthesis of dichroanone
6.2.1 Asymmetric quaternary center synthesis in the Stoltz laboratory
The Stoltz laboratory has developed a number of methodologies for the
asymmetric synthesis of quaternary stereocenters. In 2009, Stoltz and corworkers
reported the asymmetric addition of malonate derivatives to halo-oxindoles (282)
catalyzed by a copper-(bis)oxazoline complex (Scheme 6.4a).16 This process affords α-
quaternary oxindoles (283) in high yields and good to excellent ee. The Stoltz laboratory
has published considerable work in the field of asymmetric allylic alkylation,17 including
their 2004 discloser of the first asymmetric Tsuji-Trost reaction (Scheme 6.4b).18 Allyl
enol carbonate (284), or other allyl fragment-bearing precursors, undergo palladium-
catalyzed decarboxylative allylic alkylation to afford α−quaternary ketones (285).
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Scheme 6.4 Synthesis of quaternary stereocenters in Stoltz laboratory
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These methodologies for the asymmetric installation of quaternary stereocenters
have been utilized as key steps in a number of synthetic efforts from the Stoltz laboratory.
The catalytic, enantioselective decarboxylative allylic alkylation has been employed to
install the key quaternary stereocenters in a number of natural product syntheses.19
Cyanthiwigan F was constructed utilizing a double, asymmetric allylic alkylation from β-
keto ester 286 to afford α-quaternary diketones 287 in 99% ee (Scheme 6.5a).20 This
compound was rapidly advanced to Cyanthiwigan F (288) in only 5 more steps.
Vinylogous ester 289, constructed through asymmetric allylic alkylation, served as a
substrate for retro-aldol/aldol ring contraction to afford γ-quaternary acylcyclopentene
290. This compound was advanced to presilphiperfolan-1-ol (291).21 Most recently,
application of the asymmetric addition of malonates to halooxindoles has been applied
toward the synthesis of alkaloid natural products. Halooxindole 282 underwent
asymmetric malonate addition to yield oxindole 283, which has been advanced to a
formal synthesis of two members of the communesin family of natural products (292).22
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Scheme 6.5 Formation of asymmetric stereocenters in Stoltz total syntheses
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Stoltz and McFadden reported the first catalytic asymmetric total synthesis of (+)-
dichroanone (259) in 2006.13 Their retrosynthesis of (+)-dichroanone (Scheme 6.6, 259)
suggests linear sequencing, with formation of the quinone C-ring last. Bicyclic enone 293
is envisioned to form via Wacker-type oxidation and subsequent intramolecular aldol
condensation of quaternary ketone 294. 
Scheme 6.6 Stoltz retrosynthetic analysis of dichroanone
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Synthesis of enone 293 was accomplished by allylic alkylation of enol carbonate
265 to afford ketone 295 (Scheme 6.7). Wacker oxidation gives diketone 286, which
undergoes aldol condensation to supply the desired enone 293 in 96% yield.
Scheme 6.7 McFadden and Stoltz synthesis of (+)-dichroanone
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Completion of the synthesis is accomplished in short order from enone 293
(Scheme 6.8). 1,4-addition of methylvinyl ketone affords diketone 297 as an
inconsequential mixture of diastereomers. Diketone 297 is also subjected to aldol
condensation/dehydration to afford tricyclic enone 298. Enol triflate formation (299) and
subsequent Kumada-coupling and aromatization affords tricycle 300 in 65% yield.
Titanium-promoted formylation affords aldehyde 301, which undergoes Baeyer-Villager
oxidation to phenol 302. A carefully optimized, complex oxidation protocol furnishes the
desired quinone, and completes the synthesis of (+)-dichroanone (259) in 35% yield.
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Scheme 6.8 McFadden and Stoltz completion of (+)-dichroanone
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6.3 Toward the total synthesis of (+)-taiwaniaquinone H
6.3.1 Convergent Retrosynthetic Analysis
The Stoltz/McFadden synthesis of (+)-dichroanone was accomplished in a linear
fashion, with sequential formation of the A, B, and finally C rings by a series of
oxidations and aldol condensations. A more convergent retrosynthetic analysis can be
employed (Figure 6.4), invoking β-aryl ketone 304 as the key intermediate. Cyclization
of the B-ring would afford tricyclic enone 303. Oxidation of this compound to the
corresponding quinone is well-precedented, as seen in above examples of total syntheses
of taiwaniaquinoids. Here, the major synthetic disconnection of β-aryl ketone 305
suggested asymmetric conjugate addition of an appropriate arylmetal reagent (306) to 3-
methylcyclohexenone. This retrosynthetic analysis facilitates a highly convergent,
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catalytic, enantioselective key step that joins together 13 of the 20 core carbons of the
taiwaniaquinoid scaffold.
Figure 6.4 Comparative retrosynthetic analysis of dichroanone
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We envision quinone oxidation and gem-dimethyl installation to be the final two
steps, thus tricyclic enone 307 is the key late-stage intermediate. Para-acylphenylboronic
acid is a known asymmetric conjugate addition substrate that affords high yields and
enantioselectivities, so it will be employed and derivatization of the acyl group (308) to
the desired iso-propyl group (307) will be required. Aldol condensation from formyl
equivalent 309 will afford the full tricyclic core. Finally, asymmetric conjugate addition
will join the boronic acid (310) and enone (95) fragments. We will employ Hartwig
borylation of arenes to generate the boronic acids for use in the asymmetric conjugate
addition reaction from the C–H bond shown in arene 311.
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Scheme 6.9 Retrosynthetic analysis of (+)-taiwaniaquinone H
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6.3.2 Model study
A model study was employed to ascertain whether the late-stage B-ring
construction approach was synthetically tractable (Scheme 6.10). A boronic acid derived
from dimethylresorcinol (312) was employed, however poor yields and virtually no
enantioselectivity was observed in isolated ketone 313. Protection of ketone 313 with
neopentyl glycol afforded ketal 314, which was treated with N-bromosuccinimide to
afford aryl bromides 315, as an intractable mixture of isomers. Lithium/bromine
exchange and trapping with dimethylformamide afforded aldehyde 316, which was
separated from its isomer. Treatment with KOH afforded a mixture of aldol addition and
condensation products 317, demonstrating successful B-ring formation.
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Scheme 6.10 Model study
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6.3.3 Identification of a suitable arylboronic acid for highly enantioselective
asymmetric conjugate addition reaction with 3-methylcyclohexenone
The poor yield of the resorcinol-derived arylboronic acid, and low regioselectivity
for the bromination step, prompted us to examine a more suitable arylboronic acid
substrate. Early installation of the requisite iso-propyl group (ketone 318) was
unsuccessful in the conjugate addition chemistry. Para-electron-withdrawing substituents
are highly enantioselective substrates, so we reasoned that use of a p-acylphenylboronic
acid derivative would afford better results. However, ketone 319 also failed to react in
appreciable yield. Finally, removing the methyl ethers and replacing them with pivaloyl
esters produced the first quality result, affording ketone 320 in 59% yield and 80% ee.
Applying the above logic, acetylphenyl ketone 321 was synthesized in 90% yield and
93% ee, sufficiently high yielding for practical use in the synthetic route.
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Table 6.1 Identification of a suitable conjugate addition system
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O
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6.3.4 Toward the synthesis of the central B-ring: an unexpected sigmatropic
rearrangement
With ketone 321 in hand, we turned our attention toward the installation of the B-
ring. Deprotection of the aryl pivalates proved to be highly challenging. Indeed, attempts
to drive monodeprotection to completion under a variety of conditions resulted in de-acyl
phenol 322 (Scheme 6.11). However, we wished to remove both pivaloyl groups in a
single chemical transformation. We were delighted to find that treatment with lithum
ethylthioate in dimethylformamide resulted in rapid and clean double deprotection,
affording what was initially assigned as diphenol 323. Curiously, N-bromosuccinimide
failed to react with our substrate, as it had in the model system. Switching to dibromo-
dimethylhydantoin, we observed rapid bromination to what we believed was bromide
324. Smooth methylation could be obtained with cesium carbonate and methyl iodide to
afford methyl ether 325. Conversely, a synthetic sequence starting with methylation to
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afford phenol 326 could be employed. Mono-methyl ketone 326 underwent bromination
to bromide 327, and subsequent methylation generated a structure matching what we had
assigned as dimethyl ether 325. The dimethyl ether compound, however, did not undergo
bromination. Hence, we employed this stepwise approach.
Scheme 6.11 Synthesis of aryl halide cyclization precursor
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We had a number of plans developed to approach installation of the final B-ring
(Scheme 6.12). First, carbonylation of bromide 327  would afford carbonylated
intermediate 328, which we envisioned would quickly undergo Dieckmann condensation
to afford diketone 329 (Scheme 6.12a). Second, as in the model system, lithium/halogen
exchange of bromide 325 for lithated arene 330 could lead to formylation by trapping
with dimethylformamide, and cyclization to key intermediate 331 (Scheme 6.12b).
Finally, we envisioned Lewis-acid mediated Nagata-type reactions, whereby coordination
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of phenol 326 would generated metallo-ether 332 (Scheme 6.12c). This ether could
undergo metallo-ene [3,3]-sigmatropic rearrangement to afford hydroxymethyl arene 333.
Unfortunately, preliminary results in all three reaction pathways were negative. We
began to question our initial assignment of ketones 327, 325, and 326.
Scheme 6.12 Synthetic plans to install the B-ring
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Despite high resolution mass spectrometry results suggesting the proper chemical
formula, errant 13C spectra suggested that we had isolated compounds isomeric to the
desired ketones. To our great surprise we identified that our assignment of bromide 325
was actually [3,2,1]-bicycle 334 (Scheme 6.13). Likewise, all compounds generated from
double-deprotection diphenol 323 contained the undersired bicyclic framework, due to
formation of bicycle 335. Curiously, smooth monodeprotection of ketone 321 to mono-
phenol 336 was accomplished under standard ester cleavage conditions, and no
cyclization was observed.
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Scheme 6.13 Unexpected cyclization of phenolic intermediates
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Single crystal x-ray diffraction confirmed our suspicions, elucidating the bicyclic
structure of bromide 334 (Figure 6.5). This crystal structure also confirms our assignment
of the absolute stereochemistry at the quaternary carbon. A cursory search of the
literature shows that β-quaternary cyclohexanones with electron rich aryl rings as β-
substituents have been observed to undergo this type of cyclization, though it is typically
acid-catalyzed.
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Figure 6.5 X-ray crystal structure of bicyclic bromide 334
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Strangely, none of the β-quaternary ketones we synthesized underwent this
rearrangement, except those bearing the diphenol structure. We hypothesize that an ene-
type sigmatropic rearrangement may be the operable mechanism (Scheme 6.14). Electron
rich diphenol reaction intermediate 323 under goes ene reaction to afford ketone diene
337, which quickly tautomerizes to rearomatize and afford bicyclic phenol 335.
Scheme 6.14 Hypothetical mechanism for the cyclization of phenolic intermediates
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6.4 Experimental Procedures
Representative procedure for the synthesis of pivaloyl resorcinol derivatives
H
PivO OPiv
O
2-acetyl-1,3-phenylene bis(2,2-dimethylpropanoate) (339)
An oven-dred 1L round-bottom flask was charged with a magnetic stir bar, 2,6-
dihydroxyacetophenone (10 g, 65.7 mmol, 1 equiv) and DMAP (800 mg, 6.57 mmol, 10
mol %). The flask was evacuated under vacuum and backfilled three times with argon
gas. The solids were suspended in CH2Cl2 (450 mL), and NEt3 (23 mL, 165 mmol, 2.5
equiv) was added, at which time the solution became homogenous and a transparent, pale
yellow color was observed. The reaction solution was cooled to 0 °C in an ice/water bath
and pivaloyl chloride (17 mL, 138 mmol, 2.1 equiv) was added via mechanical syringe
pump addition over the course of 2 h. Slow addition is essential to maintain an internal
temperature of less than 5 °C and minimize formation of side products. Upon complete
addition, the ice/water bath was removed and the reaction mixture was allowed to warm
to ambient temperature. After 1 h, the reaction was complete by TLC analysis (30%
acetone/hexanes, stain p-anisaldehyde), and was quenched by the addition of sat. NH4Cl
(aq, 300 mL). The mixture was diluted with CH2Cl2 (400 mL) and transferred to a
separatory funnel. The aqueous layer was extracted with CH2Cl2 (3 x 100 mL) and the
combined organic extracts were washed with 1N HCl (3 x 100 mL) and brine (1 x 100
mL), dried over Mg2SO4 and concentrated in vacuo. The crude mixture was purified by
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silica gel flash column chromatography (150 g silica gel, eluent: 20% acetone/hexanes) to
afford the title compound as a white, crystalline solid (19.73 g, 94% yield). 1H NMR (500
MHz, CDCl3) δ 6.99 (d, J = 8.2 Hz, 2H), 2.45 (s, 3H), 1.32 (s, 18H); 13C NMR (125
MHz, CDCl3) δ 198.6, 176.3, 147.7, 130.3, 128.4, 119.9, 39.1, 31.5, 26.9; IR (Neat Film,
NaCl): 3487, 3395, 2976, 2936, 2874, 1755, 1705, 1611, 1576, 1478, 1457, 1397, 1368,
1274, 1251, 1233, 1117, 1101 c m-1; HRMS (MultiMode ESI/APCI) m/z calc’d for
C18H23O5 [M-H]-: 319.1551, found 319.1542.
B
PivO OPiv
O
O O
2-acetyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-phenylene bis(2,2-
dimethylpropanoate) (340)
In a nitrogen-filled glovebox, a 500 mL round-bottom flask was charged with a stir bar,
339  (16.02 g, 50.0 mmol, 1.0 equiv), B2Pin2 (9.5 g, 37.5 mmol, 0.75 equiv),
[Ir(cod)(OMe)]2 (33 mg, 0.05 mmol, 0.1 mol %), and tetramethylphenanthroline (24 mg,
0.10 mmol, 0.2 mol %). The solids were suspended in THF (50 mL) and the flask was
sealed with a rubber septum, secured with electrical tape, and removed from the glove
box. The reaction mixture was placed under an argon gas atmosphere and stirred in an oil
bath at 60 °C for 45 h, at which time the reaction was complete by TLC analysis (20%
acetone/hexanes, p-anisaldehyde stain). The reaction mixture was cooled to ambient
temperature and filtered through a silica gel plug (50 g silica gel, eluent: acetone), and
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concentrated in vacuo. The crude reaction mixture was further purified by silica gel flash
chromatography (200 g silica gel, eluent: 20% acetone/hexanes) to afford the title
compound as an amorphous off-white solid (19.85 g, 89% yield). 1H NMR (500 MHz,
CDCl3) δ 7.38 (s, 2H), 2.43 (s, 3H), 1.33 (s, 12H), 1.32 (s, 18H); 13C NMR (125 MHz,
CDCl3) δ  198.6, 176.3, 147.1, 130.8, 125.8, 84.5, 39., 31.4, 27.0, 27.0, 24.8; IR (Neat
Film, NaCl): 3509, 2981, 2935, 1766, 1707, 1482, 1459, 1405, 1396, 1354, 1331, 1259,
1212, 1147 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C24H39O7BN [M+NH4]+:
463.2850, found 463.2852.
B
PivO OPiv
O
HO OH
(4-acetyl-3,5-bis(pivaloyloxy)phenyl)boronic acid (341)
A 250 mL round bottom flask was charged with a stir bar and pinnacol boronate ester 340
(8.65 g, 19.27 mmol, 1.0 equiv). The solid was dissolved in EtOAc (250 mL), and
diethanolamine (2.35 mL, 24.10 mmol, 1.25 equiv) was added with vigorous stirring. A
glass pipet was cut to have a wide bore, and this wide-bore pipet was used to add the
viscous diethanolamine. Upon addition of diethanolamine, a white precipitate forms. This
suspension was stirred a further 4 h at ambient temperature, at which time the mixture
was concentrated in vacuo. The crude white semi-solid was suspended in Et2O (300 mL)
and stirred vigorously for 30 min. The suspension was then cooled to –20 °C in a freezer
overnight. The white solid was collected by vacuum filtration, and the compound was
washed with additional portions of Et2O (3 x 50 mL). The collected white solid (7.38 g)
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was suspended in 0.1 N HCl (200 mL) and stirred vigorously. CH2Cl2 (ca. 50 mL) was
added until the solid fully dissolved. The biphasic mixture was stirred for 12 h with
extreme vigor. The mixture was then subjected to continuous extraction with boiling
CH2Cl2 (300 mL) for 6 h. The combined organic extracts were concentrated in vacuo and
dried under high vacuum to afford the title compound as an off-white, flakey solid (6.45
g, 17.71 mmol, 92% yield over two steps). 1H NMR (500 MHz, CDCl3) δ 7.35 (s, 2H),
2.19 (s, 3H), 1.08 (s, 18H); 13C NMR (125 MHz, acetone-d6) δ  198.3, 176.5, 147.9,
130.9, 125.9, 39.32, 31.5, 27.1; IR (Neat Film, NaCl): 3446, 2975, 2359, 1751, 1700,
1653, 1635, 1558, 1540, 1480, 1456, 1407, 1340, 1247, 1100, 1038 cm-1; HRMS
(MultiMode ESI/APCI) m/z  calc’d for C18H29O7BN [M+NH4]+: 381.2068, found
381.2061.
O
OPiv
OPiv
O
(R)-2-acetyl-5-(1-methyl-3-oxocyclohexyl)-1,3-phenylene bis(2,2-
dimethylpropanoate) (321)
A 20 mL screw-top vial is charged with a stir bar, Pd(OCOCF3)2 (96 mg, 0.29 mmol, 2.5
mol %), (S)-t-BuPyOx (71 mg, 0.35 mmol, 3 mol %), NH4PF6 (570 mg, 3.45 mmol, 30
mol %), and the solids were dissolved in 1,2-dichloroethane (5 mL) and stirred at ambient
temperature for 5 min. Not all solids dissolved at this time. A 100 mL round bottom flask
was charged with a stir bar, boronic acid 341 (6.3 g, 17.29 mmol, 1.5 equiv), and NH4PF6
(570 mg, 3.45 mmol, 30 mol %), and suspended in 1,2-dichloroethane (40 mL) and
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stirred at ambient temperature. The catalyst solution was filtered through a pipet plugged
with a kimwipe and added to the suspension of boronic acid in one portion. 3-
methylcyclohexen-2-one (1.30 mL, 11.53 mmol, 1 equiv) and water (1 mL, 57 mmol, 5
equiv) were added by syringe and the flask was stirred in an oil bath heat to 50 °C for 24
h. When the reaction was complete by TLC analysis (10% acetone/hexanes, p-
anisaldehyde stain), the mixture was cooled to ambient temperature and filtered through a
plug of silica gel (eluent: CH2Cl2) and concentrated in vacuo. The crude residue was
purified by silica gel flash chromatography (200 g silica gel, eluent gradient: 5%
acetone/hexanes to 10% acetone/hexanes) to afford the title compound as a colorless oil
(3.37 g, 7.84 mmol, 68% yield). 1H NMR (500 MHz, CDCl3) δ 6.91 (s, 2H), 2.77 (d, J =
14.1 Hz, 1H), 2.42 (s, 4H), 2.33 (t, J = 6.8 Hz, 2H), 2.12 (s, 1H), 1.99–1.84 (m, 2H),
1.82–1.71 (m, 1H), 1.32 (s, 21H);13C NMR (125 MHz, CDCl3) δ 210.3, 198.3, 176.3,
151.2, 147.9, 126.3, 117.4, 52.7, 42.9, 40.6, 39.1, 37.5, 31.4, 28.7, 27.0, 26.9, 26.8, 21.9;
IR (Neat Film, NaCl): 3404, 2973, 2937, 2874, 1758, 1708, 1620, 1562, 1480, 1408,
1397, 1257, 1095 cm-1; HRMS (MultiMode ESI/APCI) m /z calc’d for C25H34O6Na
[M+Na]+: 453.2248, found 453.2234; [α]25D –36.1° (c 1.85, CHCl3, 94% ee).
OH
OH
OH
O
Br
1-((5R,9R)-4-bromo-1,3,9-trihydroxy-5-methyl-6,7,8,9-tetrahydro-5H-5,9-
methanobenzo[7]annulen-2-yl)ethanone (333)
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A 50 mL, flame-dried, round bottom flask was charged with a stir bar, tricyclic
compound 335 (110 mg, 0.419 mmol, 1 equiv) and dibromo-dimethylhydantoin (151 mg,
0.461 mmol, 1.1 equiv). The flask was evacuated under vacuum and back-filled with
argon gas, and the solids were dissolved in CH2Cl2 (5 mL) and stirred at ambient
temperature. After 30 min, an aliquot was partitioned between EtOAc (1 mL) and sat.
Na2S2O3 (aq, 1 mL), and the organic layer was subjected to LCMS analysis, where no
starting material was observed. The red colored reaction was quenched by the addition of
20% Na2S2O3 solution (aq, 20 mL) and stirred vigorously for 3 h, until the orange/red
color was no longer observed. The mixture was partitioned between CH2Cl2 (20 mL) and
water (20 mL) and transferred to a separatory funnel. 1N HCl was added until the
aqueous layer was pH 3. The aqueous layer was extracted with CH2Cl2 (5 x 25 mL) and
the combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The
crude residue was purified by silica gel column chromatography (12 g silica gel, eluent
gradient: 10% EtOAc/hexanes to 25% EtOAc/hexanes) to afford the title compound as a
yellow, semi-crystalline solid (92 mg, 0.273 mmol, 66% yield). 1H NMR (500 MHz,
CDCl3) δ 13.37 (s, 1H), 9.10 (s, 1H), 2.74 (s, 3H), 2.55 (s, 1H), 2.22 (ddd, J = 9.7, 3.0,
2.2 Hz, 1H), 1.93 (ddd, J = 11.2, 6.2, 3.0 Hz, 1H), 1.75–1.64 (m, 4H), 1.61 (s, 3H), 1.35
(td, J = 13.0, 5.5 Hz, 1H), 0.96–0.80 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 204.3,
203.6, 154.17, 151.7, 120.1, 109.9, 109.7, 97.7, 81.2, 58.9, 48.6, 34.3, 32.9, 32.8, 24.5,
21.4.; IR (Neat Film, NaCl): 3381, 2936, 2852, 1631, 1566, 1415, 1373, 1326, 1274,
1233 cm-1; HRMS (MultiMode ESI/APCI) m/z calc’d for C15H16BrO4 [M-H]-: 339.0237,
found 339.0230; [α]25D –20.8° (c 1.26, CHCl3, 94% ee).
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OH
OMe
OMe
O
Br
1-((5R,9R)-4-bromo-9-hydroxy-1,3-dimethoxy-5-methyl-6,7,8,9-tetrahydro-5H-5,9-
methanobenzo[7]annulen-2-yl)ethanone (334)
A flame-dried 20 mL vial was charged with a stir bar, Bromo-diphenol 333 (92 mg, 0.270
mmol, 1 equiv), Cs2CO3 (194 mg, 0.595 mmol, 2.2 equiv), and acetone (5 mL). The vial
was stirred under argon atmosphere at ambient temperature, and MeI (0.037 mL, 0.595
mmol, 2.2 equiv) was added in one portion. The yellow reaction slurry was stirred for 40
h at ambient temperature, at which time the color had faded to a white slurry and the
reaction was determined to be complete by TLC analysis (20% EtOAc/hexanes, p-
anisaldehyde stain). The reaction was quenched by the addition of sat. NH4Cl solution
(aq, 5 mL) and stirred for 12 h at ambient temperature. The reaction was diluted with
EtOAc (10 mL) and water (10 mL), 1N HCl was added such that the pH was 2–3, and the
mixture was transferred to a separatory funnel. The aqueous layer was extracted with
EtOAc (3 x 10 mL) and the combined organic extracts were washed with water (2 x 10
mL) and brine (1 x 10 mL), dried over MgSO4 and concentrated in vacuo. The crude
residue was purified by silica gel flash chromatography (12 g silica gel, eluent gradient
10% EtOAc/hexanes to 20% EtOAC/hexanes) to afford the title compound as a clear oil
that solidified to an amorphous white solid upon standing (62 mg, 63% yield). 1H NMR
(500 MHz, CDCl3) d 3.81 (s, 3H), 3.80 (s, 3H), 2.56 (s, 3H), 2.24 (dt, J = 10.1, 2.5 Hz,
1H), 1.84–1.71 (m, 2H), 1.71–1.61 (m, 3H), 1.60 (s, 3H), 1.35 (td, J = 12.9, 5.8 Hz, 1H),
0.81–0.67 (m, 1H).13C NMR (125 MHz, CDCl3) d 201.6, 153.7, 150.9, 147.9, 135.8,
130.4, 108.8, 79.5, 63.8, 58.5, 47.9, 36.5, 33.0, 32.5, 24.9, 21.5.; IR (Neat Film, NaCl):
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3429, 2938, 2853, 1704, 1642, 1590, 1450, 1382, 1323, 1237, 1120, 1077 cm-1; HRMS
(MultiMode ESI/APCI) m/z calc’d for C17H22BrO4 [M+H]+: 369.0696, found 369.0690;
[a]25D –5.8° (c 0.73, CHCl3, 94% ee).
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Figure A6.3 13C NMR (126 MHz, CDCl3) of compound 339 
 
 
Figure A6.2 Infrared spectrum (Thin Film, NaCl) of compound 339 
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Figure A6.6 13C NMR (126 MHz, CDCl3) of compound 340 
 
 
Figure A6.5 Infrared spectrum (Thin Film, NaCl) of compound 340 
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Figure A6.9 13C NMR (126 MHz, CDCl3) of compound 321 
 
 
Figure A6.8 Infrared spectrum (Thin Film, NaCl) of compound 321 
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Figure A6.12 13C NMR (126 MHz, CDCl3) of compound 335 
 
 
Figure A6.11 Infrared spectrum (Thin Film, NaCl) of compound 335 
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Figure A6.15 13C NMR (126 MHz, CDCl3) of compound 334 
 
 
Figure A6.14 Infrared spectrum (Thin Film, NaCl) of compound 334 
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Figure A6.18 13C NMR (126 MHz, CDCl3) of compound 333 
 
 
Figure A6.17 Infrared spectrum (Thin Film, NaCl) of compound 333 
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Figure A7.1 X-ray structure of compound 334 
 
 
 
 
 
Table A7.1.  Crystal data and structure refinement for a14105. 
Identification code  a14105 
Empirical formula  C17 H23 Br O5 
Formula weight  387.26 
Temperature  100 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 1 2 1 
Unit cell dimensions a = 18.8295(9) Å a= 90°. 
 b = 7.8451(4) Å b= 95.208(2)°. 
 c = 11.4443(5) Å g = 90°. 
Volume 1683.56(14) Å3 
Z 4 
Density (calculated) 1.528 Mg/m3 
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Absorption coefficient 2.464 mm-1 
F(000) 800 
Crystal size 0.43 x 0.42 x 0.29 mm3 
Theta range for data collection 1.787 to 48.826°. 
Index ranges -39<=h<=39, -16<=k<=16, -22<=l<=24 
Reflections collected 78240 
Independent reflections 16574 [R(int) = 0.0370] 
Completeness to theta = 25.000° 99.8 %  
Absorption correction Analytical, multi-scan 
Max. and min. transmission 0.5777 and 0.4462 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 16574 / 1 / 299 
Goodness-of-fit on F2 0.966 
Final R indices [I>2sigma(I)] R1 = 0.0256, wR2 = 0.0521 
R indices (all data) R1 = 0.0344, wR2 = 0.0538 
Absolute structure parameter 0.0289(17) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.653 and -0.707 e.Å-3 
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 Table A7.2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103)for a14105.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Br(1) 2611(1) 10106(1) 9689(1) 15(1) 
O(1) 3623(1) 7401(1) 8867(1) 14(1) 
O(2) 3898(1) 5319(1) 6487(1) 32(1) 
O(3) 2081(1) 4751(1) 5906(1) 15(1) 
O(4) 746(1) 6695(1) 5256(1) 15(1) 
C(1) 1792(1) 8548(1) 7722(1) 10(1) 
C(2) 2444(1) 8611(1) 8398(1) 10(1) 
C(3) 2985(1) 7448(1) 8188(1) 10(1) 
C(4) 2858(1) 6206(1) 7328(1) 10(1) 
C(5) 2190(1) 6066(1) 6697(1) 10(1) 
C(6) 1663(1) 7235(1) 6896(1) 9(1) 
C(7) 883(1) 7289(1) 6423(1) 11(1) 
C(8) 433(1) 6312(1) 7261(1) 15(1) 
C(9) 584(1) 6889(1) 8542(1) 17(1) 
C(10) 655(1) 8831(1) 8680(1) 17(1) 
C(11) 1110(1) 9610(1) 7757(1) 12(1) 
C(12) 734(1) 9187(1) 6539(1) 13(1) 
C(13) 4140(1) 8608(2) 8543(1) 21(1) 
C(14) 3440(1) 4958(1) 7122(1) 14(1) 
C(15) 3422(1) 3280(1) 7728(1) 21(1) 
C(16) 2247(1) 5220(2) 4744(1) 23(1) 
C(17) 1200(1) 11532(1) 7918(1) 21(1) 
O(5) 4353(1) 8297(2) 5398(1) 43(1) 
________________________________________________________________________________ 
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 Table A7.3.   Bond lengths [Å] and angles [°] for  a14105. 
_____________________________________________________  
Br(1)-C(2)  1.8906(8) 
O(1)-C(3)  1.3713(9) 
O(1)-C(13)  1.4310(12) 
O(2)-C(14)  1.2111(12) 
O(3)-C(5)  1.3751(10) 
O(3)-C(16)  1.4412(14) 
O(4)-H(4A)  0.70(4) 
O(4)-C(7)  1.4158(11) 
C(1)-C(2)  1.3921(11) 
C(1)-C(6)  1.4044(11) 
C(1)-C(11)  1.5333(11) 
C(2)-C(3)  1.4041(11) 
C(3)-C(4)  1.3893(12) 
C(4)-C(5)  1.3969(11) 
C(4)-C(14)  1.5033(12) 
C(5)-C(6)  1.3859(11) 
C(6)-C(7)  1.5183(10) 
C(7)-C(8)  1.5397(13) 
C(7)-C(12)  1.5231(12) 
C(8)-H(8A)  0.98(2) 
C(8)-H(8B)  0.949(19) 
C(8)-C(9)  1.5366(14) 
C(9)-H(9A)  1.035(18) 
C(9)-H(9B)  1.01(2) 
C(9)-C(10)  1.5357(16) 
C(10)-H(10A)  0.98(2) 
C(10)-H(10B)  0.906(18) 
C(10)-C(11)  1.5458(13) 
C(11)-C(12)  1.5417(13) 
C(11)-C(17)  1.5262(13) 
C(12)-H(12A)  0.993(18) 
C(12)-H(12B)  0.961(15) 
C(13)-H(13A)  0.92(2) 
C(13)-H(13B)  0.98(2) 
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C(13)-H(13C)  0.932(18) 
C(14)-C(15)  1.4899(15) 
C(15)-H(15A)  0.97(3) 
C(15)-H(15B)  0.95(2) 
C(15)-H(15C)  1.00(2) 
C(16)-H(16A)  1.02(2) 
C(16)-H(16B)  0.97(2) 
C(16)-H(16C)  0.84(3) 
C(17)-H(17A)  0.96(2) 
C(17)-H(17B)  0.93(2) 
C(17)-H(17C)  1.19(2) 
O(5)-H(5A)  0.83(4) 
O(5)-H(5B)  0.93(8) 
 
C(3)-O(1)-C(13) 114.67(7) 
C(5)-O(3)-C(16) 112.54(9) 
C(7)-O(4)-H(4A) 108(4) 
C(2)-C(1)-C(6) 119.34(7) 
C(2)-C(1)-C(11) 131.62(7) 
C(6)-C(1)-C(11) 108.83(6) 
C(1)-C(2)-Br(1) 122.18(6) 
C(1)-C(2)-C(3) 119.90(7) 
C(3)-C(2)-Br(1) 117.73(6) 
O(1)-C(3)-C(2) 122.13(7) 
O(1)-C(3)-C(4) 117.87(7) 
C(4)-C(3)-C(2) 119.80(7) 
C(3)-C(4)-C(5) 120.65(7) 
C(3)-C(4)-C(14) 119.20(7) 
C(5)-C(4)-C(14) 120.09(7) 
O(3)-C(5)-C(4) 118.31(7) 
O(3)-C(5)-C(6) 122.49(7) 
C(6)-C(5)-C(4) 119.20(7) 
C(1)-C(6)-C(7) 108.75(7) 
C(5)-C(6)-C(1) 120.90(7) 
C(5)-C(6)-C(7) 130.12(7) 
O(4)-C(7)-C(6) 114.47(7) 
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O(4)-C(7)-C(8) 111.11(7) 
O(4)-C(7)-C(12) 112.59(7) 
C(6)-C(7)-C(8) 109.45(7) 
C(6)-C(7)-C(12) 100.13(6) 
C(12)-C(7)-C(8) 108.47(7) 
C(7)-C(8)-H(8A) 110.3(9) 
C(7)-C(8)-H(8B) 100.8(11) 
H(8A)-C(8)-H(8B) 108.1(15) 
C(9)-C(8)-C(7) 112.54(7) 
C(9)-C(8)-H(8A) 111.3(9) 
C(9)-C(8)-H(8B) 113.4(11) 
C(8)-C(9)-H(9A) 112.7(10) 
C(8)-C(9)-H(9B) 107.0(11) 
H(9A)-C(9)-H(9B) 102.1(15) 
C(10)-C(9)-C(8) 113.37(8) 
C(10)-C(9)-H(9A) 107.8(11) 
C(10)-C(9)-H(9B) 113.4(12) 
C(9)-C(10)-H(10A) 108.4(13) 
C(9)-C(10)-H(10B) 109.6(12) 
C(9)-C(10)-C(11) 111.74(8) 
H(10A)-C(10)-H(10B) 108.0(17) 
C(11)-C(10)-H(10A) 110.9(12) 
C(11)-C(10)-H(10B) 108.2(12) 
C(1)-C(11)-C(10) 108.71(7) 
C(1)-C(11)-C(12) 100.11(7) 
C(12)-C(11)-C(10) 107.17(7) 
C(17)-C(11)-C(1) 117.14(8) 
C(17)-C(11)-C(10) 111.74(8) 
C(17)-C(11)-C(12) 111.01(8) 
C(7)-C(12)-C(11) 102.47(6) 
C(7)-C(12)-H(12A) 110.7(10) 
C(7)-C(12)-H(12B) 108.1(9) 
C(11)-C(12)-H(12A) 111.6(10) 
C(11)-C(12)-H(12B) 112.1(9) 
H(12A)-C(12)-H(12B) 111.5(14) 
O(1)-C(13)-H(13A) 108.7(14) 
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O(1)-C(13)-H(13B) 112.7(11) 
O(1)-C(13)-H(13C) 109.0(12) 
H(13A)-C(13)-H(13B) 105.4(18) 
H(13A)-C(13)-H(13C) 106.8(17) 
H(13B)-C(13)-H(13C) 113.8(16) 
O(2)-C(14)-C(4) 120.71(9) 
O(2)-C(14)-C(15) 122.24(9) 
C(15)-C(14)-C(4) 117.05(8) 
C(14)-C(15)-H(15A) 106.0(16) 
C(14)-C(15)-H(15B) 108.4(13) 
C(14)-C(15)-H(15C) 110.2(13) 
H(15A)-C(15)-H(15B) 102(2) 
H(15A)-C(15)-H(15C) 120(2) 
H(15B)-C(15)-H(15C) 109.7(18) 
O(3)-C(16)-H(16A) 112.2(11) 
O(3)-C(16)-H(16B) 110.1(12) 
O(3)-C(16)-H(16C) 102.7(17) 
H(16A)-C(16)-H(16B) 111.1(18) 
H(16A)-C(16)-H(16C) 110(2) 
H(16B)-C(16)-H(16C) 110.8(19) 
C(11)-C(17)-H(17A) 113.8(12) 
C(11)-C(17)-H(17B) 105.1(16) 
C(11)-C(17)-H(17C) 114.3(10) 
H(17A)-C(17)-H(17B) 103.5(19) 
H(17A)-C(17)-H(17C) 102.8(16) 
H(17B)-C(17)-H(17C) 117.1(19) 
H(5A)-O(5)-H(5B) 108(5) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table A7.4.   Anisotropic displacement parameters  (Å2x 103) for a14105.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Br(1) 16(1)  16(1) 13(1)  -6(1) 0(1)  -2(1) 
O(1) 9(1)  19(1) 15(1)  2(1) -3(1)  -1(1) 
O(2) 24(1)  30(1) 44(1)  12(1) 22(1)  12(1) 
O(3) 15(1)  14(1) 14(1)  -5(1) 1(1)  1(1) 
O(4) 12(1)  20(1) 11(1)  -3(1) -2(1)  1(1) 
C(1) 9(1)  10(1) 10(1)  0(1) 1(1)  1(1) 
C(2) 10(1)  11(1) 9(1)  -1(1) 1(1)  -1(1) 
C(3) 8(1)  12(1) 10(1)  1(1) 0(1)  0(1) 
C(4) 8(1)  12(1) 12(1)  1(1) 1(1)  1(1) 
C(5) 9(1)  11(1) 10(1)  -1(1) 1(1)  1(1) 
C(6) 7(1)  12(1) 9(1)  0(1) 0(1)  1(1) 
C(7) 8(1)  16(1) 10(1)  0(1) 0(1)  1(1) 
C(8) 10(1)  20(1) 16(1)  2(1) 1(1)  -2(1) 
C(9) 14(1)  25(1) 14(1)  4(1) 3(1)  -3(1) 
C(10) 12(1)  25(1) 14(1)  -2(1) 4(1)  2(1) 
C(11) 10(1)  13(1) 13(1)  0(1) 2(1)  4(1) 
C(12) 10(1)  16(1) 13(1)  2(1) 0(1)  4(1) 
C(13) 11(1)  26(1) 26(1)  1(1) -1(1)  -6(1) 
C(14) 10(1)  16(1) 16(1)  0(1) 2(1)  3(1) 
C(15) 21(1)  15(1) 29(1)  4(1) 4(1)  6(1) 
C(16) 22(1)  33(1) 15(1)  -8(1) 4(1)  1(1) 
C(17) 22(1)  14(1) 26(1)  -3(1) 0(1)  6(1) 
O(5) 34(1)  31(1) 66(1)  17(1) 12(1)  2(1) 
______________________________________________________________________________ 
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 Table A7.5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for a14105. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(4A) 730(20) 5810(50) 5270(40) 110(14) 
H(8A) 504(8) 5090(30) 7183(13) 18(3) 
H(8B) -34(10) 6580(30) 6933(16) 24(4) 
H(9A) 199(10) 6480(30) 9068(15) 23(4) 
H(9B) 1018(11) 6250(30) 8880(17) 27(5) 
H(10A) 863(11) 9080(30) 9475(18) 33(5) 
H(10B) 216(9) 9320(20) 8589(16) 24(4) 
H(12A) 213(9) 9400(20) 6506(16) 21(4) 
H(12B) 947(8) 9770(20) 5920(13) 12(3) 
H(13A) 4561(12) 8430(30) 9001(19) 37(5) 
H(13B) 4005(10) 9790(30) 8697(17) 34(5) 
H(13C) 4233(10) 8410(20) 7769(16) 23(4) 
H(15A) 3716(14) 2520(40) 7310(20) 53(7) 
H(15B) 2962(11) 2800(30) 7559(18) 34(5) 
H(15C) 3523(11) 3430(30) 8598(19) 35(5) 
H(16A) 2770(12) 5560(30) 4724(17) 36(6) 
H(16B) 1930(11) 6120(30) 4436(18) 31(5) 
H(16C) 2168(13) 4320(30) 4360(20) 43(6) 
H(17A) 1378(10) 11860(30) 8703(18) 29(5) 
H(17B) 737(13) 11970(30) 7840(20) 42(6) 
H(17C) 1619(10) 12150(30) 7333(18) 32(5) 
H(5A) 4075(17) 7470(50) 5340(30) 76(10) 
H(5B) 4760(40) 8000(110) 5030(90) 114 
________________________________________________________________________________ 
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 Table A7.6.  Torsion angles [°] for a14105. 
________________________________________________________________  
Br(1)-C(2)-C(3)-O(1) -1.53(11) 
Br(1)-C(2)-C(3)-C(4) 173.23(6) 
O(1)-C(3)-C(4)-C(5) 172.81(7) 
O(1)-C(3)-C(4)-C(14) -4.40(12) 
O(3)-C(5)-C(6)-C(1) 179.12(8) 
O(3)-C(5)-C(6)-C(7) 5.42(14) 
O(4)-C(7)-C(8)-C(9) 178.38(7) 
O(4)-C(7)-C(12)-C(11) -164.95(7) 
C(1)-C(2)-C(3)-O(1) -176.65(8) 
C(1)-C(2)-C(3)-C(4) -1.89(12) 
C(1)-C(6)-C(7)-O(4) 150.32(7) 
C(1)-C(6)-C(7)-C(8) -84.20(8) 
C(1)-C(6)-C(7)-C(12) 29.65(9) 
C(1)-C(11)-C(12)-C(7) 40.37(8) 
C(2)-C(1)-C(6)-C(5) -3.86(12) 
C(2)-C(1)-C(6)-C(7) 171.06(7) 
C(2)-C(1)-C(11)-C(10) -84.97(11) 
C(2)-C(1)-C(11)-C(12) 162.89(9) 
C(2)-C(1)-C(11)-C(17) 42.84(14) 
C(2)-C(3)-C(4)-C(5) -2.18(12) 
C(2)-C(3)-C(4)-C(14) -179.38(8) 
C(3)-C(4)-C(5)-O(3) -176.12(8) 
C(3)-C(4)-C(5)-C(6) 3.18(12) 
C(3)-C(4)-C(14)-O(2) -84.34(12) 
C(3)-C(4)-C(14)-C(15) 95.72(11) 
C(4)-C(5)-C(6)-C(1) -0.15(12) 
C(4)-C(5)-C(6)-C(7) -173.85(8) 
C(5)-C(4)-C(14)-O(2) 98.44(12) 
C(5)-C(4)-C(14)-C(15) -81.50(11) 
C(5)-C(6)-C(7)-O(4) -35.38(12) 
C(5)-C(6)-C(7)-C(8) 90.10(11) 
C(5)-C(6)-C(7)-C(12) -156.05(9) 
C(6)-C(1)-C(2)-Br(1) -170.04(6) 
C(6)-C(1)-C(2)-C(3) 4.85(12) 
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C(6)-C(1)-C(11)-C(10) 89.61(8) 
C(6)-C(1)-C(11)-C(12) -22.54(9) 
C(6)-C(1)-C(11)-C(17) -142.58(9) 
C(6)-C(7)-C(8)-C(9) 50.99(10) 
C(6)-C(7)-C(12)-C(11) -42.94(8) 
C(7)-C(8)-C(9)-C(10) 42.10(11) 
C(8)-C(7)-C(12)-C(11) 71.66(8) 
C(8)-C(9)-C(10)-C(11) -43.70(11) 
C(9)-C(10)-C(11)-C(1) -47.37(10) 
C(9)-C(10)-C(11)-C(12) 60.01(9) 
C(9)-C(10)-C(11)-C(17) -178.18(8) 
C(10)-C(11)-C(12)-C(7) -72.96(8) 
C(11)-C(1)-C(2)-Br(1) 4.07(13) 
C(11)-C(1)-C(2)-C(3) 178.96(8) 
C(11)-C(1)-C(6)-C(5) -179.21(8) 
C(11)-C(1)-C(6)-C(7) -4.29(9) 
C(12)-C(7)-C(8)-C(9) -57.35(9) 
C(13)-O(1)-C(3)-C(2) -83.51(11) 
C(13)-O(1)-C(3)-C(4) 101.63(10) 
C(14)-C(4)-C(5)-O(3) 1.06(12) 
C(14)-C(4)-C(5)-C(6) -179.64(8) 
C(16)-O(3)-C(5)-C(4) -91.05(10) 
C(16)-O(3)-C(5)-C(6) 89.68(10) 
C(17)-C(11)-C(12)-C(7) 164.77(8) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table A7.7.  Hydrogen bonds for a14105  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(4)-H(4A)...O(5)#1 0.70(4) 2.11(4) 2.7707(15) 158(5) 
 C(12)-H(12A)...O(2)#2 0.993(18) 2.577(18) 3.5655(12) 173.5(14) 
 C(13)-H(13B)...Br(1) 0.98(2) 2.963(19) 3.4746(12) 113.5(13) 
 C(16)-H(16B)...O(4) 0.97(2) 2.54(2) 3.1572(13) 121.7(15) 
 O(5)-H(5A)...O(2) 0.83(4) 2.18(4) 2.8176(15) 133(3) 
 O(5)-H(5B)...O(5)#3 0.93(8) 1.80(7) 2.678(3) 155(8) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y-1/2,-z+1    #2 x-1/2,y+1/2,z    #3 -x+1,y,-z+1       
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APPENDIX 8
Progress Toward the Total Synthesis of Nanolobatolide
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Abstract
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Nanolobatolide
Efforts toward the total synthesis of the bioactive terpenoid-derived product
nanolobatolide are described.  The investigation and application of various ring-
expansion methodologies are detailed in the context of synthetic planning toward a key
Diels–Alder reaction to generate the highly congested carbon scaffold of nanolobatolide.
Synthetic efforts toward the key guaiane-derived intermediate revealed that substrates are
prone to unselective deprotonation by strong bases and, therefore, traditional alkylation
or cross-coupling strategies are not successful in promoting the desired reactions
selectively.  The application of a strategy based on a halogen-magnesium exchange
reaction for the alkylation of bromo-enol phosphates is discussed as a potential method to
circumvent undesired reactivity.  Continued synthetic efforts and future plans aimed the
completion of nanolobatolide are detailed.
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A8.1 Background and synthetic approach
A8.1.1 Introduction and retrosynthetic analysis
Chronic diseases affecting quality of life have become a serious concern for
modern society, as increased population longevity contributes to their increased
frequency of occurrence.  Therapies for maladies affecting cerebral function, such as
Alzheimer’s disease, present an unmet challenge in health science.1 As such, the
scientific community is interested in the study of neurodegeneration, and is particularly
interested in the study of potential treatments for neurodegeneration.  In particular,
neuroprotective substances are a promising class of compounds.  One such natural
product, nanolobatolide (A8-1), has displayed promising neuroprotective properties in 6-
hydroxy dopamine neurotoxicity studies.2
Nanolobatolide (A8-1) was isolated from the marine sponge Sinularia nanolobata
in 2009 by Jyh-Horn Sheu and coworkers.2  The compound possesses a unique 18 carbon
molecular structure that is postulated to be terpenoid-related.2  Its molecular architecture
represents an interesting synthetic challenge due to its highly congested caged carbon
core featuring a fused gamma lactone and norbornane-derived bicyclic system.
Additionally, nanolobatolide contains six stereogenic centers, all of which are contiguous
and one of which is an all-carbon quaternary center.  Sheu and coworkers propose that
the biosynthesis of nanolobatolide may hinge on the Diels–Alder reaction of guaiane-type
precursor A8-2 and a suitable acrylic acid derivative in an endo transition state geometry
(Scheme A8.1).  Subsequent oxidation and lactonization of Diels-Alder adduct A8-3
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would provide nanolobatolide.  Herein, we report progress toward the total synthesis of
nanolobatolide.
Scheme A8.1  Proposed biosynthesis of nanolobatolide
Me
HO
O
Me
OHO
R O
O
O
Me
HO
Me
H H
endo
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A8-3A8-2A8-1
Synthetically, we sought to utilize a biomimetic approach for the preparation of
A8-1, targeting guaiane A8-2 for synthesis with the goal of subsequently utilizing the
cyclopentadiene moiety as a diene for Diels–Alder reaction (Scheme A8.2).  The
cyclopentadiene motif found in guaiane A8-2 is believed to be configurationally stable,
based on synthetic efforts reported for similar guaiane-derived dienes.3  We further
envisioned synthesis of guaiane A8-2 from cycloheptenone A8-3, itself ultimately
derived from (–)-menthone (A8-4) via oxidative ring expansion.4  Overall, this route
would achieve the natural product synthesis rapidly, while providing opportunity to
synthesize analogs for structure-activity relationship studies due to the short, highly
flexible route.
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Scheme A8.2  Retrosynthetic analysis of nanolobatolide
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A8.2 Synthetic progress
A8.2.1 Synthesis of key enone intermediate
Initial investigations focused on the synthesis of enone A8-3 via a reported 2-step
ring expansion/oxidation protocol uti l izing trimethylaluminum and
trimethylsilyldiazomethane to generate a mixture of silyl enol ethers, followed by
Saegusa-Ito oxidation to yield the desired enone (Scheme 5).5  Though the product was
obtained as described in the literature, yields were disappointingly low and the procedure
proved difficult to scale efficiently.  For example, performing this sequence 2 gram-scale
(13.0 mmol) with (–)-menthone (A8-4) yielded only 4% of the desired enone product and
11% yield of the undesired isomer (A8-7).  Additionally, the completely unselective
nature of the initial ring expansion step yielded a 1:1 mixture of desired:undesired silyl
enol ether isomers A8-5 and A8-6.  This represents a tremendous waste of material and
further condemns this reaction as an unattractive first step in our synthetic sequence.
After attempts to optimize the procedure proved futile, alternative preparative methods
for enone A8-3 were sought.
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Scheme A8.3  Initial investigation into ring expansion methodology
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Our Attempts, 2 g (13.0 mmol)
After searching the literature, a suitable surrogate route to enone A8-3 was
realized.4 Beginning with ring expansion of (–)-menthone (A8-4) (Scheme 6),
thermodynamic enolization and trapping with TMSCl yielded the silyl enol ether (A8-8).
Initially, standard conditions in acetonitrile led to low conversion, however use of a
pentane/acetonitrile biphase was found to drive the reaction toward completion.  The
resulting silyl enol ether (A8-8) was cyclopropanated under Simmons–Smith conditions
to afford cyclopropane A8-9.  The key step of this sequence is the iron(III) chloride-
mediated reductive ring opening, which provides the desired enone (A8-3) after reflux in
sodium acetate saturated methanol.  We believe that this ring-opening step is the low-
yielding step in our sequence, as formation of unusable cycloheptanone A8-3a is the
major byproduct.  Although the procedure was four steps, as opposed to only two, it
proved reliable and scalable and could easily be performed on 20-gram scale (140 mmol),
thus providing an ideal starting sequence for a total synthesis.  Additionally, the use of
(–)-menthone (A8-4) as a starting material provides a cheap ($ 0.70/gram from
Sigma–Aldrich) and readily available source of enantioenriched material that allowed our
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synthetic efforts to avoid tedious installation of the remote stereogenic methyl group
found in the natural product.
Scheme A8.4  Synthesis of key enone intermediate
O
Me
O
Me
(–)-menthone
A8-4
OTMS
Me
OTMS
Me
NaI, NEt3, TMSCl
pentane/MeCN, 23 °C
Et2Zn, CH2I2
CH2Cl2, 0 °C
1.  FeCl3, DMF, 0 °C
2.  NaOAc, MeOH, 90 °C
     (40% yield, 4 steps)
A8-8
A8-9 A8-3
O
Me
A8-3a
A8.2.2 Progress toward hypothesized biomimetic guaiane intermediate
Many approaches toward key guaiane A8-2 have been examined with varying
degrees of success.  Initially, we tried to install the final three carbons of guaiane A8-2 by
the addition of isopropenyllithium to allyl enone A8-10.  Treatment of enone A8-3 with
LDA and allyl iodide in DMPU/THF resulted in successful allylation to yield enone A8-
10 in 55% yield (Scheme 7).  It should be noted that this alkylation was particularly
difficult, and that reaction of the lithium enolate of enone A8-3 with allyl bromide was
sluggish, even at room temperature.  Attempts to repeat this alkylation procedure without
the use of freshly purified allyl iodide suffer from greatly diminished yields.  The
isopropenyl group was then added via treatment with isopropenyllithium.  Though the
reaction proceeded smoothly, resulting tertiary alcohol A8-11 proved difficult to
manipulate.  Ring-closing metathesis of diene A8-11 with the Grubbs-Hoveyda 3rd
generation catalyst (A8-12) did not proceed to completion; we postulate that only the syn
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diastereomers close.  Furthermore, dehydration of alcohols A8-13 proved difficult.
Treatment of alcohols A8-13 with trifluoroacetic acid yielded a complex mixture, while
attempts at mesylation and base-mediated elimination also were unsuccessful.
Scheme A8.5  Initial investigation into guaiane annulation strategy
Li
THF, –78 °C
(74% yield) Me
OH
Me
HOA8-12 (5 mol%)
CH2Cl2
Dehydration
Conditions
Me
O
Me
O
Me
LDA, DMPU
then allyl iodide
THF, 0 °C → 23 °C
(55% yield)
Ru
O
NN
Cl
Cl
A8-12
A8-3 A8-10 A8-11
A8-13 A8-2
Me Me
In revising our approach, we proposed that avoiding formation of alcohol A8-13
would alleviate our problems.  We chose to pursue a cross-coupling strategy from vinyl
triflate A8-14 that would allow for installation of the isopropenyl unit without formation
of the unnecessary tertiary alcohol.  Unfortunately, our initial attempt at enolization of
enone A8-10 and trapping with N-phenyltriflimide resulted in an inseparable mixture of
dienyl triflate isomers A8-14 and A8-15 (Table A8.1, entry 1).  A subsequent base screen
on cycloheptenone A8-10 demonstrated that base-driven elaboration of α-substituted
cyclohexenones such as allylated enone A8-10 results in the same inseparable mixtures of
α  and γ1 deprotonated dienes A8-14 and A8- 15 (entries 1–3) or no product isolated
(entries 4-6).  Attempts at thermodynamic enolizations of allyl enone A8-10 resulted in a
similar mixture of diene triflates (entries 7-8), with no quantifiable improvement in the
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ratio of desired to undesired triflates realized.  This result led us to believe enolization
under either thermodynamic or kinetic control would not successfully furnish our desired
product as a single isomer.
Table A8.1  Base screen for selective enolization of enone A8-10
O
Me
base, temperature, timea
THF
then NPhTf2
OTf
Me
OTf
Me
+
base temperature (° C) time (h) resultb
KHMDS
LHMDS
KOt-Bu
KH
KHMDSc
KH
KHMDSc
LDA
–78
–78
–78
–78
0
50
0
23
0.5
0.5
0.5
0.5
0.5
4
2
2
isomer mix (1:1)
isomer mix (1:1)
isomer mix (1:1)
no product
no product
no product
isomer mix (1:1)
isomer mix (1:1)
entry
1
2
3
4
5
6
7
8
A8-10 A8-14 A8-15
a Reaction conditions: base (1.2 equiv), THF (0.5 M), NPhTf2 (1.2 equiv).  b  As determined by crude 1H NMR.  C  0.90 equiv base
used.
With this disappointing finding at hand, we sought to find alternative means of
generating a suitable cross coupling partner.  Some investigations into Shapiro-type
reactions were conducted, with hopes of generating vinyl iodide A8-17 from hydrazones
A8-16,6 but predictably the base-mediated nature of these reactions proved ill-suited
toward our system and no synthetically useful results were obtained (Scheme A8.6a).  In
fact, no successful iodination ever occurred from hydrazones A8-16, and only trace
olefination was observed.  Similarly, attempts to generate vinyl iodide A8-17 via direct
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treatment of allyl enone A8-10 with hydrazine hydrate and iodine generated an
inseparable mixture of vinyl iodides A8-17 and A8-18 (Scheme A8.6b).7
Scheme A8.6 Attempts at selective iodination
O
Me
H2NNHR, TsOH•H2O (2 mol%)
THF, 60 °C
N
Me
NHSO2R t-BuLi (3 equiv) 
hexanes:TMEDA (1:9)
–78 °C→ 0 °C → 10 °C
then I2, –78 °C
I
Me
O
Me
1. H2NNH2•H20, THF
2. DBU (7 equiv), I2 
    benzene, reflux
I
Me
I
Me
+
A8-10 A8-16a: R = 4-MePh
A8-16b: R= 2,4,6-triisopropylbenzene
A8-17
A8-10 A8-17 A8-18
(1:1 by crude 1H NMR)
A
B
At this time, we became aware of work from the Barluenga group that utilized
hydrazones as direct substrates for cross-coupling reactions with aryl halides. 8  They
reported that treatment of N-tosylhydrazones with base, a palladium(0) source and Xphos
ligand 60 resulted in smooth cross coupling with a variety of aryl halides (Scheme 9).
With hydrazones 57 in hand, we envisioned extending their methodology toward the
installation of the isopropenyl unit of our system.
Scheme A8.7  Barluenga’s cross-coupling of N-tosylhydrazones and aryl halides
N
NHTs
Pd2(dba)3 (1 mol%), A8-19 (2 mol%),
LiOt-Bu (2.4 equiv)
dioxane, 110 °C
X = Br, I
X
R
R
i-Pri-Pr
i-Pr
PCy2
XPhos A8-19
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We attempted to utilize Barluenga’s cross-coupling on our system.  Using
hydrazones A8-16a we found that, unfortunately, while the desired cross-coupling
product was isolated (A8-20), a large quantity of diene A8-21 was present as the major
byproduct (Scheme A8.8).  In fact, when isopropenyl bromide was used as the cross-
coupling partner, only diene A8-21 was obtained.  Though discouraged, it was possible
that the volatility of the bromide was the root of the reaction’s failure.
Scheme A8.8  Attempted Barluenga couplings
N
Me Me
+
Me
H
H
N
Me Me
H
H
NHTs
NHTs
A8-16a A8-20 A8-21
A8-16a A8-21
Pd2(dba)3 (1 mol%), A8-19 (2 mol %),
LiOt-Bu (2.4 equiv)
microwave, 20 min
Br
Br
a)
2:1 by crude NMR
b)
(2 equiv)
Pd2(dba)3 (1 mol%), A8-19 (2 mol %),
LiOt-Bu (2.4 equiv)
microwave, 20 min
(50 equiv)
To probe the effect of substrate volatility, we proceeded to synthesize the less
volatile, and potentially more active, alkene cross coupling partner A8-24 (Scheme
A8.9).  Hydroboration of 1-phenylpropyne (A8-22) afforded boronic acid A8-23, which
was treated with N-iodosuccinimide to readily afford b-iodostyrene A8-24.9  To our
dismay, cross coupling attempts with this alkenyl bromide were also unsuccessful, again
yielding only diene A8-21.
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Scheme A8.9  Synthesis of iodide A8-24 and application to synthesis
Pd2(dba)3, 60, LiOt-Bu
dioxane, 130 °C
microwave, 20 min
N
Me Me
H
H
NHTs
Me
I
H
Ph
Me
Ph
1. catechol borane (neat)
    70 °C, 18 h
2. H2O, HCl (1 mol%), 1 h
    (59% yield, 2 steps)
Me
B
H
Ph
OHHO
NIS
MeCN, 23 °C, 3 h
(12% yield, unoptimized)
Me
I
H
Ph
A8-22 A8-23 A8-24
A8-16a A8-21
a)
b)
In light of these results, a route toward guaiane A8-2 that provided an acidity bias
to allow selective deprotonation was conceived (Scheme A8.10).  Enone A8-3 can be
brominated (A8-22) and subsequently selectively enolized.  This enolate can be trapped
to yield enol phosphate A8-23 as a single isomer.
Scheme A8.10  Formation of bromo enol phosphate A8-23
O
Me
Br
(EtO)2P
O
KHMDS, TMSCl
THF, 0 °C
then NBS
(40% yield, 1.5:1 dr)
Me
O
A8-3 A8-23
Me
O
A8-22
Br KHMDS, THF, –78 °C
then ClPO(OEt)2
(60% yield)
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A8.2.3 Future Plans Toward the Completion of the Total Synthesis of
Nanolobatolide
From this point on, we envision that organomagnesium reagent-mediated
exchange would facilitate allylation to yield allylated enol phosphate A8-24,10 thus
circumventing the problems observed with the initial route.  Allyl enol phosphate A8-24
is itself an excellent substrate for Kumada cross-coupling (Scheme 13).  Previous work
from our group utilizes the inexpensive reagent iron(III) acetylacetonate for cross-
coupling enol phosphates,11 and we envision applying this reaction to enol phosphate A8-
24 with isopropenylmagnesium chloride will yield tetraene A8-25.  Next, ring closing
metathesis with the Grubbs–Hoveyda third generation catalyst (A8-12) will provide
guaiane A8-2.
Scheme A8.11  Completion of guaiane intermediate
O
Me
Br
(EtO)2P
O
i-PrMgCl•LiCl,
THF, 23 °C
Cool to 0 °C
then allyl iodide
A8-23
Me Me
O
Me
(EtO)2P
O
A8-24 A8-25 A8-2
Fe(acac)2, TMEDA
THF, 0 °C
(XX% yield)
MgBrMe
Grubbs III (53)
CH2Cl2, 23 °C
(XX% yield)
Completion of the synthesis will follow the previously described biosynthetic
route.  We believe that the stereogenic C(13) methyl group will provide adequate facial
selectivity, with the acrylate approaching from the less sterically encumbered face
(Scheme A8.12).  To obtain the correct isomer, an endo-transition state is desired, which
is well-known to be the favored transition state of intermolecular Diels–Alder reactions.
In the unfortunate case that no facial selectivity is observed, we envision a number of
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catalysts can be used to override or enhance substrate bias if necessary.  For example,
chiral lewis acids such as oxazaborolidine A8-26 (CBS catalyst) are known to be
excellent catalysts for Diels–Alder reactions and will provide a means of controlling
facial bias.12  Diels–Alder adduct A8-3 will undergo epoxidation to yield epoxide A8-27,
and ring-opening/lactonization will provide synthetic A8-1 in only 11 total steps from
commercial (–)-menthone (A8-4).
Scheme A8.12  Plan for completion of the synthesis
H
N B
O
H
Me
A8-26
O
O
Me
HO
Me
Me
Me
RO
O
Me
ORO
Me
HRO O
Me
OHO
Me
H
O
Diels–Alder
A8-3A8-2
A8-27 A8-1
Oxidation
Ester Hydrolysis
Lactonization
NTf2
13
A8.3 Chen synthesis of ent-nanolobatolide
Efforts toward the total synthesis of nanolobatolide were abandoned following the
publication of a nearly identical route from Chen and coworkers.13 Their route features
many of the transformations we proposed for the synthesis of nanolobatolide, including
the synthesis of enone A8-3, as we have described herein. They transiently synthesize
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guaiane A8-2 in situ and complete the synthesis by the Diels-Alder/oxidation cascade as
we had planned.
                                                 
A8.4 Notes and citations
(1)  (a) Meek, P. D.; McKeithan, K.; Schumock, G. T.  Pharmacotherapy  1998, 18,
68.  (b) Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H. M.
Alzheimer's and Dementia  2007, 3, 186.
(2)  Tseng, Y.-J.; Wen, Z.-H.; Dai, C.-F.; Chiang, M. Y.; Sheu, J.-H.  Org. Lett.  2009,
11, 5030.
(3)  Brocksom, T. J.; Brocksom, U.; Fredericoa, D.  Tetrahedron Lett. 2004, 45, 9289.
(4)  Ito, Y.; Fujii, S.; Nakatuska, M.; Kawamoto, F.; Saegusa, T.  Org. Synth. 1979,
59, 113.
(5)  Yang, S.; Hungerhoff, B.; Metz, P.  Tetrahedron Lett. 1998, 39, 2097.
(6)  (a) Chamberlain, A. R.; Liotta, E. L.; Bond, T. F.  Org. Synth.  1983, 61, 141.  (b)
Chamberlain, A. R.; Bond, T. F.  J. Org. Chem.  1978, 43, 154.
(7)  Brossard, D.; Kihel, L. E.; Khalid, M.; Rault, S.  Synlett  2010, 2, 0215.
(8)  (a) Barluenga, J.; Moriel, P.; Valdes, C.; Aznar, F.  Angew. Chem., Int. Ed.  2007,
46, 5587.  (b) Barluenga, J.; Tomas-Gamasa, M.; Moriel, P.; Aznar, F.; Valdes, C.
Chem.–Eur. J.  2008, 14, 4792.  (c) Barluenga, J.; Escribano, M.; Aznar, F.;
Valdes, C.  Angew. Chem., Int. Ed.  2010, 49, 6856.
(9)  (a) Brown, H. C.; Gupta, S. K.  J. Am. Chem. Soc.  1972, 94, 4370.  (b) Petasis, N.
A.; Zavialov, I. A.  Tetrahedron Lett.  1996, 37, 567.
(10)  Piller, F. M.; Bresser, T.; Fischer, M. K. R.; Knochel, P.  J. Org. Chem. 2010, 75,
4365–4375.
Appendix 8 455
                                                                                                                                                  
(11)  Stoltz group, Andrew McClory postdoctoral report.
(12)  Corey, E. J.; Shibata, T.; Lee, T. W.  J. Am. Chem. Soc.  2002, 124, 3808.
(13) Cheng, H. M.; Tian, W.; Peixoto, P. A.; Dhudshia, B.; Chen, D. Y.-K. Angew.
Chem. Int. Ed. 2011, 50, 4165–4168.
Appendix 9 456
APPENDIX 9
Progress toward the total synthesis of yuccaol natural products÷
                                                 
÷ This work was conducted primarily by Emmett D. “Munchkin” Goodman while a
SURF student in the Stoltz laboratory under the mentorship of Jeffrey C. Holder.
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Abstract
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spirocyclization
Progress toward the natural products yuccaol A–E is presented. The synthetic
route utilizes chiral flavanone products that can be produced in high enantioselectivity via
asymmetric conjugate addition of arylboronic acids to chromone electrophiles. Several
strategies for the spirocyclization of the yuccaol core are discussed, and an amended
proposal for a new synthetic approach is disclosed. Finally, synthetic methods for the
construction of the highly oxygenated chromone scaffold and stilbene moiety are
presented.
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A9.1 Background and Introduction
The molecules that comprise the Yuccaol class of natural products are extracted
from the plant Yucca Schidigera, found in the Mojave Desert in areas of California, south
Nevada, and western Arizona. These natural products have been found to have
antioxidant, radical scavenging, and platelet inhibitory effects as well as anti-
inflammatory activity.1 To date, no syntheses of any of these five natural products
Yuccaols A-E have been reported (Figure A9.1). We undertook a model study targeting
the core (outlined in blue), to see if we could quickly synthesize the scaffold.
The synthesis of these compounds would also facilitate accurate total structural
assignment. The members of this class are diastereomeric pairs that differ in
stereochemistry about the spirocyclic ring junction. It is unknown which absolute
stereochemistry corresponds to A or B (A9-1), and likewise which of the A/B
diastereomers is the direct stereochemical analog of the C/D pairing (A9-2). The E
member of this family has no isolated diastereomeric relative, though it stands to reason
that this highly oxygenated natural product also has a diastereomeric partner differing at
the absolute stereochemistry of the spirocyclic ring fusion.
Figure A9.1 Yuccaol natural product family
O
O
ArylHO
OH O
R4
OH
R1
R2
R3
Yuccaol A/B (A9-1) R1=R2=R3=R4=H, Aryl = p-phenol
Yuccaol C/D (A9-2) R1=R3= OH, R2= OMe. R4= H. Aryl = p-phenol
Yuccaol E (A9-3) R1=R2=R3= OH, R4= OMe, Aryl = p-phenol
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A9.2 Retrosynthetic analysis
We were drawn to target the yuccaol core (A9-4) because we believed we could
rapidly access the structure from a skeletal rearrangement of flavanone A9-7, the product
of an asymmetric conjugate addition of an appropriate arylboronic acid to chromone (A9-
8). We envisioned late-stage spirocyclization, from aryl ether A9-5, and likewise
imagined that a variety of ethers could be employed by saponification and esterification
of methyl ester A9-6. Ring contraction compound A9-6 was the product of a relatively
well-precedented ring contraction of flavanones, and seemed an ideal mechanism by
which to access the 6-5 ring framework of the yuccaols. It should be noted that an early
alternative retrosynthetic analysis involved direct α-arylation of flavanone A9-7,
however this route was plagued by consistent competitive retro-oxa-Michael reaction of
the enolate of A9-7 and, combined with the uncertainty involved in the ring contraction
step of this α-arylated ketone, this route was abandoned.
Scheme A9.1 Retrosynthetic analysis of yuccaol natural products
O
O
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O
Yuccaol core
A9-4
O
O
Aryl
O
X
H
O
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O
O
O
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O
B(OH)2
R
A9-5 A9-6
A9-7 A9-8
spirocyclization esterification
ring contraction
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conjugate addition
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We envisioned two major routes to the spirocyclic core (A9-4, Scheme A9.2).
First, we imagined an electron-rich aromatic ring might be able to cyclize onto an
iodonium ion or similar transient electrophile formed on ring contraction product A9-9.
Second, we considered intramolecular arylation of ester A9-10 with its pendant ortho-
halo aryl ether. Aryl halide A9-10 would also serve as a suitable precursor for a radical
cyclization were either of these routes to fail.
Scheme A9.2 Spirocyclization strategies
O
O
Aryl
O
Yuccaol core
A9-4
O
O
Aryl
O
H
A9-9
O
O
Aryl
O
Br
H
A9-10
OCH3
OCH3
A9.3 Ring Contraction Approach
We first undertook optimization of the ring contraction from flavanone A9-7 to
methyl ester A9-6 (Table A9.1). Ample literature precedent suggested the use of
iodobenzene oxidants, however our trials with iodobenzene bis(trifluoroacetate) (entry 1)
afforded poor conversion.2 Likewise, iodobenzenediacetate afforded modest yield of the
desired ring contraction product (entry 2). We found that iodosobenzene, however, was
an optimal reagent for the transformation. Unfortunately, the reaction appeared to be
sensitive to scale of operation, although extensive exploration of concentrations and
reagent stoichiometry was not undertaken.
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Table A9.1 Ring contraction optimization
O
O
Aryl
A9-7
O
OMe
Aryl
O
A9-6
 oxidant
H2SO4
HC(OCH3)3
Trial Reagent(s) Yield
Lit TTN.3H2O, Trimethyl Orthoformate (TMOF), HClO4 76%9, 75%6
Lit PhI(OAc)2, TMOF, conc H2SO4 66%9, 40%7
Lit Pb(OAc)4, TMOF, conc H2SO4 33%9, 80%8
1 PhI(O2CCF3)2, TMOF, HCOOH, H2SO4 (2eq) 6%
2 PhI(OAc)2, TMOF, H2SO4 (2eq) 32% (1mmol)
3 Iodosobenzene, TMOF, H2SO4 (2eq) 71% (.5mmol)
47% (1mmol)
32% (4mmol)
We next set out to prepare the aryl ether cyclization substrates. Facile hydrolysis
of methyl ester A9-6 in 95% yield afforded carboxylic acid A9-11, which was isolated in
high purity by simple acid/base extraction. EDC-mediated coupling with a variety of
phenols afforded aryl ethers A9-12–A9-14, in modest to good yields.
Scheme A9.3 Synthesis of aryl ether intermediates
O
OMe
Ph
O
A9-6
O
OH
Ph
O
A9-11
10 equiv NaOH
CH3OH:H2O (1:!)
40 °C, 72 h
(95% yield)
EDC•HCl
CH2Cl2, 12 h
O
O
Ph
O
R
A9-12, R = o-Cl (84% yield)
A9-13, R = o-Br (68% yield)
A9-13, R = m,m'-OMe (69% yield)
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A9.4 Oxidative cyclization routes
Attempts to cyclize aryl ether A9-14 by treatment with base and iodine resulted in
no productive reaction. We had envisioned formation of iodonium ion A9-16 and
intramolecular cyclization to afford spirocycle A9-15 via putative intermediate A9-17
(Scheme A9.4). Unfortunately, the only observed product was benzofuran A9-19, leading
us to hypothesize that iodinated intermediate A9-18 was the intermediate adduct formed,
and that the tertiary iodide was insufficiently reactive in the desired Sn2 process. Similar
trials
Scheme A9.4 Attempts at oxidative cyclizations to form the yuccaol core
O
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OCH3
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THF, –78 °C
O
O
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I O
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O
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O
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Perhaps taking advantage of hypothetical iodine A9-18, we could invoke a
Kornblum-type process mediated by Ag+ to abstract the halide and promote
intramolecular cyclization to A9-15 (Scheme A9.5a). Alternatively, the undesired
benzofuran A9-19 could be used for an oxidative cyclization, however, this route
destroys the stereochemistry set by the key conjugate addition reaction, and is therefore
not optimal (Scheme A9.5b).
Scheme A9.5 Hypothetical routes to key intermediate
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A9.5 Arylation route attempts
A screen of arylation conditions demonstrates difficulty in successfully cyclizing
A9-13 to the yuccaol core (A9-15, Table A9.2).3 Mass hits failed to provide isolable
material, and the formation of isomeric benzofuran A9-22  is a likely undesired
byproduct. This benzofuran hypothetically results from Pd-catalyzed reduction of the
arylbromide and oxidative aromatization to afford the isomer A9-22. At this point in
time, we considered an alternative approach may be required, as the harsh conditions of
arylation and oxidation both readily furnished undesired side reactions.
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Table A9.2 Screen of arylation conditions
O
O
Ph
O
Br
A9-13 A9-21
O
O
Ph
O
conditions
A9-22
O
O
Ph
O
undesired isomeric product
Trial Reagent(s) Scale Result
1 Pd(OAc)2, JohnPhos, KHMDS 10 mg Mass Hit
2 Pd(OAc)2, JohnPhos, KHMDS 10 mg Mass Hit
3 Pd(NHC)(Acac)Cl, KHMDS 20 mg No productive reaction
4 Pd(NHC)(Biphenyl)Cl, KHMDS 20 mg No productive reaction
5 Pd2dba3, P(tBu)3, KHMDS 20 mg No productive reaction
6 Pd2dba3, JohnPhos, KHMDS 20 mg No productive reaction
7 Pd2dba3, SPhos, KHMDS 20 mg No productive reaction
8 Pd(OAc)2, P(tBu)3, KHMDS 20 mg No productive reaction
9 Pd(OAc)2, JohnPhos, KHMDS 20 mg No productive reaction
10 Pd(OAc)2, SPhos, KHMDS 20 mg No productive reaction
A9.6 Toward a radical cyclization approach
We envisioned a 5-endo-trig radical cyclization from silyl enol ether A9-20 to
afford desired spiro-benzofuran A9-21 (Scheme A9.6). Admittedly, the base-sensitive
and oxidation-prone nature of A9-20 provides many alternative pathways for undesired
reactivity, however we believe that a radical approach may be our best chance at
observing clean formation of the yuccaol core from ring contraction product A9-13.
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Scheme A9.6 Radical cyclization approach
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A9.7 Synthesis of fully-oxygenated framework of yuccaol A/B
The high degree of oxidation found in the yuccaols requires early installation of a
large number of hydroxy groups. We envision a fully oxygenated intermediate (A9-23)
being broken into two halves, the flavanone A9-24 and the stilbene A9-25 (Scheme
A9.7). Flavanone A9-24 can be synthesized by asymmetric conjugate addition of
arylboronic acid A9-27 to chromone A9-26. Stilbene A9-25 can be synthesized by Heck
reaction, and those intermediates will be derived from aldehyde A9-29 and iodobenzene
A9-30.
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Scheme A9.7 Retrosynthesis of yuccaol A/B
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Synthesis of flavanone A9-26 proceeded smoothly from triphenol A9-28,4
however we found that unprotected chromone A9-26 did not react in conjugate addition
reactions. A suitable protecting group scheme will need to be found. Methoxy groups
make sense, however, concern with their removal and the reactivity of electron-rich
substrates in conjugate addition reactions makes them less attractive.
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Scheme A9.8 Synthesis of chromone intermediate
O
O
HO
OH
OHHO
OH
A9-26A9-28
BF3•OEt2
CH3SO2Cl
DMF
(37% yield)
Synthesis of the requisite stilbene fragment A9-25 was less straightforward. A
three-step sequence starting from aldehyde A9-29 produced styrene A9-31 in poor yield
(Scheme A9.9), as a mix of mono- and bis-methylated isomers that were not easily
separated. Treatment of the mixture with iodide A9-30 resulted in isolation of the desired
Heck product for only the bis-methylated styrene, poising the question of how to
selectively remove one of three methyl groups chemoselectively.
Scheme A9.9 Synthesis of stilbene moiety
OHHO
A9-29
O
ORI
A9-30
ORMeO
1. TBSCl, DIPEA
2. KHMDS, CH3PPh3
3. NaH, MeI, THF
Pd(OAc)2, PPh3, NEt3
MeCN, 70 °C
OMe
OR
MeO
A9-32A9-31
mix of R = H or Me no free OH reacted
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A9.8 Conclusion and outlook
We have presented a reasonable route toward the yuccaol natural products. The
key step, the synthesis of the key spirocyclic stereocenter, remains to be demonstrated.
Currently, the preferred route is a radical cyclization. Finally, fully oxygenated pieces
have been synthesized, however, an optimal protecting group scheme and substrates for
the key conjugate addition need to be identified.
A9.9 Notebook references for compounds
See notebooks for Emmett D. Goodman (EDG), specifically notebook II. Racemic
flavanone used as starting material for majority of the studies, purchased from Sigma-
Aldrich.
– Ring contraction product A9-6: EDG-II-077, EDG-II-085, EDG-II-153
– Saponification product A9-11: EDG-II-097, EDG-II-105, EDG-II-121
– Aryl ethers A9-12, A9-13, A9-14: EDG-II-131, EDG-II-165, EDG-II-167, EDG-
II-189, EDG-II-191
– Benzofuran side reaction A9-22: EDG-II-135
– Chromone A9-26: EDG-II-155
– Stilbene synthetic intermediates: JCH-XI
Appendix 9 469
                                                                                                                                                  
A9.10 Notes and Citations
(1) (a) Wenzig, E.; Oleszek, W.; Stochmal, A.; Kunert, O.; Bauer, R. J. Agric. Food
Chem. 2008, 56, 8885–8890.  (b) Marzoco, S.; Piacente, S.; Pizza, C.; Oleszek,
W.; Stochmal, A.; Pinto, A.; Sorrentino, R.; Autore, G. Life Sciences. 2004,
75(12), pp 1491-1501.
(2) Khanna, M. S.; Singh, O. V.; Garg, C. H. P.; Kapoor, R. P. Synth. Commun. 1993,
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(4) (a) Zheng, S.; Shen, Z. Tet. Lett. 2010, 51, 2883–2887.  (b) Guo, W.; Biao, Y.
Eur. Joc. 2008, 18, 3156–3163.
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APPENDIX 10
The development of novel NHC-based ligand scaffolds for use in
heteroaromatic conjugate addition reactions
Appendix 10 471
Abstract
N
N
O
R
N N
N
N N
N
RR
stronger σ donor
bis-NHC ligand
weak σ donor:
incompatible with heteroaryl substrates
N
N
N
N N
N
N
N
Chiral PyOx Achiral Pyrimidine-NHC Chiral Pyrimidine-NHC
Efforts toward the asymmetric conjugate addition of heteroaromatic boronic acids
are discussed. Pyridine-derived ligands were observed to be incompatible with Lewis
basic functionality, such as pyridylboronic acids. Synthesis and evaluation of a number of
mono- and bis-NHC ligands was undertaken to evaluate these ligands for catalytic
activity in palladium-catalyzed conjugate addition reactions. Low conversions were
observed with these ligands, prompting the synthesis and evaluation of mixed pyridine-
NHC and pyrimidine-NHC ligands. These ligands have bite angles analogous to
bipyridine and may lead to superior function in palladium-catalyzed conjugate addition
reactions.
Appendix 10 472
A10.1 Introduction and background
Palladium-catalyzed asymmetric conjugate addition has been achieved with a
number of ligand scaffold designs. Our efforts with bipyridine (bpy) and
pyridinooxazoline (PyOx) ligands were unsuccessful in reacting heteroarylboronic acids
(Scheme A10.1). A number of heteroarylboronic acids were screened, and all failed to
afford appreciable conversion to the conjugate addition adducts with the exception of 4-
dibenzofuranboronic acid. Heteroarylboronic acids with Lewis basic functionalities, such
as 3-pyridylboronic acid and 3-thiopheneboronic acid, were observed to chelate the
palladium complex, and may out compete the relatively weak σ donor atoms of bpy or
PyOx, knocking these ligands off the metal and leaving the metal unreactive and
coordinatively saturated. The observations led us to consider alternative ligand scaffolds,
in hope that we could identify a scaffold compatible with these highly Lewis basic
heteroarylboronic acids.
Scheme A10.1 Failed reactions with bpy and PyOx ligands
O
N
B(OH)2
N
(HO)2B
S
(HO)2B
Pd(OCOCF3)2 (5 mol %)
bpy or PyOx (6 mol %)
NH4PF6, H2O
ClCH2CH2Cl, 40–90 °C
No Reaction Observed
95
Early on, we noticed that bulky, di- and triarylphosphine ligands were incapable
of catalyzing the synthesis of quaternary stereocenters via  reaction with
methylcyclohexenone (95). Presumably, the steric demands of the transition state- olefin
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insertion into the arylpalladium bond- are prohibitively high in energy for systems
involving bulky, sterically demanding ligands. There are several known systems capable
of catalyzing conjugate addition reactions that form quaternary stereocenters (Figure
A10.1), including Lu’s (bpy)Pd complexes (A10-1), our own (PyOx)Pd manifold (A10-
2), Hayashi’s chiral diene systems (A10-3) and the monodentate Cu-NHCs popularized
by Alexakis and Hoveyda (A10-4). Analysis of these systems reveals a number of
similarities, particularly in the rhodium and palladium manifolds, 1) a five-membered
chelate of the metal center; 2) a small bite angle; 3) no large groups projecting around the
metal center from the ligand. The Alexakis and Hoveyda model, based on monodentate
copper/NHCs, is the only catalytic system that does not involve bidentate ligands.
However, it demonstrates that monomeric NHC ligands may be functional with
palladium metal centers, too.
Figure A10.1 Known catalytic systems for conjugate addition forging quaternary centers
N N N
N
O
t-Bu
N NR1 R2
CuLn
Rh
HO Ln
Pd
HO Ln
PdF3COCO
OCOCF3
Lu
5-membered metallocycle
forms quaternary centers
Stoltz
5-membered metallocycle
forms quaternary centers
Hayashi
5-membered diene chelate
forms quaternary centers
Alexakis, Hoveyda
monodentate ligands
forms quaternary centers
A10-1 A10-2 A10-3 A10-4
* *
*
Taking these complexes as starting points, we began to devise an approach toward
NHC ligands that would incorporate the key features of the catalyst scaffolds. Namely,
we set out to test monodentate NHCs, bis NHCs, and mixed NHC/pyridine bidentate
ligands for competency in catalyzing conjugate addition reactions with both
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phenylboronic acid and heteroarylboronic acids. In particular, we hoped to combine the
narrow bite angle of bpy ligand derivatives with the superior σ donating ability of NHC
ligands.
A10.2 Results
A10.2.1 Synthesis of NHC complexes
A variety of NHC complexes were synthesized. See citations for appropriate
preparative references. Most of these were monodentate NHC ligands, as they were
easiest to prepare. Hermann’s bis NHC A10-5,1 derived from N-methylimidazole and
dibromomethane, was the only bis-NHC completed at the time of this writing. Sigman’s
palladium(II) acetate derivative NHCs (A10-6) was synthesized according to his
published procedures.2 We made an analog of this complex with trifluoroacetate, A10-7.
These aquo complexes are known to affect the oxidation of alcohols to ketones and
aldehydes under basic conditions. The PEPPSI-iPr catalyst (A10-8) and well-known α-
arylation catalyst A10-9 were the final complexes synthesized.
Figure A10.2 Palladium NHC complexes synthesized
N
N
Pd
N
N
F3COCO OCOCF3
N N
Pd
A10-5
i-Pr
i-Pr
i-Pr
i-Pr
OAcAcO OH2
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
OCOCF3F3COCO OH2
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
ClCl N
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
O
O Cl
ClA10-6 A10-7 A10-8 A10-9
A10.2.2 Reactions with cyclohexenone
We first tested these complexes as catalysts in the conjugate addition reaction of
phenylboronic acid to cyclohexenone and 3-methylcyclohexenone (Table A10.1).
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Catalyst A10-5 featured good conversion with cyclohexenone and chromone, albeit
conversion took several days, though no reaction was observed with
methylcyclohexenone. Catalyst A10-6, however, demonstrated almost no productive
reaction with any of the three substrates screened, however, biphenyl production was
observed. Catalyst A10-7 provided a similar reaction profile to bis-NHC A10-6, although
it catalyzed reactions much slower. Finally, chloride anion containing catalysts A10-8
and A10-9 produced no observable reactions. Observation of competent reactivity with
phenylboronic acid led us to consider a screen involving heteroarylboronic acids.
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Table A10.1 Reactions of NHC complexes with phenylboronic acid
N
N
Pd
N
N
F3COCO OCOCF3
N N
Pd
A10-5
i-Pr
i-Pr
i-Pr
i-Pr
OAcAcO OH2
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
OCOCF3F3COCO OH2
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
ClCl N
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
O
O Cl
Cl
A10-6
A10-7
A10-8
A10-9
catalyst R = H R = CH3 chromone
R
O
B(OH)2
catalyst (5 mol %)
NaSbF6, H2O
ClCH2CH2Cl, rt to 60 °C
R
O
good conversion no conversion
biphenl observed
good conversion
trace product,
biphenyl observed
no product
biphenyl observed
trace product
biphenyl observed
modest conversion
much slower than A10-5
no product
biphenyl observed
modest conversion
biphenyl observed
no reaction
no reaction no reaction
no reaction no reaction
no reaction
Next, we employed the same catalysts in the conjugate addition reaction of 3-
pyridylboronic acid to cyclohexenone and 3-methylcyclohexenone. Surprisingly,
complex A10-5 gave no conversion with either enone. Complex A10-6, on the other
hand, indicated trace conversion by TLC, and peaks on the LCMS suggested Heck
product A10-11 was forming. Trifluoroacetate analog A10-7 reacted similarly in low
conversion, and 2 mg of the Heck adduct was isolated by column chromatography.
Significant proteodeborylation and biaryl formation was observed, as well. We postulate
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that these reactions may perform better in polar solvents, where the coordination complex
of the pyridine substrate and the metal catalyst would be less stabilized. Highly polar
solvents, however, often promote oxidative Heck reactivity. Continuing the trend
observed with phenylboronic acid, chloride anion complexes A10-8 and A10-9 promoted
no reactivity whatsoever.
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Table A10.2 Reactions of NHC complexes with 3-pyridylboronic acid
N
N
Pd
N
N
F3COCO OCOCF3
N N
Pd
A10-5
i-Pr
i-Pr
i-Pr
i-Pr
OAcAcO OH2
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
OCOCF3F3COCO OH2
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
ClCl N
N N
Pd
i-Pr
i-Pr
i-Pr
i-Pr
O
O Cl
Cl
A10-6
A10-7
A10-8
A10-9
catalyst R = H R = CH3 comment
R
O
N
B(OH)2
catalyst (5 mol %)
NaSbF6, H2O
ClCH2CH2Cl, rt to 60 °C
N
R
O
N
O
no conversion no conversion
no conversion
no conversion
no conversion
no conversion
no conversion
no conversion
chloride anions hinder
reactivity, as predicted
chloride anions hinder
reactivity, as predicted
trace conversion to A10-11
by LCMS
A10-10 A10-11
low conversion to A10-11
2 mg isolated
low reactivity, probably would
benefit from more polar solvent
low reactivity, probably would
benefit from more polar solvent
most successful catalyst
with phenylboronic acid
surprisingly unreactive
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A10.3 Future Directions
We believe that NHC ligands with bite angles more closely related to bpy would
show significant activity in palladium-catalyzed conjugate addition (Figure A10.3). As
was observed with diamine ligands, bite angle is exceedingly important to high reactivity,
and we imagine a similar bite angle would accelerate NHC/palladium-catalyzed 1,4-
addition reactions.
Figure A10.3 Conceptual NHC design with bite angle analogous to bpy
N N
N
N N
N
RR
stronger σ donor
bis-NHC ligand
weak σ donor:
incompatible with heteroaryl substrates
A number of ligands are known that feature bis-NHC moieties based on the bpy
and phenanthroline scaffolds (Figure A10.4). The Crabtree group’s “bitz” ligand (A10-
12),3 and the Bertrand group’s “i-bitz” (A10-13) are bpy-derived bis-NHCs bearing
analogous bite angles.4 The Kunz group has a scaffold related to 1,10-phenanthroline
with a bidentate NHC chelate (A10-14).5
Figure A10.4 Known bis-NHC ligands with smaller bite angles
N
N
N
N
N
N
RR
N
N
N
N
NN
RR
N N N N
RR
A10-12
'bitz'
Crabtree, 2007
A10-13
'i-bitz'
Bertrand, 2011
A10-14
'veg'
Kunz, 2010
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Furthermore, a number of N-NHC bidentate ligands are known, whereby the
pyridine chelate from the PyOx scaffold is conserved, and the oxazoline is replaced with
an NHC chelate (Figure A10.5). These ligands are particularly attractive because of the
success we have seen with the C1 symmetric PyOx ligands. The Monkowius group’s
1,10-phentanthroline-derived N-NHC bidentate ligand (A10-15),6 and Strassner’s
pyrimidine-derived NHC (A10-16) are both interesting ligands to test.7 Some progress
toward the synthesis of the Strassner ligand has been performed (see notebook cross
reference at end of this chapter).
Figure A.10.5 Bidentate N-NHC ligands
N N
RN
A10-15
Monkowius, 2012
N N
R
N
N
A10-16
Strassner, 2009
Furthermore, the use of bidentate N-NHC ligands would immediately posit
analogous chiral C1 ligands (Figure A10.6). Though pyrimidine/NHC ligands are
generally aryl substituted on the NHC nitrogen atom (e.g., A10-18), we have postulated
the isopino-campheylamine-derived NHC (A10-19) based on its steric similarity to the t-
BuPyOx ligand (A10-17, R = (S)-t-Bu) currently used for the conjugate addition
methodology.
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Figure A.10.6 Logical extension to chiral NHC ligands
N
N
O
R
N
N
N
N N
N
N
N
Chiral PyOx Achiral Pyrimidine-NHC Chiral Pyrimidine-NHC
A10-17 A10-18 A10-19
Synthesis of the ligand requires mono-aryl imidazole (A10-20) and 2-chloropyrimidine
(Scheme A10.2, A10-21), which are heated neat to afford imidazolium salt A10-22. This
salt is ligated to silver(I) in the absence of light and transmetallated to Pd(nbd)Cl2 to
afford dichloride A10-23.  As chloride anions are incompatible with the conjugate
addition methodology, this species would need to be further refined, to either a
trifluoroacetate (A10-24) or dicationic (A10-25) analog via halogen abstraction or other
ligand exchange. We posit that A10-24 and A10-25 would be excellent catalysts for
palladium-catalyzed 1,4-addition reactions.
Scheme A10.2 Synthesis of idealized trifluoroacetate complex
N
I-PrPr-I
N
N
N Cl
N I-Pr
Pr-I
N
N
N
N I-Pr
i-Pr
N
N
N
Pd
Cl
Cl
neat, 120 °C 1. Ag(I)O, CH2Cl2
2. (nbd)PdCl2
•HCl
AgX
N I-Pr
i-Pr
N
N
N
Pd
X
X
A10-20 A10-21 A10-22 A10-23
A10-24, X = OCOCF3A10-25, X = PF6
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A10.4 Conclusions
Progress toward the design of a palladium-catalyzed conjugate addition system
capable of tolerating heteroarylboronic acids is presented. Suggestions for future
directions and ligand designs have been made.
A10.5 Notebook references for compounds and tables in Appendix 10
A10-5 bis-NHC: JCH-XI-075, JCH-XI-079, JCH-XI-081, JCH-XI-097
A10–6 Sigman mono-DIPP NHCs: JCH-XI-103, JCH-XI-127, JCH-XI-151, JCH-XI-
155, JCH-XI-163, JCH-XI-165
A10-7: trfluoroacetate analog JCH-XI-167
A10-14: JCH-XI-291, JCH-XI-295, JCH-XI-297, JCH-XI-299
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APPENDIX 11
Progress toward the development of a novel reductive Heck reaction÷
                                                 
÷ This work was performed in conjunction with Dr. Wen-Bo “Boger” Liu, who spent
considerable time investigating conventional reductive Heck reductants. See his
notebooks (WBL) for full details.
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Abstract
O O
Aryl
H
Pd(0)
Aryl-I, i-PrOH
THF/H2O
Efforts toward the rational design of a new reaction manifold for a reductive Heck
catalytic cycle are presented. This catalytic cycle differs from a typical palladium-
catalyzed conjugate addition in that the reactive arylpalladium(II) intermediate is formed
via oxidative addition. Thus, a reduction event is required to regenerate the palladium(0)
catalyst. Herein, we describe efforts toward the use of iso-propanol as the stoichiometric
reductant. Modest conversions to the desired adducts are reported, however significant
side products are observed. Attempts to render the transformation enantioselective by
employing the ligand (R, R)-Me-DuPhos are reported. Finally, attempts to generalize the
reaction for use with heteroaryl reagents are discussed.
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A11.1 Introduction and background
A11.1 Historical perspective
Reductive Heck reactions are attractive alternatives to conventional conjugate
addition reactions. There are numerous situations where one might be better served by the
reductive Heck reaction, such as a situation where the desired aryl congener is not stable
as a boronic acid, or is overly prone to proteodeborylation or other undesired side
reaction. Furthermore, the elevated temperatures and phosphine ligands typically
employed in reductive Heck reactions are more likely to accommodate heteroaryl
reagents, as opposed to the mild temperatures and diamine ligands scaffolds that are
typically employed in conjugate addition reactions. In the conventional diamine-
palladium-catalyzed conjugate addition reaction, heteroaryl reagents or other Lewis basic
moieties are able to out compete the ligand for metal chelation, effectively sequestering
the catalyst off-cycle. However, conventional reductive Heck reactions employ harsh
conditions and elevated temperatures (Scheme A11.1), utilizing formic acid and
triethylamine as reductants to add aryl halides (A11-2) to enones (A11-1) to form
β−arylated ketones (A11-3).
Scheme A11.1 Typical reductive Heck reaction conditions
O O
Aryl
H
Pd source, phosphine ligand
formic acid, NEt3
CH3CN or DMF
80–120 °CX
R
R R
A11-1 A11-2 A11-3
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A11.1.2 Proposed catalytic cycle
Our group has spent considerable time investigating this processes, with hopes of
synthesizing β-heteroaryl ketone products in an asymmetric fashion. This catalytic cycle
starts with palladium(0), and forms the active arylpalldium(II) intermediate (akin to that
of the conjugate addition catalytic cycle) via oxidative addition. Thus, a reduction event
(hence reductive Heck reaction) is required to regenerate the palladium(0) catalyst.
Recently, we began to pursue an alternative reduction mechanism, whereby the
stoichiometric reductant was actually an alcohol cosolvent. In this manifold, the
cosolvent (shown as iso-propanol, Figure A11.1) undergoes β-hydride elimination to
form a palladium(II) hydride (A11-11) which undergoes reductive proton loss to
regenerate the palladium(0) catalyst (A11-4). As in the conventional Heck reaction, this
catalyst undergoes oxidative addition to form arylpalladium(II) A11-5, however we
envision silver-mediated halogen abstraction enabling the quantitative generation of
cationic arylpalladium(II) A11-6, which undergoes addition to the enone olefin to
generate palladium enolate A11-8. This enolate acts as the requisite base, deprotonating
the alcoholic cosolvent to liberate arylated product A11-9 and form palladium alkoxide
A11-10, which is primed for reduction to regenerate the catalyst.
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Figure A11.1 Proposed catalytic cycle for new reductive Heck reaction
Aryl–I
Pd(0)Ln
Pd(II)Ln
Aryl
I
Pd(II)Ln
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Pd(II)Ln
O
Aryl
O
Aryl
H
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Pd(II)Ln
O H
O
Pd(II)LnH
X
Ag
HX
Ag–I
Pd-enolate
acts as required
equivalent of base
HO H
A11-4
A11-5
A11-6
A11-7
A11-8A11-9
A11-10
A11-11
A11.2 Results
A11.2.1 Identification of an operable reductive Heck reaction
A small solvent screen was undertaken to determine if the reaction was operable
as proposed. Ironically, the use of 1,2-dichloroethane was found to be unproductive, as
heating with silver salts resulted in displacement of the chlorides. THF (Table A11.1,
entries 1-2) and CH2Cl2 (entries 3–4) were screened with either water or iso-propanol as
cosolvent. Water was utilized as a control, to see if conversion to the desired product was
detected, and to assay the validity of our hypothesis for the silver additive in promoting
the desired 1,4-addition reaction. THF proved a superior solvent to CH2Cl2, and upon
scale-up 20-35% yield of the desired adduct A11-13 could be isolated via the method
described in entry 2. However, significant side product A11-14 was also observed,
accounting for a majority of the mass balance. It should be noted that reactions tried
using phenyl triflate, instead of iodobenzene and without silver salts, were unsuccessful.
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It appears that using non-coordinating counterions alone without the silver, such as
triflate, is insufficient to catalyze the reaction. Additionally, we suggest screening
additional silver salts. In particular, those with basic counterions (such as acetate, or
trifluoroacetate) may assist in reaction turnover, and increase conversion.
Table A11.1 Solvent and cosolvent screen
O O
Ph
H
Pd(OCOCF3)2,(10 mol %), 
dppbz (15 mol %)
 AgSbF6 (2 equiv)
solvent/cosolvent (9:1)I
A11-2A11-12 A11-13
entry solvent cosolvent conversion comment
1 THF H2O trace mix of A11-13, A11-14
O
Ph
A11-14
2 THF i-PrOH >90% mix of A11-13, A11-14
3 CH2Cl2 H2O trace majority A11-13
4 CH2Cl2 i-PrOH trace majority A11-13
Attempts to induce enantioselectivity by replacing dppbz with (R,R)-Me-DuPhos
failed to generate any conjugate addition product (Scheme A11.2). (R,R)-Me-DuPhos is
known to induce asymmetry in palladium-catalyzed conjugate addition reactions in
THF/H2O mixtures. Curiously, only Heck reaction product A11-14 was observed in our
attempts. Of course, further attempts with similar chiral ligands (e.g., Dipamp) should be
pursued.
Appendix 11 490
Scheme A11.2 Attempt to induce asymmetry with chiral ligand
O O
Ph
H
Pd(OCOCF3)2,(10 mol %), 
dppbz (15 mol %)
 AgSbF6 (2 equiv)
THF/i-PrOH (9:1)I
A11-2A11-12 A11-13
O
Ph
A11-14
+
O O
Ph
H
Pd(OCOCF3)2,(10 mol %), 
(R,R,)-Me-Duphos (15 mol %)
 AgSbF6 (2 equiv)
THF/i-PrOH (9:1)I
A11-2A11-12 A11-13
O
Ph
A11-14
+
We made brief attempts to apply the reaction toward the synthesis of β-heteroaryl
ketones (A11-16), however the incompatibility of silver(I) salts with heteroatom ligands
appears prohibitive to the desired reactivity. For example, use of 3-bromoquinoline
provided no conversion, and only proteodehalogenation and some dimerization was
observed (Table A11.2).
Table A11.2 Bromoquinoline screen
O O
Aryl
H
Pd(OCOCF3)2,(10 mol %), 
dppbz (15 mol %)
 AgSbF6 (2 equiv)
solvent/cosolvent (9:1)
60 °C, 48 h
A11-15A11-12 A11-16
entry solvent cosolvent conversion comment
1 THF H2O trace mostly H-quinoline, dimer
O
Aryl
A11-17
2 THF i-PrOH trace mostly H-quinoline, dimer
3 CH2Cl2 H2O trace mostly H-quinoline, dimer
4 CH2Cl2 i-PrOH trace mostly H-quinoline, dimer
N
Br
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Likewise, the use of 3-pyridyltriflate failed to produce successful reactions (Table
A11.3). Again, some proteodetriflation and dimerization signals were observed by
LCMS, but not productive conversion was detected. Again, the incompatibility of silver
salts with heteroaryl substrates may be prohibitive.
Table A11.3 Pyridine triflate screen
O O
3-pyr
H
Pd(OCOCF3)2,(10 mol %), 
dppbz (15 mol %)
 AgSbF6 (2 equiv)
solvent/cosolvent (9:1)
60 °C, 48 h
A11-18A11-12 A11-19
entry solvent cosolvent conversion comment
1 THF H2O trace mostly H-pyr, dimer
O
3-pyr
A11-20
2 THF i-PrOH trace mostly H-pyr, dimer
3 CH2Cl2 H2O trace mostly H-pyr, dimer
4 CH2Cl2 i-PrOH trace mostly H-pyr, dimer
N
OTf
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A11.3 Conclusion and future directions
The two most pressing tasks are 1) to demonstrate the compatibility of this
reaction with chiral ligands and 2) to try milder methods of halogen abstraction from the
putative arylpalladium(II) halogen intermediate.
Regarding the search for a compatible chiral ligand, bidentate phosphines forming
5-membered chelates should be examined. A rigid structure and narrow bite angle, as is
helpful in other conjugate addition systems, may be desirable.
The second goal, mild halogen abstraction, is considerably broader in scope. The
mildest method, conceivably, would entail the use of aryltriflates with additives such as
hexafluorophosphate or hexalfuoroantimonate salts. Though, to date, these approaches
have been non-productive. The use of silver, however, is not compatible with heteroaryl
substrates. Additionally, significant deposits of metal mirrors were observed in these
cases.
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APPENDIX 12
Notebook cross-reference for new compounds
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 Table A12.1 Compounds from Chapter 2
Compound product NMR and IR data filesNotebookreference
O
35
O
O
O
O
O
O
Me
OMe
OBn
Cl
F
127
129
130
131
132
133
134
O
Et
Ac
128
O
OTBS
KIX-II-031b kix-c6M3Ph1
KIX-II-057b
KIX-II-051b
kix-c6MePhpMe-1
KIX-II-075a
KIX-II-079a
kix-c6MePhpEt2
KIX-II-095
KIX-II-051a
kix-c6MePhpOMe-1
KIX-II-119c
KIX-II-151c
kix-c6-MePhpOBn-1
KIX-II-101b kix-c6MePhpOTBS-3
KIX-II-103b
KIX-II-105d
kix-c6MePhpAc
KIX-II-037b
KIX-II-043b
kix-c6MePhpCl
KIX-II-053
KIX-II-043a
kix-c6MePhpF-1
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89
135
136
90
88
137
134a
52
O
O
CF3
O
Me
O
Cl
O
Br
O
CO2Me
O
NO2
O
F
Compound product NMR and IR data filesNotebookreference
KIX-II-101a
KIX-II-105a
kix-c6MePhpCF3-1
KIX-II-057c
KIX-II-051f
kix-c6MePhmMe
KIX-II-057d
KIX-II-051e
kix-c6MePhmCl-1
KIX-II-117b
KIX-II-151d
kix-c6MePhmBr-2
KIX-II-119a
KIX-II-151b
kix-c6MePhpCOOMe
KIX-II-079c
KIX-II-153d
kix-c6MePhmNO2
KIX-II-153b
KIX-II-143
kix-c6MePhoF
JCH-c6MePhoF
KIX-II-073
KIX-II-077
kix-c5MePh-1
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entry product NMR and IR data filesNotebookreference
83
O
Et
O
O
O
138
139
140
141
142
86
88
Ph
O
O
O
BnO
O
Me
KIX-II-091c
KIX-II-087
kix-c7MePh-1
KIX-II-155a
KIX-II-089a
kix-c6EtPh
KIX-II-099c kix-c6BuPh
KIX-II-139a
KIX-II-141a
kix-c6BnPh-1
KIX-II-155b
KIX-II-089b
kix-c6iPrPh-1
KIX-II-113a
KIX-II-111a
kix-c6cPrPh-1
KIX-II-155c
KIX-II-175
kix-c6cHexPh
KIX-II-141b
KIX-II-139b
kix-c6C3ObnPh-1
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O
160
O
O
O
O
NHPiv
NH(TFA
161
163
164
165
166
O
NH(TFA)
162
O
NHCbz
NH(TFA)
O
NH(TFA)
NH(TFA)
Compound product NMR and IR data filesNotebookreference
MG-II-071
MG-III-0225
MG-III-227
MG-III-251
MG-II-127
MG-II-131
MG_2_127_Fr1
MG-II-093
MG-II-237
MG-III-0225
MG-II-071
MG-III-227
MG-III-251
MG-II-093
MG-II-237
Appendix 12 498
Table A12.2 Compounds from Chapter 3
Compound product Notebookreference
25
O
Me
O
O
O
O
O
O
O
O
35
174
175
176
177
178
O
O
84
O
O
F
Me
CO2Me
Br
NH(COCF3)
O
NMR and IR data files
JCH-VIII-301 JCH-VIII-301
JCH-c6HPh
KIX-II-031b kix-c6MePh-1
AM-I-01 AM-1-01
JCH-VII-039
JCH-VII-047
JCH-VII-095
JCH-VII-075
AM-I-11 AM-i-11
AM-i-11_1H_pure
JCH-VIII-087
JCH-VII-049
JCH-cheomone-3Br
AM-i-15 AM-i-15_finalcharac_2
JCH-VII-chromone-2F
JCH-VII-095
JCH-VII-075
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O
O
180
O
O
O
O
O
O
181
183
184
185
186
187
O
O
182
O
O
Me
Et
F
OMe
OMe
O
Me
Me
AcO
O
OMe
Me
AcO
O
OMe
Me
AcO
Et
Me
Compound product Notebookreference NMR and IR data files
AM-i-02
JCH-VII-093
JCH-VII-087
JCH-VII-059
AM-i-03
JCH-VII-063
AM-i-07
JCH-VIII-073
AM_07_1H_pure
AM-I-29 AM-i-29_Y
AM-i-29_13C
AM-i-30 AM-i-40
AM-i-40_13C
AM-i-23
JCH-VIII-097
AM-i-23
AM-i-24 AM-i-24_full
AM-i-02
JCH-VII-093
JCH-VII-087
JCH-VII-059
AM-i-03
JCH-VII-063
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188
O
O
189
191
192
194
195
85
196
190
Me
Me
O
O
Me
O
O
AcO
O
OMe
Me
O
OMe
Me
O
OMe
Me
O
O
Me
OAc
OAc
Me
F
OAc
Me
OAc
O
Me
NH(COCF3)
OMe
O
O
Me
Me
OAc
Br
O
OMe
Me
COOMe
OAc
Compound product Notebookreference NMR and IR data files
MG-III-181 AM-MG-III-181
AM-i-42 AM-i-42
AM-i-42_13C
AM-i-34 AM-i-34
AM-i-34_13C
JCH-VII-089
AM-i-33
AM-i-33
AM-i-33_13C
AM-I-41 AM-i-41
AM-i-41_13C
AM-i-30 AM-i-30_X
AM-i-30
MG-III-179 AM-MG-iii-179
AM-i-53 AM-i-53_full
AM-i-22
MG-III-157
AM_MG-iii-157
AM-i-22
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196
O
O
197
199
200
198
O
O
HO
O
O
HO
HO
Me
F
O
O
MeO
O
O
MeO
COOMe
Compound product Notebookreference NMR and IR data files
AM-i-26 AM-i-26_full
AM-i-27 AM-i-27_full
AM-i-59 AM-i-59_1H
AM-i-21
MG-iii-155
AM-i-27_F_3
AM-i-48 AM-i-48
AM-i-48_13C
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202
204
205
208
209
N
Cbz
O
N
Cbz
O
N
Cbz
O
N
Cbz
O
N
Cbz
O
NH(COCF3)
Me
OMe
OMe
CO2Me
OMe
O
Compound product Notebookreference NMR and IR data files
JCH-VIII-277 JCH-VIII-277-again
quinolone-3Me4NHTFA
JCH-VIII-261 JCH-VIII-261
quinolone-3-5-OMe
JCH-VIII-259 JCH-VIII-259
quinolone-3-CO2Me
JCH-VIII-299
JCH-VIII-297 JCH-VIII-297
quinolone-DBF
JCH-VIII-299
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Table A12.3 Compounds from Chapter 4
Compound product Notebookreference NMR and IR data files
235
236
N
N
O
t-Bu
Pd
OCOCF3
F3COCO
245
N
N
O
Pd
PPh3
+
 PF6 -
O
246
JCH-VII-101 JCH-dimethyl-ACA-pdt
JCH-dimethyl-c6MePh
JCH-XII--083
AM-i-145
AM-i-145_full
AM-i-38
AM-i-43
AM-i-140
AM-i-119
MG-III-205
AM-i-43_13C
MG-III-205
AM-PyOXPdOTFA2
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Table A12.4 Compounds from Chapter 5
Compound product Notebookreference NMR and IR data files
N
O
H
N
t-Bu
OH
N
O
H
N
t-Bu
Cl
•HCl
N
N
O
t-Bu
249
256
82
N
N
O
t-Bu
82b
•HBF4
HS-II-211 HS-II-211-amide-OH
HS-II-207
HS-II-213
HS-II-207-amide-Cl-HCl
HS-II-205
HS-II-213
HS-II-PyOx
HS-II-127 PyOx-HBF4-HS-II-127
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Table A12.5 Compounds from Chapter 6
Compound product Notebookreference NMR and IR data files
Br
O
OPiv
OPiv
O
O
OPiv
OH
O
321
336
OH
OH
OH
O
OH
OCH3
OCH3
O
335
334
PivO
O
OPiv
PivO
O
OPiv
OPiv
O
OPiv
B
B
O O
HO
HO
JCH-X-bispiv_13C
JCH-X-165
JCH-V-131
JCH-X-165
JCH-X-165Bpin
JCH-X-167
JCH-V-135
JCH-X-167
JCH-X-169 JCH-X-169A
JCH-X-183 JCH-X-183A
JCH-X-189 JCH-X-189A
JCH-X-215 JCH-X-215-A
JCH-V-125
341
340
339
506
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